<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000528" GROUP_ID="INFECTN" ID="676799102918095883" MERGED_FROM="" MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.4">
<COVER_SHEET MODIFIED="2013-01-29 15:03:29 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2012-08-22 12:34:46 +0100" MODIFIED_BY="Tony Danso-Appiah">Drugs for treating <I>Schistosoma mansoni</I> infection</TITLE>
<CONTACT>
<PERSON ID="5E3806F482E26AA200FB8E1E674745BD" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Danso-Appiah</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tdappiah@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>07951486050</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1>+44 151 705 3364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-29 15:03:29 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="5E3806F482E26AA200FB8E1E674745BD" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Danso-Appiah</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tdappiah@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>07951486050</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1>+44 151 705 3364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17054" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Piero</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Olliaro</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>olliarop@who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)</DEPARTMENT>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>1211 Geneva 27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 22 791 3734</PHONE_1>
<PHONE_2/>
<FAX_1>+41 22 791 4774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5E63C9C182E26AA200991D56B22E8EB4" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Donegan</LAST_NAME>
<SUFFIX/>
<POSITION>Research Assistant in Medical Statistics &amp; Meta-analysis</POSITION>
<EMAIL_1>Sarah.Donegan@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 7053392</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 7053364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="795C7A7F82E26AA2016E721201F60C88" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sinclair</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>sinclad@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="F8CECA1E82E26AA200FFCE219EEE489B" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Jürg</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Utzinger</LAST_NAME>
<SUFFIX/>
<POSITION>Group Leader</POSITION>
<EMAIL_1>juerg.utzinger@unibas.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology and Public Health</DEPARTMENT>
<ORGANISATION>Swiss Tropical and Public Health Institute</ORGANISATION>
<ADDRESS_1>P.O. Box CH-4002</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 61 2848129</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 2848105</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-12-10 11:11:44 +0000" MODIFIED_BY="Tony Danso-Appiah">
<UP_TO_DATE>
<DATE DAY="16" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2012-12-10 14:13:16 +0000" MODIFIED_BY="Tony Danso-Appiah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-11-06 17:34:39 +0000" MODIFIED_BY="Tony Danso-Appiah">
<DATE DAY="6" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>This review update has been prepared by new authors (Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D and Utzinger J). Each section of the review has been rewritten and updated, including the results and conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-12-10 14:13:16 +0000" MODIFIED_BY="Tony Danso-Appiah">
<DATE DAY="6" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>This is a new review with a fresh authorship team, replacing a previous version.  The previous version included 13 trials and the last search was in 2005 and only reported parasitological failure. The current version includes 52 trials, includes percentage egg reduction as an outcome, and includes new trials evaluating artesunate. All data have been re-extracted. Each section of the review has been rewritten. Results are summarized using a Summary of Findings table. Data in the intervention arm in relation to cure are explored by age.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2012-09-05 21:41:25 +0100" MODIFIED_BY="Tony Danso-Appiah">
<INTERNAL_SOURCES MODIFIED="2010-09-25 19:42:04 +0100" MODIFIED_BY="Tony Danso-Appiah">
<SOURCE MODIFIED="2010-09-25 19:42:04 +0100" MODIFIED_BY="Tony Danso-Appiah">
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-09-05 21:41:25 +0100" MODIFIED_BY="Tony Danso-Appiah">
<SOURCE MODIFIED="2010-09-25 19:43:02 +0100" MODIFIED_BY="Tony Danso-Appiah">
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-09-05 21:41:25 +0100" MODIFIED_BY="Tony Danso-Appiah">
<NAME>The World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-09-05 21:41:25 +0100" MODIFIED_BY="Tony Danso-Appiah">
<NAME>Swiss National Science Foundation (Project no PPOOB-102883, PPOOB-119129)</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-23 16:28:19 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-12-10 11:07:26 +0000" MODIFIED_BY="Tony Danso-Appiah">
<TITLE MODIFIED="2012-12-06 11:22:23 +0000" MODIFIED_BY="Anne-Marie Stephani">Drugs for treating <I>Schistosoma mansoni</I> infection</TITLE>
<SUMMARY_BODY MODIFIED="2012-12-10 11:07:26 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>
<I>Schistosoma mansoni</I> is a parasitic worm common in Africa, the Middle East and parts of South America. The worm larvae live in ponds and lakes contaminated by faeces, and can penetrate a persons&#8217; skin when they swim or bathe. Inside the host, the larvae grow into adult worms; these produce eggs, which are excreted in the faeces. Eggs rather than worms cause disease. Long-term infection can cause bloody diarrhoea, abdominal pains, and enlargement of the liver and spleen.</P>
<P>In this review, researchers in the Cochrane Collaboration evaluated drug treatments for people infected with <I>Schistosoma mansoni</I>. After searching for all relevant studies, they found 52 trials, including 10,269 people, conducted in Africa, Brazil and the Middle East. Most trials report on whether or not the treatment stops eggs excretion; three reported the persons recovery from symptoms.</P>
<P>The results show that a single dose of praziquantel (40 mg/kg), as recommended by the World Health Organization, is an effective treatment for <I>Schistosoma mansoni</I> infection. Lower doses may be less effective, and higher doses probably have no additional benefit.</P>
<P>Oxamniquine (40 mg/kg), though now rarely used, is also effective. Again, lower doses may be less effective and no advantage has been demonstrated with higher doses.</P>
<P>Only one study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg, and based on this limited evidence, we are uncertain which intervention is more effective. Adverse events were not well reported for either drug, but were mostly described as minor and transient.</P>
<P>In children aged less than 5 years, there is limited evidence that these doses may be less effective, and further research will help optimise the dose for this age-group.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-23 16:28:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<ABS_BACKGROUND MODIFIED="2012-12-10 14:11:55 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>
<I>Schistosoma mansoni </I>is a parasitic infection common in the tropics and sub-tropics. Chronic and advanced disease includes abdominal pain, diarrhoea, blood in the stool, liver cirrhosis, portal hypertension, and premature death.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-12-10 11:06:02 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating <I>S. mansoni </I>infection.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-11-06 17:52:05 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We searched MEDLINE, EMBASE and LILACS from inception to October 2012, with no language restrictions. We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2012) and mRCT. The reference lists of articles were reviewed and experts were contacted for unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-12-03 11:14:23 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Randomized controlled trials of antischistosomal drugs, used alone or in combination, versus placebo, different antischistosomal drugs, or different doses of the same antischistosomal drug for treating <I>S. mansoni</I> infection.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-12-01 18:48:05 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>One author extracted data and assessed eligibility and risk of bias in the included studies, which were independently checked by a second author. We combined dichotomous outcomes using risk ratio (RR) and continuous data weighted mean difference (WMD); we presented both with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-12-10 13:21:43 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Fifty-two trials enrolling 10,269 participants were included. The evidence was of moderate or low quality due to the trial methods and small numbers of included participants. </P>
<P>
<I>Praziquantel</I>
</P>
<P>Compared to placebo, praziquantel 40 mg/kg probably reduces parasitological treatment failure at one month post-treatment (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, <I>moderate quality evidence</I>). Compared to this standard dose, lower doses may be inferior (30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants, <I>low quality evidence</I>; 20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants, <I>low quality evidence</I>); and higher doses, up to 60 mg/kg, do not appear to show any advantage (four trials, 783 participants, <I>moderate quality evidence</I>).</P>
<P>The absolute parasitological cure rate at one month with praziquantel 40 mg/kg varied substantially across studies, ranging from 52% in Senegal in 1993 to 92% in Brazil in 2006/2007.</P>
<P>
<I>Oxamniquine</I>
</P>
<P>Compared to placebo, oxamniquine 40 mg/kg probably reduces parasitological treatment failure at three months (RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants, <I>moderate quality evidence</I>). Lower doses than 40 mg/kg may be inferior at one month (30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, <I>low quality evidence</I>; 20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants, <I>low quality evidence</I>), and higher doses, such as 60 mg/kg, do not show a consistent benefit (four trials, 317 participants, <I>low quality evidence</I>).</P>
<P>These trials are now over 20 years old and only limited information was provided on the study designs and methods.</P>
<P>
<I>Praziquantel versus oxamniquine</I>
</P>
<P>Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and we are uncertain which treatment is more effective in reducing parasitological failure (one trial, 33 participants, <I>very low quality evidence</I>). A further 10 trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any marked differences in failure rate or percent egg reduction.</P>
<P>
<I>Combination treatments</I>
</P>
<P>We are uncertain whether combining praziquantel with artesunate reduces failures compared to praziquantel alone at one month (one trial, 75 participants, <I>very low quality evidence</I>).</P>
<P>Two trials also compared combinations of praziquantel and oxamniquine in different doses, but did not find statistically significant differences in failure (two trials, 87 participants).</P>
<P>
<I>Other outcomes and analyses</I>
</P>
<P>In trials reporting clinical improvement evaluating lower doses (20 mg/kg and 30 mg/kg) against the standard 40 mg/kg for both praziquantel or oxamniquine, no dose effect was demonstrable in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly, and splenomegaly (follow up at one, three, six, 12, and 24 months; three trials, 655 participants).</P>
<P>Adverse events were not well-reported but were mostly described as minor and transient.</P>
<P>In an additional analysis of treatment failure in the treatment arm of individual studies stratified by age, failure rates with 40 mg/kg of both praziquantel and oxamniquine were higher in children.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-23 16:28:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Praziquantel 40 mg/kg as the standard treatment for <I>S. mansoni</I> infection is consistent with the evidence. Oxamniquine, a largely discarded alternative, also appears effective.</P>
<P>Further research will help find the optimal dosing regimen of both these drugs in children.</P>
<P>Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-12-10 14:43:53 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-12-10 14:11:05 +0000" MODIFIED_BY="Tony Danso-Appiah">
<CONDITION MODIFIED="2012-12-10 14:11:05 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Schistosomiasis is a parasitic blood fluke infection, of which three<I> </I>species commonly infect humans; <I>Schistosoma mansoni</I> (common in the tropics and sub-tropics), <I>S. haematobium</I> (mostly endemic in Africa and the Middle East) and <I>S. japonicum</I> (endemic in the People's Republic of China and the Philippines) (<LINK REF="REF-Engels-2002" TYPE="REFERENCE">Engels 2002</LINK>; <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-Gryseels-2006" TYPE="REFERENCE">Gryseels 2006</LINK>; <LINK REF="REF-Steinmann-2006" TYPE="REFERENCE">Steinmann 2006</LINK>; <LINK REF="REF-Utzinger-2009" TYPE="REFERENCE">Utzinger 2009</LINK>). It has been estimated that 779 million people are at risk of schistosomiasis worldwide and 207 million people may be infected (<LINK REF="REF-Steinmann-2006" TYPE="REFERENCE">Steinmann 2006</LINK>). Of these, 120 million people are estimated to be symptomatic and 20 million suffer from long-term complications (<LINK REF="REF-Chitsulo-2000" TYPE="REFERENCE">Chitsulo 2000</LINK>; <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-van-der-Werf-2003" TYPE="REFERENCE">van der Werf 2003</LINK>). In global burden of disease estimates, schistosomiasis causes 1.7 to 4.5 million disability-adjusted life years (DALYs) (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>; <LINK REF="REF-Hotez-2006" TYPE="REFERENCE">Hotez 2006</LINK>; <LINK REF="REF-Steinmann-2006" TYPE="REFERENCE">Steinmann 2006</LINK>; <LINK REF="REF-Utzinger-2009" TYPE="REFERENCE">Utzinger 2009</LINK>). Some suggest that this value may underestimate the true burden of schistosomiasis (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-van-der-Werf-2003" TYPE="REFERENCE">van der Werf 2003</LINK>; <LINK REF="REF-King-2005" TYPE="REFERENCE">King 2005</LINK>; <LINK REF="REF-King-2007" TYPE="REFERENCE">King 2007</LINK>; <LINK REF="REF-King-2008a" TYPE="REFERENCE">King 2008a</LINK>; <LINK REF="REF-King-2010" TYPE="REFERENCE">King 2010</LINK>).</P>
<P>People infected with <I>S. mansoni</I> excrete the fluke eggs in their faeces, and faecal contamination of freshwater allows these eggs to hatch into larvae (miracidia) which penetrate a specific freshwater snail (the intermediate host). Within the snail, the miracidia develop into cercariae (the infective larvae), which can penetrate a person&#8217;s skin upon contact with contaminated water bodies.</P>
<P>Following infection, the worms migrate through the human venous system, via the right chamber of the heart and the lungs, and through the mesenteric arteries and the liver via the portal vein, before finally settling in the superior mesenteric veins which drain the large intestine. Here, male and female worms mature, pair up and the female worms start to produce eggs (&#8770; 300 per day) (<LINK REF="REF-Davis-2009" TYPE="REFERENCE">Davis 2009</LINK>). An adult worm usually lives for three to five years, but some can live up to 30 years (<LINK REF="REF-Gryseels-2006" TYPE="REFERENCE">Gryseels 2006</LINK>). The eggs produced by the worms traverse the intestinal wall to be excreted in the faeces, and in the process some become trapped and initiate inflammatory reactions, which cause the underlying pathology and symptomatic illness (<LINK REF="REF-Richter-2003a" TYPE="REFERENCE">Richter 2003a</LINK>; <LINK REF="REF-King-2008b" TYPE="REFERENCE">King 2008b</LINK>). Early symptoms depend on the severity of infection (<LINK REF="STD-Gryseels-1987" TYPE="STUDY">Gryseels 1987</LINK>), and if treatment is not provided early, chronic illness and long-term serious disease can follow.</P>
<SUBSECTION>
<HEADING LEVEL="3">Symptoms and effects</HEADING>
<P>Schistosomiasis mansoni can present as an acute or chronic illness. The acute illness, or Katayama syndrome, is caused by migrating and maturing schistosomula that may result in a systemic hypersensitivity reaction characterized by fever, feeling of general discomfort (malaise), muscle pain (myalgia), fatigue, non-productive cough, diarrhoea (with or without blood), and pain in the upper right part of the abdomen just below the rib cage. Chronic and advanced disease results from the host's immune response to schistosome eggs deposited in tissues and the granulomatous reaction evoked by the antigens they secrete and is characterized by non-specific intestinal symptoms, such as abdominal pain, diarrhoea and blood in the stool (<LINK REF="REF-Gryseels-1992" TYPE="REFERENCE">Gryseels 1992</LINK>; <LINK REF="REF-Gray-2011" TYPE="REFERENCE">Gray 2011</LINK>; <LINK REF="REF-Gryseels-2012" TYPE="REFERENCE">Gryseels 2012</LINK>).</P>
<P>Inflammatory reactions in the liver lead to hepatosplenic schistosomiasis, a key feature of chronic infection, which can manifest within a couple of months for heavy infections or many years after light infections. The chronic inflammation produces fibrotic lesions, which in turn lead to liver cirrhosis that progressively occludes the portal system giving rise to portal hypertension. The portal hypertension eventually leads to enlargement of hepatic arteries, and the associated oesophageal varices may rupture with heavy blood loss, haemorrhagic shock and death. The patient may also suffer repeated episodes of variceal bleeding &#8211; the primary cause of death in hepatic schistosomiasis (<LINK REF="REF-Andersson-2007" TYPE="REFERENCE">Andersson 2007</LINK>). Severity of disease depends upon the intensity and duration of infection (<LINK REF="REF-Naus-2003" TYPE="REFERENCE">Naus 2003</LINK>), but recent evidence suggests the presence of the infection alone determines morbidity (<LINK REF="REF-King-2008a" TYPE="REFERENCE">King 2008a</LINK>).</P>
<P>
<I>S. mansoni</I> infection overlaps in distribution with <I>S. haematobium</I> in some areas of sub-Saharan Africa resulting in mixed infections (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Unlike <I>S. mansoni</I>, the main early symptoms of <I>S. haematobium</I> infection are blood in urine (haematuria) and painful urination (dysuria). Chronic and advanced disease is insidious and may result in structural damage to the bladder wall which may eventually lead to kidney failure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diagnosis</HEADING>
<P>Definitive diagnosis of <I>S. mansoni</I> infection is by microscopy for parasite eggs in the stool. Quantitative methods are recommended for epidemiological purposes because they allow estimation of intensity and evaluation of the impact of control programmes not only in terms of cure rate but also egg reduction rate (<LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-Doenhoff-2004" TYPE="REFERENCE">Doenhoff 2004</LINK>; <LINK REF="REF-Bergquist-2009" TYPE="REFERENCE">Bergquist 2009</LINK>). The Kato-Katz technique (<LINK REF="REF-Katz-1972" TYPE="REFERENCE">Katz 1972</LINK>) is the most common quantitative technique (<LINK REF="REF-Booth-2003" TYPE="REFERENCE">Booth 2003</LINK>). Recently, the FLOTAC technique has been applied for the detection and quantification of <I>S. mansoni</I> eggs in stools with promising results and hence warranting further investigation (<LINK REF="REF-Glinz-2010" TYPE="REFERENCE">Glinz 2010</LINK>).</P>
<P>Egg output can be influenced by several factors, such as day-to-day, intra-stool, and seasonal variations as well as environmental conditions (<LINK REF="REF-Braun_x002d_Munzinger-1992" TYPE="REFERENCE">Braun-Munzinger 1992</LINK>; <LINK REF="REF-Engels-1996" TYPE="REFERENCE">Engels 1996</LINK>; <LINK REF="REF-Engels-1997" TYPE="REFERENCE">Engels 1997</LINK>; <LINK REF="REF-Enk-2008" TYPE="REFERENCE">Enk 2008</LINK>). Therefore negative results following microscopic examination of a single stool are unreliable (<LINK REF="REF-de-Vlas-1992" TYPE="REFERENCE">de Vlas 1992</LINK>; <LINK REF="REF-Kongs-2001" TYPE="REFERENCE">Kongs 2001</LINK>; <LINK REF="REF-Booth-2003" TYPE="REFERENCE">Booth 2003</LINK>; <LINK REF="REF-Enk-2008" TYPE="REFERENCE">Enk 2008</LINK>), and measurement of prevalence and intensity of infection by egg count has shortcomings (<LINK REF="REF-Gryseels-1996" TYPE="REFERENCE">Gryseels 1996</LINK>; <LINK REF="REF-de-Vlas-1997" TYPE="REFERENCE">de Vlas 1997</LINK>; <LINK REF="REF-Utzinger-2001a" TYPE="REFERENCE">Utzinger 2001a</LINK>). Rectal biopsy is more sensitive than microscopy and is occasionally done when repeated stool examinations are negative for eggs. However, this method is unsuitable for use in population-based control programmes (<LINK REF="REF-Allan-2001" TYPE="REFERENCE">Allan 2001</LINK>).</P>
<P>A monoclonal antibody-based dipstick is increasingly being used for the diagnosis of the infection with promising results (<LINK REF="REF-Polman-2001" TYPE="REFERENCE">Polman 2001</LINK>; <LINK REF="REF-Legesse-2007" TYPE="REFERENCE">Legesse 2007</LINK>; <LINK REF="REF-Legesse-2008" TYPE="REFERENCE">Legesse 2008</LINK>; <LINK REF="REF-Caulibaly-2011" TYPE="REFERENCE">Caulibaly 2011</LINK>). A more specific and sensitive diagnostic technique based on polymerase chain reaction (PCR) is increasingly being used in some reference laboratories in Europe (<LINK REF="REF-Sandoval-2006" TYPE="REFERENCE">Sandoval 2006</LINK>; <LINK REF="REF-Cnops-2012" TYPE="REFERENCE">Cnops 2012</LINK>; <LINK REF="REF-Enk-2012" TYPE="REFERENCE">Enk 2012</LINK>). Ultrasound is used for diagnosing and assessing infection-related pathology (<LINK REF="REF-Hatz-1990" TYPE="REFERENCE">Hatz 1990</LINK>; <LINK REF="REF-Mohamed_x002d_Ali-1991" TYPE="REFERENCE">Mohamed-Ali 1991</LINK>; <LINK REF="REF-Doehring_x002d_Schwerdtfeger-1992" TYPE="REFERENCE">Doehring-Schwerdtfeger 1992</LINK>; <LINK REF="REF-Hatz-2001" TYPE="REFERENCE">Hatz 2001</LINK>; <LINK REF="REF-Richter-2003b" TYPE="REFERENCE">Richter 2003b</LINK>).</P>
<P>Clinically, intestinal schistosomiasis is diagnosed on the basis of presence of blood in stool, (bloody) diarrhoea, and abdominal pain, but these are non-sensitive and non-specific (<LINK REF="REF-Gryseels-1992" TYPE="REFERENCE">Gryseels 1992</LINK>; <LINK REF="REF-Utzinger-2000c" TYPE="REFERENCE">Utzinger 2000c</LINK>; <LINK REF="REF-Danso_x002d_Appiah-2004" TYPE="REFERENCE">Danso-Appiah 2004</LINK>) as diarrhoea or blood in stool can be due to other causes such as hookworm infection, dysentery and typhoid fever.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2012-12-10 13:24:40 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Schistosomiasis control measures implemented before the 1970s &#8211; when efficacious antischistosomal drugs were not available &#8211; focused mainly on interrupting transmission with molluscicides to kill the intermediate host snails (<LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-Sturrock-2001" TYPE="REFERENCE">Sturrock 2001</LINK>). The 1970s marked the turning point in schistosomiasis control when efficacious drugs that can be applied in a single oral dose were discovered, shifting the control emphasis from transmission control to chemotherapy-based morbidity control (<LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-Cioli-1995" TYPE="REFERENCE">Cioli 1995</LINK>). A body of evidence suggests that morbidity due to schistosomiasis can be prevented and pathology reversed with available antischistosomal treatments (<LINK REF="REF-Mohamed_x002d_Ali-1991" TYPE="REFERENCE">Mohamed-Ali 1991</LINK>; <LINK REF="REF-Doehring_x002d_Schwerdtfeger-1992" TYPE="REFERENCE">Doehring-Schwerdtfeger 1992</LINK>; <LINK REF="REF-Savioli-2004" TYPE="REFERENCE">Savioli 2004</LINK>; <LINK REF="REF-Zhang-2007" TYPE="REFERENCE">Zhang 2007</LINK>; <LINK REF="REF-Webster-2009" TYPE="REFERENCE">Webster 2009</LINK>; <LINK REF="REF-Koukounari-2010" TYPE="REFERENCE">Koukounari 2010</LINK>).</P>
<P>Mass drug administration, or treatment of infected individuals or entire 'at-risk' populations (eg school-aged children), usually without prior diagnosis - an approach termed 'preventive chemotherapy', is the control strategy currently pursued by the World Health Organization (WHO) and applied in many endemic countries (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). Usually, praziquantel at a single 40 mg/kg oral dose is used (<LINK REF="REF-Fenwick-2009" TYPE="REFERENCE">Fenwick 2009</LINK>), but still there are uncertainties regarding this dose. An exception is Brazil where the national policy adopted since 1995 recommends a single oral dose of 60 mg/kg for children aged between two and 15 years, and 50 mg/kg for adolescents and adults (<LINK REF="REF-Favre-2009" TYPE="REFERENCE">Favre 2009</LINK>). The recently adopted policy for schistosomiasis control in Brazil disapproves of treatment without prior diagnosis, and therefore the preventive chemotherapy strategy is no longer applied in Brazil (<LINK REF="REF-Favre-2009" TYPE="REFERENCE">Favre 2009</LINK>).</P>
<P>Oxamniquine has also been used extensively for the control of schistosomiasis mansoni in different endemic countries, most notably Brazil, where more than 12 million doses of oxamniquine have been administered by the national schistosomiasis control programme (<LINK REF="REF-Katz-2008" TYPE="REFERENCE">Katz 2008</LINK>). There are uncertainties around the standard dose of oxamniquine (<LINK REF="REF-Foster-1987" TYPE="REFERENCE">Foster 1987</LINK>; <LINK REF="REF-Cioli-1995" TYPE="REFERENCE">Cioli 1995</LINK>). Therefore, the WHO recommends total doses of 20 to 60 mg/kg (in divided doses of up to 20 mg/kg) (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>).</P>
<P>More recently, the artemisinin derivatives used in the treatment of malaria have been shown to have antischistosomal properties, particularly against the immature developing stages of the schistosome parasites (<LINK REF="REF-Borrmann-2001" TYPE="REFERENCE">Borrmann 2001</LINK>; <LINK REF="REF-Utzinger-2007" TYPE="REFERENCE">Utzinger 2007</LINK>). Praziquantel, in contrast, acts against the adult worms and the very young schistosomula just after skin penetration (<LINK REF="REF-Sabah-1986" TYPE="REFERENCE">Sabah 1986</LINK>; <LINK REF="REF-Utzinger-2007" TYPE="REFERENCE">Utzinger 2007</LINK>).</P>
<P>The current emphasis of schistosomiasis control is to reduce the burden of disease in high endemicity areas and to interrupt transmission in low endemicity areas (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Intensity of infection is highest in school-aged children and adolescents, therefore preventive chemotherapy is targeted especially to these at-risk groups (<LINK REF="REF-Magnussen-2001" TYPE="REFERENCE">Magnussen 2001</LINK>; <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-Savioli-2004" TYPE="REFERENCE">Savioli 2004</LINK>; <LINK REF="REF-Savioli-2009" TYPE="REFERENCE">Savioli 2009</LINK>).</P>
<P>The efficacy of myrrh (Mirazid) in the treatment of intestinal schistosomiasis has been evaluated in Egypt (<LINK REF="STD-Barakat-2005-EGY" TYPE="STUDY">Barakat 2005 EGY</LINK>; <LINK REF="STD-Botros-2005-EGY" TYPE="STUDY">Botros 2005 EGY</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2012-12-10 11:07:28 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Currently, entire control and treatment programmes are based on praziquantel and there is risk of drug resistance and perhaps shortages of praziquantel. There is a need to assess alternative drugs or combinations. Still there are uncertainties around effective and safe dosage of praziquantel and standard doses of oxamniquine. There are also uncertainties about adequacy of current adult doses used in children.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-12-10 11:07:30 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating <I>S. mansoni</I> infection.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-12-10 14:03:33 +0000" MODIFIED_BY="Tony Danso-Appiah">
<SELECTION_CRITERIA MODIFIED="2012-12-07 01:08:03 +0000" MODIFIED_BY="Tony Danso-Appiah">
<CRIT_STUDIES MODIFIED="2009-06-02 13:37:19 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="[Empty name]">
<P>Individuals infected with <I>S. mansoni</I> diagnosed microscopically for the presence of <I>S. mansoni</I> eggs in stool using the Kato-Katz technique (<LINK REF="REF-Katz-1972" TYPE="REFERENCE">Katz 1972</LINK>), or any other quantitative diagnostic method, such as the quantitative oogram and FLOTAC techniques.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-12-07 01:05:48 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>The following comparisons are evaluated in this review:</P>
<OL>
<LI>Antischistosomal drugs alone or in combination versus placebo;</LI>
<LI>Antischistosomal drugs alone or in combination versus a different dose of the same antischistosomal drug; and</LI>
<LI>Antischistosomal drugs alone or in combination versus different antischistosomal drugs alone or in combination.</LI>
</OL>
<P>Trials that allocated non-schistosomal drug or interventions in addition to the treatment and control of interest were eligible provided the same drug was allocated to both treatment and control groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-12-07 01:08:03 +0000" MODIFIED_BY="Tony Danso-Appiah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<UL>
<LI>Parasitological failure, defined as treated individuals who remained positive for <I>S. mansoni</I> eggs in stool using the standard Kato-Katz or other quantitative techniques (follow-up: up to one month).</LI>
<LI>Egg reduction rate, defined as percent reduction in <I>S. mansoni</I> egg count after treatment (follow-up: up to 12 months).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-12-07 01:08:03 +0000" MODIFIED_BY="Tony Danso-Appiah">
<UL>
<LI>Parasitological failure (follow-up: greater than one month).</LI>
<LI>Resolution of symptoms (eg abdominal pain, diarrhoea and bloody diarrhoea).</LI>
<LI>Resolution of pathology (eg hepatomegaly, splenomegaly, portal fibrosis, cirrhosis of the liver or colonic polyps) measured by ultrasound, by standard international classification or other standardized methods (<LINK REF="REF-CWG-1992" TYPE="REFERENCE">CWG 1992</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Non-serious adverse events.</LI>
<LI>Serious adverse events (ie any untoward medical occurrence or effect that at any dose: results in death; is life-threatening; requires hospitalisation or prolongation of existing inpatients' hospitalisation; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, under review and in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<SUBSECTION>
<HEADING LEVEL="4">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: Cochrane Infectious Diseases Group Specialized Register (October 2012); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (1966 to October 2012); EMBASE (1974 to October 2012); and LILACS (1982 to October 2012). We also searched the <I>meta</I>Register of Controlled Trials (mRCT) in October 2012 using <I>&#8217;Schisto </I>* <I>mansoni' </I>as the search term.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<SUBSECTION>
<HEADING LEVEL="4">Researchers and organizations</HEADING>
<P>We contacted individual researchers working on antischistosomal drugs, pharmaceutical industries and experts from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) for unpublished data and ongoing trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We checked the reference lists of all studies identified by the aforementioned methods for additional relevant studies.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-12-10 14:03:33 +0000" MODIFIED_BY="Tony Danso-Appiah">
<STUDY_SELECTION MODIFIED="2012-11-18 22:34:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG) Information Retrieval Specialist, searched the literature and retrieved studies using the search strategy outlined in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Anthony Danso-Appiah (ADA) screened the results to identify potentially relevant trials, obtained the full trial reports and assessed the eligibility of trials for inclusion in the review using an eligibility form based on the inclusion criteria. Jürg Utzinger (JU) independently verified the eligibility assessment results.</P>
<P>ADA contacted the authors of potentially relevant trials for clarification if eligibility was unclear. We excluded studies that did not meet our inclusion criteria and we have detailed the reasons for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. This was verified independently by JU and Piero L. Olliaro (PLO). We resolved any discrepancies through discussion between the authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-12-10 14:03:22 +0000" MODIFIED_BY="[Empty name]">
<P>ADA extracted trial characteristics such as methods, participants, interventions and outcomes, and recorded on standard forms, which were independently verified by JU. ADA and JU resolved discrepancies through discussion, and where necessary contacted a third author (PLO). ADA contacted trial authors for clarification, or insufficient or missing data when necessary.</P>
<P>We extracted the number of participants randomized and the number of patients followed-up in each treatment arm. For dichotomous outcomes, we recorded the number of participants experiencing the event in each treatment group of the trial. For continuous outcomes summarized as geometric means, we extracted means and their standard deviations (SD) on the log scale. If the data were summarized as arithmetic mean, we extracted the means and their SDs. We extracted medians or ranges when they were reported to summarize the data.</P>
<P>For each outcome, we extracted data for each follow-up time reported in the trial report.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>ADA assessed the risk of bias of each trial using The Cochrane Collaboration's risk of bias tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the assessment results were verified independently by Dave Sinclair (DS). Where information in the trial report was unclear, we attempted to contact the trial authors for clarification. We assessed the risk of bias for six domains: sequence generation, allocation concealment, blinding (investigators, outcome assessors and participants), incomplete outcome data, selective outcome reporting and other sources of bias. For each domain, we made a judgment of 'low risk' of bias, 'high risk' of bias or 'unclear'. We resolved any discrepancies by discussion between the authors.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-12-10 14:03:33 +0000" MODIFIED_BY="[Empty name]">
<P>We presented dichotomous outcomes using risk ratios (RR). Mean differences (MD) were used as the measure of effect for continuous outcomes that were summarized as arithmetic means. We used geometric mean ratios for continuous outcomes that were summarized as geometric means. We presented all results with 95% confidence intervals (CI).</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We analysed data based on the number of patients for whom an outcome was recorded (complete case analysis).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-12-07 08:38:25 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We assessed heterogeneity by inspecting the forest plots for overlapping CIs and outlying data; using the Chi<SUP>2 </SUP>test with a P value &lt; 0.1 to indicate statistically significant heterogeneity; and using the I<SUP>2 </SUP>statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-01-03 15:31:58 +0000" MODIFIED_BY="[Empty name]">
<P>We would have attempted to explore publication bias using funnel plots if there were sufficient number of trials in the comparisons.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-11-19 00:56:56 +0000" MODIFIED_BY="[Empty name]">
<P>We used <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK> to perform the statistical analyses. We stratified the analyses by: comparison; the dose of the drug; and the length of follow-up time. We used meta-analysis to combine the results across trials. When heterogeneity was detected, we used a random-effects meta-analysis approach; otherwise a fixed-effect approach was adopted. We tabulated adverse events and also data that could not be meta-analysed.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>When heterogeneity was detected, we planned to carry out subgroup analyses to explore potential causes. Subgroupings would be as follows: patient age (children versus adults); and intensity of infection (&lt; 500 eggs per gram of stool versus &gt; 500 eggs per gram of stool).</P>
<P>We conducted a subsidiary, non-randomized comparison of failure rates in children with failure rates in adults for the same drug and same dose (mg/kg) to explore issues around dose applicability in children.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-01-03 15:31:59 +0000" MODIFIED_BY="[Empty name]">
<P>Where data were sufficient we planned to conduct sensitivity analyses to assess the robustness of the results to the risk of bias components. </P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-12-10 14:43:53 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-12-10 13:26:56 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We identified 52 trials (10,269 participants) which met the inclusion criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We managed one multicentre trial carried out in Brazil, Mauritania and Tanzania as three separate trials in the analysis (<LINK REF="STD-Olliaro-2011-BRA" TYPE="STUDY">Olliaro 2011 BRA</LINK>; <LINK REF="STD-Olliaro-2011-MRT" TYPE="STUDY">Olliaro 2011 MRT</LINK>; <LINK REF="STD-Olliaro-2011-TZA" TYPE="STUDY">Olliaro 2011 TZA</LINK>), and three papers contained multiple individual studies which we again managed separately (<LINK REF="STD-de-Clarke-1976a-ZWE" TYPE="STUDY">de Clarke 1976a ZWE</LINK>; <LINK REF="STD-de-Clarke-1976b-ZWE" TYPE="STUDY">de Clarke 1976b ZWE</LINK>; <LINK REF="STD-de-Clarke-1976c-ZWE" TYPE="STUDY">de Clarke 1976c ZWE</LINK>; <LINK REF="STD-de-Clarke-1976d-ZWE" TYPE="STUDY">de Clarke 1976d ZWE</LINK>; <LINK REF="STD-Katz-1979a-BRA" TYPE="STUDY">Katz 1979a BRA</LINK>; <LINK REF="STD-Katz-1979b-BRA" TYPE="STUDY">Katz 1979b BRA</LINK>; <LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>; <LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>; <LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>).</P>
<P>Of the 52 trials we identified, 19 evaluated praziquantel, 17 evaluated oxamniquine and 12 directly compared praziquantel with oxamniquine. In addition, two compared myrrh (mirazid) with praziquantel, and two compared different brands of praziquantel.</P>
<P>Three trials assessed combination therapies: including praziquantel plus oxamniquine (<LINK REF="STD-Creasey-1986-ZWE" TYPE="STUDY">Creasey 1986 ZWE</LINK>; <LINK REF="STD-Zwingenberger-1987-BRA" TYPE="STUDY">Zwingenberger 1987 BRA</LINK>) and praziquantel plus artesunate (<LINK REF="STD-De-Clercq-2000-SEN" TYPE="STUDY">De Clercq 2000 SEN</LINK>).</P>
<P>For the two primary outcomes, 47 trials reported cure rate or failure rate, 34 trials reported egg reduction rate and 33 trials reported both outcomes. Only <LINK REF="STD-Sukwa-1993-ZMB" TYPE="STUDY">Sukwa 1993 ZMB</LINK> reported reinfection rate.</P>
<P>For secondary outcomes, five trials (<LINK REF="STD-Rugemalila-1984-TZA" TYPE="STUDY">Rugemalila 1984 TZA</LINK>; <LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>; <LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>; <LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>; <LINK REF="STD-Sukwa-1993-ZMB" TYPE="STUDY">Sukwa 1993 ZMB</LINK>) reported clinical improvement or functional indices, but we could not include <LINK REF="STD-Rugemalila-1984-TZA" TYPE="STUDY">Rugemalila 1984 TZA</LINK> and <LINK REF="STD-Sukwa-1993-ZMB" TYPE="STUDY">Sukwa 1993 ZMB</LINK> in the meta-analysis because of insufficient information. Thirty-three trials reported adverse events.</P>
<P>In the study by <LINK REF="STD-de-Jonge-1990-SDN" TYPE="STUDY">de Jonge 1990 SDN</LINK>, we excluded the two arms that received metrifonate and placebo respectively from the analysis. Also, we excluded one arm of the study by <LINK REF="STD-Ibrahim-1980-SDN" TYPE="STUDY">Ibrahim 1980 SDN</LINK> involving participants who did not have <I>S. mansoni</I> infection and also one arm each of the trials by <LINK REF="STD-Rugemalila-1984-TZA" TYPE="STUDY">Rugemalila 1984 TZA</LINK> and <LINK REF="STD-Taylor-1988-ZWE" TYPE="STUDY">Taylor 1988 ZWE</LINK> that did not receive treatment from the analysis.</P>
<P>The trial by <LINK REF="STD-Tweyongyere-2009-UGA" TYPE="STUDY">Tweyongyere 2009 UGA</LINK> assessing the effects of praziquantel was a nested cohort study within a larger mother and baby cohort study in which pregnant women found to be infected with <I>S. mansoni</I> were randomized to receive praziquantel or placebo. We obtained data on parasitological failure rate and clinical improvement from figures (<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>; <LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>; <LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>), but it was not possible to extract egg count data.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial setting and participants</HEADING>
<P>The trials were conducted in Africa (n = 36), South America (n = 15; all in Brazil) and the Middle East (n = 1). Eight trials were conducted in the late 1970s, 28 in the 1980s, seven in the 1990s and only nine since the year 2000.</P>
<P>Eighteen trials involved children, 12 trials recruited adults, and 22 recruited whole populations comprising children, adolescents and adults.</P>
<P>Seventeen trials recruited participants from the outpatient clinics, six did not specify the setting whilst one trial (<LINK REF="STD-Omer-1981-SDN" TYPE="STUDY">Omer 1981 SDN</LINK>) consisted of both participants identified in a field survey and those attending the hospital; two trials (<LINK REF="STD-Katz-1979a-BRA" TYPE="STUDY">Katz 1979a BRA</LINK>; <LINK REF="STD-Katz-1979b-BRA" TYPE="STUDY">Katz 1979b BRA</LINK>) involved military officers in a Barracks who became exposed to the infection during training and another trial (<LINK REF="STD-Ibrahim-1980-SDN" TYPE="STUDY">Ibrahim 1980 SDN</LINK>) recruited university students on campus. The remaining 25 trials recruited participants through community surveys.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-12-10 11:25:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>For risk of bias of included studies <I>see </I>the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and summary of the risk of bias graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and risk of bias summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2012-12-10 11:25:19 +0000" MODIFIED_BY="[Empty name]">
<P>We considered 16 trials as low risk of bias with regard to the generation of the randomization sequence (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). In the remaining 36 trials, the methods used to generate the sequence of allocation were not described and therefore the risk of bias is unclear.</P>
<P>Fourteen trials adequately described allocation concealment and had a low risk of bias. One trial did not conceal allocation (<LINK REF="STD-Fernandes-1986-BRA" TYPE="STUDY">Fernandes 1986 BRA</LINK>); and the methods were unclear in the remaining 37 trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty-seven trials employed blinding and stated who was blinded. However, none described the methods of blinding. Nevertheless, the studies were considered to be at low risk of bias. One trial did not employ blinding (<LINK REF="STD-Fernandes-1986-BRA" TYPE="STUDY">Fernandes 1986 BRA</LINK>) and we therefore classed it at high risk of bias; whereas in 25 trials blinding was unclear (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-11-06 17:52:06 +0000" MODIFIED_BY="[Empty name]">
<P>We considered the risk of bias for incomplete outcome data to be low in 17 trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). We deemed the risk of bias to be high in 19 trials, and in the remaining 16 trials as unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-05-09 16:44:13 +0100" MODIFIED_BY="[Empty name]">
<P>All 52 trials had low risk of selective outcome reporting (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, 42 trials were considered to be free from other biases and the level of bias was unclear in the remaining 10 trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-12-10 14:43:53 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Section 1. Monotherapies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Praziquantel</HEADING>
<P>Nineteen trials, conducted in Africa, Brazil and the Arabian Penunsula, evaluated praziquantel. Four studies compared praziquantel with placebo, and 17 trials directly compared different dosing schedules of praziquantel with the standard dose of 40 mg/kg.</P>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 1: Praziquantel versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Two trials from Kenya and Uganda used the WHO recommended dose of 40 mg/kg. Praziquantel 40 mg/kg achieved parasitological cure in 57% and 82% of the patients respectively, compared to placebo where almost all continued to excrete eggs at one to two months (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>In addition, one small trial from Brazil compared three different doses of praziquantel with placebo and presented outcomes at six and 12 months. All patients given 40 mg/kg and 60 mg/kg praziquantel achieved parasitological cure at six months, while two out of five patients given 20 mg/kg and almost all those given placebo continued to excrete eggs (one trial, 40 participants, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). At 12 months, reinfection was demonstrable in some of those given praziquantel (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). One further trial from Brazil gave 60 mg/kg praziquantel each day for three days and achieved 100% parasitological cure at six months compared to almost complete failure with placebo (one trial, 55 participants, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>None of these trials reported on percentage egg reduction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were recorded in these trials but transient dizziness and abdominal pain appeared to be more commonly reported with praziquantel than placebo (seven trials, 1255 participants, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analyses 2 and 3: Lower doses praziquantel versus 40 mg/kg</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Lower doses (20 mg/kg to 30 mg/kg) have been evaluated in Zimbabwe, Burundi, Sudan and Brazil. Compared to 40 mg/kg, parasitological failure at one month was more than double with the 20 mg/kg dose, and 50% higher with the 30 mg/kg dose (20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants; 30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Follow-up at three months (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and at six to 12 months showed a similar pattern (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>In one trial from Brazil evaluating 30 mg/kg versus 40 mg/kg, geometric mean egg reductions were high in both groups, at six months (92.5% versus 97.7%, statistical significance not reported (one trial, 138 participants, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom resolution</HEADING>
<P>One trial compared a lower dose of praziquantel at 20 mg/kg with 40 mg/kg and showed no difference in resolving symptoms at three, six, 12 and 24 months of follow-up: diarrhoea (one trial, 44 participants, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>), blood in stool (one trial, 37 participants, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>), hepatomegaly (one trial, 55 participants, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) and splenomegaly (one trial, 73 participants, <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>), except one study that showed that 40 mg/kg significantly improved abdominal pain at one month (RR 0.59, 95% CI 0.36 to 0.98, one trial, 169 participants, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Two trials compared 30 mg/kg with 40 mg/kg and did not show any difference in resolving symptoms at one, three, six, 12 and 24 months of follow-up: abdominal pain (two trials, 318 participants, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), diarrhoea (two trials, 48 participants, <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>), blood in stool (two trials, 82 participants, <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>), hepatomegaly (two trials, 109 participants, <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>) and splenomegaly (two trials, 122 participants, <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In the three trials reporting adverse events, consistent differences in frequency or severity between 20, 30 and 40 mg/kg doses have not been shown (three trials, 319 participants, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 4: Higher doses praziquantel versus 40 mg/kg</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Higher doses (50 mg/kg to 60 mg/kg) have been evaluated in Brazil (three trials), Mauritania, Senegal and Tanzania. Compared to 40 mg/kg, parasitological failure has not been shown to be improved with higher doses at one month (five trials, 783 participants, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Among participants still excreting eggs, percentage egg reductions were similar in both groups at one month (four trials, 786 participants, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>One multi-country trial reported adverse events and recorded one serious event (a seizure) with the higher dose. At the trial site in Brazil, non-severe adverse events appeared to be more common with the higher dose but this was not seen consistently at the trial sites in Mauritania or Tanzania (one trial, 653 participants, see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 5: Split dose praziquantel versus 40 mg/kg in a single dose</HEADING>
<P>Splitting 40 mg/kg into divided doses given on the same day was evaluated in the 1980s in three trials in Sudan.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>At one month, two trials did not demonstrate a statistically significant benefit with the split dose regimen compared to a single 40 mg/kg dose (two trials, 525 participants, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), but showed benefit at three months (RR 0.31, 95% CI 0.18 to 0.53, two trials, 516 participants, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>One further small trial, only reported the outcome at six months and found no difference (one trial, 64 participants, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>In the only trial reporting egg count, the mean percent reduction at one month was higher with the divided dose but statistical significance was not reported (divided dose 93.2% versus single dose 86.5%, one trial, 350 participants, <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were reported in these trials. Only one trial reported the frequency of adverse events in each treatment group (<LINK REF="STD-Kardaman-1983-SDN" TYPE="STUDY">Kardaman 1983 SDN</LINK>). Mild abdominal pain and diarrhoea were less common when the dose was given in divided doses but vomiting was more common (one trial, 350 participants, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 6: Other praziquantel dosing regimens</HEADING>
<P>Several trials from Brazil have evaluated higher praziquantel dosing regimens with 30 mg/kg to 60 mg/kg given for up to six days (see <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). It is difficult to draw conclusions from these studies as the comparator dose is also a non-standard regimen, but one trial did demonstrate improved parasitological cure rates with prolonged courses given over three to six days compared to courses lasting one day.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were reported in these trials, events were mainly transient dizziness and nausea (one trial, 79 participants, <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxamniquine</HEADING>
<P>Seventeen trials evaluated oxamniquine, with the most recent conducted in the 1980s. Oxamniquine has since fallen out of use in favour of praziquantel. Four trials compared oxamniquine with placebo and 12 trials directly compared different dosing schedules of oxamniquine in different geographical locations in Africa and Brazil. The most common comparator dose was 40 mg/kg.</P>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 7: Oxamniquine versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>In two trials in Brazil, 20 mg/kg was significantly superior to placebo at longer timepoints (RR 3.68, 95% CI 2.53 to 5.36, two trials, 146 participants, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>). In two trials from Ethiopia, oxamniquine achieved parasitological cure rates of &gt; 75% with 30, 40, and 60 mg/kg at three to four months, compared to placebo where almost all participants continued to excrete eggs (30 mg/kg: RR 4.34, 95% CI 2.47 to 7.65, two trials, 82 participants; 40 mg/kg: RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants; 60 mg/kg: RR 19.38, 95% CI 5.79 to 64.79, two trials, 89 participants; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Among those still excreting eggs at three to four months, two trials from Ethiopia reported significant reductions in egg numbers in those given oxamniquine (68.1% to 100%), compared to increases of 59 to 80.6% in the placebo groups (two trials, 227 participants, <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were reported in these trials. Dizziness was more commonly reported with oxamniquine than placebo but is described as transient, with most resolving within 24 hours (five trials, 425 participants, <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analyses 8 and 9: Lower doses oxamniquine versus 40 mg/kg</HEADING>
<P>Lower doses of oxamniquine (20 to 30 mg/kg) have been compared to 40 mg/kg in Ethiopia (two trials), Sudan (two trials), Zimbabwe (two trials), Burundi and Malawi.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Compared to 40 mg/kg, both 20 mg/kg and 30 mg/kg of oxamniquine resulted in significantly more parasitological failures at one month (20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants; 30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>), and at three to four months (20 mg/kg: RR 2.28, 95% CI 1.40 to 3.71, three trials, 209 participants; 30 mg/kg: RR 1.64, 95% CI 1.10 to 2.43, seven trials, 373 participants, <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
<P>At later time points, no statistically significant differences were shown: six months (20 mg/kg: two trials, 163 participants; 30 mg/kg: three trials, 214 participants, <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>) and 12 months (20 mg/kg: two trials, 144 participants; 30 mg/kg: one trial, 77 participants, <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Percent egg reduction was evaluated in six of these trials and both lower dose and 40 mg/kg showed a wide range of benefit at one, three and six months: lower dose (57.1% to 99%) and 40 mg/kg (42.7 to 100%) (six trials, 878 participants, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom resolution</HEADING>
<P>One trial compared a lower dose of 20 mg/kg oxamniquine with 40 mg/kg and did not find any difference between the two doses in resolving symptoms at one, three, six, 12 and 24 months of follow-up: abdominal pain (one trial, 95 participants, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>), diarrhoea (one trial, 16 participants, <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>), blood in stool (one trial, 85 participants, <LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>), hepatomegaly (one trial, 64 participants, <LINK REF="CMP-009.07" TYPE="ANALYSIS">Analysis 9.7</LINK>) and splenomegaly (one trial, 69 participants, <LINK REF="CMP-009.09" TYPE="ANALYSIS">Analysis 9.9</LINK>).</P>
<P>Also, 30 mg/kg did not show any difference statistically compared with 40 mg/kg in resolving symptoms at one, three, six, 12 and 24 months of follow-up: abdominal pain (one trial, 95 participants, <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>), diarrhoea (one trial, 15 participants, <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>), blood in stool (one trial, 41 participants, <LINK REF="CMP-009.06" TYPE="ANALYSIS">Analysis 9.6</LINK>), hepatomegaly (one trial, 51 participants, <LINK REF="CMP-009.08" TYPE="ANALYSIS">Analysis 9.8</LINK>) and splenomegaly (one trial, 54 participants, <LINK REF="CMP-009.10" TYPE="ANALYSIS">Analysis 9.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Six trials from Ethiopia (two trials), and one trial each from Malawi, Sudan, Zambia and Zimbabwe assessed adverse events and reported no serious events. Dizziness was most commonly reported, but the event rate and severity did not differ between doses (six trials, 508 participants, <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 10: Higher doses oxamniquine versus 40 mg/kg</HEADING>
<P>Higher doses of oxamniquine (50 mg/kg to 60 mg/kg) have been compared to 40 mg/kg in six trials from three countries; Sudan (three trials), Ethiopia (two trials) and Zambia (one trial).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Higher doses of oxamniquine have not shown consistent statistically significant benefits over 40 mg/kg at one month (five trials, 349 participants, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>), at three to four months (six trials, 397 participants, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>), or six months (two trials, 177 participants, <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>).</P>
<P>Losses to follow-up were high in the trial investigating 50 mg/kg, reaching 76.9% at three months, and heterogeneity between the trials was significant (I<SUP>2</SUP>= 64% to 82%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Seven trials evaluated egg count and reported a wide range of percent mean reductions among those not cured at one month (86% to 100% versus 56% to 99.1%, four trials, 561 participants, <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>), three to four months (82% to 100% versus 42% to 100%, six trials, 791 participants, <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>) and six months (62.% to 100% versus 75% to 100%, four trials, 561 participants, <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In five trials reporting adverse events, no serious events were recorded. Dizziness and nausea were most commonly reported, but these were transient and did not require additional interventions (one trial, 482 participants, <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analyses 11 and 12: Other oxamniquine dosing regimes</HEADING>
<P>Nine additional trials compared 30 mg/kg oxamniquine with higher and lower doses in Ethiopia (three trials), Zimbabwe (two trials), Burundi (one trial), Nigeria (one trial), Sudan (one trial) and Zambia (one trial).</P>
<SUBSECTION>
<HEADING LEVEL="5">Lower doses versus 30 mg/kg</HEADING>
<P>Compared to 30 mg/kg, parasitological failure was higher with 15 mg/kg to 20 mg/kg oxamniquine at one month (RR 1.77, 95% CI 1.14 to 2.74, two trials, 230 participants), and at three to four months (RR 2.16, 95% CI 1.40 to 3.32, four trials, 249 participants, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
<P>At later follow-up times, no statistically significant difference were demonstrated (six months: two trials, 179 participants; and 12 months: one trial, 95 participants, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Higher doses versus 30 mg/kg</HEADING>
<P>Compared to 30 mg/kg, 60 mg/kg oxamniquine resulted in significantly fewer parasitological failures at one month (RR 0.04, 95% CI 0.01 to 0.26, two trials, 175 participants, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>), at three to four months (RR 0.17, 95% CI 0.07 to 0.39, four trials, 265 participants, <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>) and at six months (RR 0.17, 95% CI 0.06 to 0.50, two trials, 157 participants, <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
<P>No statistically significant differences were seen between 50 mg/kg and 30 mg/kg at one month (one trial, 36 participants, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>) or at three to four months (two trials, 53 participants, <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 13: Praziquantel (40 mg/kg) versus oxamniquine</HEADING>
<P>Eleven trials from different geographical locations directly compared various doses of oxamniquine with praziquantel 40 mg/kg. Dosing schedules commonly applied across different locations are reported in <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>. The most recent trial, from Sudan, was published in 1990.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>We did not identify statistically significant differences between oxamniquine (at doses from 10 mg/kg to 60 mg/kg) and praziquantel 40 mg/kg at one month (see <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>). No difference was demonstrable at three months between 25 to 30 mg/kg (three trials, 319 participants), 40 mg/kg (one trial, 18 participants) or 50 to 60 mg/kg (one trial, 14 participants, <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>). However, 10 to 20 mg/kg of oxamniquine did result in significantly more failures (RR 3.42, 95% CI 1.10 to 10.61, two trials, 135 participants, <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>).</P>
<P>In addition, there were no differences between oxamniquine (lower or higher dose) and praziquantel (40 mg/kg) at six months (nine trials, 1167 participants, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>) or 12 months (one trial, 52 participants, <LINK REF="CMP-013.04" TYPE="ANALYSIS">Analysis 13.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Three trials from Brazil, Ethiopia and Malawi compared oxamniquine 15, 20, 30, 40, and 50 mg/kg with praziquantel 40 mg/kg and measured high percent egg reduction at one month (82.9% to 100% for oxamniquine versus 90% to 92.8% for praziquantel, two trials, 391 participants), three months (70.2% to 99.5% for oxamniquine versus 70% to 100% for praziquantel, three trials, 440 participants), six months (32.5% to 97% for oxamniquine versus 33.6% to 96.8% for praziquantel, three trials, 291 participants), and 12 months (94% for oxamniquine versus 96% for praziquantel, one trial, 91 participants, <LINK REF="CMP-013.05" TYPE="ANALYSIS">Analysis 13.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In five trials reporting from Brazil, Ethiopia, Malawi, Saudi Arabia and Tanzania that assessed adverse events, only two serious adverse events were recorded (both with oxamniquine) in two trials: one from a moderate endemicity setting in Ethiopia that used 30 mg/kg in a split dose given the same day; and one trial from Saudi Arabia that used a single dose of 25 mg/kg. No further differences were observed in the number and type of adverse events between oxamniquine and praziquantel although dizziness was recorded in excess with oxamniquine and abdominal pain with praziquantel (<LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 14: Myrrh (Mirazid) versus praziquantel</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Myrhh (Mirazid) was tested in two trials at a single daily dose of 300 mg for three days, and almost all failed treatment at three to six weeks (RR 4.08, 95% CI 2.87 to 5.78, 236 participants, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). Consequently, further investigation of this compound was abandoned.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction rate</HEADING>
<P>There were only small reductions in reported percent geometric mean egg reduction in these two studies, but they were not clinically important (<LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No trial reports adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Section 2. Combination therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 15: Praziquantel plus artesunate versus praziquantel alone</HEADING>
<P>One trial conducted from 1999 to 2000 in a high endemicity setting in Senegal evaluated artesunate plus praziquantel versus praziquantel alone.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>In this setting, parasitological failure at one month occurred in 50% of participants given praziquantel 40 mg/kg alone. The addition of artesunate 12 mg/kg given in a divided dose of 2.5 mg/kg daily for five days resulted in a lower failure rate at one month but this did not reach statistical significance (one trial, 75 participants, <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>). At three and six months no additional benefit with artesunate plus praziquantel was seen.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>Geometric mean egg reductions appear lower with combination treatment but tests of statistical significance were not reported, and the clinical relevance of this finding are unclear (one trial, 75 participants, <LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Adverse events were not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 16: Praziquantel plus oxamniquine versus praziquantel alone</HEADING>
<P>Only one trial in a high endemicity setting in Brazil published in 1987 has evaluated oxamniquine plus praziquantel versus praziquantel alone.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Compared to praziquantel alone (40 mg/kg in two divided doses on one day), a combination of oxamniquine (7.5 mg/kg) plus praziquantel (20 mg/kg) did not demonstrate any statistically significant benefits at three, six or 12 months follow-up (one trial, 52 participants, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>The combination treatment was associated with lower geometric mean egg reductions at three, six and 12 months but tests of statistical significance were not reported (one trial, 52 participants, <LINK REF="CMP-016.04" TYPE="ANALYSIS">Analysis 16.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>These were not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 17: Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</HEADING>
<P>One small trial of schoolchildren from a high endemicity setting co-endemic for <I>S. mansoni</I> and <I>S. haematobium</I> in Zimbabwe investigated different oxamniquine and praziquantel dose combinations.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>Children aged seven to 16 years and excreting more than 100 eggs per gram of stool were included in this trial. Statistically fewer failures were seen with the higher dose-combination at one month (RR 6.30, 95% CI 1.60 to 24.75, one trial, 28 participants, <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>), but not at three months (one trial, 29 participants, <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>) or six months (one trial, 20 participants, <LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction</HEADING>
<P>The percentage egg reduction also appeared to be lower in those receiving the higher dose combination but tests of statistical significance were not reported (one trial, 59 participants, <LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were recorded and the incidence of non-severe events did not differ between combinations. About 70% of children reported abdominal discomfort but these were transient and had resolved by the following day (<LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 18: Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</HEADING>
<P>One trial in Zimbabwe investigated slightly higher oxamniquine and praziquantel dose combinations. The included children had to excrete more than 100 eggs per gram of stool.</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitological failure</HEADING>
<P>A statistically significant difference was not demonstrated at one, three and six months (one trial, 48 participants, <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>, <LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>, <LINK REF="CMP-018.03" TYPE="ANALYSIS">Analysis 18.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Egg reduction rate</HEADING>
<P>Percent egg reductions were high at one, three and six months (82% to 96.1% versus 66.3% to 96.6%, one trial, 59 participants, <LINK REF="CMP-018.04" TYPE="ANALYSIS">Analysis 18.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were recorded apart from one child who reported dizziness immediately after treatment but required no further treatment (<LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Section 3. Do failure rates vary in children and adults?</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Praziquantel</HEADING>
<P>A subgroup analysis conducted in two studies from Burundi raised concern that parasitological failure following 40 mg/kg may be higher in children than in adults. The frequency of parasitological treatment failure was consistently higher in children than adults at one, three, six, and 12 months, and this was also observed for doses of 20 mg/kg and 30 mg/kg (see <LINK REF="TBL-13" TYPE="TABLE">Table 13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oxamniquine</HEADING>
<P>Similarly, a subgroup analysis of two studies from Burundi and Sudan administering oxamniquine has shown a consistent pattern of higher parasitological treatment failure in children than adults at one to 12 months (see <LINK REF="TBL-14" TYPE="TABLE">Table 14</LINK>).</P>
<P>Subgroup analysis of treatment arms receiving 40 mg/kg in the other included studies was not possible given the available data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-12-10 14:12:36 +0000" MODIFIED_BY="Tony Danso-Appiah">
<SUMMARY_OF_RESULTS MODIFIED="2012-12-10 13:31:41 +0000" MODIFIED_BY="[Empty name]">
<P>Compared to placebo, praziquantel 40 mg/kg substantially reduced parasitological treatment failure at one month post-treatment (<I>moderate quality evidence</I>). Compared to this standard dose, lower doses of 20 mg/kg and 30 mg/kg were inferior (<I>low quality evidence</I>); and higher doses, up to 60 mg/kg, have not shown any advantage (<I>moderate quality evidence</I>).</P>
<P>Compared to placebo, oxamniquine 40 mg/kg substantially reduced parasitological treatment failure at three months (<I>moderate quality evidence</I>). Lower doses than 40 mg/kg were inferior at one month (<I>low quality evidence</I>), and higher doses such as 60 mg/kg have not shown a consistent benefit (<I>low quality evidence</I>).</P>
<P>Ten trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any convincing differences in failure rate and percent egg reduction. Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and did not demonstrate a statistically significant difference in parasitological failure (<I>very low quality evidence</I>).</P>
<P>Combining praziquantel with artesunate has not been shown to have benefits in terms of failure rate compared to praziquantel alone at one month, three or six months (one trial, 75 participants, <I>very low quality evidence</I>). Two trials have also compared combinations of praziquantel and oxamniquine in different doses but did not find statistically significant differences in failure rate.</P>
<P>Compared to 40 mg/kg, no dose effect was demonstrable for clinical improvement with lower doses (20 and 30 mg/kg) of praziquantel or oxamniquine in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly, and splenomegaly at one, three, six, and 12 months, or up to two years of follow-up. Adverse events were not well reported but were mostly described as minor and transient.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-12-10 13:33:53 +0000" MODIFIED_BY="[Empty name]">
<P>For praziquantel, the evidence presented is generally supportive of the current WHO recommended dose of 40 mg/kg to treat <I>S. mansoni</I> infection (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Parasitological cure as low as 57% has been reported in Kenya in the 1990s (<LINK REF="STD-Olds-1999-KEN" TYPE="STUDY">Olds 1999 KEN</LINK>), and 52% in Senegal in 1993 (<LINK REF="STD-Guisse-1997-SEN" TYPE="STUDY">Guisse 1997 SEN</LINK>). However, higher efficacy has been seen in more recent trials; Tanzania (81%), Mauritania (95%) and Brazil (92%) in 2006/2007 (<LINK REF="STD-Olliaro-2011-BRA" TYPE="STUDY">Olliaro 2011 BRA</LINK>; <LINK REF="STD-Olliaro-2011-MRT" TYPE="STUDY">Olliaro 2011 MRT</LINK>; <LINK REF="STD-Olliaro-2011-TZA" TYPE="STUDY">Olliaro 2011 TZA</LINK>), and Uganda (87%) in 2003/2005 (<LINK REF="STD-Tweyongyere-2009-UGA" TYPE="STUDY">Tweyongyere 2009 UGA</LINK>). The lower cure rates from the earlier studies could be expected from the high endemicities where pre-treatment intensity of infection were very high (prevalence &gt; 80%) compared to the recent studies (prevalence &lt; 30%). In such situations, even at 95% efficacy, a sufficient number of surviving schistosomes would remain, causing sustained egg excretion in most of the treated participants (<LINK REF="REF-Danso_x002d_Appiah-2002" TYPE="REFERENCE">Danso-Appiah 2002</LINK>). Furthermore, as a result of intense transmission, most treated participants might have acquired large numbers of new infections just before treatment and as immature worms are less sensitive to praziquantel most would have escaped drug action and developed into egg-laying adult worms shortly after treatment to present as failures. The high diagnostic sensitivity (mostly duplicate slides from two or more consecutive stool specimens) and lower dose of praziquantel applied in the earlier studies (except <LINK REF="STD-Guisse-1997-SEN" TYPE="STUDY">Guisse 1997 SEN</LINK>) would have also contributed to the observed lower cure rates.</P>
<P>The results in this review appear to be generalizable elsewhere but it should be noted that these trials excluded preschool children under five years and concerns remain that this dose may be less effective in this group. This is because praziquantel works in synergy with host immune status (<LINK REF="REF-Sabah-1986" TYPE="REFERENCE">Sabah 1986</LINK>) and this is not yet fully developed in very young children. A subgroup analysis conducted in two studies from Burundi with praziquantel at 40 mg/kg and another two studies from Burundi and Sudan with oxamniquine 40 mg/kg raises concern as parasitological failure was consistently higher in children than in adults at one to 12 months of follow-up. This trend was also observed for doses of 20 mg/kg and 30 mg/kg for both treatments, and a higher dose (60 mg/kg) for oxamniquine.</P>
<P>Higher doses than 40 mg/kg have been national policy in Brazil since 1995: 60 mg/kg for children and 50 mg/kg for adolescents and adults. We found little direct evidence from randomized controlled trials to support or refute this as a policy. Only a single trial from Brazil reported outcomes at one month and this failed to show a statistically significant advantage with 60 mg/kg compared to 40 mg/kg, and excluded children aged less than 10 years (<LINK REF="STD-Olliaro-2011-BRA" TYPE="STUDY">Olliaro 2011 BRA</LINK>). Several further trials from Brazil have evaluated higher doses and longer regimens but these only reported outcomes at six months or beyond. These do offer some limited evidence that increasing the dose of praziquantel might have parasitological benefits.</P>
<P>There is no justification for using lower doses, even if potentially effective in morbidity control, as sub-curative doses may eventually select for drug resistant parasites (<LINK REF="REF-Doenhoff-1998" TYPE="REFERENCE">Doenhoff 1998</LINK>; <LINK REF="REF-Doenhoff-2008" TYPE="REFERENCE">Doenhoff 2008</LINK>).</P>
<P>Praziquantel is known to be less effective on immature schistosomes than adult worms (<LINK REF="REF-Sabah-1986" TYPE="REFERENCE">Sabah 1986</LINK>), and combination therapy (with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes), has potential as a future control strategy. Potential partner drugs include oxamniquine and the artemisinin derivatives. Of these, the artemisinin derivatives have been shown to be effective against immature schistosomes in laboratory studies (<LINK REF="REF-Utzinger-2001" TYPE="REFERENCE">Utzinger 2001</LINK>; <LINK REF="REF-Utzinger-2002" TYPE="REFERENCE">Utzinger 2002</LINK>; <LINK REF="REF-Utzinger-2003" TYPE="REFERENCE">Utzinger 2003</LINK>; <LINK REF="REF-Utzinger-2007" TYPE="REFERENCE">Utzinger 2007</LINK>), and there is some indirect evidence for efficacy from non-randomized studies in urinary schistosomiasis (<LINK REF="REF-De-Clercq-2002" TYPE="REFERENCE">De Clercq 2002</LINK>; <LINK REF="REF-Inyang_x002d_Etoh-2004" TYPE="REFERENCE">Inyang-Etoh 2004</LINK>; <LINK REF="REF-Boulanger-2007" TYPE="REFERENCE">Boulanger 2007</LINK>; <LINK REF="REF-Inyang_x002d_Etoh-2009" TYPE="REFERENCE">Inyang-Etoh 2009</LINK>), and from people with malaria co-infected <I>S. haematobium</I> (<LINK REF="REF-Boulanger-2007" TYPE="REFERENCE">Boulanger 2007</LINK>). However, to date only a single trial has directly evaluated praziquantel plus artesunate and no additional benefit was observed compared to praziquantel alone (<LINK REF="STD-De-Clercq-2000-SEN" TYPE="STUDY">De Clercq 2000 SEN</LINK>).</P>
<P>For oxamniquine, there is no current consensus on the optimal dosing regimen and it has largely fallen out of use in favour of praziquantel. Although the presented data are now more than 20 years old, and suffers some methodological problems, there is sufficient evidence of its efficacy against <I>S. mansoni</I> to suggest that it could be reinstated as an alternate treatment to decrease the pressure on praziquantel. However, a limitation of oxamniquine is that its effect is restricted to <I>S. mansoni </I>as this is the only species possessing the enzyme which converts oxamniquine to its active metabolite (<LINK REF="REF-Cioli-1995" TYPE="REFERENCE">Cioli 1995</LINK>). It is therefore unsuitable for use in areas where co-infection with <I>S. haematobium</I> is common.</P>
<P>The optimal dose of oxamniquine may also be 40 mg/kg but further studies are required to confirm this, preferably in direct comparison with praziquantel, and trials should include and evaluate the efficacy of this dose in young children.</P>
<P>Safety was under reported and inconsistently assessed in most of these clinical trials. Furthermore, only the few studies comparing the intervention versus placebo allow identification of potentially drug-related events. From these few studies it is therefore not possible to provide a reliable account of treatment tolerability.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-12-10 14:12:36 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of evidence was assessed using the GRADE methodology and displayed in summary of findings (SOF) tables for the main comparisons. The level of quality is judged on a 4-point scale. High quality evidence implies that level of confidence in the effect estimate is high and that further research is unnecessary. Moderate quality evidence implies lower confidence in the result and further research may have an important impact on the result. Low and very low quality evidence reflect increasing uncertainty in the result and a greater need for further research.</P>
<P>The evidence presented is generally considered to be of moderate or low quality due to concerns related to three key factors: i) the age of the trials, with the majority more than 20 years old, ii) the poor methodological reporting of many of these older trials, and iii) the number and size of the trials being small and often underpowered to reliably detect statistically significant differences. The specific reasons for downgrading the quality of the evidence are given in the footnotes to the SOF tables.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>A few minor difficulties in extracting the data from the available papers should be noted but these are unlikely to have introduced major bias into this review. For three trials (<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>; <LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>; <LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>), data on parasitological failure were obtained from figures and might not be the exact estimates. One trial (<LINK REF="STD-Sukwa-1993-ZMB" TYPE="STUDY">Sukwa 1993 ZMB</LINK>) actually reported reinfection rate but this is included in this review because this outcome is similar to failure rate. The trial by <LINK REF="STD-Tweyongyere-2009-UGA" TYPE="STUDY">Tweyongyere 2009 UGA</LINK> was a nested cohort study within a larger mother and baby cohort study in which pregnant women found to be infected with <I>S. mansoni</I> were randomized to receive praziquantel or placebo. Despite representing a special population, this is not likely to affect the validity of the results.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-09-03 12:17:15 +0100" MODIFIED_BY="[Empty name]">
<P>A non-Cochrane review compared praziquantel with placebo in two studies in Brazil and showed slightly higher cure rate with praziquantel (<LINK REF="REF-Liu-2011" TYPE="REFERENCE">Liu 2011</LINK>). The reliability of the evidence in this review cannot be established given that the two studies that assessed this outcome involved only 25 participants.</P>
<P>The effects of praziquantel and artesunate in urinary schistosomiasis due to <I>S. haematobium</I> have been evaluated in a separate Cochrane review last published in 2008. Praziquantel was found to be effective against <I>S. haematobium</I> with few adverse events, and similarly to this review there was insufficient evidence for the use of artesunate monotherapy or combination therapy (<LINK REF="REF-Danso_x002d_Appiah-2008" TYPE="REFERENCE">Danso-Appiah 2008</LINK>).</P>
<P>Limitations in the design and methodology in schistosomiasis trials identified during the earlier Cochrane review, and consequent future research needs have also been reported elsewhere (<LINK REF="REF-Danso_x002d_Appiah-2009" TYPE="REFERENCE">Danso-Appiah 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<IMPLICATIONS_PRACTICE MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>The available evidence supports single dose praziquantel at 40 mg/kg as the standard treatment for <I>S. mansoni</I> infection as recommended by the WHO.</P>
<P>Oxamniquine, a largely discarded alternative, appears efficacious and production and distribution should continue to ease selective pressure on praziquantel. However, its use should be limited to areas without <I>S. haematobium</I> co-endemicity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Further research is necessary to find the optimal dosing regimen of praziquantel and oxamniquine in children under five years, given the observational evidence that failure rates with 40 mg/kg may be higher in this age-group.</P>
<P>Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research; for example; praziquantel plus oxamniquine, praziquantel plus mefloquine, and praziquantel plus an artemisinin derivative.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-12-10 11:07:38 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>We thank Dr. Vittoria Lujte (Information Specialist) for developing the search strategy and doing the search for studies and Christianne Esparza for retrieving hard copies of published studies. We are grateful to Dr. Harriet MacLehose (former Deputy Editor), Anne-Marie Stephani (Managing Editor), Phil Hinds (Editorial Assistant &amp; Administrator), Reive Robbs (former CIDG Co-ordinator) and the entire International Health Group for their support during the preparation of this review. Our sincere thanks go to Dr Otavio Pieri and Prof Martin Meremikwu for critically reading this review and for providing useful comments, and to Dr Deirdre Walshe (Associate Editor) for drafting the plain language summary.</P>
<P>This document is funded by the UK Department for International Development (DFID) for the benefit of developing countries. . The views expressed are not necessarily those of DFID. PLO is a staff member of the WHO; the author alone is responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of WHO.</P>
<P>H. Saconato and A. Atallah prepared the original version of this review (Issue 3, 1999).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-12-03 12:47:04 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>PLO was the lead author in three of the included trials (<LINK REF="STD-Olliaro-2011-BRA" TYPE="STUDY">Olliaro 2011 BRA</LINK>; <LINK REF="STD-Olliaro-2011-MRT" TYPE="STUDY">Olliaro 2011 MRT</LINK>; <LINK REF="STD-Olliaro-2011-TZA" TYPE="STUDY">Olliaro 2011 TZA</LINK>) and helped secure additional financial support from WHO. The rest of the authors have no known conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-12-01 19:57:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>ADA, JU and PLO developed the protocol. ADA selected studies, extracted data, assessed risk of bias in the included studies, analysed the data and drafted the review. JU independently verified study selection, data extraction, risk of bias assessment, results of the analysis and edited the draft review. PLO verified study selection, risk of bias assessment and edited the draft review. SD provided statistical advice and edited the methods section. DS helped restructure the review, verified risk of bias assessment and prepared the SOF tables, which were checked by ADA. ADA, JU and PLO interpreted the data, and all authors helped with revisions following the referees' comments.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-20 18:19:51 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-12-10 14:01:12 +0000" MODIFIED_BY="Tony Danso-Appiah">
<STUDIES MODIFIED="2012-12-10 13:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<INCLUDED_STUDIES MODIFIED="2012-12-10 13:49:50 +0000" MODIFIED_BY="Tony Danso-Appiah">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdel-Rahim-1988-SDN" MODIFIED="2012-11-18 23:04:47 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Abdel Rahim 1988 SDN" YEAR="1988">
<REFERENCE MODIFIED="2010-03-11 21:21:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abdel Rahim IM, Haridi AA, Abdel-Hameed AA</AU>
<TI>Field study of different oxamniquine dose for <I>Schistosoma mansoni</I> in Gezira, Sudan</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>91</VL>
<NO>3</NO>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-18 23:04:47 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Rahim IM, Haridi AA, Abdel-Hameed AA</AU>
<TI>A field evaluation of three dose levels of oxamniquine in Gezira- Sudan</TI>
<SO>East African Medical Journal</SO>
<YR>1988</YR>
<VL>65</VL>
<NO>11</NO>
<PG>771-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Aska-1990-SAU" MODIFIED="2012-02-28 15:25:04 +0000" MODIFIED_BY="[Empty name]" NAME="Al Aska 1990 SAU" YEAR="1990">
<REFERENCE MODIFIED="2010-03-11 21:22:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Aska AK, Al-Mofleh IA, Al-Rashed R, Hafez MA, Al-Nozha M, Abu-Aisha H, et al</AU>
<TI>Praziquantel, oxamniquine, and metrifonate in the treatment of schistosomiasis in Riyadh</TI>
<SO>Annals of Saudi Medicine</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>3</NO>
<PG>296-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayele-1984-ETH" MODIFIED="2012-02-28 14:19:31 +0000" MODIFIED_BY="[Empty name]" NAME="Ayele 1984 ETH" YEAR="1984">
<REFERENCE MODIFIED="2010-03-11 21:22:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayele T</AU>
<TI>Preliminary clinical trial of oral oxamniquine in the treatment of <I>Schistosoma mansoni</I> in Ethiopia</TI>
<SO>East African Medical Journal</SO>
<YR>1984</YR>
<VL>61</VL>
<NO>8</NO>
<PG>632-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayele-1986-ETH" MODIFIED="2012-02-29 10:05:25 +0000" MODIFIED_BY="[Empty name]" NAME="Ayele 1986 ETH" YEAR="1984">
<REFERENCE MODIFIED="2010-03-11 21:23:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayele T</AU>
<TI>Preliminary clinical trial of oral oxamniquine in the treatment of <I>Schistosoma</I> <I>mansoni</I> in children in Ethiopia</TI>
<SO>East African Medical Journal</SO>
<YR>1986</YR>
<VL>63</VL>
<NO>4</NO>
<PG>291-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barakat-2005-EGY" MODIFIED="2012-02-28 15:19:36 +0000" MODIFIED_BY="[Empty name]" NAME="Barakat 2005 EGY" YEAR="2005">
<REFERENCE MODIFIED="2010-03-11 21:27:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barakat R, Elmorshedy H, Fenwick A</AU>
<TI>Efficacy of myrrh in the treatment of human schistosomiasis mansoni</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2005</YR>
<VL>73</VL>
<NO>2</NO>
<PG>365-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Botros-2005-EGY" MODIFIED="2012-11-18 23:05:24 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Botros 2005 EGY" YEAR="2005">
<REFERENCE MODIFIED="2012-11-18 23:05:24 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Botros S, Sayed H, El-Dusoki H, Sabry H, Rabie I, El-Ghannam M, et al</AU>
<TI>Efficacy of mirazid in comparison with praziquantel in Egyptian <I>Schistosoma</I> <I>mansoni</I>-infected school children and households</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2005</YR>
<VL>72</VL>
<NO>2</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branchini-1982-BRA" MODIFIED="2012-02-28 15:22:23 +0000" MODIFIED_BY="[Empty name]" NAME="Branchini 1982 BRA" YEAR="1982">
<REFERENCE MODIFIED="2010-03-11 21:30:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branchini ML, Pedro R J de, Dias LC, Deberaldini ER</AU>
<TI>Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1982</YR>
<VL>24</VL>
<NO>5</NO>
<PG>315-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creasey-1986-ZWE" MODIFIED="2012-03-01 21:38:46 +0000" MODIFIED_BY="[Empty name]" NAME="Creasey 1986 ZWE" YEAR="1986">
<REFERENCE MODIFIED="2010-03-11 21:31:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Creasey AM, Taylor P, Thomas JE</AU>
<TI>Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren</TI>
<SO>Central African Journal of Medicine</SO>
<YR>1986</YR>
<VL>32</VL>
<NO>7</NO>
<PG>165-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Cunha-1986-BRA" MODIFIED="2012-12-07 10:17:37 +0000" MODIFIED_BY="[Empty name]" NAME="da Cunha 1986 BRA" YEAR="1986">
<REFERENCE MODIFIED="2010-03-11 21:33:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>da Cunha AS, Pedrosa RC</AU>
<TI>Double-blind therapeutical evaluation based on the quantitative oogram technique, comparing praziquantel and oxamniquine in human Schistosomiasis mansoni</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1986</YR>
<VL>28</VL>
<NO>5</NO>
<PG>337-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Cunha-1987-BRA" MODIFIED="2012-12-07 10:17:49 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="da Cunha 1987 BRA" YEAR="1987">
<REFERENCE MODIFIED="2010-01-26 23:05:49 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>da Cunha AS, Cançado JR, de Rezende GL</AU>
<TI>Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>5</NO>
<PG>295-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Silva-1986-BRA" MODIFIED="2012-02-29 19:36:45 +0000" MODIFIED_BY="[Empty name]" NAME="da Silva 1986 BRA" YEAR="1986">
<REFERENCE MODIFIED="2010-03-11 21:35:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>da Silva LC, Zeitune JM, Rosa-Eid LM, Lima DM, Antonelli RH, Christo CH, et al</AU>
<TI>Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1986</YR>
<VL>28</VL>
<NO>3</NO>
<PG>174-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Clarke-1976a-ZWE" MODIFIED="2012-03-14 16:39:21 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="de Clarke 1976a ZWE" YEAR="1975">
<REFERENCE MODIFIED="2010-08-26 20:22:17 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Clarke V, Blair DM, Weber MC, Garnett PA</AU>
<TI>Dose-finding trials of oral oxamniquine in Rhodesia</TI>
<SO>South African Medical Journal</SO>
<YR>1976</YR>
<VL>50</VL>
<NO>46</NO>
<PG>1867-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Clarke-1976b-ZWE" MODIFIED="2012-02-29 19:42:24 +0000" MODIFIED_BY="[Empty name]" NAME="de Clarke 1976b ZWE" YEAR="1976">
<REFERENCE MODIFIED="2010-03-11 21:41:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Clarke V, Blair DM, Weber MC, Garnett PA</AU>
<TI>Dose-finding trials of oral oxamniquine in Rhodesia</TI>
<SO>South African Medical Journal</SO>
<YR>1976</YR>
<VL>50</VL>
<NO>46</NO>
<PG>1867-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Clarke-1976c-ZWE" MODIFIED="2012-02-29 19:42:57 +0000" MODIFIED_BY="[Empty name]" NAME="de Clarke 1976c ZWE" YEAR="1976">
<REFERENCE MODIFIED="2010-03-11 21:42:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Clarke V, Blair DM, Weber MC, Garnett PA</AU>
<TI>Dose-finding trials of oral oxamniquine in Rhodesia</TI>
<SO>South African Medical Journal</SO>
<YR>1976</YR>
<VL>50</VL>
<NO>46</NO>
<PG>1867-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Clarke-1976d-ZWE" MODIFIED="2012-02-29 19:43:28 +0000" MODIFIED_BY="[Empty name]" NAME="de Clarke 1976d ZWE" YEAR="1976">
<REFERENCE MODIFIED="2010-03-11 21:42:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Clarke V, Blair DM, Weber MC, Garnett PA</AU>
<TI>Dose-finding trials of oral oxamniquine in Rhodesia</TI>
<SO>South African Medical Journal</SO>
<YR>1976</YR>
<VL>50</VL>
<NO>46</NO>
<PG>1867-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Clercq-2000-SEN" MODIFIED="2012-11-18 23:02:30 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="De Clercq 2000 SEN" YEAR="1999">
<REFERENCE MODIFIED="2012-11-18 23:02:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Clercq D, Vercruysse J, Verle P, Kongs A, Diop M</AU>
<TI>What is the effect of combining artesunate and praziquantel in the treatment of <I>Schistosoma mansoni</I> infections?</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>10</NO>
<PG>744-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jonge-1990-SDN" MODIFIED="2012-12-10 13:37:32 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="de Jonge 1990 SDN" YEAR="1990">
<REFERENCE MODIFIED="2010-03-30 10:17:25 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doehring E, Ehrich JH, Vester U, Feldmeier H, Poggensee U, Brodehl J</AU>
<TI>Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis</TI>
<SO>Kidney International</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>3</NO>
<PG>520-5</PG>
<IDENTIFIERS MODIFIED="2010-03-30 10:17:25 +0100" MODIFIED_BY="Tony Danso-Appiah"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-10 13:37:32 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doehring E, Poggensee U, Feldmeier H</AU>
<TI>The effect of metrifonate in mixed <I>Schistosoma haematobium</I> and <I>Schistosoma mansoni </I>infections in humans</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1986</YR>
<VL>35</VL>
<NO>2</NO>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-30 10:32:37 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldmeier H, Gastl GA, Poggensee U, Kortmann C, Daffalla AA, Peter HH</AU>
<TI>Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation</TI>
<SO>Clinical and Experimental Immunology</SO>
<YR>1985</YR>
<VL>60</VL>
<NO>2</NO>
<PG>234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-18 22:37:28 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldmeier H, Nogueira-Queiroz JA, Peixoto-Queiroz MA, Doehring E, Dessaint JP, de Alencar JE, et al</AU>
<TI>Detection and quantification of circulating antigen in schistosomiasis by monoclonal antibody. II. The quantification of circulating antigens in human schistosomiasis mansoni and haematobium: relationship to intensity of infection and disease status</TI>
<SO>Clinical and Experimental Immunology</SO>
<YR>1986</YR>
<VL>65</VL>
<NO>2</NO>
<PG>232-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-30 10:16:44 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Jonge N, Schommer G, Feldmeier H, Krijger FW, Dafalla AA, Bienzle U, et al</AU>
<TI>Mixed <I>Schistosoma haematobium</I> and <I>S. mansoni</I> infection: effect of different treatments on the serum level of circulating anodic antigen (CAA)</TI>
<SO>Acta Tropica</SO>
<YR>1990</YR>
<VL>48</VL>
<NO>1</NO>
<PG>25-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-11-05 16:26:02 +0000" MODIFIED_BY="Tony Danso-Appiah"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandes-1986-BRA" MODIFIED="2012-02-29 20:38:26 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Fernandes 1986 BRA" YEAR="1986">
<REFERENCE MODIFIED="2012-02-29 20:38:26 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandes P, Oliveira CC</AU>
<TI>Efficacy of two regimes of praziquantel versus oxamniquine</TI>
<TO>Estudo comparativo da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica</TO>
<SO>Folha Medica</SO>
<YR>1986</YR>
<VL>93</VL>
<NO>5-6</NO>
<PG>389-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-2003-BRA" MODIFIED="2012-02-28 14:19:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ferrari 2003 BRA" YEAR="2003">
<REFERENCE MODIFIED="2010-03-11 21:48:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari ML, Coelho PM, Antunes CM, Tavares CA, da Cunha AS</AU>
<TI>Efficacy of oxamniquine and praziquantel in the treatment of <I>Schistosoma</I> <I>mansoni</I> infection: a controlled trial</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>3</NO>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gryseels-1989a-BDI" MODIFIED="2012-02-29 19:51:40 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 1989a BDI" YEAR="1989">
<REFERENCE MODIFIED="2010-03-11 21:49:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Nkulikyinka L</AU>
<TI>Two-year follow-up of <I>Schistosoma mansoni</I> infection and morbidity after treatment with different regimens of oxamniquine and praziquantel</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>2</NO>
<PG>219-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gryseels-1989b-BDI" MODIFIED="2012-02-29 19:52:40 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 1989b BDI" YEAR="1989">
<REFERENCE MODIFIED="2010-03-11 21:50:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Nkulikyinka L</AU>
<TI>Two-year follow-up of <I>Schistosoma mansoni</I> infection and morbidity after treatment with different regimens of oxamniquine and praziquantel</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>2</NO>
<PG>219-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gryseels-1989c-BDI" MODIFIED="2012-02-29 19:53:47 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 1989c BDI" YEAR="1989">
<REFERENCE MODIFIED="2010-03-11 21:50:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Nkulikyinka L</AU>
<TI>Two-year follow-up of <I>Schistosoma mansoni</I> infection and morbidity after treatment with different regimens of oxamniquine and praziquantel</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>2</NO>
<PG>219-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guisse-1997-SEN" MODIFIED="2012-11-18 23:06:21 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Guisse 1997 SEN" YEAR="1993">
<REFERENCE MODIFIED="2012-11-18 23:06:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, et al</AU>
<TI>Therapeutic evaluation of two different dose regimens of praziquantel in a recent <I>Schistosoma mansoni</I> focus in Northern Senegal</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>5</NO>
<PG>511-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-1984-ZMB" MODIFIED="2012-11-18 23:06:30 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Gupta 1984 ZMB" YEAR="1982">
<REFERENCE MODIFIED="2012-11-18 23:06:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta KK</AU>
<TI>
<I>Schistosoma mansoni</I> treatment with oral oxamniquine in Zambia</TI>
<SO>East African Medical Journal</SO>
<YR>1984</YR>
<VL>61</VL>
<NO>8</NO>
<PG>641-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homeida-1989-SDN" MODIFIED="2012-12-10 13:40:49 +0000" MODIFIED_BY="[Empty name]" NAME="Homeida 1989 SDN" YEAR="1989">
<REFERENCE MODIFIED="2012-12-10 13:40:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Homeida MM, Eltom IA, Sulaiman SM, Ali HM, Bennett JL</AU>
<TI>Tolerance of two brands of praziquantel</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>334</VL>
<NO>8659</NO>
<PG>391</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibrahim-1980-SDN" MODIFIED="2012-11-18 23:25:44 +0000" MODIFIED_BY="[Empty name]" NAME="Ibrahim 1980 SDN" YEAR="1980">
<REFERENCE MODIFIED="2012-11-18 23:25:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibrahim AM</AU>
<TI>Evaluation of oxamniquine in the treatment of <I>S. mansoni</I> infection among Sudanese patients</TI>
<SO>East African Medical Journal</SO>
<YR>1980</YR>
<VL>57</VL>
<NO>8</NO>
<PG>566-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaoko-1996-KEN" MODIFIED="2012-02-29 20:00:58 +0000" MODIFIED_BY="[Empty name]" NAME="Jaoko 1996 KEN" YEAR="1996">
<REFERENCE MODIFIED="2010-03-11 22:01:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaoko WG, Muchemi G, Oguya FO</AU>
<TI>Praziquantel side effects during treatment of <I>Schistosoma mansoni</I> infected pupils in Kibwezi, Kenya</TI>
<SO>East African Medical Journal</SO>
<YR>1996</YR>
<VL>73</VL>
<NO>8</NO>
<PG>499-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kardaman-1983-SDN" MODIFIED="2012-12-07 10:22:21 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Kardaman 1983 SDN" YEAR="1980">
<REFERENCE MODIFIED="2012-12-07 10:22:21 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kardaman MW, Amin MA, Fenwick A, Cheesmond AK, Dixon HG</AU>
<TI>A field trial using praziquantel (Biltricide) to treat <I>Schistosoma mansoni</I> and <I>Schistosoma haematobium</I> infection in Gezira, Sudan</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>3</NO>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kardaman-1985-SDN" MODIFIED="2012-02-29 20:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="Kardaman 1985 SDN" YEAR="1985">
<REFERENCE MODIFIED="2010-03-11 22:04:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kardaman MW, Fenwick A, el Igail AB, el Tayeb M, Daffalla AA, Dixon HG</AU>
<TI>Treatment with praziquantel of schoolchildren with concurrent <I>Schistosoma</I> <I>mansoni</I> and <I>S. haematobium</I> infections in Gezira, Sudan</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1985</YR>
<VL>88</VL>
<NO>2</NO>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1979a-BRA" MODIFIED="2012-02-29 20:06:11 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 1979a BRA" YEAR="1979">
<REFERENCE MODIFIED="2010-03-11 22:04:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N</AU>
<TI>Preliminary trials with praziquantel in human infections due to <I>Schistosoma</I> <I>mansoni</I>
</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1979</YR>
<VL>57</VL>
<NO>5</NO>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1979b-BRA" MODIFIED="2012-02-29 20:06:42 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 1979b BRA" YEAR="1979">
<REFERENCE MODIFIED="2010-03-11 22:05:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N</AU>
<TI>Preliminary trials with praziquantel in human infections due to <I>Schistosoma mansoni</I>
</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1979</YR>
<VL>57</VL>
<NO>5</NO>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1981-BRA" MODIFIED="2012-02-29 20:07:14 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 1981 BRA" YEAR="1981">
<REFERENCE MODIFIED="2010-03-11 22:07:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N</AU>
<TI>Clinical trials with praziquantel in schistosomiasis mansoni</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1981</YR>
<VL>23</VL>
<NO>2</NO>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1982-BRA" MODIFIED="2012-02-29 20:09:19 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 1982 BRA" YEAR="1982">
<REFERENCE MODIFIED="2010-03-11 22:07:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Rocha RS</AU>
<TI>Double-blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1982</YR>
<VL>24</VL>
<NO>5</NO>
<PG>310-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambertucci-1982-BRA" MODIFIED="2012-03-15 16:46:02 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Lambertucci 1982 BRA" YEAR="1979">
<REFERENCE MODIFIED="2010-03-11 22:08:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambertucci JR, Greco DB, Pedroso ER, da Costa Rocha MO, Salazar HM, de Lima DP</AU>
<TI>A double blind trial with oxamniquine in chronic schistosomiasis mansoni</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1982</YR>
<VL>76</VL>
<NO>6</NO>
<PG>751-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metwally-1995-EGY" MODIFIED="2012-02-29 20:09:55 +0000" MODIFIED_BY="[Empty name]" NAME="Metwally 1995 EGY" YEAR="1995">
<REFERENCE MODIFIED="2010-03-11 22:09:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Metwally A, Bennett J, Botros S, Ebeid F, el attar Gel D</AU>
<TI>Impact of drug dosage and brand on bioavailability and efficacy of praziquantel</TI>
<SO>Pharmacological Research</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-02 16:59:28 +0100" MODIFIED_BY="Tony Danso-Appiah"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olds-1999-KEN" MODIFIED="2012-11-18 23:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="Olds 1999 KEN" YEAR="1999">
<REFERENCE MODIFIED="2012-11-18 23:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olds GR, King CH, Hewlett J, Olveda R, Wu G, Ouma J, et al</AU>
<TI>Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>179</VL>
<NO>4</NO>
<PG>996-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olliaro-2011-BRA" MODIFIED="2012-11-18 22:31:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Olliaro 2011 BRA" YEAR="2007">
<REFERENCE MODIFIED="2012-11-18 12:09:59 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro P, Vaillant M, Belizario V, Lwambo N, Ouldabdallahi M, Pieri OS, et al</AU>
<TI>A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e1165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olliaro-2011-MRT" MODIFIED="2012-11-18 22:32:05 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Olliaro 2011 MRT" YEAR="2007">
<REFERENCE MODIFIED="2012-11-18 12:11:29 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro P, Vaillant M, Belizario V, Lwambo N, Ouldabdallahi M, Pieri OS, et al</AU>
<TI>A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e1165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olliaro-2011-TZA" MODIFIED="2012-11-18 22:32:17 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Olliaro 2011 TZA" YEAR="2007">
<REFERENCE MODIFIED="2012-11-18 12:14:08 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro P, Vaillant M, Belizario V, Lwambo N, Ouldabdallahi M, Pieri OS, et al</AU>
<TI>A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e1165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omer-1978-SDN" MODIFIED="2012-03-15 19:52:39 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Omer 1978 SDN" YEAR="1976">
<REFERENCE MODIFIED="2010-03-11 21:00:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omer AH</AU>
<TI>Oxamniquine for treating <I>Schistosoma mansoni</I> infection in Sudan</TI>
<SO>British Medical Journal</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>6131</NO>
<PG>163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omer-1981-SDN" MODIFIED="2012-03-15 20:03:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Omer 1981 SDN" YEAR="1979">
<REFERENCE MODIFIED="2010-03-11 22:11:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omer AH</AU>
<TI>Praziquantel in the treatment of mixed <I>S. haematobium</I> and <I>S. mansoni</I> infections</TI>
<SO>Arzneimittelforschung</SO>
<YR>1981</YR>
<VL>31</VL>
<NO>3a</NO>
<PG>605-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Queiroz-2010-BRA" MODIFIED="2012-11-18 23:07:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Queiroz 2010 BRA" YEAR="2002">
<REFERENCE MODIFIED="2012-11-18 23:07:07 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Queiroz LC, Drummond SC, Matos ML, Paiva MB, Batista TS, Kansaon AZ, et al</AU>
<TI>Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>4</NO>
<PG>445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rezende-1985-BRA" MODIFIED="2012-02-29 20:22:47 +0000" MODIFIED_BY="[Empty name]" NAME="Rezende 1985 BRA" YEAR="1985">
<REFERENCE MODIFIED="2010-03-11 22:19:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rezende GL de</AU>
<TI>Survey on the clinical results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of <I>S. mansoni</I> schistosomiasis</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>6</NO>
<PG>328-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rugemalila-1984-TZA" MODIFIED="2012-02-29 20:23:14 +0000" MODIFIED_BY="[Empty name]" NAME="Rugemalila 1984 TZA" YEAR="1984">
<REFERENCE MODIFIED="2010-03-11 22:15:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rugemalila JB, Asila J, Chimbe A</AU>
<TI>Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1984</YR>
<VL>87</VL>
<NO>6</NO>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shafei-1979-NGA" MODIFIED="2012-02-29 20:24:46 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Shafei 1979 NGA" YEAR="1979">
<REFERENCE MODIFIED="2010-01-26 23:49:24 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shafei AZ</AU>
<TI>A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1979</YR>
<VL>82</VL>
<NO>1</NO>
<PG>18-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stelma-1997-SEN" MODIFIED="2012-02-29 20:29:25 +0000" MODIFIED_BY="[Empty name]" NAME="Stelma 1997 SEN" YEAR="1997">
<REFERENCE MODIFIED="2010-03-11 22:15:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B</AU>
<TI>Oxamniquine cures <I>Schistosoma mansoni</I> infection in a focus in which cure rates with praziquantel are unusually low</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1</NO>
<PG>304-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sukwa-1993-ZMB" MODIFIED="2012-03-15 21:07:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Sukwa 1993 ZMB" YEAR="1991">
<REFERENCE MODIFIED="2010-03-11 22:16:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sukwa TY</AU>
<TI>A community-based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>2</NO>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taddese-1988-ETH" MODIFIED="2012-11-18 23:07:42 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Taddese 1988 ETH" YEAR="1983">
<REFERENCE MODIFIED="2012-11-18 23:07:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taddese K, Zein ZA</AU>
<TI>Comparison between the efficacy of oxamniquine and praziquantel in the treatment of <I>Schistosoma mansoni</I> infections on a sugar estate in Ethiopia</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>2</NO>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1988-ZWE" MODIFIED="2012-02-29 20:30:45 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 1988 ZWE" YEAR="1988">
<REFERENCE MODIFIED="2010-03-11 22:16:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor P, Murare HM, Manomano K</AU>
<TI>Efficacy of low doses of praziquantel for <I>Schistosoma mansoni</I> and <I>S. haematobium</I>
</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>91</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teesdale-1984-MWI" MODIFIED="2012-02-29 20:31:29 +0000" MODIFIED_BY="[Empty name]" NAME="Teesdale 1984 MWI" YEAR="1984">
<REFERENCE MODIFIED="2010-03-11 22:17:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teesdale CH, Chitsulo L, Pugh RN</AU>
<TI>Oxamniquine dosage in Malawi</TI>
<SO>East African Medical Journal</SO>
<YR>1984</YR>
<VL>61</VL>
<NO>1</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tweyongyere-2009-UGA" MODIFIED="2012-12-10 13:49:50 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Tweyongyere 2009 UGA" YEAR="2005">
<REFERENCE MODIFIED="2012-12-10 13:49:50 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tweyongyere R, Mawa PA, Emojong NO, Mpairwe H, Jones FM, Duong T, et al</AU>
<TI>Effect of praziquantel treatment of <I>Schistosoma mansoni</I> during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-18 23:08:53 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tweyongyere R, Mawa PA, Ngom-Wegi S, Ndibazza J, Duong T, Vennervald BJ, et al</AU>
<TI>Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>198</VL>
<NO>12</NO>
<PG>1870-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwingenberger-1987-BRA" MODIFIED="2012-11-18 23:08:21 +0000" MODIFIED_BY="[Empty name]" NAME="Zwingenberger 1987 BRA" YEAR="1987">
<REFERENCE MODIFIED="2012-11-18 23:08:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwingenberger K, Queiroz JA, Poggensee U, Alencar JE, Valdegunas J, Esmeralda F, et al</AU>
<TI>Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>5</NO>
<PG>305-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-12-10 13:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<STUDY DATA_SOURCE="PUB" ID="STD-Abu_x002d_Elyazeed-1997" MODIFIED="2012-11-18 23:28:00 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Abu-Elyazeed 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-11-18 23:28:00 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Elyazeed RR, Youssef FG, Merrell BR, El-Gamal RL, El-Khoby TA, Hassanein YA, et al</AU>
<TI>Praziquantel in the treatment of <I>Schistosoma mansoni</I> infection: comparison of 40 and 60 mg/kg bodyweight regimens</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>4</NO>
<PG>404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adam-2008" MODIFIED="2012-11-05 16:41:39 +0000" MODIFIED_BY="[Empty name]" NAME="Adam 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-11-05 16:41:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adam I, Elhardello OA, Elhadi MO, Abdalla E, Elmardi KA, Jansen FH</AU>
<TI>The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated <I>Plasmodium falciparum</I> malaria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>1</NO>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Almeida-2012" MODIFIED="2012-11-18 23:28:55 +0000" MODIFIED_BY="[Empty name]" NAME="Almeida 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-11-18 23:28:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almeida MCF, Lima GS, Cardoso LS, Souza RPD, Campos RA, Cruz AA, et al</AU>
<TI>The effect of antihelminthic treatment on subjects with asthma from an endemic area of schistosomiasis: A randomized, double-blinded, and placebo-controlled trial</TI>
<SO>Journal of Parasitology Research</SO>
<YR>2012</YR>
<VL>2012</VL>
<NO>296856</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Assis-1998" MODIFIED="2012-11-18 23:29:13 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Assis 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-11-18 23:29:13 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Assis AM, Barreto ML, Prado MS, Reis MG, Parraga IM, Blanton RE</AU>
<TI>
<I>Schistosoma mansoni</I> infection and nutritional status in schoolchildren: a randomized, double-blind trial in northeastern Brazil</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>6</NO>
<PG>1247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boisier-1998" MODIFIED="2012-11-18 23:29:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Boisier 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-11-18 23:29:29 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boisier P, Ramarokoto CE, Ravaoalimalala VE, Rabarijaona L, Serieye J, Roux J, et al</AU>
<TI>Reversibility of <I>Schistosoma mansoni</I>-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>4</NO>
<PG>451-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coura-1980" MODIFIED="2012-12-10 13:50:52 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Coura 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-12-10 13:50:52 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coura JR, Argento CA, Conceição MJ, Lewis EM, dos Santos ML, Magalhães P</AU>
<TI>Field experiences with oral oxamniquine in the treatment of schistosomiasis mansoni</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1980</YR>
<VL>22</VL>
<NO>1 Suppl 4</NO>
<PG>77-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Clercq-2000b" MODIFIED="2012-12-07 10:26:36 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="De Clercq 2000b" YEAR="2000">
<REFERENCE MODIFIED="2012-12-07 10:26:36 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Clercq D, Vercruysse J, Verlé P, Niasse F, Kongs A, Diop M</AU>
<TI>Efficacy of artesunate against <I>Schistosoma mansoni</I> infections in Richard Toll, Senegal</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>1</NO>
<PG>90-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doehring-1992" MODIFIED="2012-11-18 23:30:03 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Doehring 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-11-18 23:30:03 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D, Schlake J, et al</AU>
<TI>Ultrasonographical investigation of periportal fibrosis in children with <I>Schistosoma mansoni</I> infection: reversibility of morbidity twenty-three months after treatment with praziquantel</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1992</YR>
<VL>46</VL>
<NO>4</NO>
<PG>409-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eigege-2008" MODIFIED="2012-11-18 23:30:14 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Eigege 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-11-18 23:30:14 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eigege A, Pede E, Miri E, Umaru J, Ogbu Pearce P, Jinadu MY, et al</AU>
<TI>Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>2</NO>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-el-Guiniady-1994" MODIFIED="2012-11-18 23:30:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="el Guiniady 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-11-18 23:30:29 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>el Guiniady MA, el Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A</AU>
<TI>Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>6</NO>
<PG>809-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-el_x002d_Hawey-1991" MODIFIED="2012-11-18 23:31:26 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="el-Hawey 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-11-18 23:31:26 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>el-Hawey AM, Massoud AM, el-Rakieby A, Royzeik MS, Nassar MO</AU>
<TI>Study of some aspects of cell mediated immune response in bilharzial children on a field level</TI>
<SO>Journal of the Egyptian Society of Parasitology</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>2</NO>
<PG>411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friis-1997" MODIFIED="2010-08-26 21:08:23 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Friis 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-26 21:08:23 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friis H, Ndhlovu P, Mduluza T, Kaondera K, Sandström B, Michaelsen KF, et al</AU>
<TI>The impact of zinc supplementation on growth and body composition: a randomized, controlled trial among rural Zimbabwean schoolchildren</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>51</VL>
<NO>1</NO>
<PG>38-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friis-2003" MODIFIED="2012-11-18 23:31:41 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Friis 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-11-18 23:31:41 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friis H, Mwaniki D, Omondi B, Muniu E, Thiong'o F, Ouma J, et al</AU>
<TI>Effects on haemoglobin of multi-micronutrient supplementation and multi-helminth chemotherapy: a randomized, controlled trial in Kenyan school children</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>4</NO>
<PG>573-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gryseels-1987" MODIFIED="2012-11-18 23:31:55 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Gryseels 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-11-18 23:31:55 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Nkulikyinka L, Coosemans MH</AU>
<TI>Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>4</NO>
<PG>641-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homeida-1988" MODIFIED="2010-08-26 21:09:17 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Homeida 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-08-26 21:09:17 +0100" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homeida M, Abdel-Gadir AF, Cheever AW, Bennett JL, Arbab BM, Ibrahium SZ, et al</AU>
<TI>Diagnosis of pathologically confirmed Symmers' periportal fibrosis by ultrasonography: a prospective blinded study</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabatereine-2003" MODIFIED="2012-12-07 10:26:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Kabatereine 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-12-07 10:26:16 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, Madsen H, et al</AU>
<TI>Efficacy and side effects of praziquantel treatment in a highly endemic <I>Schistosoma mansoni</I> focus at Lake Albert, Uganda</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>5</NO>
<PG>599-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1973" MODIFIED="2012-12-10 13:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Katz 1973" YEAR="1973">
<REFERENCE MODIFIED="2012-12-10 13:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Pellegrino J, Grinbaum E, Chaves A, Zicker F</AU>
<TI>Preliminary clinical trials with oxamniquine, a new antischistosomal agent</TI>
<SO>Revisto do Instituto de Medecina Tropical de São Paulo</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohamed-2009" MODIFIED="2012-11-18 23:41:47 +0000" MODIFIED_BY="[Empty name]" NAME="Mohamed 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-18 23:41:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed AA, Mahgoub HM, Magzoub M, Gasim GI, Eldein WN, Ahmed AA, et al</AU>
<TI>Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of <I>Schistosoma mansoni </I>in eastern Sudan</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>10</NO>
<PG>1062-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navaratnam-2012" MODIFIED="2012-11-18 23:42:03 +0000" MODIFIED_BY="[Empty name]" NAME="Navaratnam 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-11-18 23:42:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navaratnam AMD, Sousa-Figueiredo JC, Stothard JR, Kabatereine NB, Fenwick A, Mutumba-Nakalembe MJ</AU>
<TI>Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2012</YR>
<VL>106</VL>
<NO>7</NO>
<PG>400-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obonyo-2010" MODIFIED="2012-12-07 10:27:42 +0000" MODIFIED_BY="[Empty name]" NAME="Obonyo 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-12-07 10:27:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obonyo CO, Muok MO, Mwinzi NM</AU>
<TI>Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of <I>Schistosoma mansoni</I> in Kenyan children: an open-label randomised controlled trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>9</NO>
<PG>603-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odongo_x002d_Aginya-1996" MODIFIED="2012-11-18 23:43:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Odongo-Aginya 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-11-18 23:43:11 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odongo-Aginya EI, Doehring M, Lakwo TL, Etyono S, Luyinda LB, Roth J, et al</AU>
<TI>Integrated control trial of schistosomiasis at Nakiwogo fishing village near Entebbe, Uganda</TI>
<SO>East African Medical Journal</SO>
<YR>1996</YR>
<VL>73</VL>
<NO>8</NO>
<PG>495-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-2000" MODIFIED="2012-12-07 10:59:32 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Olsen 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-12-07 10:59:32 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen A, Nawiri J, Friis H</AU>
<TI>The impact of iron supplementation on reinfection with intestinal helminths and Schistosoma mansoni in western Kenya</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>5</NO>
<PG>493-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-2003" MODIFIED="2012-11-18 23:43:41 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Olsen 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-11-18 23:43:41 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen A, Thiong'o FW, Ouma JH, Mwaniki D, Magnussen P, Michaelsen KF, et al</AU>
<TI>Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>1</NO>
<PG>109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitchford-1978" MODIFIED="2012-11-18 23:44:01 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Pitchford 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-11-18 23:44:01 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitchford RJ, Lewis M</AU>
<TI>Oxamniquine in the treatment of various schistosome infections in South Africa</TI>
<SO>South African Medical Journal</SO>
<YR>1978</YR>
<VL>53</VL>
<NO>17</NO>
<PG>677-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polderman-1988" MODIFIED="2012-11-18 23:44:14 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Polderman 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-11-18 23:44:14 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polderman AM, Gryseels B, de Caluwe P</AU>
<TI>Cure rates and egg reduction in treatment of intestinal schistosomiasis with oxamniquine and praziquantel in Maniema, Zaire</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>1</NO>
<PG>115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Utzinger-2000a" MODIFIED="2012-11-18 23:44:48 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-11-18 23:44:48 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao SH, Tanner M</AU>
<TI>Oral artemether for prevention of <I>Schistosoma mansoni</I> infection: randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9212</NO>
<PG>1320-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Utzinger-2000b" MODIFIED="2012-11-18 23:44:57 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2000b" YEAR="2000">
<REFERENCE MODIFIED="2012-11-18 23:44:57 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M</AU>
<TI>Efficacy of praziquantel against <I>Schistosoma mansoni</I> with particular consideration for intensity of infection</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>11</NO>
<PG>771-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Lieshout-1994" MODIFIED="2012-11-18 23:45:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="van Lieshout 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-11-18 23:45:08 +0000" MODIFIED_BY="Tony Danso-Appiah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Lieshout L, de Jonge N, el-Masry N, Mansour MM, Bassily S, Krijger FW, et al</AU>
<TI>Monitoring the efficacy of different doses of praziquantel by quantification of circulating antigens in serum and urine of schistosomiasis patients</TI>
<SO>Parasitology</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>Pt 5</NO>
<PG>519-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-12-10 14:01:12 +0000" MODIFIED_BY="Tony Danso-Appiah">
<ADDITIONAL_REFERENCES MODIFIED="2012-12-10 14:01:12 +0000" MODIFIED_BY="Tony Danso-Appiah">
<REFERENCE ID="REF-Allan-2001" MODIFIED="2010-08-26 21:14:39 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Allan 2001" TYPE="CORRESPONDENCE">
<AU>Allan RW</AU>
<TI>The Johns Hopkins Hospital, Department of Pathology</TI>
<SO>Johns Hopkins Microbiology Newsletter</SO>
<YR>2001;20:30</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersson-2007" MODIFIED="2010-03-11 22:20:37 +0000" MODIFIED_BY="[Empty name]" NAME="Andersson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Andersson KL, Chung RT</AU>
<TI>Hepatic schistosomiasis: Current Treatment Options</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>6</NO>
<PG>504-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergquist-2009" MODIFIED="2010-03-11 22:28:32 +0000" MODIFIED_BY="[Empty name]" NAME="Bergquist 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bergquist R, Johansen MV, Utzinger J</AU>
<TI>Diagnostic dilemmas in helminthology: what tools to use and when?</TI>
<SO>Trends in Parasitology</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>4</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Booth-2003" MODIFIED="2010-03-11 22:29:37 +0000" MODIFIED_BY="[Empty name]" NAME="Booth 2003" TYPE="JOURNAL_ARTICLE">
<AU>Booth M, Vounatsou P, N'Goran EK, Tanner M, Utzinger J</AU>
<TI>The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing <I>Schistosoma mansoni</I> and hookworm co-infections in rural Côte d'Ivoire</TI>
<SO>Parasitology</SO>
<YR>2003</YR>
<VL>127</VL>
<NO>Pt 6</NO>
<PG>525-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borrmann-2001" MODIFIED="2010-03-11 21:02:07 +0000" MODIFIED_BY="[Empty name]" NAME="Borrmann 2001" TYPE="JOURNAL_ARTICLE">
<AU>Borrmann S, Szlezák N, Faucher JF, Matsiegui PB, Neubauer R, Binder RK, et al</AU>
<TI>Artesunate and praziquantel for the treatment of <I>Schistosoma haematobium</I> infections: a double-blind, randomized, placebo-controlled study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>184</VL>
<NO>10</NO>
<PG>1363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boulanger-2007" MODIFIED="2012-12-07 11:02:24 +0000" MODIFIED_BY="[Empty name]" NAME="Boulanger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme JL, et al</AU>
<TI>Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>2</NO>
<PG>113-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun_x002d_Munzinger-1992" MODIFIED="2010-03-11 22:32:01 +0000" MODIFIED_BY="[Empty name]" NAME="Braun-Munzinger 1992" TYPE="JOURNAL_ARTICLE">
<AU>Braun-Munzinger RA, Southgate BA</AU>
<TI>Repeatability and reproducibility of egg counts of <I>Schistosoma haematobium</I> in urine</TI>
<SO>Tropical Medicine and Parasitology</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>3</NO>
<PG>149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caulibaly-2011" MODIFIED="2012-11-18 22:39:26 +0000" MODIFIED_BY="[Empty name]" NAME="Caulibaly 2011" TYPE="JOURNAL_ARTICLE">
<AU>Coulibaly JT, Knopp S, N'Guessan NA, Silué KD, Fürst T, Lohourignon LK, et al</AU>
<TI>Accuracy of urine circulating cathodic antigen (CCA) test for Schistosoma mansoni diagnosis in different settings of Côte d'Ivoire</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>11</NO>
<PG>e1384</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chitsulo-2000" MODIFIED="2009-06-16 22:07:09 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Chitsulo 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chitsulo L, Engels D, Montresor A, Savioli L</AU>
<TI>The global status of schistosomiasis and its control</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>77</VL>
<NO>1</NO>
<PG>41-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cioli-1995" MODIFIED="2009-06-16 22:09:05 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Cioli 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cioli D, Pica-Mattoccia L, Archer S</AU>
<TI>Antischistosomal drugs: past, present ... and future?</TI>
<SO>Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>68</VL>
<NO>1</NO>
<PG>35-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cnops-2012" MODIFIED="2012-11-18 22:39:40 +0000" MODIFIED_BY="[Empty name]" NAME="Cnops 2012" TYPE="JOURNAL_ARTICLE">
<AU>Cnops L, Tannich E, Polman K, Clerinx J, Van Esbroeck M</AU>
<TI>
<I>Schistosoma</I> real-time PCR as diagnostic tool for international travellers and migrants</TI>
<SO>Tropical Medical International Health</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1208-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CWG-1992" MODIFIED="2009-09-21 12:35:06 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="CWG 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cairo Working Group (CWG)</AU>
<TI>The use of diagnostic ultrasound in schistosomiasis--attempts at standardization of methodology</TI>
<SO>Acta Tropica</SO>
<YR>1992</YR>
<VL>51</VL>
<NO>1</NO>
<PG>45-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danso_x002d_Appiah-2002" MODIFIED="2012-11-18 22:40:33 +0000" MODIFIED_BY="[Empty name]" NAME="Danso-Appiah 2002" TYPE="JOURNAL_ARTICLE">
<AU>Danso-Appiah A, De Vlas SJ</AU>
<TI>Interpreting low praziquantel cure rates of <I>Schistosoma mansoni </I>infections in Senegal</TI>
<SO>Trends in Parasitology</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>3</NO>
<PG>125-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danso_x002d_Appiah-2004" MODIFIED="2010-03-11 22:37:42 +0000" MODIFIED_BY="[Empty name]" NAME="Danso-Appiah 2004" TYPE="JOURNAL_ARTICLE">
<AU>Danso-Appiah A, de Vlas SJ, Bosompem KM, Habbema JDF</AU>
<TI>Determinants of health-seeking behaviour for schistosomiasis-related symptoms in the context of integrating schistosomiasis control within the regular health services in Ghana</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>7</NO>
<PG>784&#8211;94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danso_x002d_Appiah-2008" MODIFIED="2012-11-18 22:40:49 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Danso-Appiah 2008" TYPE="COCHRANE_REVIEW">
<AU>Danso-Appiah A, Utzinger J, Liu J, Olliaro PL</AU>
<TI>Drugs for treating urinary schistosomiasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>Issue 3. Art. No: CD000053. DOI: 10.1002/14651858.CD000053.pub2</NO>
<IDENTIFIERS MODIFIED="2012-11-05 17:31:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Danso_x002d_Appiah-2009" MODIFIED="2010-05-04 13:05:23 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Danso-Appiah 2009" TYPE="JOURNAL_ARTICLE">
<AU>Danso-Appiah A, Garner P, Olliaro PL, Utzinger J</AU>
<TI>Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review</TI>
<SO>Parasitology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>13</NO>
<PG>1837-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2009" MODIFIED="2012-11-18 22:41:42 +0000" MODIFIED_BY="[Empty name]" NAME="Davis 2009" TYPE="BOOK_SECTION">
<AU>Davis A</AU>
<TI>Schistosomiasis</TI>
<TO>Section 11, Chapter 82: Helminth infections</TO>
<SO>Manson's Tropical Diseases</SO>
<YR>2009</YR>
<PG>1425-60</PG>
<EN>22nd</EN>
<PB>WB Saunders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Clercq-2002" MODIFIED="2012-11-19 00:00:57 +0000" MODIFIED_BY="[Empty name]" NAME="De Clercq 2002" TYPE="JOURNAL_ARTICLE">
<AU>De Clercq D, Vercruysse J, Kongs A, Verle P, Dompnier JP, Faye PC</AU>
<TI>Efficacy of artesunate and praziquantel in <I>Schistosoma haematobium</I> infected schoolchildren</TI>
<SO>Acta Tropica</SO>
<YR>2002</YR>
<VL>82</VL>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Vlas-1992" MODIFIED="2010-05-23 13:50:12 +0100" MODIFIED_BY="[Empty name]" NAME="de Vlas 1992" TYPE="JOURNAL_ARTICLE">
<AU>de Vlas SJ, Gryseels B</AU>
<TI>Underestimation of <I>Schistosoma mansoni</I> prevalences</TI>
<SO>Parasitology Today</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>274-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Vlas-1997" MODIFIED="2010-08-26 20:42:02 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="de Vlas 1997" TYPE="JOURNAL_ARTICLE">
<AU>de Vlas SJ, Engels D, Rabello AL, Oostburg BF, Van Lieshout L, Polderman AM, et al</AU>
<TI>Validation of a chart to estimate true <I>Schistosoma mansoni</I> prevalences from simple egg counts</TI>
<SO>Parasitology</SO>
<YR>1997</YR>
<VL>114</VL>
<NO>Pt 2</NO>
<PG>113-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doehring_x002d_Schwerdtfeger-1992" MODIFIED="2010-03-11 22:41:41 +0000" MODIFIED_BY="[Empty name]" NAME="Doehring-Schwerdtfeger 1992" TYPE="JOURNAL_ARTICLE">
<AU>Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D, Schlake J, et al</AU>
<TI>Ultrasonographical investigations of periportal fibrosis in children with <I>Schistosoma mansoni</I> infection: reversibility of morbidity twenty-three months after treatment with praziquantel</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1992</YR>
<VL>46</VL>
<PG>409-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doenhoff-1998" MODIFIED="2012-11-18 22:42:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Doenhoff 1998" TYPE="JOURNAL_ARTICLE">
<AU>Doenhoff MJ</AU>
<TI>Is schistosomacidal chemotherapy sub-curative? Implications for drug resistance</TI>
<SO>Parasitology Today</SO>
<YR>1998</YR>
<VL>14</VL>
<PG>434-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doenhoff-2004" MODIFIED="2010-03-11 22:41:55 +0000" MODIFIED_BY="[Empty name]" NAME="Doenhoff 2004" TYPE="JOURNAL_ARTICLE">
<AU>Doenhoff MJ, Chiodini PL, Hamilton JV</AU>
<TI>Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies?</TI>
<SO>Trends in Parasitology</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doenhoff-2008" MODIFIED="2010-03-11 22:42:36 +0000" MODIFIED_BY="[Empty name]" NAME="Doenhoff 2008" TYPE="JOURNAL_ARTICLE">
<AU>Doenhoff MJ, Cioli D, Utzinger J</AU>
<TI>Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>6</NO>
<PG>659-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engels-1996" MODIFIED="2010-03-11 22:42:48 +0000" MODIFIED_BY="[Empty name]" NAME="Engels 1996" TYPE="JOURNAL_ARTICLE">
<AU>Engels D, Sinzinkayo E, Gryseels B</AU>
<TI>Day-to-day egg count fluctuation in <I>Schistosoma mansoni</I> infection and its operational implications</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1996</YR>
<VL>54</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engels-1997" MODIFIED="2012-09-02 10:38:28 +0100" MODIFIED_BY="[Empty name]" NAME="Engels 1997" TYPE="JOURNAL_ARTICLE">
<AU>Engels D, Sinzinkayo E, De Vlas SJ, Gryseels B</AU>
<TI>Intraspecimen fecal egg count variation in <I>Schistosoma mansoni</I> infection</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>5</NO>
<PG>571-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engels-2002" MODIFIED="2010-03-11 22:43:24 +0000" MODIFIED_BY="[Empty name]" NAME="Engels 2002" TYPE="JOURNAL_ARTICLE">
<AU>Engels D, Chitsulo L, Montresor A, Savioli L</AU>
<TI>The global epidemiological situation of schistosomiasis and new approaches to control and research</TI>
<SO>Acta Tropica</SO>
<YR>2002</YR>
<VL>82</VL>
<NO>2</NO>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enk-2008" MODIFIED="2010-03-11 22:43:36 +0000" MODIFIED_BY="[Empty name]" NAME="Enk 2008" TYPE="JOURNAL_ARTICLE">
<AU>Enk MJ, Lima AC, Drummond SC, Schall VT, Coelho PM</AU>
<TI>The effect of the number of stool samples on the observed prevalence and the infection intensity with <I>Schistosoma mansoni</I> among a population in an area of low transmission</TI>
<SO>Acta Tropica</SO>
<YR>2008</YR>
<VL>108</VL>
<NO>2-3</NO>
<PG>222-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enk-2012" MODIFIED="2012-11-05 17:09:52 +0000" MODIFIED_BY="[Empty name]" NAME="Enk 2012" TYPE="JOURNAL_ARTICLE">
<AU>Enk MJ, Oliveira e Silva G, Rodrigues NB</AU>
<TI>Diagnostic accuracy and applicability of a PCR system for the detection of <I>Schistosoma mansoni </I>DNA in human urine samples from an endemic area</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>6</NO>
<PG>e38947</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Favre-2009" MODIFIED="2012-11-18 22:43:06 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Favre 2009" TYPE="JOURNAL_ARTICLE">
<AU>Favre TC, Pereira AP, Galvão AF, Zani LC, Barbosa CS, Pieri OS</AU>
<TI>A rationale for schistosomiasis control in elementary schools of the rainforest zone of Pernambuco, Brazil</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>3</NO>
<PG>e395.doi:10.1371/journal.pntd.0000395</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenwick-2009" MODIFIED="2010-03-11 22:45:06 +0000" MODIFIED_BY="[Empty name]" NAME="Fenwick 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, et al</AU>
<TI>The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008</TI>
<SO>Parasitology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>13</NO>
<PG>1719-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-1987" MODIFIED="2010-03-11 22:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="Foster 1987" TYPE="JOURNAL_ARTICLE">
<AU>Foster R</AU>
<TI>A review of clinical experience with oxamniquine</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>1</NO>
<PG>55-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glinz-2010" MODIFIED="2010-08-25 23:05:48 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Glinz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Glinz D, Kigbafori SD, Knopp S, Yao PK, Lohourignon LK, Steinmann P, et al</AU>
<TI>Comparison of Kato-Katz, koga agar plate, ether-concentration, and FLOTAC techniques for the diagnosis of <I>Schistosoma mansoni</I> and soil-transmitted helminths</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>7</NO>
<PG>e754</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2011" MODIFIED="2012-08-24 09:38:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gray DJ, Ross AG, Li Y-S, McManus DP</AU>
<TI>Diagnosis and management of schistosomiasis</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d2651</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryseels-1992" MODIFIED="2012-11-18 22:43:27 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Polderman AM, Engels D</AU>
<TI>Experiences with the control of schistosomiasis mansoni in two foci in central Africa</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>1992</YR>
<VL>87</VL>
<NO>Suppl 4</NO>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryseels-1996" MODIFIED="2010-03-11 22:46:38 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, de Vlas SJ</AU>
<TI>Worm burdens in schistosome infections</TI>
<SO>Parasitology Today</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryseels-2006" MODIFIED="2010-03-11 22:46:49 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B, Polman K, Clerinx J, Kestens L</AU>
<TI>Human schistosomiasis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9541</NO>
<PG>1106-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryseels-2012" MODIFIED="2012-11-18 22:43:41 +0000" MODIFIED_BY="[Empty name]" NAME="Gryseels 2012" TYPE="JOURNAL_ARTICLE">
<AU>Gryseels B</AU>
<TI>Schistosomiasis</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>2</NO>
<PG>383-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hackett-1944" MODIFIED="2010-03-30 09:47:20 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Hackett 1944" TYPE="JOURNAL_ARTICLE">
<AU>Hackett W</AU>
<TI>Spleen measurement in malaria</TI>
<SO>Journal of the Malaria Society</SO>
<YR>1944</YR>
<VL>3</VL>
<PG>121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hatz-1990" MODIFIED="2010-01-27 12:22:45 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Hatz 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hatz CF, Savioli L, Mayombana C, Dhunputh J, Kisumku UM, Tanner M</AU>
<TI>Measurement of schistosomiasis-related morbidity at community level in areas of different endemicity</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1990</YR>
<VL>68</VL>
<NO>6</NO>
<PG>777-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hatz-2001" MODIFIED="2010-03-11 22:49:09 +0000" MODIFIED_BY="[Empty name]" NAME="Hatz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hatz CF</AU>
<TI>The use of ultrasound in schistosomiasis</TI>
<SO>Advances in Parasitology</SO>
<YR>2001</YR>
<VL>48</VL>
<PG>225-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-02-29 09:32:15 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</SO>
<YR>2011</YR>
<PB>www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hotez-2006" MODIFIED="2010-01-27 12:29:18 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Hotez 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD</AU>
<TI>Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria</TI>
<SO>PLoS Medicine</SO>
<YR>2006</YR>
<VL>3</VL>
<PG>e102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inyang_x002d_Etoh-2004" MODIFIED="2012-11-18 22:44:58 +0000" MODIFIED_BY="[Empty name]" NAME="Inyang-Etoh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC</AU>
<TI>Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>5</NO>
<PG>491-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inyang_x002d_Etoh-2009" MODIFIED="2009-06-17 12:07:25 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Inyang-Etoh 2009" TYPE="JOURNAL_ARTICLE">
<AU>Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC</AU>
<TI>Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>103</VL>
<PG>38-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katz-1972" MODIFIED="2010-03-11 22:54:47 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 1972" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Chaves A, Pellegrino J</AU>
<TI>A simple device for quantitative stool thick-smear technique in <I>Schistosomiasis mansoni</I>
</TI>
<SO>Revista do Instituto de Medicina Tropical de São Paulo</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>6</NO>
<PG>397-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katz-2008" MODIFIED="2010-03-11 22:55:04 +0000" MODIFIED_BY="[Empty name]" NAME="Katz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Coelho PM</AU>
<TI>Clinical therapy of schistosomiasis mansoni: the Brazilian contribution</TI>
<SO>Acta Tropica</SO>
<YR>2008</YR>
<VL>108</VL>
<NO>2-3</NO>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2005" MODIFIED="2010-03-11 22:56:23 +0000" MODIFIED_BY="[Empty name]" NAME="King 2005" TYPE="JOURNAL_ARTICLE">
<AU>King CH, Dickman K, Tisch DJ</AU>
<TI>Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9470</NO>
<PG>1561-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2007" MODIFIED="2010-03-11 22:56:39 +0000" MODIFIED_BY="[Empty name]" NAME="King 2007" TYPE="JOURNAL_ARTICLE">
<AU>King CH</AU>
<TI>Lifting the burden of schistosomiasis--defining elements of infection-associated disease and the benefits of antiparasite treatment</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>5</NO>
<PG>653-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2008a" MODIFIED="2010-01-27 12:41:33 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="King 2008a" TYPE="JOURNAL_ARTICLE">
<AU>King CH, Bertino A-M</AU>
<TI>Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>3</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2008b" MODIFIED="2009-06-17 12:33:43 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="King 2008b" TYPE="JOURNAL_ARTICLE">
<AU>King CH, Dangerfield-Cha M</AU>
<TI>The unacknowledged impact of chronic schistosomiasis</TI>
<SO>Chronic Illness</SO>
<YR>2008</YR>
<VL>4</VL>
<PG>65-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2010" MODIFIED="2012-09-02 10:50:19 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="King 2010" TYPE="JOURNAL_ARTICLE">
<AU>King CH</AU>
<TI>Health metrics for helminthic infections</TI>
<SO>Advances in Parasitology</SO>
<YR>2010</YR>
<VL>73</VL>
<PG>51-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kongs-2001" MODIFIED="2010-03-11 22:57:21 +0000" MODIFIED_BY="[Empty name]" NAME="Kongs 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kongs A, Marks G, Verlé P, Van der Stuyft P</AU>
<TI>The unreliability of the Kato-Katz technique limits its usefulness for evaluating <I>S. mansoni</I> infections</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>3</NO>
<PG>163-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koukounari-2010" MODIFIED="2010-08-26 00:03:03 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Koukounari 2010" TYPE="JOURNAL_ARTICLE">
<AU>Koukounari A, Donnelly CA, Sacko M, Keita AD, Landoure A, Dembele R, et al</AU>
<TI>The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>1</NO>
<PG>227</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Legesse-2007" MODIFIED="2010-03-11 22:57:32 +0000" MODIFIED_BY="[Empty name]" NAME="Legesse 2007" TYPE="JOURNAL_ARTICLE">
<AU>Legesse M, Erko B</AU>
<TI>Field-based evaluation of a reagent strip test for diagnosis of <I>Schistosoma mansoni</I> by detecting circulating cathodic antigen in urine before and after chemotherapy</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>7</NO>
<PG>668-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Legesse-2008" MODIFIED="2010-03-11 22:57:43 +0000" MODIFIED_BY="[Empty name]" NAME="Legesse 2008" TYPE="JOURNAL_ARTICLE">
<AU>Legesse M, Erko B</AU>
<TI>Field-based evaluation of a reagent strip test for diagnosis of schistosomiasis mansoni by detecting circulating cathodic antigen (CCA) in urine in low endemic area in Ethiopia</TI>
<SO>Parasite</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>2</NO>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2011" MODIFIED="2012-12-10 14:00:20 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS</AU>
<TI>Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis</TI>
<SO>Parasites and Vectors</SO>
<YR>2011</YR>
<VL>4</VL>
<PG>201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magnussen-2001" MODIFIED="2012-12-10 14:00:32 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Magnussen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Magnussen P, Ndawi B, Sheshe AK, Byskov J, Mbwana K, Christensen NO</AU>
<TI>The impact of a school health programme on the prevalence and morbidity of urinary schistosomiasis in Mwera Division, Pangani District, Tanzania</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>1</NO>
<PG>58-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohamed_x002d_Ali-1991" MODIFIED="2010-03-11 23:00:05 +0000" MODIFIED_BY="[Empty name]" NAME="Mohamed-Ali 1991" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed-Ali Q, Doehring-Schwerdtfeger E, Abdel-Rahim IM, Schlake J, Kardorff R, Franke D, et al</AU>
<TI>Ultrasonographical investigations of periportal fibrosis in children with <I>Schistosoma mansoni</I> infection: reversibility of morbidity seven months after treatment with praziquantel</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>44</VL>
<PG>444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naus-2003" MODIFIED="2010-03-11 23:00:44 +0000" MODIFIED_BY="[Empty name]" NAME="Naus 2003" TYPE="JOURNAL_ARTICLE">
<AU>Naus CW, Booth M, Jones FM, Kemijumbi J, Vennervald BJ, Kariuki CH, et al</AU>
<TI>The relationship between age, sex, egg-count and specific antibody responses against <I>Schistosoma mansoni</I> antigens in a Ugandan fishing community</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>6</NO>
<PG>561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polman-2001" MODIFIED="2010-08-26 20:46:00 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Polman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Polman K, Stelma FF, de Vlas SJ, Sow S, Fathers L, Le Cessie S, et al</AU>
<TI>Dynamics of egg counts and circulating antigen levels in a recent <I>Schistosoma mansoni</I> focus in northern Senegal</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>538-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2012-11-19 00:03:42 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richter-2003a" MODIFIED="2010-08-25 23:34:15 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Richter 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Richter J</AU>
<TI>The impact of chemotherapy on morbidity due to schistosomiasis</TI>
<SO>Acta Tropica</SO>
<YR>2003</YR>
<VL>86</VL>
<NO>2-3</NO>
<PG>161-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richter-2003b" MODIFIED="2010-08-25 23:39:34 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Richter 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Richter J, Hatz C, Häussinger D</AU>
<TI>Ultrasound in tropical and parasitic diseases</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9387</NO>
<PG>900-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sabah-1986" MODIFIED="2010-01-22 16:26:32 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Sabah 1986" TYPE="JOURNAL_ARTICLE">
<AU>Sabah AA, Fletcher C, Webbe G, Doenhoff MJ</AU>
<TI>
<I>Schistosoma mansoni</I>: chemotherapy of infections of different ages</TI>
<SO>Experimental Parasitology</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>294-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandoval-2006" MODIFIED="2012-12-10 14:01:12 +0000" MODIFIED_BY="[Empty name]" NAME="Sandoval 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sandoval N, Siles-Lucas M, Pérez-Arellano JL, Carranza C, Puente S, López-Abán J, et al</AU>
<TI>A new PCR-based approach for the specific amplification of DNA from different <I>Schistosoma</I> species applicable to human urine samples</TI>
<SO>Parasitology</SO>
<YR>2006</YR>
<VL>133</VL>
<NO>Pt 5</NO>
<PG>581-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savioli-2004" MODIFIED="2010-03-11 23:03:40 +0000" MODIFIED_BY="[Empty name]" NAME="Savioli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Savioli L, Albonico M, Engels D, Montresor A</AU>
<TI>Progress in the prevention and control of schistosomiasis and soil-transmitted helminthiasis</TI>
<SO>Parasitology International</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>2</NO>
<PG>103-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savioli-2009" MODIFIED="2010-03-11 21:13:57 +0000" MODIFIED_BY="[Empty name]" NAME="Savioli 2009" TYPE="JOURNAL_ARTICLE">
<AU>Savioli L, Gabrielli AF, Montresor A, Chitsulo L, Engels D</AU>
<TI>Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54.19</TI>
<SO>Parasitology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>13</NO>
<PG>1677-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinmann-2006" MODIFIED="2012-11-19 00:50:57 +0000" MODIFIED_BY="[Empty name]" NAME="Steinmann 2006" TYPE="JOURNAL_ARTICLE">
<AU>Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J</AU>
<TI>Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>7</NO>
<PG>411-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturrock-2001" MODIFIED="2012-11-18 22:47:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Sturrock 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sturrock RF</AU>
<TI>Schistosomiasis epidemiology and control: how did we get here and where should we go?</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>Suppl</NO>
<PG>17-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teesdale-1976" MODIFIED="2012-11-18 22:47:56 +0000" MODIFIED_BY="[Empty name]" NAME="Teesdale 1976" TYPE="JOURNAL_ARTICLE">
<AU>Teesdale CH, Amin MA</AU>
<TI>A simple thick-smear technique for the diagnosis of <I>Schistosoma mansoni</I> infection</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1976</YR>
<VL>54</VL>
<NO>6</NO>
<PG>703-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2000c" MODIFIED="2012-11-18 22:48:06 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2000c" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, N'Goran EK, Ossey YA, Booth M, Traoré M, Lohourignon KL, et al</AU>
<TI>Rapid screening for <I>Schistosoma mansoni</I> in western Côte d'Ivoire using a simple school questionnaire</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2000</YR>
<VL>78</VL>
<NO>3</NO>
<PG>389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2001" MODIFIED="2012-11-19 00:04:26 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2001" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Xiao S, NGoran EK, Bergquist R, Tanner M</AU>
<TI>The potential of artemether for the control of schistosomiasis</TI>
<SO>International Journal for Parasitology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>14</NO>
<PG>1549-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2001a" MODIFIED="2010-03-11 21:15:25 +0000" MODIFIED_BY="[Empty name]" NAME="Utzinger 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Booth M, NGoran EK, Müller I, Tanner M, Lengeler C</AU>
<TI>Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of <I>Schistosoma mansoni</I> before and after treatment with praziquantel</TI>
<SO>Parasitology</SO>
<YR>2001</YR>
<VL>122</VL>
<NO>Pt 5</NO>
<PG>537-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2002" MODIFIED="2012-12-10 11:08:00 +0000" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2002" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Chollet J, Tu Z, Xiao S, Tanner M</AU>
<TI>Comparative study of the effects of artemether and artesunate on juvenile and adult <I>Schistosoma mansoni</I> in experimentally infected mice</TI>
<SO>Transactions of the Royal Society of Tropical Medicine Hygiene</SO>
<YR>2002</YR>
<VL>96</VL>
<NO>3</NO>
<PG>318&#8211;23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2003" MODIFIED="2010-05-04 12:02:51 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Utzinger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Keiser J, Xiao SH, Tanner M, Singer BH</AU>
<TI>Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2003</YR>
<VL>47</VL>
<PG>1487-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2007" MODIFIED="2010-03-11 23:06:33 +0000" MODIFIED_BY="[Empty name]" NAME="Utzinger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Xiao SH, Tanner M, Keiser J</AU>
<TI>Artemisinins for schistosomiasis and beyond</TI>
<SO>Current Opinion on Investigational Drugs</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>2</NO>
<PG>105-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Utzinger-2009" MODIFIED="2010-03-11 23:06:53 +0000" MODIFIED_BY="[Empty name]" NAME="Utzinger 2009" TYPE="JOURNAL_ARTICLE">
<AU>Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, Ornbjerg N, et al</AU>
<TI>Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution</TI>
<SO>Parasitology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>13</NO>
<PG>1859-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Werf-2003" MODIFIED="2012-11-18 22:48:38 +0000" MODIFIED_BY="[Empty name]" NAME="van der Werf 2003" TYPE="JOURNAL_ARTICLE">
<AU>van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JDF, et al</AU>
<TI>Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa</TI>
<SO>Acta Tropica</SO>
<YR>2003</YR>
<VL>86</VL>
<NO>2-3</NO>
<PG>125-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Webster-2009" MODIFIED="2010-08-25 22:53:09 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Webster 2009" TYPE="JOURNAL_ARTICLE">
<AU>Webster JP, Koukounari A, Lamberton PH, Stothard JR, Fenwick A</AU>
<TI>Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes</TI>
<SO>Parasitology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>13</NO>
<PG>1789-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1985" MODIFIED="2010-05-23 14:32:19 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1985" TYPE="CONFERENCE_PROC">
<AU>WHO</AU>
<SO>The control of schistosomiasis. Report of WHO expert committee. WHO Technical Report Series No. 728. Geneva</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2012-11-18 22:49:18 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="CONFERENCE_PROC">
<AU>WHO Expert Committee on the Control of Schistosomiasis (Geneva, Switzerland)</AU>
<TI>Prevention and Control of Schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee</TI>
<SO>WHO Technical Report Series 912</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2012-11-18 22:50:53 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="CONFERENCE_PROC">
<AU>WHO</AU>
<SO>Prevention and control of schistosomiasis and soil-transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1-57</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" MODIFIED="2010-05-23 14:33:51 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2004" TYPE="CONFERENCE_PROC">
<AU>WHO</AU>
<SO>World Health Report, World Health Organization, Geneva, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2012-11-18 22:58:19 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2006" TYPE="CONFERENCE_PROC">
<AU>WHO</AU>
<TI>Preventive Chemotherapy guidelines</TI>
<SO>Report of a WHO expert committee, World Health Organization, Geneva, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2007" MODIFIED="2012-09-02 18:13:03 +0100" MODIFIED_BY="Tony Danso-Appiah" NAME="Zhang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E, et al</AU>
<TI>Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda</TI>
<SO>BMC Medicine</SO>
<YR>2007</YR>
<VL>3</VL>
<PG>5:27</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-12-07 12:26:35 +0000" MODIFIED_BY="Tony Danso-Appiah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-12-07 12:26:35 +0000" MODIFIED_BY="Tony Danso-Appiah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-12-07 12:06:35 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:06:35 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two, three and six months, with additional examination for children at 8 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-09 20:56:14 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 296</P>
<P>Inclusion criteria: children and adults with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: modified Kato-Katz thick smear (three smears from a single stool sample)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 02:31:35 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days</P>
<P>2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days</P>
<P>3. Oxamniquine (20 mg/kg): 10 mg/kg twice daily for one day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:01:54 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 20:56:39 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence 80%)</P>
<P>Communities studied: not stated</P>
<P>Brand of drug: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:23:48 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Al-Aska-1990-SAU">
<CHAR_METHODS MODIFIED="2012-12-07 12:23:48 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 200</P>
<P>Inclusion criteria: patients aged 10 to 63 years (mean: 26 years) with chronic <I>S. mansoni</I> infection with no previous treatment history</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear, three consecutive stools plus rectal biopsy, infection intensity expressed as geometric mean egg per gram of stool (EPG)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-22 23:03:52 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Oxamniquine (25 mg/kg x 1)</P>
<P>One arm consisting of patients with <I>S. haematobium</I> was excluded from this review</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:15:43 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 23:07:57 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Saudi Arabia</P>
<P>Date of trial: not stated</P>
<P>Endemicity: hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand of drug: not stated</P>
<P>Proctoscopy was done in those patients who were suspected of having schistosomiasis, but in whom frequent stool examination yielded negative findings. Three rectal specimens obtained during proctoscopy were placed between slides and examined under a microscope. The diagnosis was positive if living ova were seen.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:07:00 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Ayele-1984-ETH">
<CHAR_METHODS MODIFIED="2012-12-07 12:07:00 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:11:00 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 65</P>
<P>Inclusion criteria: adolescents and adults aged over 15 years with a geometric mean of 200 EPG or above</P>
<P>Exclusion criteria: subjects who had a history of seizure disorder, had received antischistosomal treatment in the last six months or had received any other drugs or were pregnant or lactating</P>
<P>Diagnostic criteria: modified Kato-Katz thick smear (quantity not stated)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-09 21:02:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days</P>
<P>2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days</P>
<P>3. Oxamniquine (30 mg/kg): 15 mg/kg twice in one day</P>
<P>4. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:06:25 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 23:11:36 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Ethiopia</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: not stated</P>
<P>Brand of drug: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:07:13 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Ayele-1986-ETH">
<CHAR_METHODS MODIFIED="2012-12-07 12:07:13 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:12:43 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 162</P>
<P>Inclusion criteria: children below 15 years of age (specific age range not stated)</P>
<P>Exclusion criteria: subjects with a history of seizure disorder, geometric mean of less than 200 EPG or who had received antischistosomal treatment in the previous six months</P>
<P>Diagnostic criteria: modified Kato-Katz smear method (three daily consecutive stool samples)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-02 02:31:36 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days</P>
<P>2. Oxamniquine (40 mg/kg): 20 mg/kg twice for one day</P>
<P>3. Oxamniquine (30 mg/kg): 15 mg/kg twice for one day</P>
<P>4. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:10:02 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 20:58:44 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Ethiopia</P>
<P>Date of trial: 1984</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand of drug: Vansil</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:07:30 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Barakat-2005-EGY">
<CHAR_METHODS MODIFIED="2012-12-07 12:07:30 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three and six weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:15:01 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 104</P>
<P>Inclusion criteria: <I>S. mansoni-</I>positive individuals from a whole population</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two consecutive stools (duplicate Kato-Katz thick smear, each 41.7 mg)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-09 21:05:48 +0000" MODIFIED_BY="[Empty name]">
<P>1. Myrrh given in the form of Mirazid capsules (two capsules in three consecutive days which was repeated at three weeks time) regardless of weight or age of the patient as recommended by the manufacturer</P>
<P>2. Praziquantel (40 mg/kg, two doses given at a three-week interval)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:52:28 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 21:06:23 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Egypt</P>
<P>Date of trial: not stated</P>
<P>Endemicity: moderate (prevalence 14.5%)</P>
<P>Communities studied: one</P>
<P>Study was conducted during the transmission period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:07:50 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Botros-2005-EGY">
<CHAR_METHODS MODIFIED="2012-12-07 12:07:50 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four weeks for children and five to six weeks for adults</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 271 including 30 who did not comply fully with the treatment protocol</P>
<P>Inclusion criteria: children and adolescent aged 12 to 18 years and adults aged over 18 years who had <I>S. mansoni</I> eggs in their stool</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: standard Kato-Katz thick smear (one stool, 4 slides pre-treatment), but three consecutive stools and 4 slides per stool (post-treatment): 41.7 mg of stool</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-27 20:39:23 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Myrrh (Mirazid; 300 mg/day x 3 days)</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:58:21 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-15 09:17:54 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Egypt</P>
<P>Date of trial: not stated</P>
<P>Endemicity: moderate (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Study was conducted during period of low transmission</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:08:01 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Branchini-1982-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:08:01 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 101</P>
<P>Inclusion criteria: patients aged 10 to 65 years with chronic intestinal <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: three consecutive stool (3 slides each) from Kato-Katz and spontaneous sedimentation methods. EPG expressed as geometric mean</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 04:18:28 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (45.4 mg/kg x 1) </P>
<P>2. Oxamniquine (13.8 mg/kg x 1) </P>
<P>3. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:18:41 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate </P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 21:08:48 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand of drug: not stated</P>
<P>Chronic schistosomiasis cases were included in the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:08:19 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Creasey-1986-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:08:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 107 (59 participants were randomized into <I>S. mansoni</I> treatment and were included in this review)</P>
<P>Inclusion criteria: schoolchildren aged 7 to 16 years with both <I>S. mansoni</I> and <I>S. haematobium</I> infections</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear (three consecutive stools)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-22 23:24:14 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (8 mg/kg x 1) plus oxamniquine (4 mg/kg x 1)</P>
<P>2. Praziquantel (15 mg/kg x 1) plus oxamniquine (7.5 mg/kg x 1)</P>
<P>3. Praziquantel (20 mg/kg x 1) plus oxamniquine (10 mg/kg x 1)</P>
<P>Three arms consisting of 58 participants infected with <I>S. haematobium</I> was excluded</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:52:46 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 21:09:20 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Zimbabwe</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand of drug: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:08:28 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-da-Cunha-1986-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:08:28 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 58</P>
<P>Inclusion criteria: adolescent and adult patients aged 15 to 55 years with chronic <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: pregnant and lactating women, with associated kidney, lung, liver or heart disease, acute or sever chronic illness as well marked anaemia or nutritional deficiencies</P>
<P>Diagnostic criteria: Quantitative oogram for the estimation of number of viable eggs per gram of tissue found in rectal mucosa biopsies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-15 09:17:54 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (65 mg/kg x 1)</P>
<P>2. Oxamniquine (18 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:21:59 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Adverse events</P>
<P>2. Cure rate</P>
<P>3. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 20:16:52 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand of drug: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:08:52 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-da-Cunha-1987-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:08:52 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: two, four and six months, but only six months follow-up was used in the analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 80</P>
<P>Inclusion criteria: adolescent and adults patients aged 15 to 55 years with no previous antischistosomal treatment who were infected with <I>S. mansoni</I>
</P>
<P>Exclusion criteria: children, elderly patients, patients with concomitant acute or serious chronic disease, severe anaemia or nutritional deficiency, pregnant and lactating women, with associated kidney, lung, liver or heart disease</P>
<P>Diagnostic criteria: Quantitative oogram for the estimation of number of viable eggs per gram of tissue found in rectal mucosa biopsies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-22 23:26:32 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (60 mg/kg, given as 30 mg/kg x 2 for 1 day)</P>
<P>2. Praziquantel (120 mg/kg, given as 30 mg/kg x 2 for 2 days)</P>
<P>3. Praziquantel (180 mg/kg, given as 30 mg/kg x 2 for 3 days)</P>
<P>4. Praziquantel (180 mg/kg, given as 30 mg/kg x 1 for 6 days)</P>
<P>Divided doses were given 4 hours apart</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:02:12 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Adverse events</P>
<P>2. Cure rate</P>
<P>3. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 21:13:04 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand: not stated</P>
<P>All patients lived away from endemic areas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:10:32 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-da-Silva-1986-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:09:13 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:28:08 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 120</P>
<P>Inclusion criteria: patients with chronic intestinal or hepato-intestinal <I>S. mansoni</I> infection aged over 14 years</P>
<P>Exclusion criteria: clinical form (hepatosplenic cases), patients with associated acute and/or serious disease, pregnant women and those treated in the past six months with antischistosomal drug</P>
<P>Diagnostic criteria: Kato-Katz smear (three slides of three consecutive stools)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-11 15:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (15 mg/kg)</P>
<P>2. Praziquantel (55 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:26:27 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Adverse events</P>
<P>2. Cure rate</P>
<P>3. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-07 12:10:32 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand: not stated</P>
<P>Efficacy assessment was based on only those who finished three negative post treatment parasitological follow-up (one, three and six months)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:10:42 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:10:42 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:33:39 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 30</P>
<P>Inclusion criteria: individuals aged over 5 years who presented with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two stools on two consecutive days using the following three methods: sedimentation, hatching and Visser and Pitchford method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 14:32:17 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (15 mg/kg x 1)</P>
<P>2. Oxamniquine (20 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-21 14:18:44 +0000" MODIFIED_BY="[Empty name]">
<P>1. Failure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Zimbabwe</P>
<P>Date of trial: 1972 to 1975</P>
<P>Endemicity: N/A; referral cases</P>
<P>Communities studied: patients referred to the Blair Research Laboratory</P>
<P>Brand: not stated</P>
<P>As far as possible those infected with both <I>S. haematobium</I> and <I>S. mansoni</I> were included in the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:10:56 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:10:56 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 26</P>
<P>Inclusion criteria: individuals aged over 5 years who presented with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two stools on two consecutive days using the following three methods: sedimentation, hatching and Visser and Pitchford method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-10 20:25:31 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (20 mg/kg): 5 x 2 mg/kg daily for 2 days</P>
<P>2. Oxamniquine (30 mg/kg): 7.5 mg/kg x 2 daily for 2 days</P>
<P>3. Oxamniquine (40 mg/kg): 10 x 2 mg/kg daily for 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:19:15 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 23:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Zimbabwe</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; referral cases</P>
<P>Communities studied: patients referred to the Blair Research Laboratory</P>
<P>Brand: not stated</P>
<P>As far as possible those infected with both <I>S. haematobium</I> and <I>S. mansoni</I> were included in the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:11:07 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:11:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:35:11 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 30</P>
<P>Inclusion criteria: individuals aged over 5 years who presented with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two stools on two consecutive days using the following three methods: sedimentation, hatching and Visser and Pitchford method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-10 20:27:19 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (60 mg/kg): 15 x 2 mg/kg daily for 2 days</P>
<P>2. Oxamniquine (50 mg/kg): 12.5 x 2 mg/kg daily for 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-21 14:21:09 +0000" MODIFIED_BY="[Empty name]">
<P>1. Failure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 23:37:58 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Zimbabwe</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; referral cases</P>
<P>Communities studied: patients referred to the Blair Research Laboratory</P>
<P>Brand: not stated</P>
<P>As far as possible those infected with both <I>S. haematobium</I> and <I>S. mansoni</I> were included in the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:11:18 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:11:18 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: four months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:36:14 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomized: 45</P>
<P>Inclusion criteria: individuals aged over 5 years who presented with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two stools on two consecutive days using the following three methods: sedimentation, hatching and Visser and Pitchford method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-10 20:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (50 mg/kg): 12.5 x 2 mg/kg daily for 2 days</P>
<P>2. Oxamniquine (30 mg/kg): 15 x 2 mg/kg in a single day</P>
<P>3. Oxamniquine (30 mg/kg): 10 x 3 mg/kg in a single day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-21 14:21:52 +0000" MODIFIED_BY="[Empty name]">
<P>1. Failure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-22 23:37:47 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Zimbabwe</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; referral cases</P>
<P>Communities studied: patients referred to the Blair Research Laboratory</P>
<P>Brand: not stated</P>
<P>As far as possible those infected with both <I>S. haematobium</I> and <I>S. mansoni</I> were included in the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:11:47 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-De-Clercq-2000-SEN">
<CHAR_METHODS MODIFIED="2012-12-07 12:11:47 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: five, 12 and 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-22 23:43:03 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 110</P>
<P>Inclusion criteria: individuals positive for <I>S. mansoni</I>
</P>
<P>Exclusion criteria: children under 1 year, pregnant women and severely ill patients were excluded if they were receiving medication for any other infection or if they had received medication for schistosomiasis within the preceding six months</P>
<P>Diagnostic criteria: single stool (duplicate Kato-Katz thick smear)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-15 09:17:55 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Artesunate (12 mg/kg): 2.4 mg/kg x 5</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
<P>3. Artesunate (12 mg/kg: 2.4 mg/kg x 5) plus praziquantel (40 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:37:14 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Senegal</P>
<P>Date of trial: 1999 to 2000</P>
<P>Endemicity: high (prevalence 60%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Compliance with the 5-day regimen of artesunate was excellent; all completed this regime</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:12:06 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-de-Jonge-1990-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:12:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one month</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 182 (123 participants were included in the analysis)</P>
<P>Inclusion criteria: boys aged 6 to 13 years having both <I>S. haematobium</I> and <I>S. mansoni</I> infections</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: three consecutive stools and three slides each of modified Kato-Katz thick smear technique (Teesdale and Amin). Five Kato-Katz thick smears of 40 mg each were examined daily</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-22 23:45:14 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Oxamniquine (60 mg/kg x 1)</P>
<P>A third arm (38 patients) that received metrifonate and a fourth arm of 21 patients (control) selected from a nearby village with low prevalence where children without infection were given multivitamin preparation to act as non-randomized control group, were excluded from this analysis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:30:27 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-14 18:03:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Sudan</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:12:20 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Fernandes-1986-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:12:20 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 120</P>
<P>Inclusion criteria: patients aged 15 to 72 years excreting more than 100 to 2,500 EPG of <I>S. mansoni</I> were included</P>
<P>Exclusion criteria: pregnant or lactating women, weak patients or those with cardiac, renal or hepatic insufficiency, and patients with other acute or more severe illnesses than schistosomiasis</P>
<P>Diagnostic criteria: three consecutive stools using Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-10 20:33:30 +0000" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (70 mg/kg x 1)</P>
<P>2. Praziquantel (35 mg/kg x 2)</P>
<P>3. Oxamniquine (15 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 02:25:17 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
<P>3. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; outpatient setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Chronic schistosomiasis cases were included in the trial</P>
<P>Adverse events were evaluated during a 6 to 8 hour period after administration of the drugs, based on clinical observations by the researchers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:12:40 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Ferrari-2003-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:12:31 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 106</P>
<P>Inclusion criteria: patients aged 12 to 56 years attending the hospital found to have <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: children of pre-school age, the aged, pregnant and lactating women, suckling infants, patients with acute or chronic severe concomitant diseases, patients with hepatosplenic form of schistosomiasis and those whose water contact put them at risk for reinfection</P>
<P>Diagnostic criteria: Kato-Katz thick smear (three consecutive stools) in addition to quantitative oogram (rectal biopsies)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-15 09:17:55 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (60 mg/kg per day for 3 consecutive days)</P>
<P>2. Oxamniquine (10 mg/kg x 1, followed by starch in days 2 and 3)</P>
<P>3. Placebo (starch)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:36:18 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-07 12:12:40 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A; hospital setting</P>
<P>Brand: not stated</P>
<P>Very sensitive diagnosis was applied. Efficacy was assessed as patient testing negative after treatment and remaining negative for up to six months</P>
<P>All patients were advised to stay away from the transmission foci, and they reported doing so</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:25:31 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Gryseels-1989a-BDI">
<CHAR_METHODS MODIFIED="2012-12-07 12:25:31 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5, three, six, 12 and 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-23 22:52:39 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 163 children and 267 adults</P>
<P>Inclusion criteria: all individuals excreting eggs for <I>S. mansoni</I> in their stool</P>
<P>Exclusion criteria: those with contraindication</P>
<P>Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 14:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (40 mg/kg x 1)</P>
<P>2. Oxamniquine (30 mg/kg x 1)</P>
<P>3. Oxamniquine (20 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-01 12:50:20 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Resolution of abdominal pain</P>
<P>3. Resolution of diarrhoea</P>
<P>4. Resolution of blood in stool</P>
<P>5. Resolution of hepatomegaly</P>
<P>6. Resolution of splenomegaly</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Burundi</P>
<P>Date of trial: 1983 to 1986</P>
<P>Endemicity: high (prevalence 66%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Hepatomegaly was measured under the costal arch and splenomegaly was measured as described by <LINK REF="REF-Hackett-1944" TYPE="REFERENCE">Hackett 1944</LINK>
</P>
<P>Children only were included in the efficacy analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:25:53 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Gryseels-1989b-BDI">
<CHAR_METHODS MODIFIED="2012-12-07 12:25:53 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5, three, six, 12 and 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-23 22:53:54 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 299 children and 153 adults</P>
<P>Inclusion criteria: all individuals excreting eggs for <I>S. mansoni</I> in their stool</P>
<P>Exclusion criteria: those with contraindication</P>
<P>Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 14:25:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (30 mg/kg x 1)</P>
<P>3. Praziquantel (20 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-01 12:50:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Failure rate</P>
<P>2. Resolution of abdominal pain</P>
<P>3. Resolution of diarrhoea</P>
<P>4. Resolution of blood in stool</P>
<P>5. Resolution of hepatomegaly</P>
<P>6. Resolution of splenomegaly</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Burundi</P>
<P>Date of trial: 1983 to 1986</P>
<P>Endemicity: moderate (prevalence 38%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Hepatomegaly was measured under the costal arch and splenomegaly was measured as described by <LINK REF="REF-Hackett-1944" TYPE="REFERENCE">Hackett 1944</LINK>
</P>
<P>Children only were included in the efficacy analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:26:08 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Gryseels-1989c-BDI">
<CHAR_METHODS MODIFIED="2012-12-07 12:26:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5, three, six, 12 and 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-23 22:55:22 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 193 children and 125 adults</P>
<P>Inclusion criteria: all individuals excreting eggs for <I>S. mansoni</I> in their stool</P>
<P>Exclusion criteria: those with contraindication</P>
<P>Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 21:34:38 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (30 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-01 12:51:05 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Resolution of abdominal pain</P>
<P>3. Resolution of diarrhoea</P>
<P>4. Resolution of blood in stool</P>
<P>5. Resolution of hepatomegaly</P>
<P>6. Resolution of splenomegaly</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Burundi</P>
<P>Date of trial: 1983 to 1986</P>
<P>Endemicity: moderate (prevalence 42%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Hepatomegaly was measured under the costal arch and splenomegaly was measured as described by <LINK REF="REF-Hackett-1944" TYPE="REFERENCE">Hackett 1944</LINK>
</P>
<P>Children only were included in the efficacy analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:14:30 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Guisse-1997-SEN">
<CHAR_METHODS MODIFIED="2012-12-07 12:14:30 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three, six and 21 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-23 22:59:41 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 130</P>
<P>Inclusion criteria: children infected with <I>S. mansoni</I> with no previous history of antischistosomal treatment</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: two consecutive stools (duplicate Kato-Katz thick smear, 25 mg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 03:16:17 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1) </P>
<P>2. Praziquantel (30 mg/kg x 2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-10 20:47:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 20:47:57 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Senegal</P>
<P>Date of trial: 1993</P>
<P>Endemicity: high (100%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:14:53 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Gupta-1984-ZMB">
<CHAR_METHODS MODIFIED="2012-12-07 12:14:53 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-10 20:49:27 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 60</P>
<P>Inclusion criteria: adults patient with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: pregnant and lactating women, patients with concurrent systematic diseases and those who received antischistosomal treatment within one month before the trial</P>
<P>Diagnostic criteria: Stoll/Hauseer&#8217;s method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 11:15:37 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days</P>
<P>2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days</P>
<P>3. Oxamniquine (30 mg/kg): 15 mg/kg twice daily for one day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:25:26 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Zambia</P>
<P>Date of trial: March 1980 to 1982</P>
<P>Endemicity: patients visiting Lusaka hospital</P>
<P>Communities studied: not stated</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:26:35 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Homeida-1989-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:26:35 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5 and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-01 21:32:51 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 885</P>
<P>Inclusion criteria: individuals who were positive for <I>S. mansoni</I>
</P>
<P>Exclusion criteria: pregnant women, patients who vomited the drug within half an hour or those who reported to have received antischistosomal treatment within the previous 6 months</P>
<P>Diagnostic criteria: modified Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 01:22:02 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1): Biltricide</P>
<P>2. Praziquantel (40 mg/kg x 1): Distocide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:22:41 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-14 19:54:15 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Sudan</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: Biltricide and Distocide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:15:39 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Ibrahim-1980-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:15:39 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two and three months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-10 20:55:50 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 129 (89 participants were included in the analysis)</P>
<P>Inclusion criteria: all university students attending the university hospital found to have <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: only one patient who had chronic valvular heart disease was excluded</P>
<P>Diagnostic criteria: modified Kato-Katz thick smear (three daily stool examinations)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 15:43:11 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days</P>
<P>2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days</P>
<P>One arm of 40 participants with no current or previous schistosomiasis was excluded</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:29:51 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:00:15 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: not stated</P>
<P>Endemicity: low (prevalence not stated)</P>
<P>Communities studied: university students on campus</P>
<P>Brand: Vansil</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Jaoko-1996-KEN">
<CHAR_METHODS MODIFIED="2012-01-03 15:32:04 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 436</P>
<P>Inclusion criteria: schoolchildren aged 7 to 16 years infected with <I>S. mansoni</I>
</P>
<P>Exclusion criteria: children who were on medication for whatever reason</P>
<P>Diagnostic criteria: duplicate modified Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 03:19:27 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1) </P>
<P>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 11:34:05 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Adverse events </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Kenya</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence &gt; 83%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:16:07 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Kardaman-1983-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:16:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one month</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-23 23:08:33 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 350</P>
<P>Inclusion criteria: all schoolchildren who provided two stool samples positive for <I>S. mansoni</I> or two urine samples positive for <I>S. haematobium</I> were included</P>
<P>Exclusion criteria: children aged &lt; 6 years, patients with contraindications, patients with serious or acute disease, those who had received antischistosomal treatment within the preceding six months, pregnant and lactating women</P>
<P>Diagnostic criteria: single stool (three slides) from locally developed thick-smear method, Teesdale &amp; Amin (<LINK REF="REF-Teesdale-1976" TYPE="REFERENCE">Teesdale 1976</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (20 mg/kg x 2) given 4 to 6 hours apart</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:23:04 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:06:00 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: December 1979 to March 1980</P>
<P>Endemicity: moderate (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: Biltricide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:16:26 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Kardaman-1985-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:16:26 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: five weeks and three months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 237, but only 220 received treatment</P>
<P>Inclusion criteria: children aged 7 to 11 years who provided two positive stool samples for <I>S. mansoni</I> and two positive urine samples for <I>S. haematobium</I>
</P>
<P>Exclusion criteria: children were excluded if they were receiving medication for any other infection or if they had received medication for schistosomiasis within the preceding six months</P>
<P>Diagnostic criteria: locally developed thick-smear method, Teesdale &amp; Amin (<LINK REF="REF-Teesdale-1976" TYPE="REFERENCE">Teesdale 1976</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (20 mg/kg x 2) given 4 to 6 hours apart</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:26:21 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:11:10 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: not stated</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:16:39 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Katz-1979a-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:16:39 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six and 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 55</P>
<P>Inclusion criteria: male patients aged 20 to 48 years from the military police of Minas Gerais who were excreting &gt; 100 EPG of <I>S. mansoni</I> (calculated from a minimum of two stool samples)  </P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear (plus hatching test), three consecutive stool (two slides from each stool plus three hatching tests on each stool); EPG expressed as geometric mean</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 14:30:16 +0000" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (20 mg/kg x 1)</P>
<P>2. Praziquantel (20 mg/kg x 2)</P>
<P>3. Praziquantel (20 mg/kg x 3, 4 hours apart)</P>
<P>4. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:30:55 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:15:27 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; military police</P>
<P>Communities studied: N/A</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:16:48 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Katz-1979b-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:16:48 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six and 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 61</P>
<P>Inclusion criteria: male patients aged 20 to 48 years from the military police of Minas Gerais who were excreting &gt; 100 EPG of <I>S. mansoni</I> (calculated from a minimum of two stool samples).  </P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear (plus hatching test), three consecutive stool (two slides from each stool plus three hatching tests on each stool); EPG expressed as geometric mean</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 14:28:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (20 mg/kg x 3, 4 hours apart)</P>
<P>2. Praziquantel (50 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-21 14:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:19:15 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; military police</P>
<P>Communities studied: N/A</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:16:56 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Katz-1981-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:16:56 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-10 21:19:56 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 138</P>
<P>Inclusion criteria: patients attending the hospital found to have <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz method (plus hatching test), three consecutive stools (two slides from each stool plus three hatching tests on each stool ); EPG expressed as geometric mean</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 03:50:47 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (30 mg/kg x 1)</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
<P>3. Praziquantel (25 mg/kg x 2, 6 hours apart)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:51:10 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate </P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:21:11 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:17:04 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Katz-1982-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:17:04 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 120</P>
<P>Inclusion criteria: children aged 8 to 14 years excreting between 90 and &lt; 2,500 EPG, weighing between 17 and 50 kg.</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear, three consecutive stool samples (2 slides from each stool); EGP expressed as geometric mean</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-11 14:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oxamniquine (20 mg/kg x 1)</P>
<P>2. Praziquantel (65 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:39:42 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: outpatients (coming from two endemic communities)</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-18 15:43:03 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Lambertucci-1982-BRA">
<CHAR_METHODS MODIFIED="2012-11-18 15:43:03 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P> Table 15</P>
<P>Length of follow-up: 10 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 91</P>
<P>Inclusion criteria: children aged 6 to 14 years with chronic <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: duplicate of two consecutive stools using Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 02:32:49 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (20 mg/kg x 1) </P>
<P>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:33:12 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-15 16:43:45 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Brazil</P>
<P>Date of trial: November 1978 to January 1979</P>
<P>Endemicity: low (prevalence 8%)</P>
<P>Communities studied: outpatient clinic</P>
<P>Brand: not stated</P>
<P>Follow-up comprised 20 quantitative parasitological stool examinations (two each month for 10 months)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:18:06 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Metwally-1995-EGY">
<CHAR_METHODS MODIFIED="2012-12-07 12:18:06 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5 and 2.5 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 366</P>
<P>Inclusion criteria: schoolchildren aged 8 to 16 years who were positive for <I>S. mansoni</I>
</P>
<P>Exclusion criteria: children showing any signs of hepatosplenic disease, those who received antischistosomal treatment within the previous six months</P>
<P>Diagnostic criteria: three consecutive stools (three slides per stool) using modified Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 01:27:52 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1): Biltricide</P>
<P>2. Praziquantel (40 mg/kg x 1): Distocide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:28:10 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:30:20 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Egypt</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: Biltricide and Distocide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:18:17 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olds-1999-KEN">
<CHAR_METHODS MODIFIED="2012-12-07 12:18:17 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: five, 12 and 24 weeks, but the authors reported treatment effects for 5 weeks only</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 367</P>
<P>Inclusion criteria: schoolchildren aged 6 to 19 years positive for <I>S. mansoni</I>
</P>
<P>Exclusion criteria: failure to submit two stool specimens prior to the initial treatment, known allergy to either drug, treatment with either drug within six months, lack of consent, or possible pregnancy</P>
<P>Diagnostic criteria: two 50 mg stool slides each were prepared from 2 separate stool samples for Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-15 16:54:50 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Albandazole (400 mg x 1) + praziquantel (40 mg/kg)</P>
<P>2. Praziquantel (40 mg/kg) + albendazole placebo</P>
<P>3. Albandazole (400 mg x 1) + praziquantel placebo</P>
<P>4. Both placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 01:44:37 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Kenya</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence &gt; 80%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Losses to follow-up were not statistically different in terms of treatment, infection status or adverse events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:18:34 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olliaro-2011-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:18:34 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 196</P>
<P>Inclusion criteria: participants aged 10 to 19 years with <I>S.</I> <I>mansoni</I> infection (&#8805; 100 EPG) using Kato-Katz technique, written informed consent, but under 18 years of age, written informed consent from parents/guardians and their verbal assent, able and willing to be examined on follow-up visits and provide stool samples  </P>
<P>Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated with praziquantel, history of acute or chronic severe disease including hepato-splenic schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic malaria, currently using other medication or in the past week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-03 22:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (60 mg/kg x 1)</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-03 22:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Reinfection rates</P>
<P>4. Hb level</P>
<P>5. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Brazil</P>
<P>Date of trial: March 2006 to Dec 2007</P>
<P>Endemicity: prevalence 25%</P>
<P>Communities studied:</P>
<P>Brand: DistocideH by Shin-Poong, Korea</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:18:43 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olliaro-2011-MRT">
<CHAR_METHODS MODIFIED="2012-12-07 12:18:43 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized:186</P>
<P>Inclusion criteria: participants aged 10 to 19 years with <I>S.</I> <I>mansoni</I> infection (&#8805; 100 EPG) using Kato-Katz technique, written informed consent, but under 18 years of age, written informed consent from parents/guardians and their verbal assent, able and willing to be examined on follow-up visits and provide stool samples  </P>
<P>Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated with praziquantel, history of acute or chronic severe disease including hepato-splenic schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic malaria, currently using other medication or in the past week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-09 00:16:33 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (60 mg/kg x 1)</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-09 00:16:43 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Reinfection rates</P>
<P>4. Hb level</P>
<P>5. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Mauritania</P>
<P>Date of trial: August 2005 to December 2006</P>
<P>Endemicity: <I>S. mansoni</I>, prevalence 18.7%, <I>S.haematobium</I> prevalence 30.9%, Coinfection 7.3% and total prevalence 57%</P>
<P>Communities studied: not stated</P>
<P>Brand: DistocideH by Shin-Poong, Korea</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:18:54 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olliaro-2011-TZA">
<CHAR_METHODS MODIFIED="2012-12-07 12:18:54 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 271</P>
<P>Inclusion criteria: participants aged 10 to 19 years with <I>S.</I> <I>mansoni</I> infection (&#8805; 100 EPG) using Kato-Katz technique, written informed consent, but under 18 years of age, written informed consent from parents/guardians and their verbal assent, able and willing to be examined on follow-up visits and provide stool samples  </P>
<P>Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated with praziquantel, history of acute or chronic severe disease including hepato-splenic schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic malaria, currently using other medication or in the past week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-09 00:17:30 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (60 mg/kg x 1)</P>
<P>2. Praziquantel (40 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-09 00:17:37 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Reinfection rates</P>
<P>4. Hb level</P>
<P>5. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Tanzania</P>
<P>Date of trial: August 2005 to September 2006</P>
<P>Endemicity: high (prevalent not reported)</P>
<P>Communities studied: not stated</P>
<P>Brand: DistocideH by Shin-Poong, Korea</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:19:19 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Omer-1978-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:19:19 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 176</P>
<P>Inclusion criteria: individuals who were positive for <I>S. mansoni</I> and excreting &gt; 250 EPG</P>
<P>Exclusion criteria: those with &lt; 250 EPG, those with severe anaemia, ascites, or poor general health, those who received antischistosomal drug within the last six months, and pregnant women</P>
<P>Diagnostic criteria: three consecutive stools using modified Kato-Katz thick smear, Teesdale &amp; Amin (<LINK REF="REF-Teesdale-1976" TYPE="REFERENCE">Teesdale 1976</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-15 09:17:56 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (60 mg/kg): 15 mg/kg x 2 daily for 2 days</P>
<P>2. Oxamniquine (40 mg/kg): 20 mg/kg daily for 2 days</P>
<P>3. Oxamniquine (30 mg/kg): 15 mg/kg x 2 in one day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:40:01 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: 1975 to 1976</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: outpatients</P>
<P>Brand: Biltricide</P>
<P>Only patients with moderate or heavy infections &gt;250 EPG were included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:20:20 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Omer-1981-SDN">
<CHAR_METHODS MODIFIED="2012-12-07 12:20:20 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 3 to 4 months, and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 153</P>
<P>Inclusion criteria: individuals who were positive for <I>S. mansoni</I> and <I>S. haematobium</I> (mixed infection)</P>
<P>Exclusion criteria: those &lt; 8 years, with advanced disease, severe anaemia and poor general health</P>
<P>Diagnostic criteria: three consecutive stools, using modified Kato-Katz thick smear (Teesdale &amp; Amin 1976)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 03:58:26 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (20 mg/kg x 2)</P>
<P>3. Praziquantel (30 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 03:59:07 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Sudan</P>
<P>Date of trial: 1978 to 1979</P>
<P>Endemicity: very high in the community (prevalence not given)</P>
<P>Communities studied: patients reporting to the Hospital of Tropical Diseases, Khartoum and those detected during a field survey</P>
<P>Brand: Biltricide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:20:42 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Queiroz-2010-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:20:42 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Follow-up: one, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Inclusion criteria: inhabitants aged &#8805; 13 years from Chonin (a district of Governador Valadares) with a positive stool sample for <I>S. mansoni </I>infection</P>
<P>Criteria for exclusion from the study included pregnancy, cardiomyopathies and chronic liver and renal diseases; however, no participants were excluded</P>
<P>Two parasitological stool examinations (2 slides per stool sample) by the quantitative Kato-Katz thick smear. Diagnostic criteria same pre-and post- treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (80 mg/kg: 2 x 40 given 1 hour apart)</P>
<P>2. Praziquantel (50 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-03 15:32:08 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate </P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-24 00:00:07 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Brazil</P>
<P>Date of trial: 2002</P>
<P>Endemicity: moderate (prevalence 22.5%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Patients with chronic schistosomiasis mansoni were recruited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:20:50 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Rezende-1985-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:20:50 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-10 21:37:55 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 539</P>
<P>Inclusion criteria: outpatients of all ages free from previous antischistosomal treatment; whole population who received previous treatment of children and adults with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear (three smears from three consecutive stool samples)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 04:42:47 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (16 mg/kg x 1) </P>
<P>2. Praziquantel  (55 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:43:06 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:40:54 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: N/A; hospital setting</P>
<P>Communities studied: N/A</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:21:07 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Rugemalila-1984-TZA">
<CHAR_METHODS MODIFIED="2012-12-07 12:21:07 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 188 (125 included in the analysis)</P>
<P>Inclusion criteria: children aged 8 to 14 years attending primary school in Mwanza district infected with <I>S. mansoni</I>
</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: single stool (duplicate slides) from formal-ether method</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-21 19:05:11 +0000" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Oxamniquine (15 mg/kg x 1)</P>
<P>A third arm consisted of control (63 participants) who received no treatment and were excluded</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:48:17 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Adverse events</P>
<P>2. Resolution of symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:44:25 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Tanzania</P>
<P>Date of trial: not stated</P>
<P>Endemicity: not stated</P>
<P>Communities studied: not stated</P>
<P>Brand: praziquantel (Biltricide, Bayer) and oxamniquine (Vancil, Pfizer)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:21:27 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Shafei-1979-NGA">
<CHAR_METHODS MODIFIED="2012-12-07 12:21:27 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, two and three months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-15 09:17:56 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 45</P>
<P>Inclusion criteria: individuals with <I>S. manson</I>i infection detected in stool by the McMaster technique</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: McMaster technique but did not state number of stool and slides</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-05 21:47:28 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (15 mg/kg x 1)</P>
<P>2. Oxamniquine (15 mg/kg x 2 given one day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:43:43 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:45:34 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Nigeria</P>
<P>Date of trial: not stated</P>
<P>Endemicity: moderate (prevalence not stated)</P>
<P>Communities: one</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Stelma-1997-SEN">
<CHAR_METHODS MODIFIED="2012-01-03 15:32:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 1.5 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 138</P>
<P>Inclusion criteria: patients aged &gt; 5 years with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: pregnant women and children aged &lt; 5 years</P>
<P>Diagnostic criteria: Kato-Katz thick smear (duplicate, two consecutive stools)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 04:51:35 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Oxamniquine (20 mg/kg x 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:51:56 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate </P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:47:31 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Senegal</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: praziquantel (Distocide, Shin Poong, Seoul Korea) and oxamniquine (Vansil, Pfizer)</P>
<P>Cure rate extracted from graph</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-19 00:58:28 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Sukwa-1993-ZMB">
<CHAR_METHODS MODIFIED="2012-11-19 00:58:28 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 377</P>
<P>Inclusion criteria: schoolchildren aged 7 to 19 years infected with <I>S. mansoni</I>
</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: single stool, duplicate slides of modified Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-03 15:32:10 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 2, given 6 months apart)</P>
<P>2. Praziquantel (40 mg/kg x 1, followed by placebo at 6 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:03:29 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Re-infection rate</P>
<P>2. Egg reduction rate</P>
<P>3. Resolution of pathology</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Zambia</P>
<P>Date of trial: 1990 to 1991</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>All children were treated with 40 mg/kg praziquantel at the start. Six months later the children in group A were retreated with 40 mg/kg praziquantel and group B with placebo (multivitamin). They were all followed up for another six months (12 months total follow-up)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:21:59 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Taddese-1988-ETH">
<CHAR_METHODS MODIFIED="2012-12-07 12:21:59 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 200</P>
<P>Inclusion criteria: adolescents and adults aged 17 to 52 years infected with <I>S. mansoni</I> and excreting at least 50 EPG (geometric mean)</P>
<P>Exclusion criteria: patients who had received antischistosomal treatment within the last six months, lactating and pregnant women or having concurrent systemic diseases or with a history of seizure disorders</P>
<P>Diagnostic criteria: Kato-Katz thick smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-11 14:56:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (20 mg/kg x 2)</P>
<P>3. Oxamniquine (15 mg/kg x 1)</P>
<P>4. Oxamniquine (15 mg/kg x 2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:57:39 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
<P>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-23 21:07:34 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Ethiopia</P>
<P>Date of trial: 1983</P>
<P>Endemicity: moderate (prevalence &lt;30%)</P>
<P>Communities studied: one</P>
<P>Brand: praziquantel (Biltricide) and oxamniquine (Vansil)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:22:13 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Taylor-1988-ZWE">
<CHAR_METHODS MODIFIED="2012-12-07 12:22:13 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one, three and six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 373 (283 participants were included in the analysis)</P>
<P>Inclusion criteria: children aged 10 to 15 years who were all infected with both <I>S. mansoni</I> and <I>S. haematobium</I>
</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: three consecutive stools using Kato-Katz thick smear (duplicate 41.5 mg)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-14 02:25:04 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1)</P>
<P>2. Praziquantel (30 mg/kg x 1)</P>
<P>3. Praziquantel (20 mg/kg x 1)</P>
<P>4. Praziquantel (10 mg/kg x 1)</P>
<P>A 5<SUP>th</SUP> arm consisting of 90 participants not treated was excluded from the analysis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:08:48 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Failure rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:56:27 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Zimbabwe</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence 76%)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
<P>Study was carried out during period of low transmission</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:22:26 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Teesdale-1984-MWI">
<CHAR_METHODS MODIFIED="2012-12-07 12:22:26 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: one and three months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 119</P>
<P>Inclusion criteria: children aged 6 to 14 years with <I>S. mansoni</I> infection</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: quantitative thick smear (Teesdale 25 mg) from 4 consecutive stools</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Oxamniquine (50 mg/kg): 25 mg/kg x 2</P>
<P>2. Oxamniquine (40 mg/kg x 1)</P>
<P>3. Oxamniquine (30 mg/kg x 1)</P>
<P>4. Praziquantel (40 mg/kg x 1)</P>
<P>A 5th arm involving 18 participants treated with oxamniquine (20 mg/kg x 1) was excluded because it was not randomized as part of the trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:48:32 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 21:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Malawi</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one main village with another where only the 20 mg/kg was tested</P>
<P>Brand: Vansil</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:22:34 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Tweyongyere-2009-UGA">
<CHAR_METHODS MODIFIED="2012-12-07 12:22:34 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: six weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomized: 387</P>
<P>Inclusion criteria: pregnant women found to have <I>S. mansoni</I> infected detected during a population survey</P>
<P>Exclusion criteria: those &lt; 8 years, with advanced disease, severe anaemia and poor general health</P>
<P>Diagnostic criteria: single stool sample of duplicate Kato-Katz thick smear for both pre- and post-treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 04:12:11 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (40 mg/kg x 1) </P>
<P>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 04:12:19 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Location: Uganda</P>
<P>Date of trial: 2003 to 2005</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: not stated</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-07 12:22:44 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Zwingenberger-1987-BRA">
<CHAR_METHODS MODIFIED="2012-12-07 12:22:44 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Length of follow-up: three, six and 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Number randomized: 91</P>
<P>Inclusion criteria: individuals aged 10 to 62 years with <I>S. mansoni</I> diagnosed in a parasitological survey</P>
<P>Exclusion criteria: not stated</P>
<P>Diagnostic criteria: Kato-Katz thick smear (single stool)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-29 20:25:00 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Praziquantel (20 mg/kg x 2)</P>
<P>2. Oxamniquine (15 mg/kg x 1)</P>
<P>3. Oxamniquine (7.5 mg/kg) plus praziquantel (20 mg/kg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 02:56:41 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>1. Cure rate</P>
<P>2. Egg reduction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-10 22:02:01 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Brazil</P>
<P>Date of trial: not stated</P>
<P>Endemicity: high (prevalence not stated)</P>
<P>Communities studied: one</P>
<P>Brand: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-27 13:35:35 +0100" MODIFIED_BY="Tony Danso-Appiah" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abu_x002d_Elyazeed-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-02 14:25:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adam-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-02 14:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>Praziquantel versus anti-malaria treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-27 13:35:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almeida-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-27 13:35:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial, but not outcome of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-22 15:32:59 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Assis-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-22 15:32:59 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Reported anthropometry, which is not part of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boisier-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coura-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-03 15:32:11 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-De-Clercq-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-03 15:32:11 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-27 13:35:35 +0100" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Doehring-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-27 13:35:35 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>Randomized, but did not report results of each arm separately. The results of the different arms were rather combined and presented as one</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eigege-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-el-Guiniady-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-el_x002d_Hawey-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-22 16:52:37 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Friis-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-22 16:52:37 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Effect of zinc supplementation on growth and body weight</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-15 09:11:36 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Friis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-15 09:11:36 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Mineral supplementation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gryseels-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Homeida-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kabatereine-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katz-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-02 14:24:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohamed-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-02 14:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>Praziquantel versus anti-malaria treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-27 13:34:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navaratnam-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-27 13:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>The study recruited both children with and without the infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-02 14:24:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Obonyo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-02 14:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>Praziquantel versus anti-malaria treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odongo_x002d_Aginya-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-22 16:58:59 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olsen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-22 16:58:59 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>No drug treatment, mineral supplementation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-22 16:59:09 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Olsen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-22 16:59:09 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>No drug treatment, mineral supplementation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-15 22:02:33 +0100" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Pitchford-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-15 22:02:33 +0100" MODIFIED_BY="Tony Danso-Appiah">
<P>No comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polderman-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-22 17:00:04 +0000" MODIFIED_BY="Tony Danso-Appiah" STUDY_ID="STD-Utzinger-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-22 17:00:04 +0000" MODIFIED_BY="Tony Danso-Appiah">
<P>Artemether given to non-infected people for the prevention of <I>S. mansoni </I>infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Utzinger-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Lieshout-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 20:53:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomized, selective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-19 00:58:17 +0000" MODIFIED_BY="Tony Danso-Appiah">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:00:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>'Patients were stratified according to age, sex and intensity, and randomly allocated to one of three groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:04:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:10:13 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>Described as 'patients were allocated randomly', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 12:45:57 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>'Each subject selected for inclusion in the study was randomly assigned to one of four treatment groups', no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:17:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>'Of the infected person, 104 individuals were randomized in two groups, the first for myrrh and the second for praziquantel, the characteristics of the two groups being comparable', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:20:08 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>'All positive eligible subjects were stratified into low, moderate and heavy infection strata. Each stratum was then randomly assigned into two groups. One group received Mirazid while the second group received praziquantel', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:21:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>'Patients were randomly allocated into three parallel groups, one received praziquantel, one oxamniquine, and one placebo'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:22:50 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>'The children were randomly assigned to three groups of 10, 30 and 19, respectively, and the combination drug administered at three dosage levels', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:43:25 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>'Patients were allocated to one of three groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:48:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>'Patients were assigned randomly to one of three groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:48:10 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>'Patients were randomly allocated to one of three groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:52:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>'All patients excreting eggs of <I>S. mansoni</I> were treated with one of the randomly allocated schedules', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:54:47 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>'All patients excreting eggs of S. mansoni were treated with one of the randomly allocated schedules', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:56:48 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>All patients excreting eggs of <I>S. mansoni</I> were treated with one of the randomly allocated schedules', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:57:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>'Patients with no history of previous treatment with praziquantel, were selected and randomly allocated into two treatment groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:00:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>Patients were randomly allocated to three oxamniquine groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:00:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>'1050 infected individuals who agreed to take part were randomly allocated to biltricide or distocide', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:14 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>Described as 'Double-blind random allocation', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>Described as 'patients were randomly assigned to treatment', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>'In one Arab village, 350 patients with <I>S. mansoni</I> were randomly assigned to one of two treatment groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:10:30 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>'All children who provided two positive stool were then randomly assigned to take either a single 40 mg/ kg dose a divided dose', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:12:34 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>Described as 'patients were randomly allocated to treatment', the authors refer to WHO coordinated well-designed multi-country trials of which this trial was part</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:14:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>Described as 'patients were randomly allocated to treatment'. the authors refer to WHO coordinated well-designed multi-country trials of which this trial was part</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:15:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>'Patients were randomly allocated to treatment', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:16:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>'This investigation was designed a double-blind comparative trial between two parallel groups established by random allocation of patients', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>Described as 'double-blind trial', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:47 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>'Children were stratified into light, moderate and heavy infection. Each stratified group was randomly divided into four groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:21:03 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>'Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 80'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:23:56 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>'Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 4'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:26:23 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>'Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 4'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-15 19:42:38 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>'Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 4'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:37:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>Patients randomly divided into blocks of 15 patients each', no further details were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:57:06 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>The study was based on a protocol indicating stratification according to the degree of infection which was determined by the geometric means of three stool sample examinations. Each stratum was then randomly divided into 3 blocks with 15 patients each to receive one of three dosages'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 15:32:08 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>'Participants were randomly assigned into two groups using small blocks to achieve balance between them'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:01:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>Randomized double-blind parallel group clinical trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:02:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>Described as randomized single-blind comparative trial. 'The children found positive for egg excretion were stratified for egg output counts before being randomly allocated by their serial numbers to one of the three groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:03:51 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>Patients were randomly allocated to treatment, no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:10 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>Double-blind randomized trial, patients were randomly allocated to treatment A and B, with a 1:1 allocation ratio and the school serving as the block'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>Patients were randomly assigned to four treatment groups, no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:14 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>'Children were randomly assigned to treatment groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>'The positive subjects included in the study were stratified by age and intensity of infection, and then randomized from each stratum to four treatment groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:09:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>Prepared by statistician with Stata 7 in blocks of 100</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:09:59 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>Patients were randomly allocated to one of three groups, no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:25:22 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>'Following parallel group design, the patients upon entering the trial were allocated into one of the two groups distributed according to age, sex, body weight, clinical form of the disease and worm burden'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:26:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>'Patients were randomly allocated into four groups with equal number of cases...' The authors make reference to their earlier trial which used parallel group design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:28:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>'The patients were randomly allocated into two groups having an equal number of cases', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:34:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:35:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:36:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>Described as 'randomized', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:45:25 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>'The patients were randomly divided into four groups', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-08-24 00:10:01 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:01:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:04:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:10:18 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:12:54 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:17:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:20:11 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:21:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>The trial was double-blind placebo control trial. 'The drugs were administered as a single oral dose in conformity to a double-blind technique'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:22:53 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:44:13 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:48:44 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>'No methods were taken to conceal allocation of participants to the treatment groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:48:06 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>The identity of each treatment was kept in a sealed envelope and the capsules were identical in shape and appearance as the active drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:49:50 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:54:50 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:55:50 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:58:12 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:00:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:01:02 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>'Tablets were similar in appearance and were dispensed by a doctor', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:17 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>Double-blind random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>Placebo controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:06:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:10:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:12:37 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:14:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:15:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:16:13 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>Not described, but given that it was double-blind trial, it is more likely allocation was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:19 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>Double-blind trial. The patients were identified on arrival at the hospital by a code number in relation to oxamniquine or placebo administration, to make it impossible for the doctor in charge to know which child took active drug and which the placebo (double-blind). The code was broken 8 months after the treatment of the last patient'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:49 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:21:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>Physically identical treatment and placebo were manufactured and packaged on the same equipment, and all bottles were identified only with a letter code. Randomization code was not broken until after the 6-month results were tabulated and submitted to WHO</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:23:59 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>'Physically identical treatment and placebo were manufactured and packaged on the same equipment, and all bottles were identified only with a letter code. Sealed and numbered envelopes were kept in a locked cabinet by one responsible person; two different people preparing treatment and evaluating patients; stool specimens read by a technician blinded as to the treatment. Randomization code was not broken until after the 6-month results were tabulated and submitted to WHO'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:29:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>'Physically identical treatment and placebo were manufactured and packaged on the same equipment, and all bottles were identified only with a letter code. Sealed and numbered envelopes were kept in a locked cabinet by one responsible person; two different people preparing treatment and evaluating patients; stool specimens read by a technician blinded as to the treatment. Randomization code was not broken until after the 6-month results were tabulated and submitted to WHO'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:32:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>'Physically identical treatment and placebo were manufactured and packaged on the same equipment, and all bottles were identified only with a letter code. Sealed and numbered envelopes were kept in a locked cabinet by one responsible person; two different people preparing treatment and evaluating patients; stool specimens read by a technician blinded as to the treatment. Randomization code was not broken until after the 6-month results were tabulated and submitted to WHO'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:37:18 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-15 20:11:22 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:00:23 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:01:39 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>Physically identical capsules were dispensed in individually coded bottles</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:02:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>'The investigator giving treatment used case serial numbers to check out the treatment to be given. Case treatment groups were not revealed to the examiners'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:03:53 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:12 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:20 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>Described as 'allocation concealed and randomization code not broken until the end of the trial', methods not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:09:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>Opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:10:01 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:25:27 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>'The two drugs were dispensed in individually coded bottles and presented in capsules of identical appearance but containing different dosages. The double-blind code was provided prior to the beginning of the study within sealed envelopes, for each case, to be opened only at the end of the trial'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:27:01 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>Not explicitly stated, but the authors make reference to their earlier parallel double-blind trial where the two drugs were dispensed in individually coded bottles and presented in capsules of identical appearance but containing different dosages. The double-blind code was provided prior to the beginning of the study within sealed envelopes, for each case, to be opened only at the end of the trial'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:28:27 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>'Both drugs were given in a single oral dose in accordance with a double-blind technique', no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:30:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:34:27 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:35:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:36:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:45:27 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:01:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:04:56 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:10:21 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:12:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>All laboratory technicians were unaware of the different treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:17:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:20:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>'All parasitologists who examined the slides, the technicians who processed them, the clinicians who performed rectal snips, and those responsible for data entry were blinded to the type of treatment given'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:21:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>Double-blind placebo controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:22:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:44:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:49:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>Outcomes assessment was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>Triple masked randomized controlled trial. 'The investigators were blind to which patients were given which treatment, the identity of each was kept in a sealed envelope'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 22:49:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 22:54:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 22:55:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 22:58:14 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>None reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:00:34 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:01:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>Outcome assessor of side effects blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 20:19:25 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>Double-blind random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:07:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>Placebo controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:06:37 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:10:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:12:39 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>Investigators, participants and assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:14:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>Participants and assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:15:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>Decribed as single-blind randomized trial, no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:16:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>'Double-blind trial'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-15 16:53:44 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:19:51 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:21:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:24:01 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:26:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-11 01:10:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>Participants, investigators and outcome assessors were blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:37:20 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>Participants and assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-23 23:57:10 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>'Single blind trial, participants and assessors were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:00:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>Single blind study, did not state who was blinded. 'To keep the study masked, patients who received 50 mg/kg received placebo 1 hour after the first dose'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:01:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>Double-blind (investigators, participants and assessors were blind)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:02:39 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>Only the investigators were blind but this is not likely to introduce bias into the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:03:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:04:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:06:14 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>Investigators, assessors and participants were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:06:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:08:22 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>Participants and assessors were blind, only the principal investigator was aware of the groups to which participants had been assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:08:47 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:09:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>Investigators, assessors and participants were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-24 00:10:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:25:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>'Patients were treated in accordance with double-blind administration'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:27:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>The authors make reference to their earlier trial where they stated 'Patients were treated in accordance with double-blind administration'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 16:07:39 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>'Double-blind clinical trial'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:30:10 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:34:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:35:31 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:36:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-22 23:45:30 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>None described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-11-19 00:58:17 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>Attrition did not show a particular trend, but high &gt; 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:05:02 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>Sample size small &lt; 20 participants in each arm: attrition same across arms, but high ( &gt; 20%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:13:56 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>No losses recorded up to six months follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:17:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>No losses recorded, used ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:20:21 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>Losses were high: 11/66 (16.7%) in myrrh versus 19/51 (37.3%) in praziquantel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:22:01 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>Attrition not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:22:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>Losses were differential: very low in some arms but high reaching &gt;40% in other arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:44:20 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>No losses at one month, but losses were high in the artesunate arm (reaching 25%) at six months compared to 5% in the praziquantel arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:49:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 22:48:26 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>Losses were high: 10/36 (28%) in the praziquantel arm, 3/34 (9%) in the oxamniquine and 7/36 (19%) in the placebo arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-19 00:58:17 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>Number lost to follow-up not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 22:54:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>Number lost to follow-up not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 22:55:54 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>Number lost to follow-up not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 22:58:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:00:37 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>Sample size small, losses not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:04:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>There was differential loss of participants to follow-up at six months: Biltricide (7%) versus Distocide (12%), but the sample was large (&gt; 400 patients in each arm) and this is not likely to introduce bias into the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>Losses low &lt; 10% and did not differ across arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:06:02 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:09:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>Losses were 12% in the single dose (40 mg/kg) versus 9% in the divided dose (20 mg/kg x 2) of praziquantel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:08 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>Randomized 237 participants but 220 received treatment. Losses were &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>Very small sample sizes (&#8804; 8 participants) across arms, but losses reached over 50%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>Losses &gt; 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:15:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>Losses were low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:16:19 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>Attrition rate high</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>Attrition low (&lt; 10%) and similar across arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:19:53 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:09 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>Loss to follow-up &lt; 1% at 45 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:24:03 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>Missing or incomplete data considered as missing in ITT and per protocol analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:26:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>Missing or incomplete data considered as missing in ITT and per protocol analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 16:10:06 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>Missing or incomplete data considered as missing in ITT and per protocol analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:37:22 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>Losses were differential across arms: 14/73 (19%), 3/37 (8%) and 8/66 (12%) in the 60 mg/kg, 40 mg/kg and 30 mg/kg arms at six months' follow-up, respectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 23:57:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:00:31 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>Eighteen participants were lost to follow-up: 11/156 (7%) from the 80 mg/kg arm versus 7/150 (5%) from the 50 mg/kg arm. Analysed by ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:01:47 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>Losses were high: 80/272 (29%) in oxamniquine 16 mg/kg arm versus 83/267 (31%) in the praziquantel 55 mg/kg arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:10 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>Losses were high &gt; 30% at three months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:03:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>Sample size small, losses not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:04:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>No losses were recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:06:18 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:06:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>Losses were low in all arms (up to 10%), but losses in one arm reached 18% by six months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:08:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:08:50 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>Losses at three months were high, reaching 77% in the oxamniquine 50 mg/kg arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-24 00:09:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>Losses were high in both the praziquantel 59/186 (32%) and placebo 88/201 (44%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:11 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>Losses were high reaching &gt; 40% in one arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:25:37 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>Number of participants across arms very small; 3/27 in the praziquantel arm and 5/27 in the oxamniquine arm were lost to follow-up at 6 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:27:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>Losses did not differ across arms, but around &gt; 20% was high. 'Eefficacy was assessed based on those who finished three negative post treatment parasitological follow-ups (1, 3 and 6 months)'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 17:52:07 +0000" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>Sample size very small across arms &#8804; 15 and attrition was high reaching 33%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:34:31 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>No losses recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:35:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>No losses recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:36:47 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>No losses recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-22 23:45:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="NO" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>Losses were similar at one month, but different at three months: 27% in the 40 mg/kg praziquantel arm versus 17% in the 60 mg/kg in the oxamniquine arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-08-24 00:10:09 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:01:11 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:05:06 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:10:30 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:13:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:17:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>No evidence of selecting reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:21:12 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:22:03 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:23:02 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:44:23 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:49:12 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:47:48 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:50:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:55:03 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:55:56 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>Noevidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:58:18 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:00:39 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:01:10 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:23 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:06:04 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:06:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:10:41 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:12:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:14:49 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:15:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:16:21 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:21:13 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:24:05 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:26:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-11 01:10:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:37:25 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:57:19 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:00:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:01:49 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>No evidence of selecting reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:02:44 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:00 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:46 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:20 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:27 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:53 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:09:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:10:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:25:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:27:09 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:28:37 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:30:16 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:34:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:35:39 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:36:49 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:45:36 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-08-24 00:10:13 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:01:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:05:11 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Al-Aska-1990-SAU">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:10:33 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1984-ETH">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:13:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ayele-1986-ETH">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:17:46 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Barakat-2005-EGY">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:21:14 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Botros-2005-EGY">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:22:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Branchini-1982-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:23:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Creasey-1986-ZWE">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:44:25 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-De-Clercq-2000-SEN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:49:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Fernandes-1986-BRA">
<DESCRIPTION>
<P>Only patients with moderate to heavy infection were included in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:47:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ferrari-2003-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:50:12 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989a-BDI">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:55:01 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989b-BDI">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:55:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Gryseels-1989c-BDI">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 22:58:20 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Guisse-1997-SEN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:00:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1984-ZMB">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:01:57 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Homeida-1989-SDN">
<DESCRIPTION>
<P>No other bias identified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:05:25 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Ibrahim-1980-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:06:06 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Jaoko-1996-KEN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:06:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Kardaman-1983-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:10:43 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Kardaman-1985-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:12:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1979a-BRA">
<DESCRIPTION>
<P>Only male patients entered the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:14:51 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1979b-BRA">
<DESCRIPTION>
<P>Only male patients entered the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:15:44 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1981-BRA">
<DESCRIPTION>
<P>Only male patients entered the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:16:24 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Katz-1982-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:32 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Lambertucci-1982-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:19:58 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Metwally-1995-EGY">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:21:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olds-1999-KEN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:24:07 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:26:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-MRT">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-11 01:11:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Olliaro-2011-TZA">
<DESCRIPTION>
<P>No other bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:37:26 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1978-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 23:57:21 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Omer-1981-SDN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:00:35 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Queiroz-2010-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:01:51 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rezende-1985-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:02:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Rugemalila-1984-TZA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:02 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Shafei-1979-NGA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:04:48 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Stelma-1997-SEN">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:22 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Sukwa-1993-ZMB">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:06:52 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Taddese-1988-ETH">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:29 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Taylor-1988-ZWE">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:08:55 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Teesdale-1984-MWI">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:09:45 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Tweyongyere-2009-UGA">
<DESCRIPTION>
<P>No other bias reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-24 00:10:13 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-Zwingenberger-1987-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:25:42 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-da-Cunha-1986-BRA">
<DESCRIPTION>
<P>No other bias identified, but low numbers were included in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:27:11 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Cunha-1987-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:28:40 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-da-Silva-1986-BRA">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:34:00 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976a-ZWE">
<DESCRIPTION>
<P>Used very sensitive diagnostic technique: two stools on two consecutive days using a combination of sedimentation, hatching and Visser and Pitchford method. Pretreatment diagnostic sensitivity differed at one time point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:34:38 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="YES" STUDY_ID="STD-de-Clarke-1976b-ZWE">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:40:15 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976c-ZWE">
<DESCRIPTION>
<P>Used very sensitive diagnostic technique: 'two stools on two consecutive days using a combination of sedimentation, hatching and Visser and Pitchford method'. Pretreatment diagnostic sensitivity differed at one time point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:39:59 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Clarke-1976d-ZWE">
<DESCRIPTION>
<P>Used very sensitive diagnostic technique: 'two stools on two consecutive days using a combination of sedimentation, hatching and Visser and Pitchford method'. Pretreatment diagnostic sensitivity differed at one time point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-22 23:48:22 +0100" MODIFIED_BY="Tony Danso-Appiah" RESULT="UNKNOWN" STUDY_ID="STD-de-Jonge-1990-SDN">
<DESCRIPTION>
<P>Only boys aged 6 years were included in the trial, but no reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-12-10 14:04:04 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-12-07 01:00:46 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-11-18 14:29:50 +0000" MODIFIED_BY="[Empty name]">Praziquantel 40 mg/kg for treating <I>S. mansoni</I> infection</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Praziquantel 40 mg/kg for treating <I>S. mansoni</I> infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>S. mansoni</I> infection<BR/>
<B>Settings:</B> Endemic settings<BR/>
<B>Intervention:</B> Praziquantel 40 mg/kg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comparison</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks<SUP>1</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Praziquantel 40 mg/kg</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comparator</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP">
<P>
<B>Parasitological failure</B>
</P>
<P>at 1 month</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>versus placebo</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 100</B>
<BR/>(23 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.13 </B>
<BR/>(1.03 to 9.53)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>414<BR/>(2 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3,4</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 20 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 100</B>
<BR/>(34 to 72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.23 </B>
<BR/>(1.64 to 3.02)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>341<BR/>(2 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 30 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 100</B>
<BR/>(25 to 44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.52</B>
<BR/>(1.15 to 2.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>521<BR/>(3 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 60 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 100</B>
<BR/>(16 to 28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.73 to 1.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>783<BR/>(4 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6,7</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus split dose</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>22 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>10 per 100</B>
<BR/>(3 to 37)</P>
</TD>
<TD>
<P>
<B>RR 0.47 </B>
<BR/>(0.13 to 1.69)</P>
</TD>
<TD>
<P>525<BR/>(2 trials)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,8</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is given in the footnotes.</P>
<P>The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Treatment failure with praziquantel 40 mg/kg ranged from 5% to 48% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<BR/>
<SUP>2</SUP> No serious risk of bias. Both studies adequately concealed allocation and blinded participants and investigators. Loss to follow-up was high in one study.<BR/>
<SUP>3</SUP> No serious inconsistency: Both trials showed statistically significant benefits with praziquantel but the size of the effect varied. In Kenya in 1999 failure with praziquantel was 43% at one month and in Uganda in 2009 it was 18%.<BR/>
<SUP>4</SUP> Downgraded by 1 for indirectness: Only two trials from limited settings have evaluated this comparison.<BR/>
<SUP>5</SUP> Downgraded by 1 for risk of bias: These trials are more than twenty years old and do not provide an adequate description of methods to reduce the risk of bias.<BR/>
<SUP>6</SUP> No serious risk of bias: The three trials by Olliaro in 2010 adequately concealed allocation and blinded participants and investigators to be considered at low risk of bias.<BR/>
<SUP>7</SUP> Downgraded by 1 for indirectness: The trials so far do not indicate a benefit with higher doses than 40 mg/kg. However, we cannot be certain that there might not be some benefit in specific settings.<BR/>
<SUP>8</SUP> Downgraded by 1 for inconsistency: One trial found a significant benefit with splitting the dose and one did not. The trials were of similar size and power.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2012-12-10 14:03:59 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-11-18 14:29:37 +0000" MODIFIED_BY="[Empty name]">Oxamniquine 40 mg/kg for treating <I>S. mansoni </I>infection</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Oxamniquine 40 mg/kg for treating <I>S. mansoni</I> infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>S. mansoni</I> infection<BR/>
<B>Settings:</B> Endemic settings<BR/>
<B>Intervention:</B> Oxamniquine 40 mg/kg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comparison</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks<SUP>1</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oxamniquine 40 mg/kg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comparator</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Parasitological failure</B>
</P>
<P>at 1 month</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>versus placebo<SUP>2</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 100</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 100</B>
<BR/>(66 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 8.74</B>
<BR/>(3.74 to 20.43)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>82<BR/>(2 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 20 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 100</B>
<BR/>(37 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.78</B>
<BR/>(2.05 to 6.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>190<BR/>(2 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 30 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 100</B>
<BR/>(21 to 50)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.78</B>
<BR/>(1.15 to 2.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>268</P>
<P>(4 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>versus 60 mg/kg</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 100</B>
<BR/>(2 to 38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.45</B>
<BR/>(0.09 to 2.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>317<BR/>(4 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is given in the footnotes.</P>
<P>The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P>
<P>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Treatment failure with oxamniquine 40 mg/kg ranged from 5% to 24% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<BR/>
<SUP>2 </SUP>Parasitological failure for the comparison with placebo was only reported at three months.<BR/>
<SUP>3 </SUP>Downgraded by 1 for serious risk of bias: These studies did not adequately describe any methods to reduce the risk of bias.<BR/>
<SUP>4</SUP> Only two small studies have assessed this comparison. However, due to the very large effect size we have not downgraded further for indirectness or imprecision.<BR/>
<SUP>5 </SUP>Downgraded by 1 for indirectness: These studies are either too few, too small, or too old to have full confidence that the results can be generalized to widespread control of <I>S. mansoni</I> today.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2012-12-07 00:58:09 +0000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2012-11-18 14:35:05 +0000" MODIFIED_BY="[Empty name]">Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Praziquantel 40 mg/kg versus oxamniquine 40 mg/kg for treating <I>S. mansoni</I> infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> People with <I>S. mansoni</I> infection<BR/>
<B>Settings:</B> Endemic settings<BR/>
<B>Intervention:</B> Oxamniquine 40 mg/kg</P>
<P>
<B>Control:</B> Praziquantel 40 mg/kg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Praziquantel </B>
</P>
<P>
<B>40 mg/kg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Oxamniquine</P>
<P>40 mg/kg</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Parasitological failure</B>
</P>
<P>at 1 month</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 100</B>
<BR/>(7 to 61)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.40</B>
<BR/>(0.13 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>33<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes.</P>
<P>The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<BR/>
<SUP>2</SUP> Downgraded by 1 for indirectness: This single study is over 20 years old. <BR/>
<SUP>3</SUP> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2012-12-10 14:04:04 +0000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2012-12-03 12:01:53 +0000" MODIFIED_BY="[Empty name]">Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone for treating <I>S. mansoni </I>infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> People with <I>S. mansoni</I> infection<BR/>
<B>Settings:</B> Endemic settings<BR/>
<B>Intervention:</B> Artesunate (12 mg/kg) plus praziquantel (40 mg/kg)</P>
<P>
<B>Control:</B> Praziquantel (40 mg/kg)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Praziquantel </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Artesunate plus praziquantel</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Parasitological failure</B>
</P>
<P>at 1 month</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 100</B>
<BR/>(17 to 55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.62</B>
<BR/>(0.35 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>75<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (eg the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<BR/>
<SUP>2</SUP> Downgraded by 1 for indirectness: This is a single study and the result is not easily generalized.<BR/>
<SUP>3</SUP> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-12-07 10:17:49 +0000" MODIFIED_BY="Tony Danso-Appiah">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-02-29 09:26:47 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-01 04:59:57 +0100" MODIFIED_BY="Tony Danso-Appiah">Detailed search strategies</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD>
<P>
<B>Search set</B>
</P>
</TD>
<TD>
<P>
<B>CIDG SR^</B>
</P>
</TD>
<TD>
<P>
<B>CENTRAL</B>
</P>
</TD>
<TD>
<P>
<B>MEDLINE^^</B>
</P>
</TD>
<TD>
<P>
<B>EMBASE^^</B>
</P>
</TD>
<TD>
<P>
<B>LILACS^^</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Schisto* mansoni</P>
</TD>
<TD>
<P>
<I>SCHISTOSOMA MANSONI</I>
</P>
</TD>
<TD>
<P>
<I>SCHISTOSOMA MANSONI</I>
</P>
</TD>
<TD>
<P>
<I>SCHISTOSOMA MANSONI</I>
</P>
</TD>
<TD>
<P>Schisto$ mansoni</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Esquistossomose</P>
</TD>
<TD>
<P>SCHISTOSOMIASIS MANSONI</P>
</TD>
<TD>
<P>SCHISTOSOMIASIS MANSONI</P>
</TD>
<TD>
<P>SCHISTOSOMIASIS MANSONI</P>
</TD>
<TD>
<P>Esquistossomose</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>1 or 2</P>
</TD>
<TD>
<P>Intestinal schistosom* ti, ab</P>
</TD>
<TD>
<P>Intestinal schistosom* ti, ab</P>
</TD>
<TD>
<P>Intestinal schistosom$ ti, ab</P>
</TD>
<TD>
<P>1 or 2</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Bilharzia*</P>
</TD>
<TD>
<P>Bilharzia*</P>
</TD>
<TD>
<P>Bilharzia$</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Esquistossomose ti, ab</P>
</TD>
<TD>
<P>Esquistossomose ti, ab</P>
</TD>
<TD>
<P>Esquistossomose ti, ab</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Schistosomicide*</P>
</TD>
<TD>
<P>Schistosomicide*</P>
</TD>
<TD>
<P>Schistosomicide$</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD>
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD>
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Limit 7 to humans</P>
</TD>
<TD>
<P>Limit 7 to humans</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>^Cochrane Infectious Diseases Group Specialized Register</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>^^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>); Upper case: MeSH or EMTREE heading; Lower case: free text term</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-11-19 00:32:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2">
<TITLE MODIFIED="2012-03-02 15:14:42 +0000" MODIFIED_BY="[Empty name]">Adverse events: Praziquantel versus placebo</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Praziquantel dose</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jaoko-1996-KEN" TYPE="STUDY">Jaoko 1996 KEN</LINK>
</P>
</TD>
<TD>
<P>436</P>
</TD>
<TD>
<P>40 mg/kg single dose</P>
<P/>
</TD>
<TD>
<P>Adverse events described as minor and transient.</P>
<P>Dizziness: Praziquantel 36% versus 6% control</P>
<P>Abdominal pain 35% versus 14 % control</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1979a-BRA" TYPE="STUDY">Katz 1979a BRA</LINK>
</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>20 mg/kg single dose</P>
<P/>
<P>40 mg/kg: 20 mg/kg twice in one day</P>
<P/>
<P>60 mg/kg: 20 mg/kg three times in one day</P>
</TD>
<TD>
<P>Adverse events were minor, did not differ between intervention and placebo groups, but were not reported separately for the different dose schedules.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1979b-BRA" TYPE="STUDY">Katz 1979b BRA</LINK>
</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>50 mg/kg single dose</P>
<P/>
<P>60 mg/kg: 20 mg/kg three times in one day</P>
</TD>
<TD>
<P>Adverse events were minor, did not differ between the two intervention groups, but were not reported separately for the two dosing schedules.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olds-1999-KEN" TYPE="STUDY">Olds 1999 KEN</LINK>
</P>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>Abdominal pain: Praziquantel 80% versus 50% control</P>
<P>Diarrhoea: Praziquantel 54% versus 25% control</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tweyongyere-2009-UGA" TYPE="STUDY">Tweyongyere 2009 UGA</LINK>
</P>
</TD>
<TD>
<P>387</P>
</TD>
<TD>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>Adverse events were minor and transient. The authors pooled adverse events together over the intervention and placebo groups. Event rates were not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Branchini-1982-BRA" TYPE="STUDY">Branchini 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>41.2 to 51.6 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events. Dizziness: Praziquantel 46.9% (control group not reported).</P>
<P>Abdominal pain: Praziquantel 24.5% versus 17.6% control</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferrari-2003-BRA" TYPE="STUDY">Ferrari 2003 BRA</LINK>
</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>180 mg/kg: 60 mg/kg once daily for three days</P>
<P/>
</TD>
<TD>
<P>No serious adverse events. Events were mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also reported having abdominal pain and drowsiness.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-11-19 00:32:36 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3">
<TITLE MODIFIED="2012-03-11 21:14:48 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: praziquantel (lower dose) versus 40 mg/kg</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1979a-BRA" TYPE="STUDY">Katz 1979a BRA</LINK>
</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>20 mg/kg single dose</P>
<P/>
<P>40 mg/kg: 20 mg/kg twice in one day</P>
</TD>
<TD>
<P>No serious adverse events. Minor adverse events, did not differ between intervention and control groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1981-BRA" TYPE="STUDY">Katz 1981 BRA</LINK>
</P>
</TD>
<TD>
<P>138</P>
</TD>
<TD>
<P>30 mg/kg single dose</P>
<P/>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events. Minor adverse events (lower dose first):</P>
<P>Abdominal pain: 42.6% versus 44.4%</P>
<P>Giddiness: 14.9% versus 26.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1981-SDN" TYPE="STUDY">Omer 1981 SDN</LINK>
</P>
</TD>
<TD>
<P>153</P>
</TD>
<TD>
<P>30 mg/kg single dose</P>
<P/>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events. Diarrhoea, vomiting, nausea and abdominal pain were commonly reported but these were transient.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-11-18 22:34:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4">
<TITLE MODIFIED="2012-03-11 21:14:42 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: praziquantel (higher dose) versus 40 mg/kg</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olliaro-2011-BRA" TYPE="STUDY">Olliaro 2011 BRA</LINK>
</P>
</TD>
<TD>
<P>196</P>
</TD>
<TD>
<P/>
<P/>
<P>60 mg/kg single dose</P>
<P/>
<P>40 mg/kg single dose</P>
<P/>
</TD>
<TD>
<P>No serious adverse event. Minor adverse events (highest dose first):</P>
<P>Abdominal pain: 48 versus 47.9%</P>
<P>Nausea: 20.4% versus 18.4%</P>
<P>Dizziness: 20.4% versus 11.2%</P>
<P>Headache: 14.3% versus 12.2%</P>
<P>Vomiting: 11.2% versus 5.19%</P>
<P>Diarrhoea: 8.2% versus 4.1%</P>
<P>Rarely sleepiness was also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olliaro-2011-MRT" TYPE="STUDY">Olliaro 2011 MRT</LINK>
</P>
</TD>
<TD>
<P>186</P>
</TD>
<TD>
<P>60 mg/kg single dose</P>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>One incidence of serious event was recorded in the higher dose (60 mg/kg). The rest of the events were minor. Transient dizziness, abdominal pain, diarrhoea, vomiting and headache were commonly reported (highest dose first):</P>
<P>Dizziness: 77.8% versus 9.7%</P>
<P>Abdominal pain:79.6% versus 71.0%</P>
<P>Diarrhoea: 41.9% versus 49.5%</P>
<P>Vomiting: 10.7% versus 32.3%</P>
<P>Headache: 9.7% versus 14.0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olliaro-2011-TZA" TYPE="STUDY">Olliaro 2011 TZA</LINK>
</P>
</TD>
<TD>
<P>271</P>
</TD>
<TD>
<P>60 mg/kg single dose</P>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>Minor adverse events (highest dose first):</P>
<P>Abdominal pain: 88.9% versus 83.8%</P>
<P>Diarrhoea: 47.4% versus 49.3%</P>
<P>Nausea: 26.7% versus 30.9%</P>
<P>Headache: 14.1% versus 9.6%</P>
<P>Vomiting: 11.1% versus 16.9%</P>
<P>Dizziness: 6.7% versus 9.6%</P>
<P>Fever: 0% versus 1.5%.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2012-11-19 00:33:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="5">
<TITLE MODIFIED="2012-03-12 21:09:37 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose</TITLE>
<TABLE COLS="4" ROWS="3">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kardaman-1983-SDN" TYPE="STUDY">Kardaman 1983 SDN</LINK>
</P>
</TD>
<TD>
<P>350</P>
</TD>
<TD>
<P>40 mg/kg: 20 mg/kg twice in a day</P>
<P/>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events. Events were transient (divided dose first): Abdominal pain: 13.5% versus 24.6%</P>
<P>Vomiting: 7.6% versus 4%</P>
<P>Diarrhoea: 7.6% versus 12.8%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1981-SDN" TYPE="STUDY">Omer 1981 SDN</LINK>
</P>
</TD>
<TD>
<P>306</P>
</TD>
<TD>
<P>40 mg/kg: 20 mg/kg twice in a day</P>
<P/>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events.</P>
<P>Adverse events were transient and required no additional intervention.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2012-12-07 10:17:49 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="6">
<TITLE MODIFIED="2012-03-11 21:14:28 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: praziquantel alternative dosing (Brazil)</TITLE>
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-da-Cunha-1987-BRA" TYPE="STUDY">da Cunha 1987 BRA</LINK>
</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P/>
<P>180 mg/kg: 30 mg/kg twice daily for three days</P>
<P>180 mg/kg: 30 mg/kg daily for six days</P>
<P>120 mg/kg: 30 mg/kg twice daily for two days</P>
<P/>
<P>60 mg/kg: 30 mg/kg twice in one day</P>
<P/>
</TD>
<TD>
<P>No serious adverse events.</P>
<P>Minor and transient events (highest dose first):</P>
<P>Dizziness: 65%, 15%, 45% versus 15%</P>
<P>Nausea: 55%, 15, 20% versus 20%</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2012-11-19 00:33:48 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="7">
<TITLE MODIFIED="2012-03-11 21:14:20 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: oxamniquine versus placebo</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Oxamniquine dose</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1984-ETH" TYPE="STUDY">Ayele 1984 ETH</LINK>
</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for two days</P>
<P/>
<P>40 mg/kg: 10 mg/kg twice daily for two days</P>
<P/>
<P>30 mg/kg: 15 mg/kg twice in one day</P>
</TD>
<TD>
<P>Adverse events were minor and transient.</P>
<P>Dizziness: Oxamniquine (15 mg/kg BD for 2 days) 50% versus 38.9% (10 mg/kg BD for two days) versus 30% control.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1986-ETH" TYPE="STUDY">Ayele 1986 ETH</LINK>
</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for two days</P>
<P/>
<P>40 mg/kg: 20 mg/kg twice in one day</P>
<P/>
<P>30 mg/kg: 15 mg/kg twice in one day</P>
</TD>
<TD>
<P>All the doses were well tolerated and accepted. Dizziness was the most frequently reported complaint, but this was mild and transient.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lambertucci-1982-BRA" TYPE="STUDY">Lambertucci 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>20 mg/kg single dose</P>
<P/>
</TD>
<TD>
<P>Adverse events were minor and transient.</P>
<P>Dizziness: Oxamniquine 14.6% versus 2.8% control</P>
<P>Nausea: Oxamniquine 14.6% versus 5.6% control.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Branchini-1982-BRA" TYPE="STUDY">Branchini 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>14 mg/kg single dose</P>
</TD>
<TD>
<P>Adverse events were few and minor. Dizziness: Oxamniquine 44.2% (control not reported)</P>
<P>Abdominal pain: Oxamniquine 11.5% versus 17.6% control.</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferrari-2003-BRA" TYPE="STUDY">Ferrari 2003 BRA</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>20 mg/kg: 10 mg/kg twice in one day</P>
</TD>
<TD>
<P>No serious adverse events.</P>
<P>Adverse events were mild, mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also had abdominal pain and drowsiness.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2012-11-19 00:45:26 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="8">
<TITLE MODIFIED="2012-03-11 14:27:07 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: oxamniquine (lower dose) versus 40 mg/kg</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1984-ETH" TYPE="STUDY">Ayele 1984 ETH</LINK>
</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>30 mg/kg: 15 mg/kg twice in one day.</P>
</TD>
<TD>
<P>No serious adverse events were reported. Transient dizziness and nausea were commonly reported (lower dose first):</P>
<P>Dizziness: 38.9% versus 42%</P>
<P>Nausea: 22.2% versus 26.3%</P>
<P>A few mild headaches and abdominal pain were also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1986-ETH" TYPE="STUDY">Ayele 1986 ETH</LINK>
</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>30 mg/kg:15 mg/kg twice in one day.</P>
</TD>
<TD>
<P>All doses were well tolerated and no serious event was recorded. Dizziness was more commonly reported, but this was transient.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Clarke-1976b-ZWE" TYPE="STUDY">de Clarke 1976b ZWE</LINK>
</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>20 mg/kg: 5 x 2 mg/kg daily for two days</P>
<P/>
<P>30 mg/kg: 7.5 x 2 mg/kg daily for two days.</P>
</TD>
<TD>
<P>No serious adverse events were recorded. Transient dizziness was more commonly reported and very rarely headache, nausea, and vomiting. Adverse events did not differ between dose.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gupta-1984-ZMB" TYPE="STUDY">Gupta 1984 ZMB</LINK>
</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>30 mg/kg:15 mg/kg twice in one day</P>
<P/>
<P>40 mg/kg: 10 mg/kg twice daily for two days</P>
</TD>
<TD>
<P>No serious events were reported. Adverse events were mainly dizziness and nausea, but were minor and transient (lower dose first):</P>
<P>Dizziness: 20% versus 25%</P>
<P>Nausea: 15% versus 30%</P>
<P>A few events of vomiting, headache and abdominal pain were also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1978-SDN" TYPE="STUDY">Omer 1978 SDN</LINK>
</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>30 mg/kg: 15 mg/kg twice in one day</P>
<P/>
<P>40 mg/kg: 20 mg/kg daily for 2 days</P>
<P/>
</TD>
<TD>
<P>No serious adverse events were recorded. Asthenia (weakness) was reported among a few receiving 40 mg/kg, but this did not require additional intervention. Transient dizziness was more commonly reported (lower dose first)</P>
<P>Dizziness: 3% versus 8%</P>
<P>Minor abdominal pain, headache and vomiting also reported.</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Teesdale-1984-MWI" TYPE="STUDY">Teesdale 1984 MWI</LINK>
</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>20 mg/kg single dose</P>
<P/>
<P>30 mg/kg single dose</P>
<P/>
</TD>
<TD>
<P>Noserious adverse events were recorded. Transient dizziness, nausea and vomiting were most commonly reported.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2012-11-19 00:46:19 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="9">
<TITLE MODIFIED="2012-03-11 21:14:10 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: oxamniquine (higher dose) versus 40 mg/kg</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1984-ETH" TYPE="STUDY">Ayele 1984 ETH</LINK>
</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for two days</P>
<P/>
<P>40 mg/kg: 10 mg/kg twice daily for two days</P>
<P/>
<P/>
<P/>
</TD>
<TD>
<P>No serious adverse event was recorded. Dizziness and nausea were commonly reported but these were transient (higher dose first):</P>
<P>Dizziness: 50% versus 42%</P>
<P>Nausea: 11% versus 26.3%</P>
<P/>
<P>A few mild headaches and abdominal pain were also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1986-ETH" TYPE="STUDY">Ayele 1986 ETH</LINK>
</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for 2 days</P>
<P/>
<P>40 mg/kg: 20 mg/kg twice in one day</P>
</TD>
<TD>
<P>No serious adverse events were recorded. Dizziness was more commonly reported, but this was transient and did not differ between dose.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gupta-1984-ZMB" TYPE="STUDY">Gupta 1984 ZMB</LINK>
</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for two days</P>
<P/>
<P>40 mg/kg: 10 mg/kg twice for daily for two days</P>
</TD>
<TD>
<P>No serious events were reported. Transient dizziness and nausea were more commonly reported (higher dose first):</P>
<P>Dizziness: 40% versus 25%</P>
<P>Nausea: 25% versus 30%</P>
<P/>
<P>A few events of vomiting, headache and abdominal pain were also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1978-SDN" TYPE="STUDY">Omer 1978 SDN</LINK>
</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>60 mg/kg: 15 mg/kg twice daily for 2 days</P>
<P/>
<P>40 mg/kg: 20 mg/kg daily for 2 days</P>
</TD>
<TD>
<P>No serious adverse events was recorded. Transient dizziness was more commonly reported (higher dose first):</P>
<P>Dizziness: 15% versus 8%</P>
<P/>
<P>Few minor abdominal pain, headache and vomiting were also reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Teesdale-1984-MWI" TYPE="STUDY">Teesdale 1984 MWI</LINK>
</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>50 mg/kg single dose</P>
<P/>
<P>40 mg/kg single dose</P>
</TD>
<TD>
<P>No serious adverse events was recorded. Transient dizziness, nausea and vomiting were most commonly reported and did not differ between dose.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2012-12-07 10:17:49 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="10">
<TITLE MODIFIED="2010-04-24 17:22:04 +0100" MODIFIED_BY="[Empty name]">Commonly used dosing schedule of oxamniquine and praziquantel according to location</TITLE>
<TABLE COLS="4" ROWS="54">
<TR>
<TH ROWSPAN="2">
<P>
<B>Trial</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Location (country)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>
<B>Dose</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>Oxamniquine (mg/kg)</B>
</P>
</TH>
<TH>
<P>
<B>Praziquantel (mg/kg)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>South America</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Branchini-1982-BRA" TYPE="STUDY">Branchini 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>45.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-da-Cunha-1986-BRA" TYPE="STUDY">da Cunha 1986 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-da-Cunha-1987-BRA" TYPE="STUDY">da Cunha 1987 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>60, 120, 180</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-da-Silva-1986-BRA" TYPE="STUDY">da Silva 1986 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fernandes-1986-BRA" TYPE="STUDY">Fernandes 1986 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>70</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferrari-2003-BRA" TYPE="STUDY">Ferrari 2003 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>180</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1979a-BRA" TYPE="STUDY">Katz 1979a BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>20, 40, 60</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1979b-BRA" TYPE="STUDY">Katz 1979b BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1981-BRA" TYPE="STUDY">Katz 1981 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>30, 30, 50</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Katz-1982-BRA" TYPE="STUDY">Katz 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lambertucci-1982-BRA" TYPE="STUDY">Lambertucci 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Queiroz-2010-BRA" TYPE="STUDY">Queiroz 2010 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>50, 80</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rezende-1985-BRA" TYPE="STUDY">Rezende 1985 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zwingenberger-1987-BRA" TYPE="STUDY">Zwingenberger 1987 BRA</LINK>
</P>
</TD>
<TD>
<P>Brazil</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>North Africa</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>20, 40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Jonge-1990-SDN" TYPE="STUDY">de Jonge 1990 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homeida-1989-SDN" TYPE="STUDY">Homeida 1989 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ibrahim-1980-SDN" TYPE="STUDY">Ibrahim 1980 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kardaman-1983-SDN" TYPE="STUDY">Kardaman 1983 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1978-SDN" TYPE="STUDY">Omer 1978 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>30, 40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Omer-1981-SDN" TYPE="STUDY">Omer 1981 SDN</LINK>
</P>
</TD>
<TD>
<P>Sudan</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>30, 40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Barakat-2005-EGY" TYPE="STUDY">Barakat 2005 EGY</LINK>
</P>
</TD>
<TD>
<P>Egypt</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Botros-2005-EGY" TYPE="STUDY">Botros 2005 EGY</LINK>
</P>
</TD>
<TD>
<P>Egypt</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Metwally-1995-EGY" TYPE="STUDY">Metwally 1995 EGY</LINK>
</P>
</TD>
<TD>
<P>Egypt</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>East Africa</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1984-ETH" TYPE="STUDY">Ayele 1984 ETH</LINK>
</P>
</TD>
<TD>
<P>Ethiopia</P>
</TD>
<TD>
<P>30, 40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayele-1986-ETH" TYPE="STUDY">Ayele 1986 ETH</LINK>
</P>
</TD>
<TD>
<P>Ethiopia</P>
</TD>
<TD>
<P>30, 40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jaoko-1996-KEN" TYPE="STUDY">Jaoko 1996 KEN</LINK>
</P>
</TD>
<TD>
<P>Kenya</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olds-1999-KEN" TYPE="STUDY">Olds 1999 KEN</LINK>
</P>
</TD>
<TD>
<P>Kenya</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Taddese-1988-ETH" TYPE="STUDY">Taddese 1988 ETH</LINK>
</P>
</TD>
<TD>
<P>Ethiopia</P>
</TD>
<TD>
<P>15, 30</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Teesdale-1984-MWI" TYPE="STUDY">Teesdale 1984 MWI</LINK>
</P>
</TD>
<TD>
<P>Malawi</P>
</TD>
<TD>
<P>30, 40, 50</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rugemalila-1984-TZA" TYPE="STUDY">Rugemalila 1984 TZA</LINK>
</P>
</TD>
<TD>
<P>Tanzania</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tweyongyere-2009-UGA" TYPE="STUDY">Tweyongyere 2009 UGA</LINK>
</P>
</TD>
<TD>
<P>Uganda</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>West Africa</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shafei-1979-NGA" TYPE="STUDY">Shafei 1979 NGA</LINK>
</P>
</TD>
<TD>
<P>Nigeria</P>
</TD>
<TD>
<P>15, 30</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-Clercq-2000-SEN" TYPE="STUDY">De Clercq 2000 SEN</LINK>
</P>
</TD>
<TD>
<P>Senegal</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guisse-1997-SEN" TYPE="STUDY">Guisse 1997 SEN</LINK>
</P>
</TD>
<TD>
<P>Senegal</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40, 60</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stelma-1997-SEN" TYPE="STUDY">Stelma 1997 SEN</LINK>
</P>
</TD>
<TD>
<P>Senegal</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Central Africa</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD>
<P>Burundi</P>
</TD>
<TD>
<P>20, 30, 40</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD>
<P>Burundi</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>20, 30, 40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Southern Africa</B>
</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gupta-1984-ZMB" TYPE="STUDY">Gupta 1984 ZMB</LINK>
</P>
</TD>
<TD>
<P>Zambia</P>
</TD>
<TD>
<P>30, 40, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sukwa-1993-ZMB" TYPE="STUDY">Sukwa 1993 ZMB</LINK>
</P>
</TD>
<TD>
<P>Zambia</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Clarke-1976a-ZWE" TYPE="STUDY">de Clarke 1976a ZWE</LINK>
</P>
</TD>
<TD>
<P>Zimbabwe</P>
</TD>
<TD>
<P>15, 20</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Clarke-1976b-ZWE" TYPE="STUDY">de Clarke 1976b ZWE</LINK>
</P>
</TD>
<TD>
<P>Zimbabwe</P>
</TD>
<TD>
<P>30, 40</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Clarke-1976c-ZWE" TYPE="STUDY">de Clarke 1976c ZWE</LINK>
</P>
</TD>
<TD>
<P>Zimbabwe</P>
</TD>
<TD>
<P>50, 60</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Taylor-1988-ZWE" TYPE="STUDY">Taylor 1988 ZWE</LINK>
</P>
</TD>
<TD>
<P>Zimbabwe</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>10, 20, 30, 40</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Middle East</B>
</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Al-Aska-1990-SAU" TYPE="STUDY">Al Aska 1990 SAU</LINK>
</P>
</TD>
<TD>
<P>Saudi Arabia</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2012-11-19 00:47:05 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="11">
<TITLE MODIFIED="2012-03-12 12:27:36 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg)</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Al-Aska-1990-SAU" TYPE="STUDY">Al Aska 1990 SAU</LINK>
</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>Oxamniquine (25 mg/kg) single dose</P>
<P/>
<P>Praziquantel (40 mg/kg) single dose</P>
</TD>
<TD VALIGN="MIDDLE">
<P>One serious adverse event (seizure) was recorded in the oxamniquine 25 mg/kg group. Transient dizziness, abdominal pain and nausea were most commonly reported (oxamniquine first):</P>
<P>Dizziness: 36% versus 20%</P>
<P>Abdominal pain: 25% versus 12%</P>
<P>Nausea: 10% versus 8 %</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Branchini-1982-BRA" TYPE="STUDY">Branchini 1982 BRA</LINK>
</P>
</TD>
<TD>
<P>101</P>
</TD>
<TD>
<P>Oxamniquine (14 mg/kg) single dose</P>
<P/>
<P>Praziquantel (45 mg/kg) single dose</P>
</TD>
<TD VALIGN="MIDDLE">
<P>No serious adverse events were recorded. Adverse events were minor and transient. Dizziness, abdominal pain and nausea were most frequently reported (oxamniquine first):</P>
<P>Dizziness: 44.2% versus 46.9%</P>
<P>Abdominal pain: 3.8% versus 24.5%</P>
<P>Nausea: 5.8% versus 8.2%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rugemalila-1984-TZA" TYPE="STUDY">Rugemalila 1984 TZA</LINK>
</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>Oxamniquine (15 mg/kg) single dose</P>
<P/>
<P>Praziquantel (40 mg/kg) single dose</P>
</TD>
<TD VALIGN="MIDDLE">
<P>No serious adverse events were recorded. Transient abdominal pain and drowsiness were commonly reported (oxamniquine first):</P>
<P>Abdominal pain: 16% versus 63%</P>
<P>Drowsiness: 25% versus 11%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Taddese-1988-ETH" TYPE="STUDY">Taddese 1988 ETH</LINK>
</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>Oxamniquine (15 mg/kg) single dose</P>
<P/>
<P>Oxamniquine 30 mg/kg :15 mg/kg twice in one day</P>
<P/>
<P>Praziquantel (40 mg/kg) single dose</P>
</TD>
<TD VALIGN="MIDDLE">
<P>One serious adverse event (seizure) was recorded with oxamniquine 30 mg/kg. Adverse events were minor and transient. Dizziness and abdominal pain were commonly reported (oxamniquine lower dose first):</P>
<P>Dizziness: 22%, 16% versus 20%</P>
<P>Abdominal pain: 20%, 28% versus 24%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Teesdale-1984-MWI" TYPE="STUDY">Teesdale 1984 MWI</LINK>
</P>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>Oxamniquine (30 mg/kg) single dose</P>
<P/>
<P>Oxamniquine (40 mg/kg) single dose</P>
<P/>
<P>Oxamniquine (50 mg/kg): 25 mg/kg twice in one day</P>
<P/>
<P>Praziquantel (40 mg/kg) single dose</P>
</TD>
<TD VALIGN="MIDDLE">
<P>No serious adverse events were recorded. Transient dizziness was commonly reported among participants receiving oxamniquine. There was no difference in events between oxamniquine 30, 40 and 50 mg/kg (oxamniquine lower dose first):</P>
<P/>
<P>Dizziness: 30.8%, 29.2%, 30.8% versus 8.3%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" MODIFIED="2012-12-03 11:31:22 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="12">
<TITLE MODIFIED="2012-03-12 19:20:00 +0000" MODIFIED_BY="Tony Danso-Appiah">Adverse events: oxamniquine plus praziquantel versus oxamniquine plus praziquantel</TITLE>
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>
<B>Trial</B>
</P>
</TH>
<TH>
<P>
<B>No. of participants</B>
</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Remarks</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Creasey-1986-ZWE" TYPE="STUDY">Creasey 1986 ZWE</LINK>
</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>Oxamniquine (4 mg/kg) plus praziquantel (8 mg/kg) versus oxamniquine (10 mg/kg) plus praziquantel (20 mg/kg)</P>
<P/>
<P>Oxamniquine (7.5 mg/kg) plus</P>
<P>praziquantel (15 mg/kg) versus</P>
<P>praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</P>
</TD>
<TD>
<P>No serious adverse events. Adverse events were minor and did not differ between combinations. One child reported dizziness five minutes after treatment but required no further treatment and was well the following day. About 70% of children reported abdominal discomfort but these were transient and had resolved the following day.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-13" MODIFIED="2012-12-03 11:31:28 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="13">
<TITLE MODIFIED="2012-11-18 22:36:13 +0000" MODIFIED_BY="[Empty name]">Non-randomized exploratory analysis of age (praziquantel)</TITLE>
<TABLE COLS="5" ROWS="21">
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Dose (mg/kg)</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Time point (months)</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>
<B>Number failed/number examined  (%)</B>
<SUP>1</SUP>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Children (&lt;20 years)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Adults (&#8805;20 years)</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>48/109 (44)</P>
</TD>
<TD VALIGN="TOP">
<P>26/61 (43)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>49/100 (49)</P>
</TD>
<TD VALIGN="TOP">
<P>16/54 (30)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>61/109 (56)</P>
</TD>
<TD VALIGN="TOP">
<P>19/58 (33)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>60/101 (59)</P>
</TD>
<TD VALIGN="TOP">
<P>21/59 (36)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>1</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>37/93 (40)</P>
</TD>
<TD VALIGN="TOP">
<P>2/48 (4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>37/104 (36)</P>
</TD>
<TD VALIGN="TOP">
<P>12/65 (18)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>3</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>38/91 (42)</P>
</TD>
<TD VALIGN="TOP">
<P>4/40 (10)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>37/98 (38)</P>
</TD>
<TD VALIGN="TOP">
<P>10/66 (15)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>6</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>41/94 (44)</P>
</TD>
<TD VALIGN="TOP">
<P>6/46 (13)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>40/94 (43)</P>
</TD>
<TD VALIGN="TOP">
<P>19/61 (31)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>12</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>55/91 (60)</P>
</TD>
<TD VALIGN="TOP">
<P>9/44 (20)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>73/92 (79)</P>
</TD>
<TD VALIGN="TOP">
<P>19/51 (37)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>1</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>22/94 (23)</P>
</TD>
<TD VALIGN="TOP">
<P>5/42 (12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>18/81 (22)</P>
</TD>
<TD VALIGN="TOP">
<P>2/54 (4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>3</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>23/87 (26)</P>
</TD>
<TD VALIGN="TOP">
<P>1/32 (3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>26/83 (31)</P>
</TD>
<TD VALIGN="TOP">
<P>11/54 (20)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="MIDDLE">
<P>6</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>29/92 (32)</P>
</TD>
<TD VALIGN="TOP">
<P>4/37 (11)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989c-BDI" TYPE="STUDY">Gryseels 1989c BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>23/76 (30)</P>
</TD>
<TD VALIGN="TOP">
<P>10/51 (20)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989b-BDI" TYPE="STUDY">Gryseels 1989b BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>34/84 (40)</P>
</TD>
<TD VALIGN="TOP">
<P>10/38 (26)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Number failed/number examined (%) presented for the praziquantel treatment group of each study that presents data for adults and children separately.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-14" MODIFIED="2012-11-18 23:04:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="14">
<TITLE MODIFIED="2012-11-18 22:37:02 +0000" MODIFIED_BY="[Empty name]">Non-randomized exploratory analysis of age (oxamniquine)</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH ROWSPAN="2">
<P>
<B>Dose (mg/kg)</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Time point (month)</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>
<B>Number failed/number examined (%)</B>
<SUP>1</SUP>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Children (&lt; 20 years)</B>
</P>
<P/>
</TH>
<TH VALIGN="TOP">
<P>
<B>Adults (&#8805; 20 years)</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="7">
<P>20</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>1</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>11/41 (26)</P>
</TD>
<TD VALIGN="TOP">
<P>3/55 (6)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>31/57 (60)</P>
</TD>
<TD VALIGN="TOP">
<P>17/95 (17)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P> 6/41 (15)</P>
</TD>
<TD VALIGN="TOP">
<P>4/55 (7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30/56 (54)</P>
</TD>
<TD VALIGN="TOP">
<P>22/102 (22)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>6</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10/41 (24)</P>
</TD>
<TD VALIGN="TOP">
<P>9/55 (16)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>29/49 (59)</P>
</TD>
<TD VALIGN="TOP">
<P>20/86 (23)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>38/41 (93)</P>
</TD>
<TD VALIGN="TOP">
<P>20/83 (24)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>16/42 (38)</P>
</TD>
<TD VALIGN="TOP">
<P>2/76 (3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12/46 (26)</P>
</TD>
<TD VALIGN="TOP">
<P>8/77 (10)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>22/41 (54)</P>
</TD>
<TD VALIGN="TOP">
<P>3/62 (5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>24/39 (62)</P>
</TD>
<TD VALIGN="TOP">
<P>10/67 (15)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7">
<P>40</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>1</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2/43 (5)</P>
</TD>
<TD VALIGN="TOP">
<P>1/57 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>8/49 (19)</P>
</TD>
<TD VALIGN="TOP">
<P>2/67 (3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>5/43 (12)</P>
</TD>
<TD VALIGN="TOP">
<P>3/57 (5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10/51 (20)</P>
</TD>
<TD VALIGN="TOP">
<P>5/65 (8)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>6</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>13/31 (42)</P>
</TD>
<TD VALIGN="TOP">
<P>5/57 (9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>24/42 (57)</P>
</TD>
<TD VALIGN="TOP">
<P>11/62 (18)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gryseels-1989a-BDI" TYPE="STUDY">Gryseels 1989a BDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>25/38 (66)</P>
</TD>
<TD VALIGN="TOP">
<P>11/60 (18)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2/42 (5)</P>
</TD>
<TD VALIGN="TOP">
<P>0/58 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10/42 (24)</P>
</TD>
<TD VALIGN="TOP">
<P>1/58 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abdel-Rahim-1988-SDN" TYPE="STUDY">Abdel Rahim 1988 SDN</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>16/42 (38)</P>
</TD>
<TD VALIGN="TOP">
<P>1/58 (2)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Number failed/number examined (%) presented for the oxamniquine treatment group of each study that presents data for adults and children separately.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-12-06 23:16:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1">
<NAME>Praziquantel versus placebo</NAME>
<DICH_OUTCOME CHI2="23.799381800957455" CI_END="9.531955211206075" CI_START="1.0297280173376742" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1329413242170276" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="58" I2="95.79821018729247" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9791819930143522" LOG_CI_START="0.012722529396749215" LOG_EFFECT_SIZE="0.4959522612055507" METHOD="MH" MODIFIED="2012-12-06 23:16:20 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.069186705504599E-6" P_Q="1.0" P_Z="0.04426569091345135" Q="0.0" RANDOM="YES" SCALE="17.78" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6175778514829039" TOTALS="SUB" TOTAL_1="205" TOTAL_2="209" WEIGHT="99.99999999999999" Z="2.0115661475868984">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.799381800957455" CI_END="9.531955211206075" CI_START="1.0297280173376742" DF="1" EFFECT_SIZE="3.1329413242170276" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="58" I2="95.79821018729247" ID="CMP-001.01.01" LOG_CI_END="0.9791819930143522" LOG_CI_START="0.012722529396749215" LOG_EFFECT_SIZE="0.4959522612055507" MODIFIED="2012-09-04 23:39:21 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.069186705504599E-6" P_Z="0.04426569091345135" STUDIES="2" TAU2="0.6175778514829039" TOTAL_1="205" TOTAL_2="209" WEIGHT="99.99999999999999" Z="2.0115661475868984">
<NAME>40 mg/kg single dose</NAME>
<DICH_DATA CI_END="2.408994342659671" CI_START="1.395549270780811" EFFECT_SIZE="1.8335403726708075" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="35" LOG_CI_END="0.38183578009192076" LOG_CI_START="0.14474517414638768" LOG_EFFECT_SIZE="0.26329047711915426" MODIFIED="2012-08-22 13:27:21 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="1" O_E="0.0" SE="0.13926819554983344" STUDY_ID="STD-Olds-1999-KEN" TOTAL_1="92" TOTAL_2="82" VAR="0.019395630291706645" WEIGHT="50.596577140635304"/>
<DICH_DATA CI_END="7.81583804479414" CI_START="3.762622806149395" EFFECT_SIZE="5.422918999626726" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="23" LOG_CI_END="0.8929755516087529" LOG_CI_START="0.575490683528849" LOG_EFFECT_SIZE="0.734233117568801" MODIFIED="2012-09-04 23:39:21 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="2" O_E="0.0" SE="0.1864921830855786" STUDY_ID="STD-Tweyongyere-2009-UGA" TOTAL_1="113" TOTAL_2="127" VAR="0.03477933435202497" WEIGHT="49.40342285936468"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:16:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="47" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:35:57 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>20 mg/kg single dose</NAME>
<DICH_DATA CI_END="5.8717390351499805" CI_START="0.8458364008539488" EFFECT_SIZE="2.2285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.7687667454582776" LOG_CI_START="-0.07271362877786809" LOG_EFFECT_SIZE="0.3480265583402048" MODIFIED="2012-09-05 21:35:57 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="159" O_E="0.0" SE="0.49428973722134306" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="6" TOTAL_2="5" VAR="0.24432234432234437" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:35:56 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="3" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>40 mg/kg in two divided doses on the same day</NAME>
<DICH_DATA CI_END="181.64728755661196" CI_START="0.826120235642009" EFFECT_SIZE="12.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.259228917156118" LOG_CI_START="-0.08295673975501548" LOG_EFFECT_SIZE="1.0881360887005513" MODIFIED="2012-09-05 21:35:56 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="160" O_E="0.0" SE="1.3758114488755873" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="3" TOTAL_2="6" VAR="1.8928571428571428" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:35:57 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>60 mg/kg in 3 divided doses 3 hours apart</NAME>
<DICH_DATA CI_END="345.1333300101604" CI_START="1.5062005167240635" EFFECT_SIZE="22.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.537986901744499" LOG_CI_START="0.17788279225640885" LOG_EFFECT_SIZE="1.3579348470004537" MODIFIED="2012-09-05 21:35:57 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="161" O_E="0.0" SE="1.3863368366170623" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="9" TOTAL_2="11" VAR="1.9219298245614034" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:35:38 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>60 mg/kg daily for 3 days</NAME>
<DICH_DATA CI_END="772.8726249865348" CI_START="3.1703154191063385" EFFECT_SIZE="49.5" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" LOG_CI_END="2.8881079249355883" LOG_CI_START="0.5011024729315497" LOG_EFFECT_SIZE="1.6946051989335686" MODIFIED="2012-09-05 21:35:38 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="162" O_E="0.0" SE="1.4021388183747234" STUDY_ID="STD-Ferrari-2003-BRA" TOTAL_1="29" TOTAL_2="26" VAR="1.965993265993266" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-05 21:36:47 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="489.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at 12 months</NAME>
<GROUP_LABEL_1>Favours placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:35:37 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>20 mg/kg single dose</NAME>
<DICH_DATA CI_END="1.8053206312494898" CI_START="0.39084469970946023" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.25655434530879445" LOG_CI_START="-0.4079957731850311" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2012-09-05 21:35:37 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="159" O_E="0.0" SE="0.3903600291794133" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="4" TOTAL_2="2" VAR="0.1523809523809524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-05 21:36:47 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>40 mg/kg in two divided doses on the same day</NAME>
<DICH_DATA CI_END="14.969707168259669" CI_START="0.8981100494036888" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.1752133049220224" LOG_CI_START="-0.04667044404489703" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2012-09-05 21:36:47 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="160" O_E="0.0" SE="0.7177405625652734" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="5" TOTAL_2="5" VAR="0.5151515151515151" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-22 13:23:45 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>60 mg/kg in 3 divided doses 3 hours apart</NAME>
<DICH_DATA CI_END="10.170175788944146" CI_START="0.9221970637120818" EFFECT_SIZE="3.0625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.007328459659089" LOG_CI_START="-0.03517626491391151" LOG_EFFECT_SIZE="0.4860760973725889" MODIFIED="2012-08-22 13:23:45 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="161" O_E="0.0" SE="0.6123724356957945" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="8" TOTAL_2="7" VAR="0.37499999999999994" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-12-07 00:26:56 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Praziquantel (lower dose) versus praziquantel 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="5.902659267522219" CI_END="2.2102387546636075" CI_START="1.4650050369374972" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7994473897329275" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="98" I2="32.23393357619481" I2_Q="69.52615231605232" ID="CMP-002.01" LOG_CI_END="0.3444391896273434" LOG_CI_START="0.1658391178712888" LOG_EFFECT_SIZE="0.2551391537493161" METHOD="MH" MODIFIED="2012-12-06 23:17:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.20653673034261577" P_Q="0.0700648321414662" P_Z="2.145824551123699E-8" Q="3.2815022584980547" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="439" TOTAL_2="423" WEIGHT="200.0" Z="5.599813566454908">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4266352288691015" CI_END="3.0210643474522527" CI_START="1.6387553301635989" DF="1" EFFECT_SIZE="2.2250360226644856" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="40" I2="29.904997453854882" ID="CMP-002.01.01" LOG_CI_END="0.480159975669116" LOG_CI_START="0.21451411727289219" LOG_EFFECT_SIZE="0.3473370464710041" MODIFIED="2012-03-16 10:29:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.23231460804534898" P_Z="2.9693685624817614E-7" STUDIES="2" TAU2="0.0" TOTAL_1="170" TOTAL_2="171" WEIGHT="100.0" Z="5.1253808788111">
<NAME>Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="4.272807471703261" CI_START="1.750623119981775" EFFECT_SIZE="2.7349726775956285" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="18" LOG_CI_END="0.6307133243967342" LOG_CI_START="0.24319265977308183" LOG_EFFECT_SIZE="0.43695299208490795" MODIFIED="2012-03-07 03:29:41 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="127" O_E="0.0" SE="0.22763155665816057" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="61" TOTAL_2="77" VAR="0.05181612558661737" WEIGHT="40.24679587879051">
<FOOTNOTE>Praziquantel 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.8709325703917608" CI_START="1.2331526259799654" EFFECT_SIZE="1.8815679733110926" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="22" LOG_CI_END="0.4580229923395318" LOG_CI_START="0.0910168320853801" LOG_EFFECT_SIZE="0.27451991221245603" MODIFIED="2012-03-07 03:30:12 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="157" O_E="0.0" SE="0.2155812352430815" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="109" TOTAL_2="94" VAR="0.04647526898893285" WEIGHT="59.7532041212095">
<FOOTNOTE>Praziquantel 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0596631087406472" CI_END="2.006766144018667" CI_START="1.146332625406361" DF="2" EFFECT_SIZE="1.516714047686484" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="58" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.3024967654721669" LOG_CI_START="0.05931065290036855" LOG_EFFECT_SIZE="0.18090370918626772" MODIFIED="2012-03-16 10:28:00 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.5887042222723453" P_Z="0.003545560845773576" STUDIES="3" TAU2="0.0" TOTAL_1="269" TOTAL_2="252" WEIGHT="100.0" Z="2.91599508643908">
<NAME>Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.0590971968676572" CI_START="0.6857322758976722" EFFECT_SIZE="1.1882716049382716" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.31367684737907303" LOG_CI_START="-0.163845408775296" LOG_EFFECT_SIZE="0.07491571930188852" MODIFIED="2012-03-07 03:30:21 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="616" O_E="0.0" SE="0.2804989370383668" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="72" TOTAL_2="77" VAR="0.07867965367965368" WEIGHT="29.22898924372163">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5939342010255984" CI_START="0.9881044193872529" EFFECT_SIZE="1.6009615384615385" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="18" LOG_CI_END="0.4139589553664374" LOG_CI_START="-0.0051971582793206555" LOG_EFFECT_SIZE="0.20438089854355834" MODIFIED="2012-03-07 03:30:28 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="615" O_E="0.0" SE="0.24621437601174367" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="104" TOTAL_2="81" VAR="0.060621518954852294" WEIGHT="34.00393523428757">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.6474207235474285" CI_START="1.0915029968743093" EFFECT_SIZE="1.699902248289345" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="22" LOG_CI_END="0.4228229641180001" LOG_CI_START="0.0380249324631046" LOG_EFFECT_SIZE="0.23042394829055232" MODIFIED="2012-03-07 03:30:35 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="614" O_E="0.0" SE="0.22603226857506217" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="93" TOTAL_2="94" VAR="0.05109058643718904" WEIGHT="36.767075521990805">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.675498143181038" CI_END="2.005709148072213" CI_START="1.4179323437452136" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.686404421601547" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="124" I2="53.893137500766926" I2_Q="83.01515013079073" ID="CMP-002.02" LOG_CI_END="0.30226795533172207" LOG_CI_START="0.1516555090987378" LOG_EFFECT_SIZE="0.2269617322152299" METHOD="MH" MODIFIED="2012-12-06 23:17:23 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.06974256273886503" P_Q="0.015247908588068904" P_Z="3.4831064006001295E-9" Q="5.887599876951724" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="422" TOTAL_2="411" WEIGHT="200.0" Z="5.9070393202770415">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.209075628316275" CI_END="2.7906304005815814" CI_START="1.662921223559211" DF="1" EFFECT_SIZE="2.1542048463961487" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="49" I2="17.292187801968005" ID="CMP-002.02.01" LOG_CI_END="0.4457023210400439" LOG_CI_START="0.22087167616847841" LOG_EFFECT_SIZE="0.3332869986042612" MODIFIED="2012-03-16 10:33:27 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.2715153364450429" P_Z="6.215003853720997E-9" STUDIES="2" TAU2="0.0" TOTAL_1="161" TOTAL_2="164" WEIGHT="100.0" Z="5.8108672343395265">
<NAME>Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.774881490000842" CI_START="1.238028245853132" EFFECT_SIZE="1.8534782608695652" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.4432444399496049" LOG_CI_START="0.09273055330947366" LOG_EFFECT_SIZE="0.2679874966295393" MODIFIED="2012-03-08 19:31:50 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="219" O_E="0.0" SE="0.20589359208413485" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="100" TOTAL_2="87" VAR="0.04239217126130811" WEIGHT="51.69532657309172"/>
<DICH_DATA CI_END="3.450901642990507" CI_START="1.7765721728350654" EFFECT_SIZE="2.4760403530895334" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="26" LOG_CI_END="0.5379325812807032" LOG_CI_START="0.2495828552969633" LOG_EFFECT_SIZE="0.3937577182888332" MODIFIED="2012-03-08 19:32:11 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="220" O_E="0.0" SE="0.1693780563970125" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="61" TOTAL_2="77" VAR="0.028688925988829553" WEIGHT="48.30467342690829"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8453789918833302" CI_END="1.7677816088345357" CI_START="1.1032873794722236" DF="2" EFFECT_SIZE="1.3965568870225968" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="75" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.24742861139173578" LOG_CI_START="0.04268865030325054" LOG_EFFECT_SIZE="0.14505863084749315" MODIFIED="2012-03-16 10:33:37 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.6552820866408531" P_Z="0.005481660609260291" STUDIES="3" TAU2="0.0" TOTAL_1="261" TOTAL_2="247" WEIGHT="100.0" Z="2.7772760197497894">
<NAME>Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.4192393242668864" CI_START="1.031308051997403" EFFECT_SIZE="1.57955088389871" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" LOG_CI_END="0.3836788332512177" LOG_CI_START="0.013388408542266673" LOG_EFFECT_SIZE="0.1985336208967422" MODIFIED="2012-03-08 19:32:46 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="221" O_E="0.0" SE="0.21751042844120191" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="91" TOTAL_2="87" VAR="0.047310786480675215" WEIGHT="30.621275621022797"/>
<DICH_DATA CI_END="1.8116471197905737" CI_START="0.8018390036023476" EFFECT_SIZE="1.2052590266875982" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" LOG_CI_END="0.25807360788136907" LOG_CI_START="-0.09591282232185686" LOG_EFFECT_SIZE="0.08108039277975611" MODIFIED="2012-03-08 19:33:21 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="222" O_E="0.0" SE="0.2079333813624645" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="98" TOTAL_2="83" VAR="0.0432362910848281" WEIGHT="36.66020602814739"/>
<DICH_DATA CI_END="2.132196084854138" CI_START="0.9720278509209618" EFFECT_SIZE="1.4396367521367521" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="0.32882714156197557" LOG_CI_START="-0.012321291320633386" LOG_EFFECT_SIZE="0.15825292512067107" MODIFIED="2012-03-08 19:36:26 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="223" O_E="0.0" SE="0.20039227818722247" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="72" TOTAL_2="77" VAR="0.04015706515706516" WEIGHT="32.71851835082981"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.380864492107351" CI_END="1.9320109764825761" CI_START="1.277173873127211" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.570832244944869" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="128" I2="43.46113710829794" I2_Q="60.074619647011325" ID="CMP-002.03" LOG_CI_END="0.2860095894771308" LOG_CI_START="0.10625002568893882" LOG_EFFECT_SIZE="0.19612980758303483" METHOD="MH" MODIFIED="2012-12-07 00:26:56 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.08870939055710492" P_Q="0.11350936945955958" P_Z="1.895089578563464E-5" Q="2.504672444341895" RANDOM="YES" SCALE="364.36" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.051566456789558464" TOTALS="SUB" TOTAL_1="509" TOTAL_2="492" WEIGHT="200.0" Z="4.276905785223874">
<NAME>Parasitological failure at six to 12 months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.255059678641921" CI_END="4.755950480452999" CI_START="1.3529550920097946" DF="2" EFFECT_SIZE="2.536648856242289" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="42" I2="61.94144077699864" ID="CMP-002.03.01" LOG_CI_END="0.6772373240421186" LOG_CI_START="0.13128338150817898" LOG_EFFECT_SIZE="0.40426035277514877" MODIFIED="2012-09-05 21:35:59 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.07225685729021147" P_Z="0.0037011026073465506" STUDIES="3" TAU2="0.16501479269036806" TOTAL_1="175" TOTAL_2="175" WEIGHT="100.0" Z="2.9025735326290554">
<NAME>Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="99.22583668797061" CI_START="0.34293263643402505" EFFECT_SIZE="5.833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9966247696344968" LOG_CI_START="-0.4647911817012328" LOG_EFFECT_SIZE="0.7659167939666319" MODIFIED="2012-09-05 21:35:59 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="131" O_E="0.0" SE="1.445847914020071" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="5" TOTAL_2="6" VAR="2.0904761904761906" WEIGHT="4.559803439752815">
<FOOTNOTE>Praziquantel 20 mg/kg single dose versus Praziquantel 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.13565093978953" CI_START="2.1036712875913297" EFFECT_SIZE="3.592686002522068" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="13" LOG_CI_END="0.7878606444162615" LOG_CI_START="0.32297787942748446" LOG_EFFECT_SIZE="0.5554192619218731" MODIFIED="2012-03-07 03:30:48 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="132" O_E="0.0" SE="0.2730744373612077" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="61" TOTAL_2="77" VAR="0.07456964834014014" WEIGHT="42.92680901621952">
<FOOTNOTE>Praziquantel 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.504706248604244" CI_START="1.2584313642706837" EFFECT_SIZE="1.775387535590003" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.3987567992288546" LOG_CI_START="0.09982953380463058" LOG_EFFECT_SIZE="0.24929316651674255" MODIFIED="2012-03-07 03:30:53 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="518" O_E="0.0" SE="0.17559135542401758" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="109" TOTAL_2="92" VAR="0.03083232409964367" WEIGHT="52.513387544027665">
<FOOTNOTE>Praziquantel 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4896570326450345" CI_END="1.845058322670724" CI_START="1.1902419410035896" DF="4" EFFECT_SIZE="1.4819128851725494" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="86" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2660100988494045" LOG_CI_START="0.07563524959664723" LOG_EFFECT_SIZE="0.17082267422302586" MODIFIED="2012-03-16 10:34:04 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.6464889038075682" P_Z="4.358993116947606E-4" STUDIES="5" TAU2="0.0" TOTAL_1="334" TOTAL_2="317" WEIGHT="99.99999999999999" Z="3.5173374060082176">
<NAME>Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.0963252281297953" CI_START="0.6577439666271829" EFFECT_SIZE="1.1742424242424243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.3214586608618144" LOG_CI_START="-0.1819431269329311" LOG_EFFECT_SIZE="0.06975776696444164" MODIFIED="2012-03-03 21:53:09 +0000" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.29570070202967164" STUDY_ID="STD-Omer-1981-SDN" TOTAL_1="33" TOTAL_2="31" VAR="0.08743890518084066" WEIGHT="14.301765003413221">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.920001856937057" CI_START="1.020407679889583" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.593286272749367" LOG_CI_START="0.008773718578595328" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-03-03 21:52:04 +0000" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="0.3433455677037183" STUDY_ID="STD-Katz-1981-BRA" TOTAL_1="41" TOTAL_2="41" VAR="0.11788617886178862" WEIGHT="10.607949855752413">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.574427474150693" CI_START="1.0905504134079638" EFFECT_SIZE="1.9743589743589745" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5532064895695192" LOG_CI_START="0.03764574672244613" LOG_EFFECT_SIZE="0.2954261181459827" MODIFIED="2012-03-07 04:00:17 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="623" O_E="0.0" SE="0.3028429324152071" STUDY_ID="STD-Taylor-1988-ZWE" TOTAL_1="72" TOTAL_2="77" VAR="0.0917138417138417" WEIGHT="13.635135664188194">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.0210806311191436" CI_START="0.9473446897648385" EFFECT_SIZE="1.3837123991195892" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" LOG_CI_END="0.30558364006235444" LOG_CI_START="-0.0234919749290824" LOG_EFFECT_SIZE="0.14104583256663603" MODIFIED="2012-03-07 04:00:24 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="624" O_E="0.0" SE="0.19330064519653561" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="94" TOTAL_2="92" VAR="0.03736513943339695" WEIGHT="33.46784444043556">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.1278745067882805" CI_START="0.9291584407139875" EFFECT_SIZE="1.4061054579093433" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.3279460114912172" LOG_CI_START="-0.031910223508292805" LOG_EFFECT_SIZE="0.14801789399146223" MODIFIED="2012-03-07 04:00:27 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="621" O_E="0.0" SE="0.21138133375580417" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="94" TOTAL_2="76" VAR="0.04468206826038268" WEIGHT="27.987305036210596">
<FOOTNOTE>Praziquantel 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.04" MODIFIED="2012-09-02 11:45:04 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Geometric mean % egg reduction at 6 months 30 mg/kg</P>
</TH>
<TH>
<P>Geometric mean % egg reduction at 6 months 40 mg/kg</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-05-09 15:36:58 +0100" MODIFIED_BY="[Empty name]" ORDER="63" STUDY_ID="STD-Katz-1981-BRA">
<TR>
<TD>
<P>138</P>
</TD>
<TD>
<P>92.5%</P>
</TD>
<TD>
<P>97.7%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-12-06 23:25:22 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="89" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:18:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="440" TOTAL_2="405" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="28" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:18:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="0.9848375432607711" CI_START="0.3555240993376059" EFFECT_SIZE="0.5917207792207793" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="28" LOG_CI_END="-0.006635403902693455" LOG_CI_START="-0.4491309551181706" LOG_EFFECT_SIZE="-0.227883179510432" MODIFIED="2012-09-02 14:51:22 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.2599240771722759" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="88" TOTAL_2="81" VAR="0.06756052589385922" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:18:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.400049203827081" CI_START="0.5594930755128839" EFFECT_SIZE="0.8850524475524476" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.1461432989461569" LOG_CI_START="-0.25220528408675535" LOG_EFFECT_SIZE="-0.0530309925702992" MODIFIED="2012-09-02 15:06:46 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.2339919295308204" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="88" TOTAL_2="81" VAR="0.054752223085556426" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:18:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="2.3089113713621834" CI_START="0.5733468843506944" EFFECT_SIZE="1.1505681818181819" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.3634072626412651" LOG_CI_START="-0.24158254316818997" LOG_EFFECT_SIZE="0.06091235973653756" MODIFIED="2012-09-02 15:06:54 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.3553740066803113" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="88" TOTAL_2="81" VAR="0.12629068462401796" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:07:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.5724337657792007" CI_START="0.404703088614704" EFFECT_SIZE="0.7977272727272727" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.19657236110463736" LOG_CI_START="-0.39286348114536407" LOG_EFFECT_SIZE="-0.09814556002036334" MODIFIED="2012-09-02 15:07:03 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.3462375314921269" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="88" TOTAL_2="81" VAR="0.11988042821376155" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="26" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:07:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.0715262617625265" CI_START="0.37896594802431927" EFFECT_SIZE="0.6372377622377622" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.030002819520436295" LOG_CI_START="-0.4213998117984979" LOG_EFFECT_SIZE="-0.19569849613903081" MODIFIED="2012-09-02 15:07:11 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.2651561401158042" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="88" TOTAL_2="81" VAR="0.07030777864111197" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.285282860410603" CI_END="0.8958931934695044" CI_START="0.6307146605208149" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7517000541319837" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.04774376294022574" LOG_CI_START="-0.20016707401810696" LOG_EFFECT_SIZE="-0.12395541847916633" METHOD="MH" MODIFIED="2012-12-06 23:19:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9861118798769631" P_Q="0.910680304995104" P_Z="0.001433554920003265" Q="0.9941598821304566" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="835" TOTAL_2="755" WEIGHT="500.0" Z="3.187808402661212">
<NAME>Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3194028482586788" CI_END="1.0972014566867965" CI_START="0.550617229721588" DF="1" EFFECT_SIZE="0.7772631642676596" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="50" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.04028637551890963" LOG_CI_START="-0.2591502029391742" LOG_EFFECT_SIZE="-0.10943191371013225" MODIFIED="2012-12-06 23:18:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5719668584362374" P_Z="0.15197946141313615" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="151" WEIGHT="100.0" Z="1.4325745420656968">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.1457058790009946" CI_START="0.4345233509115139" EFFECT_SIZE="0.705574912891986" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" LOG_CI_END="0.05907314160929375" LOG_CI_START="-0.36198687997590373" LOG_EFFECT_SIZE="-0.15145686918330498" MODIFIED="2012-09-02 15:07:33 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.2473327409598667" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="82" TOTAL_2="81" VAR="0.06117348475072053" WEIGHT="53.8648988179025">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4074553882119802" CI_START="0.5266643246503743" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.148434638009765" LOG_CI_START="-0.27846609901906355" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2012-09-02 15:07:45 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.2507636061234633" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="85" TOTAL_2="70" VAR="0.06288238615604344" WEIGHT="46.13510118209751">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1235845488700043" CI_END="1.108444573893514" CI_START="0.5324355192280007" DF="1" EFFECT_SIZE="0.7682286523141747" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.04471398174999853" LOG_CI_START="-0.2737329800753181" LOG_EFFECT_SIZE="-0.1145094991626598" MODIFIED="2012-12-06 23:19:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.725178878635194" P_Z="0.1586706759214778" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="151" WEIGHT="100.0" Z="1.4095565111382393">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.1968566671893737" CI_START="0.4353722011413831" EFFECT_SIZE="0.7218574108818011" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.07804214340895065" LOG_CI_START="-0.3611393044550626" LOG_EFFECT_SIZE="-0.14154858052305597" MODIFIED="2012-09-02 15:07:52 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.25797735645854986" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="82" TOTAL_2="81" VAR="0.0665523164453417" WEIGHT="54.391335835143856">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4033049923747285" CI_START="0.48328816310547307" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.14715207025171487" LOG_CI_START="-0.3157938416517867" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2012-09-02 15:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.2719367202713395" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="85" TOTAL_2="70" VAR="0.07394957983193277" WEIGHT="45.60866416485614">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04525004683589867" CI_END="1.084754994363265" CI_START="0.5177880979004308" DF="1" EFFECT_SIZE="0.7494486141286456" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="46" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.03533165835821046" LOG_CI_START="-0.2858479366658709" LOG_EFFECT_SIZE="-0.1252581391538302" MODIFIED="2012-12-06 23:19:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8315450576819358" P_Z="0.12632675839487217" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="151" WEIGHT="100.0" Z="1.528748683387601">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.1968566671893737" CI_START="0.4353722011413831" EFFECT_SIZE="0.7218574108818011" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.07804214340895065" LOG_CI_START="-0.3611393044550626" LOG_EFFECT_SIZE="-0.14154858052305597" MODIFIED="2012-09-02 15:08:23 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.25797735645854986" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="82" TOTAL_2="81" VAR="0.0665523164453417" WEIGHT="54.391335835143856">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3457310862745167" CI_START="0.45482795991725805" EFFECT_SIZE="0.7823529411764706" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.1289582846910823" LOG_CI_START="-0.3421528455134586" LOG_EFFECT_SIZE="-0.10659728041118814" MODIFIED="2012-09-02 15:08:30 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.2767330099198525" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="85" TOTAL_2="70" VAR="0.07658115877930119" WEIGHT="45.60866416485614">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.15951924582305863" CI_END="1.0123229563274883" CI_START="0.34785696607788635" DF="1" EFFECT_SIZE="0.5934168789974521" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="29" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.005319085404586919" LOG_CI_START="-0.45859929516993875" LOG_EFFECT_SIZE="-0.2266401048826759" MODIFIED="2012-09-02 15:08:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6895997261185298" P_Z="0.05548997811051296" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="151" WEIGHT="100.0" Z="1.9150198035797212">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.3787303977359395" CI_START="0.31454331824224907" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.13947935085848645" LOG_CI_START="-0.5023195359799828" LOG_EFFECT_SIZE="-0.18142009256074818" MODIFIED="2012-09-02 15:08:39 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.37699584308464396" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="82" TOTAL_2="81" VAR="0.14212586570310148" WEIGHT="49.56840517913785">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1495240317576696" CI_START="0.24381988446160777" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.060518054988203424" LOG_CI_START="-0.6129308788661015" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2012-09-02 15:08:45 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.39558723737200535" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="85" TOTAL_2="70" VAR="0.1564892623716153" WEIGHT="50.43159482086215">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6883675778539129" CI_END="1.2473639207819278" CI_START="0.5454353339582209" DF="1" EFFECT_SIZE="0.824837169809367" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" I2="0.0" ID="CMP-003.02.05" LOG_CI_END="0.09599317820162394" LOG_CI_START="-0.26325673136317607" LOG_EFFECT_SIZE="-0.08363177658077604" MODIFIED="2012-09-02 15:09:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4067205706713042" P_Z="0.3614836140469476" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="151" WEIGHT="100.00000000000001" Z="0.9125417471085268">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.1968566671893737" CI_START="0.4353722011413831" EFFECT_SIZE="0.7218574108818011" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.07804214340895065" LOG_CI_START="-0.3611393044550626" LOG_EFFECT_SIZE="-0.14154858052305597" MODIFIED="2012-09-02 15:08:55 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.25797735645854986" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="82" TOTAL_2="81" VAR="0.0665523164453417" WEIGHT="68.43734791297776">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.160993233090815" CI_START="0.5083648597307562" EFFECT_SIZE="1.0481283422459893" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.33465340694065926" LOG_CI_START="-0.29382447730070516" LOG_EFFECT_SIZE="0.02041446481997707" MODIFIED="2012-09-02 15:09:03 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.36917102021907827" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="85" TOTAL_2="70" VAR="0.1362872421695951" WEIGHT="31.562652087022254">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="121" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:20:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="140" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="16" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:19:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.061242856105624" CI_START="0.7733917582512528" EFFECT_SIZE="0.9059561128526645" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.0258147797520332" LOG_CI_START="-0.11160046035329979" LOG_EFFECT_SIZE="-0.04289284030063329" MODIFIED="2012-09-02 15:09:54 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.0807183922542815" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="28" TOTAL_2="16" VAR="0.006515458848116051" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="14" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:20:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3115462636829143" CI_START="0.8586791399795275" EFFECT_SIZE="1.0612244897959184" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.11778361456635161" LOG_CI_START="-0.06616908735378055" LOG_EFFECT_SIZE="0.025807263606285526" MODIFIED="2012-09-02 15:10:07 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.1080547276884458" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="28" TOTAL_2="16" VAR="0.011675824175824176" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="14" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:20:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.2093073245218788" CI_START="0.7287638474424781" EFFECT_SIZE="0.9387755102040817" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.08253668331164622" LOG_CI_START="-0.13741318000552533" LOG_EFFECT_SIZE="-0.027438248346939566" MODIFIED="2012-09-02 15:10:18 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.12919963848188945" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="28" TOTAL_2="16" VAR="0.01669254658385093" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="13" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:10:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.3537411115235032" CI_START="0.7550179067770693" EFFECT_SIZE="1.010989010989011" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.13153561812536727" LOG_CI_START="-0.12204274807644397" LOG_EFFECT_SIZE="0.0047464350244616526" MODIFIED="2012-09-02 15:10:31 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.14895318754010076" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="28" TOTAL_2="16" VAR="0.02218705207835643" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="13" I2="0.0" ID="CMP-003.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:10:40 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.3955088210970787" CI_START="0.7974933960489852" EFFECT_SIZE="1.054945054945055" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.1447325860354544" LOG_CI_START="-0.09827290459850478" LOG_EFFECT_SIZE="0.023229840718474823" MODIFIED="2012-09-02 15:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.14274262809496632" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="28" TOTAL_2="16" VAR="0.020375457875457872" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1672034134599674" CI_END="1.0579472057479733" CI_START="0.8511207318985503" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9489155916446105" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.02446399584244588" LOG_CI_START="-0.07000883065769567" LOG_EFFECT_SIZE="-0.02277241740762491" METHOD="MH" MODIFIED="2012-12-06 23:21:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9885389790512815" P_Q="0.7561052412408157" P_Z="0.3447160925182581" Q="1.8893280151325114" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="125" TOTAL_2="115" WEIGHT="500.0" Z="0.9448879558989575">
<NAME>Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10284395729139974" CI_END="1.0339962115051524" CI_START="0.6966893311401805" DF="1" EFFECT_SIZE="0.8487485664170545" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.014518947534112097" LOG_CI_START="-0.15696084005022326" LOG_EFFECT_SIZE="-0.07122094625805558" MODIFIED="2012-12-06 23:20:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7484431323357691" P_Z="0.1035101904322589" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.628069308658314">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.0567633189459353" CI_START="0.6518433186769428" EFFECT_SIZE="0.82996632996633" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.02397773017815395" LOG_CI_START="-0.18585678158608093" LOG_EFFECT_SIZE="-0.08093952570396351" MODIFIED="2012-09-02 15:11:11 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.12325783090789671" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="17" TOTAL_2="16" VAR="0.01519249288011966" WEIGHT="68.12386156648452">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2520992706489458" CI_START="0.6310389881311993" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.09763876256925678" LOG_CI_START="-0.1999438074640194" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2012-09-02 15:10:58 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.17480147469502527" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="8" TOTAL_2="7" VAR="0.030555555555555558" WEIGHT="31.876138433515486">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0025741895293825727" CI_END="1.2544826312745236" CI_START="0.8167482117527529" DF="1" EFFECT_SIZE="1.0122235157159487" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.09846465274201995" LOG_CI_START="-0.08791180772704216" LOG_EFFECT_SIZE="0.005276422507488933" MODIFIED="2012-12-06 23:20:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.959535531960089" P_Z="0.9116358800872247" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.11097536733842531">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.2997794859815892" CI_START="0.7823460441853489" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.11386967834939216" LOG_CI_START="-0.10660110903920403" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2012-09-02 15:12:01 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.12950563186006003" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="17" TOTAL_2="16" VAR="0.0167717086834734" WEIGHT="69.26658905704306">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.523020082896734" CI_START="0.6842330617613414" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.1827056300817599" LOG_CI_START="-0.16479594477590712" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2012-09-02 15:12:09 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.20412414523193156" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="8" TOTAL_2="7" VAR="0.041666666666666685" WEIGHT="30.733410942956926">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10472147791278089" CI_END="1.2200087092797216" CI_START="0.7643346041236079" DF="1" EFFECT_SIZE="0.9656577415599534" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.08636293098509555" LOG_CI_START="-0.11671647792682115" LOG_EFFECT_SIZE="-0.015176773470862803" MODIFIED="2012-12-06 23:21:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7462356338383986" P_Z="0.769561326528295" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.2929487491005649">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.2548136519115938" CI_START="0.7059320301779248" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.09857923501584138" LOG_CI_START="-0.15123711246053972" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2012-09-02 15:12:27 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.14674335911849007" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="17" TOTAL_2="16" VAR="0.021533613445378144" WEIGHT="69.26658905704306">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.523020082896734" CI_START="0.6842330617613414" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.1827056300817599" LOG_CI_START="-0.16479594477590712" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2012-09-02 15:12:34 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.20412414523193156" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="8" TOTAL_2="7" VAR="0.041666666666666685" WEIGHT="30.733410942956926">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01022451736407013" CI_END="1.3685290306655455" CI_START="0.7661291312642631" DF="1" EFFECT_SIZE="1.023948220064725" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="0.13625401455149572" LOG_CI_START="-0.11569802374988705" LOG_EFFECT_SIZE="0.010277995400804322" MODIFIED="2012-09-02 15:12:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9194580955403883" P_Z="0.8729539996350826" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.1599074248786042">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.3989276143833127" CI_START="0.7343722306397966" EFFECT_SIZE="1.0135746606334841" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.14579524309282368" LOG_CI_START="-0.13408375379471948" LOG_EFFECT_SIZE="0.0058557446490520885" MODIFIED="2012-09-02 15:12:46 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.1644023081951213" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="17" TOTAL_2="16" VAR="0.027028118939883647" WEIGHT="71.52103559870551">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9442667127676674" CI_START="0.5670518312945806" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.28875584080529215" LOG_CI_START="-0.24637724266541597" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2012-09-02 14:55:37 +0100" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.3143398221821789" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="8" TOTAL_2="7" VAR="0.09880952380952385" WEIGHT="28.478964401294498">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05430553485796479" CI_END="1.228053149369305" CI_START="0.6888907171739722" DF="1" EFFECT_SIZE="0.919779546846295" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" ID="CMP-003.04.05" LOG_CI_END="0.0892171632044168" LOG_CI_START="-0.16184966734145415" LOG_EFFECT_SIZE="-0.03631625206851864" MODIFIED="2012-09-02 15:13:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8157338568428107" P_Z="0.5707082328506172" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.5670087598032603">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.34022280773492" CI_START="0.6609446904474188" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12717700442897872" LOG_CI_START="-0.17983488187367708" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2012-09-02 15:13:02 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.18034030174752716" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="17" TOTAL_2="16" VAR="0.03252262443438915" WEIGHT="67.66687078995713">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.444828141149404" CI_START="0.5299073143681452" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.15981619187507792" LOG_CI_START="-0.2758000858304514" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-09-02 15:13:10 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.2558831578595795" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="8" TOTAL_2="7" VAR="0.06547619047619047" WEIGHT="32.33312921004286">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="90" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:22:18 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of blood in stool: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:21:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.1703685459211743" CI_START="0.8597305003058443" EFFECT_SIZE="1.0030959752321982" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.06832264145249974" LOG_CI_START="-0.0656376657014812" LOG_EFFECT_SIZE="0.001342487875509265" MODIFIED="2012-09-02 15:13:32 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.07868894753646338" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="19" TOTAL_2="18" VAR="0.006191950464396287" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:22:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.1703685459211743" CI_START="0.8597305003058443" EFFECT_SIZE="1.0030959752321982" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.06832264145249974" LOG_CI_START="-0.0656376657014812" LOG_EFFECT_SIZE="0.001342487875509265" MODIFIED="2012-09-02 15:14:37 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.07868894753646338" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="19" TOTAL_2="18" VAR="0.006191950464396287" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:22:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.2288771185388376" CI_START="0.9118677957973063" EFFECT_SIZE="1.0585714285714285" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.08950845781841227" LOG_CI_START="-0.040068121888269664" LOG_EFFECT_SIZE="0.024720167965071305" MODIFIED="2012-09-02 15:14:32 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.07611392433411909" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="19" TOTAL_2="18" VAR="0.005793329477540007" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:14:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.1703685459211743" CI_START="0.8597305003058443" EFFECT_SIZE="1.0030959752321982" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.06832264145249974" LOG_CI_START="-0.0656376657014812" LOG_EFFECT_SIZE="0.001342487875509265" MODIFIED="2012-09-02 15:14:18 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.07868894753646338" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="19" TOTAL_2="18" VAR="0.006191950464396287" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="15" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 14:44:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.3894552231641502" CI_START="0.8296760951449003" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.1428445556862127" LOG_CI_START="-0.08109142274007308" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2012-09-02 14:44:03 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.13154110222857113" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="19" TOTAL_2="18" VAR="0.0173030615755074" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7058829477318549" CI_END="1.075848067139779" CI_START="0.9276970702658593" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9990300795955849" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="145" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.03175094394956591" LOG_CI_START="-0.032593814933603873" LOG_EFFECT_SIZE="-4.214354920189504E-4" METHOD="MH" MODIFIED="2012-12-06 23:22:55 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9998678626882027" P_Q="0.9632515724970394" P_Z="0.979517245082736" Q="0.598307829712953" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="238" TOTAL_2="166" WEIGHT="500.0" Z="0.025674146597202054">
<NAME>Resolution of blood in stool: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05686334350456729" CI_END="1.1137464735971663" CI_START="0.8886888498979413" DF="1" EFFECT_SIZE="0.9948738978880457" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="32" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.04678634196101093" LOG_CI_START="-0.05125026875507309" LOG_EFFECT_SIZE="-0.002231963397031065" MODIFIED="2012-12-06 23:22:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8115240584824219" P_Z="0.9288883508748776" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="34" WEIGHT="99.99999999999999" Z="0.08924355587243617">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.1684497230888184" CI_START="0.8702790707013294" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.0676100299889625" LOG_CI_START="-0.060341460678774335" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2012-09-02 15:16:09 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.07515933898832226" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="21" TOTAL_2="18" VAR="0.005648926237161539" WEIGHT="50.020504408447806">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.164773799520786" CI_START="0.8267829440422827" EFFECT_SIZE="0.9813333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.06624159303736714" LOG_CI_START="-0.08260849114576954" LOG_EFFECT_SIZE="-0.008183449054201215" MODIFIED="2012-09-02 15:15:18 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.08743527626897446" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.007644927536231888" WEIGHT="49.97949559155218">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.02052375527398133" CI_END="1.1287203755281225" CI_START="0.9148938732547521" DF="1" EFFECT_SIZE="1.0161984826737749" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="32" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.05258636494858165" LOG_CI_START="-0.03862928072366258" LOG_EFFECT_SIZE="0.006978542112459529" MODIFIED="2012-12-06 23:22:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8860839514607123" P_Z="0.7642550213497092" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="34" WEIGHT="99.99999999999999" Z="0.29989792001612064">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.1684497230888184" CI_START="0.8702790707013294" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.0676100299889625" LOG_CI_START="-0.060341460678774335" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2012-09-02 15:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.07515933898832226" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="21" TOTAL_2="18" VAR="0.005648926237161539" WEIGHT="50.020504408447806">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1893551251445473" CI_START="0.8816340702887728" EFFECT_SIZE="1.024" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.0753115483639003" LOG_CI_START="-0.054711635084276386" LOG_EFFECT_SIZE="0.010299956639811961" MODIFIED="2012-09-02 15:16:33 +0100" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.0763762615825973" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.005833333333333329" WEIGHT="49.97949559155218">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.015695989864538858" CI_END="1.0743145486273964" CI_START="0.8662693495447911" DF="1" EFFECT_SIZE="0.9646998316813166" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="0.031131457092279092" LOG_CI_START="-0.0623470515932075" LOG_EFFECT_SIZE="-0.015607797250464194" MODIFIED="2012-12-06 23:22:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9002990090343277" P_Z="0.5127914051456459" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="34" WEIGHT="100.0" Z="0.6544974009338813">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.1450248606315285" CI_START="0.8014950855264633" EFFECT_SIZE="0.957983193277311" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.05881491612383595" LOG_CI_START="-0.09609913623595226" LOG_EFFECT_SIZE="-0.018642110056058148" MODIFIED="2012-09-02 15:16:43 +0100" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.09099728119306617" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="21" TOTAL_2="18" VAR="0.008280505184529954" WEIGHT="47.84926126800075">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1013077526233113" CI_START="0.8558678853244921" EFFECT_SIZE="0.9708624708624709" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.04190869643755429" LOG_CI_START="-0.0675932693213899" LOG_EFFECT_SIZE="-0.012842286441917834" MODIFIED="2012-09-02 15:16:50 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.06432199673027629" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.004137319263369674" WEIGHT="52.150738731999255">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2227265721958789" CI_START="0.7928734662895629" DF="1" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="0.0873293503618326" LOG_CI_START="-0.10079611567976933" LOG_EFFECT_SIZE="-0.0067333826589683786" MODIFIED="2012-09-02 15:17:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8884214015436636" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="32" WEIGHT="100.0" Z="0.14030197807229516">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.3374926684672306" CI_START="0.7248394540601958" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.12629141009292782" LOG_CI_START="-0.1397581754108646" LOG_EFFECT_SIZE="-0.0067333826589683786" MODIFIED="2012-09-02 15:17:02 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.1562788434916157" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.02442307692307691" WEIGHT="50.0">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3374926684672306" CI_START="0.7248394540601958" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.12629141009292782" LOG_CI_START="-0.1397581754108646" LOG_EFFECT_SIZE="-0.0067333826589683786" MODIFIED="2012-09-02 15:17:09 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.1562788434916157" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.02442307692307691" WEIGHT="50.0">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4004340253401137" CI_START="0.7831716064045853" DF="1" EFFECT_SIZE="1.0472727272727274" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="22" I2="0.0" ID="CMP-003.06.05" LOG_CI_END="0.1462626539624191" LOG_CI_START="-0.10614306610448257" LOG_EFFECT_SIZE="0.020059793928968235" MODIFIED="2012-09-02 15:17:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7553947492846307" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="32" WEIGHT="100.0" Z="0.3115339353454581">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.5795653205150806" CI_START="0.6943556882672045" EFFECT_SIZE="1.0472727272727274" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.1985375901985478" LOG_CI_START="-0.15841800234061137" LOG_EFFECT_SIZE="0.020059793928968235" MODIFIED="2012-09-02 15:17:16 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.2096774820161823" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.043964646464646456" WEIGHT="50.0">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5795653205150806" CI_START="0.6943556882672045" EFFECT_SIZE="1.0472727272727274" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.1985375901985478" LOG_CI_START="-0.15841800234061137" LOG_EFFECT_SIZE="0.020059793928968235" MODIFIED="2012-09-02 15:17:26 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.2096774820161823" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="25" TOTAL_2="16" VAR="0.043964646464646456" WEIGHT="50.0">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="92" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:23:37 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="125" TOTAL_2="150" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:23:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.5944199647041501" CI_START="0.8150926536103333" EFFECT_SIZE="1.14" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.20260272379238123" LOG_CI_START="-0.08879302111943611" LOG_EFFECT_SIZE="0.05690485133647256" MODIFIED="2012-09-02 15:18:20 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.17116730299340202" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.029298245614035094" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:23:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3603160412493482" CI_START="0.7086345473537378" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.13363981941818548" LOG_CI_START="-0.14957767876073616" LOG_EFFECT_SIZE="-0.00796892967127534" MODIFIED="2012-09-02 15:19:03 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.1663633603795249" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.027676767676767675" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:23:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.3603160412493482" CI_START="0.7086345473537378" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.13363981941818548" LOG_CI_START="-0.14957767876073616" LOG_EFFECT_SIZE="-0.00796892967127534" MODIFIED="2012-09-02 15:19:14 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.1663633603795249" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.027676767676767675" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-003.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:19:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.2184409381588857" CI_START="0.6647839666516322" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.0858044823485211" LOG_CI_START="-0.1773194634698713" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2012-09-02 15:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.1545603082582617" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.023888888888888876" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-003.07.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:19:28 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.3325066629205962" CI_START="0.7374704662752307" EFFECT_SIZE="0.991304347826087" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12466938930267266" LOG_CI_START="-0.13225536733695079" LOG_EFFECT_SIZE="-0.0037929890171390676" MODIFIED="2012-09-02 15:19:28 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.1509188738481715" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.0227765064836003" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.276113393780283" CI_END="1.0863294862979473" CI_START="0.8755714767555125" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9752738654147106" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="195" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.03596156777444941" LOG_CI_START="-0.05770839476223354" LOG_EFFECT_SIZE="-0.010873413493892061" METHOD="MH" MODIFIED="2012-12-06 23:24:15 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9863114311011304" P_Q="0.8455365271171107" P_Z="0.649084934070717" Q="1.39227540928847" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="275" TOTAL_2="270" WEIGHT="500.0" Z="0.4550337858562563">
<NAME>Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>40 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.029105426830732417" CI_END="1.347927124518868" CI_START="0.8292107236641997" DF="1" EFFECT_SIZE="1.0572207084468666" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.1296664127669072" LOG_CI_START="-0.08133509008267138" LOG_EFFECT_SIZE="0.024165661342117933" MODIFIED="2012-12-06 23:23:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8645358708461554" P_Z="0.6534727630907908" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="100.0" Z="0.448943019395538">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.5353914173698453" CI_START="0.759675993238301" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.18621910863025715" LOG_CI_START="-0.11937159765635771" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2012-09-02 15:20:28 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.17950549357115014" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.03222222222222223" WEIGHT="49.04632152588556">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4478096150151396" CI_START="0.7403141261935839" EFFECT_SIZE="1.035294117647059" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.16071145648510302" LOG_CI_START="-0.13058396361335117" LOG_EFFECT_SIZE="0.015063746435875934" MODIFIED="2012-09-02 15:20:04 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.17110837170141668" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="30" TOTAL_2="24" VAR="0.02927807486631017" WEIGHT="50.95367847411443">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.049392464233569355" CI_END="1.2732121481612524" CI_START="0.7977029873249852" DF="1" EFFECT_SIZE="1.007792207792208" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.10490077372388507" LOG_CI_START="-0.09815878155247185" LOG_EFFECT_SIZE="0.003370996085706615" MODIFIED="2012-12-06 23:24:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8241238242037049" P_Z="0.9481144371599585" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="100.0" Z="0.06507480931905447">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3603160412493482" CI_START="0.7086345473537378" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.13363981941818548" LOG_CI_START="-0.14957767876073616" LOG_EFFECT_SIZE="-0.00796892967127534" MODIFIED="2012-09-02 15:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.1663633603795249" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.027676767676767675" WEIGHT="51.42857142857143">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4478096150151396" CI_START="0.7403141261935839" EFFECT_SIZE="1.035294117647059" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.16071145648510302" LOG_CI_START="-0.13058396361335117" LOG_EFFECT_SIZE="0.015063746435875934" MODIFIED="2012-09-02 15:20:42 +0100" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.17110837170141668" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="30" TOTAL_2="24" VAR="0.02927807486631017" WEIGHT="48.57142857142858">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07220860644217161" CI_END="1.294777400392856" CI_START="0.7939594870881186" DF="1" EFFECT_SIZE="1.013903743315508" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="0.11219511043216361" LOG_CI_START="-0.10020165750106666" LOG_EFFECT_SIZE="0.005996726465548486" MODIFIED="2012-12-06 23:24:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7881477892201543" P_Z="0.911875103624384" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="100.0" Z="0.11067369821096365">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.3603160412493482" CI_START="0.7086345473537378" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.13363981941818548" LOG_CI_START="-0.14957767876073616" LOG_EFFECT_SIZE="-0.00796892967127534" MODIFIED="2012-09-02 15:20:48 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.1663633603795249" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.027676767676767675" WEIGHT="52.94117647058823">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.516020665816871" CI_START="0.7272328305669532" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.18070512147351397" LOG_CI_START="-0.13832652333363782" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2012-09-02 15:20:55 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.18740076739183228" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="30" TOTAL_2="24" VAR="0.035119047619047626" WEIGHT="47.05882352941177">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03511993971348719" CI_END="1.1606951963174788" CI_START="0.7278027239269247" DF="1" EFFECT_SIZE="0.919106699751861" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" I2="0.0" ID="CMP-003.08.04" LOG_CI_END="0.0647181870624902" LOG_CI_START="-0.13798632332491567" LOG_EFFECT_SIZE="-0.036634068131212755" MODIFIED="2012-09-02 15:21:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8513446157812872" P_Z="0.47867535739511924" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="99.99999999999999" Z="0.7084346964666716">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.2184409381588857" CI_START="0.6647839666516322" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.0858044823485211" LOG_CI_START="-0.1773194634698713" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2012-09-02 15:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.1545603082582617" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.023888888888888876" WEIGHT="53.59801488833746">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3496371409705905" CI_START="0.6563343004564142" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.13021702119386797" LOG_CI_START="-0.18287489863856626" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2012-09-02 15:21:14 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.1839117435395704" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="30" TOTAL_2="24" VAR="0.03382352941176472" WEIGHT="46.401985111662526">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.35563335984103245" CI_END="1.1411725893742202" CI_START="0.6888142172717477" DF="1" EFFECT_SIZE="0.88659793814433" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="40" I2="0.0" ID="CMP-003.08.05" LOG_CI_END="0.05735133148618735" LOG_CI_START="-0.1618978975315416" LOG_EFFECT_SIZE="-0.05227328302267709" MODIFIED="2012-09-02 15:21:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5509416384379937" P_Z="0.35000113361495744" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="100.0" Z="0.9345871138258965">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.1012829905849018" CI_START="0.626703145961003" EFFECT_SIZE="0.8307692307692308" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.04189893155801364" LOG_CI_START="-0.2029381251977877" LOG_EFFECT_SIZE="-0.08051959681988705" MODIFIED="2012-09-02 15:21:20 +0100" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.14381849910133496" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="25" TOTAL_2="30" VAR="0.020683760683760682" WEIGHT="60.30927835051547">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5398992617312537" CI_START="0.6128150670887502" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.18749231076812595" LOG_CI_START="-0.21267056538416695" LOG_EFFECT_SIZE="-0.012589127308020516" MODIFIED="2012-09-02 15:21:30 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.23505765429004036" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="30" TOTAL_2="24" VAR="0.055252100840336126" WEIGHT="39.69072164948454">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="129" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:24:47 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="220" TOTAL_2="145" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="19" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:24:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.2937453182769227" CI_START="0.6287548464946355" EFFECT_SIZE="0.9019138755980861" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.11184879120665316" LOG_CI_START="-0.20151865434513785" LOG_EFFECT_SIZE="-0.04483493156924235" MODIFIED="2012-09-02 15:22:01 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.18407358871099486" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="44" TOTAL_2="29" VAR="0.03388308606094449" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="19" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:24:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.174362917999095" CI_START="0.5420467983533636" EFFECT_SIZE="0.7978468899521531" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.06980232938855832" LOG_CI_START="-0.2659632164334932" LOG_EFFECT_SIZE="-0.0980804435224674" MODIFIED="2012-09-02 15:22:31 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.19723034368213033" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="44" TOTAL_2="29" VAR="0.038899808468971245" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="18" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:24:47 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.3865980991275526" CI_START="0.6536446758616334" EFFECT_SIZE="0.952020202020202" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.14195060049351843" LOG_CI_START="-0.18465827193295736" LOG_EFFECT_SIZE="-0.021353835719719463" MODIFIED="2012-09-02 15:22:37 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.1918516684033048" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="44" TOTAL_2="29" VAR="0.03680706266913163" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="15" I2="0.0" ID="CMP-003.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:22:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.754515874503538" CI_START="0.7438708128234564" EFFECT_SIZE="1.1424242424242423" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.2441573019775297" LOG_CI_START="-0.12850248132171896" LOG_EFFECT_SIZE="0.057827410327905344" MODIFIED="2012-09-02 15:22:46 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.21890220140565683" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="44" TOTAL_2="29" VAR="0.047918173780242754" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="20" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:22:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.2846459190489148" CI_START="0.6627706570422627" EFFECT_SIZE="0.9227272727272727" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.10878344160236823" LOG_CI_START="-0.1786367274203549" LOG_EFFECT_SIZE="-0.03492664290899332" MODIFIED="2012-09-02 15:22:52 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.16883203003673009" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="44" TOTAL_2="29" VAR="0.028504254366323326" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 20 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5448018490028208" CI_END="1.083071582719211" CI_START="0.8247687708551175" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9451368250298103" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="163" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.03465716110601463" LOG_CI_START="-0.08366779159222007" LOG_EFFECT_SIZE="-0.02450531524310272" METHOD="MH" MODIFIED="2012-12-06 23:25:22 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9968005572719476" P_Q="0.9272454505727628" P_Z="0.41689247020388065" Q="0.8811783428215851" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="335" TOTAL_2="275" WEIGHT="500.0" Z="0.8118242891467186">
<NAME>Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04799653879518802" CI_END="1.150140555750161" CI_START="0.6500402424344225" DF="1" EFFECT_SIZE="0.8646604221852044" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.060750917620231805" LOG_CI_START="-0.18705975639373643" LOG_EFFECT_SIZE="-0.06315441938675233" MODIFIED="2012-12-06 23:25:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8265868556139913" P_Z="0.3177987871375513" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="55" WEIGHT="100.0" Z="0.9989915725389268">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.266848252772569" CI_START="0.553017216817252" EFFECT_SIZE="0.8370118845500849" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.10272459678525883" LOG_CI_START="-0.25726134780500204" LOG_EFFECT_SIZE="-0.07726837550987162" MODIFIED="2012-09-02 15:23:07 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.21145752581148403" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="31" TOTAL_2="29" VAR="0.04471428522231444" WEIGHT="49.86209344875611">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3216410546752848" CI_START="0.6022390609973387" EFFECT_SIZE="0.8921568627450981" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.12111352085251931" LOG_CI_START="-0.2202310797341671" LOG_EFFECT_SIZE="-0.04955877944082394" MODIFIED="2012-09-02 15:23:18 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.2005075080676434" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="36" TOTAL_2="26" VAR="0.04020326079149608" WEIGHT="50.137906551243894">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03719775002653879" CI_END="1.254023420301308" CI_START="0.6625990612828437" DF="1" EFFECT_SIZE="0.9115452490789187" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.09830564750956343" LOG_CI_START="-0.17874918372717957" LOG_EFFECT_SIZE="-0.04022176810880805" MODIFIED="2012-12-06 23:25:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8470630614951117" P_Z="0.5693016806223498" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="55" WEIGHT="100.0" Z="0.5690802541567854">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3208270171070167" CI_START="0.594654175497184" EFFECT_SIZE="0.8862478777589134" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.12084594370453444" LOG_CI_START="-0.2257355272742134" LOG_EFFECT_SIZE="-0.05244479178483947" MODIFIED="2012-09-02 15:23:28 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.2035836716588668" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="31" TOTAL_2="29" VAR="0.041446311366105285" WEIGHT="56.531161955478495">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5833947246605382" CI_START="0.5633309842138097" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.1995891936827416" LOG_CI_START="-0.24923636113280598" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2012-09-02 15:23:34 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.26364235262098046" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="36" TOTAL_2="26" VAR="0.0695072900955254" WEIGHT="43.468838044521505">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005370460142262423" CI_END="1.3568280149635017" CI_START="0.7034496270763184" DF="1" EFFECT_SIZE="0.9769647696476965" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="0.13252480205477662" LOG_CI_START="-0.1527669962620017" LOG_EFFECT_SIZE="-0.01012109710361251" MODIFIED="2012-12-06 23:25:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9415805825412282" P_Z="0.8893991519214123" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="55" WEIGHT="100.0" Z="0.13906453619873688">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.4716622011593612" CI_START="0.6625622140570476" EFFECT_SIZE="0.9874551971326165" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.16780813540358025" LOG_CI_START="-0.1787733355751676" LOG_EFFECT_SIZE="-0.005482600085793679" MODIFIED="2012-09-02 15:23:43 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.2035836716588668" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="31" TOTAL_2="29" VAR="0.041446311366105285" WEIGHT="57.168352171326596">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.673994655598455" CI_START="0.553943027797122" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.22375406712928114" LOG_CI_START="-0.25653489950561986" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2012-09-02 15:23:48 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.282124116470069" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="36" TOTAL_2="26" VAR="0.07959401709401707" WEIGHT="42.831647828673404">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5252791189952317" CI_END="1.4636091649408596" CI_START="0.7585915773786532" DF="1" EFFECT_SIZE="1.053699001185035" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" I2="0.0" ID="CMP-003.10.04" LOG_CI_END="0.1654251203217988" LOG_CI_START="-0.1199919835661056" LOG_EFFECT_SIZE="0.022716568377846604" MODIFIED="2012-09-02 15:24:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.46859847801486865" P_Z="0.7550480450474694" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="55" WEIGHT="100.0" Z="0.3119901033710102">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.8571203662508144" CI_START="0.7560617012511067" EFFECT_SIZE="1.1849462365591399" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.26884005274595124" LOG_CI_START="-0.1214427608222889" LOG_EFFECT_SIZE="0.07369864596183116" MODIFIED="2012-09-02 15:24:00 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.22925405662106918" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="31" TOTAL_2="29" VAR="0.0525574224772164" WEIGHT="48.806500761808024">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5052421974601617" CI_START="0.5728280136007842" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.1776063846858429" LOG_CI_START="-0.24197575142864536" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2012-09-02 15:24:08 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.24646462371872102" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="36" TOTAL_2="26" VAR="0.06074481074481074" WEIGHT="51.193499238191976">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002277468158303656" CI_END="1.2339545402397165" CI_START="0.718160345532887" DF="1" EFFECT_SIZE="0.9413698630136985" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="36" I2="0.0" ID="CMP-003.10.05" LOG_CI_END="0.09129916027525616" LOG_CI_START="-0.14377857886979628" LOG_EFFECT_SIZE="-0.026239709297270066" MODIFIED="2012-09-02 15:24:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9619371551571131" P_Z="0.6617140493485514" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="55" WEIGHT="100.0" Z="0.4375478969169127">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.3374291034970933" CI_START="0.6543375424929151" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.12627076955228286" LOG_CI_START="-0.18419816142291615" LOG_EFFECT_SIZE="-0.028963695935316617" MODIFIED="2012-09-02 15:24:15 +0100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.1823709869008262" STUDY_ID="STD-Gryseels-1989b-BDI" TOTAL_1="31" TOTAL_2="29" VAR="0.03325917686318132" WEIGHT="52.657534246575345">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4291424280553908" CI_START="0.6287309013469569" EFFECT_SIZE="0.9479166666666666" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.15507551265112252" LOG_CI_START="-0.20153519408807222" LOG_EFFECT_SIZE="-0.02322984071847483" MODIFIED="2012-09-02 15:24:52 +0100" MODIFIED_BY="[Empty name]" ORDER="308" O_E="0.0" SE="0.20947489439007094" STUDY_ID="STD-Gryseels-1989c-BDI" TOTAL_1="36" TOTAL_2="26" VAR="0.043879731379731376" WEIGHT="47.34246575342466">
<FOOTNOTE>Praziquantel 30 mg/kg in a single dose versus praziquantel 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-12-07 00:36:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4">
<NAME>Praziquantel (higher dose) versus praziquantel 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="3.269527419125036" CI_END="1.292217936733507" CI_START="0.7282299533775263" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9700679397965098" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" I2="8.243620088592644" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.11133576500497158" LOG_CI_START="-0.13773146173956838" LOG_EFFECT_SIZE="-0.01319784836729837" METHOD="MH" MODIFIED="2012-12-06 23:25:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.35190648958678716" P_Q="1.0" P_Z="0.8354527090112525" Q="0.0" RANDOM="NO" SCALE="21.52" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="389" TOTAL_2="394" WEIGHT="99.99999999999999" Z="0.20771345802036664">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>60 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.269527419125036" CI_END="1.292217936733507" CI_START="0.7282299533775263" DF="3" EFFECT_SIZE="0.9700679397965098" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" I2="8.243620088592644" ID="CMP-004.01.01" LOG_CI_END="0.11133576500497158" LOG_CI_START="-0.13773146173956838" LOG_EFFECT_SIZE="-0.01319784836729837" MODIFIED="2012-03-16 10:27:03 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.35190648958678716" P_Z="0.8354527090112525" STUDIES="4" TAU2="0.0" TOTAL_1="389" TOTAL_2="394" WEIGHT="99.99999999999999" Z="0.20771345802036664">
<NAME>Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.1925741173249664" CI_START="0.533464659246297" EFFECT_SIZE="0.7976190476190477" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.07648537953183789" LOG_CI_START="-0.27289434625394826" LOG_EFFECT_SIZE="-0.0982044833610552" MODIFIED="2012-03-06 15:22:09 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="722" O_E="0.0" SE="0.20522738038410573" STUDY_ID="STD-Guisse-1997-SEN" TOTAL_1="63" TOTAL_2="67" VAR="0.042118277659322426" WEIGHT="45.00237229163371">
<FOOTNOTE>Praziquuantel 60 mg/kg given as a divided dose of 30 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.012649149488972" CI_START="0.07949721392853062" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3037680740833235" LOG_CI_START="-1.0996480914273987" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-03-03 22:03:27 +0000" MODIFIED_BY="[Empty name]" ORDER="721" O_E="0.0" SE="0.8243736026430576" STUDY_ID="STD-Olliaro-2011-BRA" TOTAL_1="98" TOTAL_2="98" VAR="0.6795918367346938" WEIGHT="7.2548467236016645">
<FOOTNOTE>Praziquuantel 60 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.023262965314264" CI_START="0.4320240958079616" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4804759240279621" LOG_CI_START="-0.3644920300725886" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2012-03-03 22:02:47 +0000" MODIFIED_BY="[Empty name]" ORDER="723" O_E="0.0" SE="0.4963383588974933" STUDY_ID="STD-Olliaro-2011-MRT" TOTAL_1="93" TOTAL_2="93" VAR="0.24635176651305685" WEIGHT="10.15678541304233">
<FOOTNOTE>Praziquuantel 60 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9629879252838736" CI_START="0.7831517311457584" EFFECT_SIZE="1.2398860398860398" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.2929176281793681" LOG_CI_START="-0.10615408773076934" LOG_EFFECT_SIZE="0.0933817702242994" MODIFIED="2012-03-03 22:03:04 +0000" MODIFIED_BY="[Empty name]" ORDER="720" O_E="0.0" SE="0.23441670136246792" STUDY_ID="STD-Olliaro-2011-TZA" TOTAL_1="135" TOTAL_2="136" VAR="0.05495118987766047" WEIGHT="37.58599557172228">
<FOOTNOTE>Praziquuantel 60 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:25:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.76" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="103" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:35:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 50 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.5048866736920363" CI_START="0.5178150033122161" EFFECT_SIZE="1.1388888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.39878808225774515" LOG_CI_START="-0.2858253703528487" LOG_EFFECT_SIZE="0.05648135595244821" MODIFIED="2012-03-06 15:23:26 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="673" O_E="0.0" SE="0.40214533095470856" STUDY_ID="STD-Katz-1981-BRA" TOTAL_1="40" TOTAL_2="41" VAR="0.1617208672086721" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 50 mg/kg given as a divided dose of 25 mg/kg 6 hours apart versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="44" EVENTS_2="46" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-11-18 19:54:35 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.2792143156295994" CI_START="0.8089373447500581" EFFECT_SIZE="1.0172532781228434" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="46" LOG_CI_END="0.10694331093529498" LOG_CI_START="-0.0920851148315788" LOG_EFFECT_SIZE="0.007429098051858105" MODIFIED="2012-07-21 13:14:14 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="725" O_E="0.0" SE="0.11691028250205841" STUDY_ID="STD-Guisse-1997-SEN" TOTAL_1="63" TOTAL_2="67" VAR="0.013668014154711106" WEIGHT="0.0">
<FOOTNOTE>Praziquantel 60 mg/kg given as two divided doses given on the same day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-07 00:36:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="169.53677000201333" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six to 12 months</NAME>
<GROUP_LABEL_1>Higher dose (60 mg/kg)</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-11-18 19:53:55 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="11.763711174706504" CI_START="0.17348405585803833" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0705443530697272" LOG_CI_START="-0.7607404330982406" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2012-03-06 15:25:47 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="729" O_E="0.0" SE="1.0757057484009542" STUDY_ID="STD-Katz-1979a-BRA" TOTAL_1="7" TOTAL_2="5" VAR="1.1571428571428573" WEIGHT="0.0">
<FOOTNOTE>Praziquuantel 60 mg/kg given as a divided dose of 20 mg/kg 4 hours apart versus Praziquantel 40 mg/kg given as a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.04" MODIFIED="2012-11-18 20:55:28 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Percent egg reduction at one month</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Praziquantel (60 mg/kg)</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-05-09 15:35:41 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="146" STUDY_ID="STD-Guisse-1997-SEN">
<TR>
<TD>
<P>130</P>
</TD>
<TD>
<P>99%</P>
</TD>
<TD>
<P>99%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-11-18 20:55:28 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="147" STUDY_ID="STD-Olliaro-2011-BRA">
<TR>
<TD>
<P>196</P>
</TD>
<TD>
<P>91.8%</P>
</TD>
<TD>
<P>91.7%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:35:54 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="148" STUDY_ID="STD-Olliaro-2011-MRT">
<TR>
<TD>
<P>186</P>
</TD>
<TD>
<P>89.6%</P>
</TD>
<TD>
<P>89.2%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG of participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:36:05 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="149" STUDY_ID="STD-Olliaro-2011-TZA">
<TR>
<TD>
<P>271</P>
</TD>
<TD>
<P>92.3%</P>
</TD>
<TD>
<P>91.9%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-12-10 11:45:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="5">
<NAME>Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose</NAME>
<DICH_OUTCOME CHI2="7.0219885063519705" CI_END="1.6923061626725306" CI_START="0.1289004873622029" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4670536255448068" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="57" I2="85.75901969797562" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.22847893596712704" LOG_CI_START="-0.8897454406115677" LOG_EFFECT_SIZE="-0.33063325232222035" METHOD="MH" MODIFIED="2012-12-06 23:26:50 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.008051492825227546" P_Q="1.0" P_Z="0.24644290722447504" Q="0.0" RANDOM="YES" SCALE="11.09" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7446841173808851" TOTALS="YES" TOTAL_1="257" TOTAL_2="268" WEIGHT="100.0" Z="1.1590326238918136">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>20 mg/kg x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg x1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 20 mg/kg x 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.552160967345659" CI_START="0.09893616662957445" EFFECT_SIZE="0.23372781065088757" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" LOG_CI_END="-0.2579342971997309" LOG_CI_START="-1.004644920774696" LOG_EFFECT_SIZE="-0.6312896089872133" MODIFIED="2012-12-01 18:36:19 +0000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.43862151656513393" STUDY_ID="STD-Kardaman-1983-SDN" TOTAL_1="156" TOTAL_2="158" VAR="0.19238883479389807" WEIGHT="46.042586454885914"/>
<DICH_DATA CI_END="1.3348220873627685" CI_START="0.5326210595013093" EFFECT_SIZE="0.8431810923027787" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.12542338433307476" LOG_CI_START="-0.2735816658272431" LOG_EFFECT_SIZE="-0.07407914074708416" MODIFIED="2012-08-09 15:53:19 +0100" MODIFIED_BY="[Empty name]" ORDER="874" O_E="0.0" SE="0.23437754157102317" STUDY_ID="STD-Kardaman-1985-SDN" TOTAL_1="101" TOTAL_2="110" VAR="0.0549328319928767" WEIGHT="53.95741354511409"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6979196424088528" CI_END="0.5346555740027525" CI_START="0.1795510399584706" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3098353826337258" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.27192590111946424" LOG_CI_START="-0.7458120750997727" LOG_EFFECT_SIZE="-0.5088689881096184" METHOD="MH" MODIFIED="2012-12-06 23:27:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40348403031001656" P_Q="1.0" P_Z="2.5616138662738843E-5" Q="0.0" RANDOM="YES" SCALE="11.09" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="263" WEIGHT="100.0" Z="4.209301491820427">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>20 mg/kg x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg x1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 20 mg/kg x 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.552160967345659" CI_START="0.09893616662957445" EFFECT_SIZE="0.23372781065088757" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" LOG_CI_END="-0.2579342971997309" LOG_CI_START="-1.004644920774696" LOG_EFFECT_SIZE="-0.6312896089872133" MODIFIED="2012-08-24 10:39:10 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.43862151656513393" STUDY_ID="STD-Kardaman-1983-SDN" TOTAL_1="156" TOTAL_2="158" VAR="0.19238883479389807" WEIGHT="40.27572952620989"/>
<DICH_DATA CI_END="0.759074200234946" CI_START="0.18496485735018137" EFFECT_SIZE="0.3747026169706582" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" LOG_CI_END="-0.11971576932515031" LOG_CI_START="-0.7329107781304495" LOG_EFFECT_SIZE="-0.42631327372779987" MODIFIED="2012-08-09 15:53:51 +0100" MODIFIED_BY="[Empty name]" ORDER="875" O_E="0.0" SE="0.36019378353647996" STUDY_ID="STD-Kardaman-1985-SDN" TOTAL_1="97" TOTAL_2="105" VAR="0.1297395616983246" WEIGHT="59.72427047379011"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2050432923031726" CI_START="0.7114688014015418" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2525252525252526" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.3434171205266721" LOG_CI_START="-0.1478441393973018" LOG_EFFECT_SIZE="0.09778649056468518" METHOD="MH" MODIFIED="2012-12-06 23:27:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.4352324817284905" Q="0.0" RANDOM="YES" SCALE="11.09" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.7802691370820048">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>20 mg/kg x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg x1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 20 mg/kg x 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2050432923031726" CI_START="0.7114688014015418" EFFECT_SIZE="1.2525252525252526" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3434171205266721" LOG_CI_START="-0.1478441393973018" LOG_EFFECT_SIZE="0.09778649056468518" MODIFIED="2012-08-09 15:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="876" O_E="0.0" SE="0.28856929586179814" STUDY_ID="STD-Omer-1981-SDN" TOTAL_1="33" TOTAL_2="31" VAR="0.08327223851417398" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-005.04" MODIFIED="2012-12-10 11:45:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Percent egg reduction at one month</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg) in a divided dose of 20 mg/kg</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg) single dose</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-12-10 11:45:38 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="155" STUDY_ID="STD-Kardaman-1983-SDN">
<TR>
<TD>
<P>350</P>
</TD>
<TD>
<P>93.2%</P>
</TD>
<TD>
<P>86.5%</P>
</TD>
<TD>
<P>P &gt; 0.1</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-12-06 23:28:27 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="6">
<NAME>Praziquantel alternative dosing (Brazil)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:27:49 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="54.23" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="239" TOTAL_2="233" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="15" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:39:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 30 mg/kg x 2 daily for 2 days versus praziquantel 30 mg/kg x 2 in one day</NAME>
<DICH_DATA CI_END="0.9654122235034559" CI_START="0.29463522163848604" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="-0.015287206691458747" LOG_CI_START="-0.5307153374360167" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2011-07-28 09:58:01 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-da-Cunha-1987-BRA" TOTAL_1="20" TOTAL_2="20" VAR="0.09166666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="15" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:39:00 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 30 mg/kg x 2 daily for 3 days versus praziquantel 30 mg/kg x 2 in one day</NAME>
<DICH_DATA CI_END="0.5334020150682606" CI_START="0.036929685626175976" EFFECT_SIZE="0.14035087719298245" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.2729453479799012" LOG_CI_START="-1.4326243893811943" LOG_EFFECT_SIZE="-0.8527848686805478" MODIFIED="2012-03-09 10:56:09 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1017" O_E="0.0" SE="0.6812012094229563" STUDY_ID="STD-da-Cunha-1987-BRA" TOTAL_1="19" TOTAL_2="20" VAR="0.4640350877192983" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="15" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:38:52 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 30 mg/kg x 1 daily for 6 days versus 30 mg/kg x 2 in one day</NAME>
<DICH_DATA CI_END="0.5086512197657855" CI_START="0.03495082108711695" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.29357990970960274" LOG_CI_START="-1.4565426170737974" LOG_EFFECT_SIZE="-0.8750612633917001" MODIFIED="2012-02-28 14:05:06 +0000" MODIFIED_BY="[Empty name]" ORDER="926" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-da-Cunha-1987-BRA" TOTAL_1="20" TOTAL_2="20" VAR="0.4666666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:39:25 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 20 mg/kg x 3, 4 hours apart versus praziquantel 50 mg/kg single dose</NAME>
<DICH_DATA CI_END="19.725639100100512" CI_START="0.18623534033391048" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2012-03-02 10:02:20 +0000" MODIFIED_BY="[Empty name]" ORDER="778" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Katz-1979b-BRA" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="24" I2="0.0" ID="CMP-006.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-16 10:39:39 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="156" TOTAL_2="150" WEIGHT="0.0" Z="0.0">
<NAME>Praziquantel 40 mg/kg x 2, 1 hour apart versus praziquantel 50 mg/kg single dose</NAME>
<DICH_DATA CI_END="1.1581830337079588" CI_START="0.3547918252064016" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.0637771986382968" LOG_CI_START="-0.4500263953472199" LOG_EFFECT_SIZE="-0.19312459835446155" MODIFIED="2012-03-02 10:03:02 +0000" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.30181077447590166" STUDY_ID="STD-Queiroz-2010-BRA" TOTAL_1="156" TOTAL_2="150" VAR="0.09108974358974357" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-006.02" MODIFIED="2012-12-06 23:28:00 +0000" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Percent egg reduction at six months</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Geometric mean % egg reduction at 6 months 30 mg/kg x 2 daily for 2 days</P>
</TH>
<TH>
<P>Geometric mean % egg reduction at 6 months 30 mg/kg x 2 in one day</P>
</TH>
<TH>
<P>p-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-08-23 16:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="161" STUDY_ID="STD-da-Cunha-1987-BRA">
<TR>
<TD>
<P>79</P>
</TD>
<TD>
<P>73.1%</P>
</TD>
<TD>
<P>63.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-006.03" MODIFIED="2012-12-06 23:28:17 +0000" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Percent egg reduction at six months</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Geometric mean % egg reduction 30 mg/kg x 2 daily for 3 days</P>
</TH>
<TH>
<P>Geometric mean % egg reduction 30 mg/kg x 2 in one day</P>
</TH>
<TH>
<P>p-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-08-23 16:10:54 +0100" MODIFIED_BY="[Empty name]" ORDER="162" STUDY_ID="STD-da-Cunha-1987-BRA">
<TR>
<TD>
<P>79</P>
</TD>
<TD>
<P>86.6%</P>
</TD>
<TD>
<P>63.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-006.04" MODIFIED="2012-12-06 23:28:27 +0000" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Percent egg reduction at six months</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Geometric mean % egg reduction 30 mg/kg daily for 6 days</P>
</TH>
<TH>
<P>Geometric mean % egg reduction 30 mg/kg x 2 in one day</P>
</TH>
<TH>
<P>p-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-08-23 16:11:02 +0100" MODIFIED_BY="[Empty name]" ORDER="163" STUDY_ID="STD-da-Cunha-1987-BRA">
<TR>
<TD>
<P>79</P>
</TD>
<TD>
<P>83.8%</P>
</TD>
<TD>
<P>63.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-12-07 00:29:04 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="7">
<NAME>Oxamniquine versus placebo</NAME>
<DICH_OUTCOME CHI2="7.312051967110575" CI_END="12.047494826277303" CI_START="4.941740784077712" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="7.715931345533074" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="15" I2="31.61974200279383" I2_Q="63.97170340253407" ID="CMP-007.01" LOG_CI_END="1.0808967484681868" LOG_CI_START="0.6938799610180694" LOG_EFFECT_SIZE="0.8873883547431283" METHOD="MH" MODIFIED="2012-12-07 00:28:41 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.19844780752603708" P_Q="0.062312364496144856" P_Z="2.5182007491749163E-19" Q="5.551192226336537" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="139" WEIGHT="300.0" Z="8.987978154931877">
<NAME>Parasitological failure at three to four months</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxamniquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxamniquine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3390748763807181" CI_END="7.65126157861157" CI_START="2.4669414429412155" DF="1" EFFECT_SIZE="4.3445614599244315" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="9" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.8837330497231639" LOG_CI_START="0.39215884089252145" LOG_EFFECT_SIZE="0.6379459453078427" MODIFIED="2012-08-24 10:34:34 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.5603638817341425" P_Z="3.6352169359405964E-7" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="44" WEIGHT="100.0" Z="5.087130506138913">
<NAME>30 mg/kg</NAME>
<DICH_DATA CI_END="7.6741398421206295" CI_START="2.098909136025634" EFFECT_SIZE="4.013392857142857" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="7" LOG_CI_END="0.8850297088716763" LOG_CI_START="0.3219936379264555" LOG_EFFECT_SIZE="0.603511673399066" MODIFIED="2012-08-22 14:02:01 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="168" O_E="0.0" SE="0.33073017514672326" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="32" TOTAL_2="29" VAR="0.10938244875258223" WEIGHT="82.83624085537423">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="18.900998108487038" CI_START="1.868554814814233" EFFECT_SIZE="5.942857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.2764847386474671" LOG_CI_START="0.27150584257750465" LOG_EFFECT_SIZE="0.773995290612486" MODIFIED="2012-08-22 14:01:47 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="304" O_E="0.0" SE="0.5903295782772628" STUDY_ID="STD-Ayele-1984-ETH" TOTAL_1="6" TOTAL_2="15" VAR="0.348489010989011" WEIGHT="17.163759144625775">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.84783750884441" CI_END="20.429924000268286" CI_START="3.7380408700842027" DF="1" EFFECT_SIZE="8.73887240356083" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="4" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="1.31026675105117" LOG_CI_START="0.5726440454523933" LOG_EFFECT_SIZE="0.9414553982517818" MODIFIED="2012-08-24 10:34:51 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.35716489527097217" P_Z="5.64008979142591E-7" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="44" WEIGHT="99.99999999999999" Z="5.0031504171944405">
<NAME>40 mg/kg</NAME>
<DICH_DATA CI_END="18.130357843243377" CI_START="2.9116527702898" EFFECT_SIZE="7.265625" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="1.2584063759549846" LOG_CI_START="0.46413958185714876" LOG_EFFECT_SIZE="0.8612729789060668" MODIFIED="2012-08-22 14:02:25 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="169" O_E="0.0" SE="0.46655624653710903" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="32" TOTAL_2="30" VAR="0.21767473118279568" WEIGHT="92.84536762281569">
<FOOTNOTE>Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg in one day versus Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="428.3937705659064" CI_START="1.8114652020689868" EFFECT_SIZE="27.857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.631843146967189" LOG_CI_START="0.25802999572933316" LOG_EFFECT_SIZE="1.4449365713482611" MODIFIED="2012-08-22 14:02:44 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="305" O_E="0.0" SE="1.3943895956017258" STUDY_ID="STD-Ayele-1984-ETH" TOTAL_1="6" TOTAL_2="14" VAR="1.9443223443223443" WEIGHT="7.1546323771843054">
<FOOTNOTE>Oxamniquine 40 mg/kg in a divided doses of 10 mg/kg twice daily for two days versus Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08063061402072424" CI_END="64.79445037822514" CI_START="5.794445151741485" DF="1" EFFECT_SIZE="19.37647772052137" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="2" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="1.8115378102945805" LOG_CI_START="0.763011856335241" LOG_EFFECT_SIZE="1.2872748333149109" MODIFIED="2012-08-24 10:35:14 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.7764446442155406" P_Z="1.4905851947713311E-6" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="51" WEIGHT="100.00000000000001" Z="4.812493771803889">
<NAME>60 mg/kg</NAME>
<DICH_DATA CI_END="69.08822709860263" CI_START="4.649035255416493" EFFECT_SIZE="17.921875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="2" LOG_CI_END="1.8394040482176481" LOG_CI_START="0.6673628396171125" LOG_EFFECT_SIZE="1.2533834439173805" MODIFIED="2012-08-22 14:03:01 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="170" O_E="0.0" SE="0.6884628076295058" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="32" TOTAL_2="37" VAR="0.473981037489102" WEIGHT="85.35919975750228">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="428.3937705659064" CI_START="1.8114652020689868" EFFECT_SIZE="27.857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.631843146967189" LOG_CI_START="0.25802999572933316" LOG_EFFECT_SIZE="1.4449365713482611" MODIFIED="2012-08-22 14:03:20 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="306" O_E="0.0" SE="1.3943895956017258" STUDY_ID="STD-Ayele-1984-ETH" TOTAL_1="6" TOTAL_2="14" VAR="1.9443223443223443" WEIGHT="14.640800242497727">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9301009312894097" CI_END="5.359728822798857" CI_START="2.5334936662426313" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6849476285747915" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-007.02" LOG_CI_END="0.7291428169798319" LOG_CI_START="0.40371982288786484" LOG_EFFECT_SIZE="0.5664313199338483" METHOD="MH" MODIFIED="2012-12-07 00:28:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3348368513566665" P_Q="0.0" P_Z="8.914170570098471E-12" Q="1.3493007875324198E-30" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="77" WEIGHT="100.0" Z="6.823027302564126">
<NAME>Parasitological failure at six to 10 months</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxamniquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxamniquine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9301009312894097" CI_END="5.359728822798857" CI_START="2.5334936662426313" DF="1" EFFECT_SIZE="3.6849476285747915" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="20" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.7291428169798319" LOG_CI_START="0.40371982288786484" LOG_EFFECT_SIZE="0.5664313199338483" MODIFIED="2012-09-02 11:48:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3348368513566665" P_Z="8.914170570098471E-12" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="77" WEIGHT="100.0" Z="6.823027302564126">
<NAME>20 mg/kg</NAME>
<DICH_DATA CI_END="4.9189292826363165" CI_START="2.084161962586867" EFFECT_SIZE="3.2018502943650127" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="14" LOG_CI_END="0.6918705789363206" LOG_CI_START="0.3189314654550305" LOG_EFFECT_SIZE="0.5054010221956756" MODIFIED="2012-08-09 15:50:34 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.2190662813372948" STUDY_ID="STD-Lambertucci-1982-BRA" TOTAL_1="40" TOTAL_2="46" VAR="0.047990035618950794" WEIGHT="69.96587030716724">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="9.935577199524879" CI_START="2.3289454548641526" EFFECT_SIZE="4.810344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" LOG_CI_END="0.9971931021742789" LOG_CI_START="0.36715931724704165" LOG_EFFECT_SIZE="0.6821762097106603" MODIFIED="2012-08-09 15:50:34 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.37008496398379254" STUDY_ID="STD-Ferrari-2003-BRA" TOTAL_1="29" TOTAL_2="31" VAR="0.13696288056688502" WEIGHT="30.034129692832764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-007.03" MODIFIED="2012-12-07 00:29:04 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Percent egg reduction at three to four months</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>p-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-007.03.01" MODIFIED="2012-05-09 14:33:10 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="2">
<NAME>Oxamniquine (40 mg/kg) versus placebo</NAME>
<OTHER_DATA MODIFIED="2012-05-09 14:33:10 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="172" STUDY_ID="STD-Ayele-1984-ETH">
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>59% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:32:16 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="173" STUDY_ID="STD-Ayele-1986-ETH">
<TR>
<TD>
<P>162</P>
</TD>
<TD>
<P>42.7%</P>
</TD>
<TD>
<P>80.6% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-007.03.02" MODIFIED="2012-11-19 00:06:05 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="2">
<NAME>Oxamniquine (20 to 30 mg/kg) versus placebo</NAME>
<OTHER_DATA MODIFIED="2012-05-09 14:33:02 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="174" STUDY_ID="STD-Ayele-1984-ETH">
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>73.7%</P>
</TD>
<TD>
<P>59% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:32:25 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="175" STUDY_ID="STD-Ayele-1986-ETH">
<TR>
<TD>
<P>162</P>
</TD>
<TD>
<P>68.1%</P>
</TD>
<TD>
<P>80.6% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-007.03.03" MODIFIED="2012-05-09 14:32:51 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="2">
<NAME>Oxamniquine (60 mg/kg) versus placebo</NAME>
<OTHER_DATA MODIFIED="2012-05-09 14:32:51 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="176" STUDY_ID="STD-Ayele-1984-ETH">
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>59% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:32:40 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="177" STUDY_ID="STD-Ayele-1986-ETH">
<TR>
<TD>
<P>162</P>
</TD>
<TD>
<P>82%</P>
</TD>
<TD>
<P>80.6% increase</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Geometric mean EPG based on participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2012-12-10 11:47:51 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="8">
<NAME>Oxamniquine (lower dose) versus oxamniquine 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="5.29640736804159" CI_END="3.391925370209628" CI_START="1.6798703278365443" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3870472939703435" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="32" I2="5.596385388142653" I2_Q="74.02666259773497" ID="CMP-008.01" LOG_CI_END="0.5304462882595874" LOG_CI_START="0.22527575906005837" LOG_EFFECT_SIZE="0.3778610236598229" METHOD="MH" MODIFIED="2012-12-06 23:29:10 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.3807870972600882" P_Q="0.04974301390629521" P_Z="1.2121548148397372E-6" Q="3.850102066255043" RANDOM="NO" SCALE="30.43" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="245" TOTAL_2="213" WEIGHT="200.0" Z="4.853640353000596">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.46303879743546583" CI_END="6.988538097641476" CI_START="2.0465996841051544" DF="1" EFFECT_SIZE="3.78189633160269" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="10" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.8443863370434841" LOG_CI_START="0.3110329027572292" LOG_EFFECT_SIZE="0.5777096199003566" MODIFIED="2012-03-16 10:40:43 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.4962072335258827" P_Z="2.176908665837964E-5" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="92" WEIGHT="100.0" Z="4.245927655991483">
<NAME>Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="24.458911481650837" CI_START="1.3603712700325556" EFFECT_SIZE="5.7682926829268295" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3884371253073116" LOG_CI_START="0.13365745140087826" LOG_EFFECT_SIZE="0.7610472883540949" MODIFIED="2012-03-06 17:33:08 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1105" O_E="0.0" SE="0.7370637917121987" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="41" TOTAL_2="43" VAR="0.5432630330531635" WEIGHT="18.49519108009192">
<FOOTNOTE>Oxamniquine 20 mg/kg in a divided dose of 10 mg/kg in one day versus Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.5554718868521835" CI_START="1.69270744025272" EFFECT_SIZE="3.331140350877193" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.8166039592571818" LOG_CI_START="0.22858190313952095" LOG_EFFECT_SIZE="0.5225929311983514" MODIFIED="2012-03-06 16:29:37 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1104" O_E="0.0" SE="0.3454070665196358" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="57" TOTAL_2="49" VAR="0.11930604160170011" WEIGHT="81.50480891990807">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1335748442230646" CI_END="2.7507816375253835" CI_START="1.152336884720421" DF="3" EFFECT_SIZE="1.7804008376576717" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="22" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.43945611660497946" LOG_CI_START="0.06157946327698669" LOG_EFFECT_SIZE="0.25051778994098306" MODIFIED="2012-03-16 10:40:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.7689758234393953" P_Z="0.009356046928383193" STUDIES="4" TAU2="0.0" TOTAL_1="147" TOTAL_2="121" WEIGHT="100.0" Z="2.5987625403504877">
<NAME>Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="2.659036084736681" CI_START="0.7062389874167474" EFFECT_SIZE="1.3703703703703705" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.42472423101177986" LOG_CI_START="-0.15104831119576445" LOG_EFFECT_SIZE="0.1368379599080077" MODIFIED="2012-03-06 17:34:45 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="77" O_E="0.0" SE="0.33821164141276155" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="66" TOTAL_2="37" VAR="0.11438711438711441" WEIGHT="47.520602070976466">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="9.711596264208866" CI_START="0.41187873663381236" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9872906193787466" LOG_CI_START="-0.3852306280507843" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-03-06 16:36:24 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="76" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="8.240104399512754">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.940542984036888" CI_START="0.5712191309232929" EFFECT_SIZE="1.8421052631578947" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.7738261426568744" LOG_CI_START="-0.24319725586198107" LOG_EFFECT_SIZE="0.26531444339744664" MODIFIED="2012-03-06 16:53:13 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="78" O_E="0.0" SE="0.5974045786369913" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="19" TOTAL_2="15" VAR="0.3568922305764411" WEIGHT="13.814292669771381">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.899808741666001" CI_START="1.1111544820407133" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.6901791281794982" LOG_CI_START="0.04577444240969055" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2012-03-06 16:30:15 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="79" O_E="0.0" SE="0.3785265022758249" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="42" TOTAL_2="49" VAR="0.14328231292517007" WEIGHT="30.425000859739402">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.881328497188677" CI_END="2.542718593473192" CI_START="1.377237332639985" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8713436278057307" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="45" I2="0.0" I2_Q="6.491412594816345" ID="CMP-008.02" LOG_CI_END="0.4052982988055632" LOG_CI_START="0.1390087865709683" LOG_EFFECT_SIZE="0.27215354268826575" METHOD="MH" MODIFIED="2012-12-07 00:29:34 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.9190480705491061" P_Q="0.3010767854239269" P_Z="6.169042738699327E-5" Q="1.0694204968222683" RANDOM="NO" SCALE="224.96" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="308" TOTAL_2="274" WEIGHT="200.0" Z="4.006249720147163">
<NAME>Parasitological failure at three to four months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4540939122604513" CI_END="3.712324320493287" CI_START="1.4012639999543866" DF="2" EFFECT_SIZE="2.2807775925026914" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="17" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.5696459105554034" LOG_CI_START="0.1465199646378655" LOG_EFFECT_SIZE="0.3580829375966344" MODIFIED="2012-03-16 10:41:14 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.4833342732727738" P_Z="9.087380204405504E-4" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="102" WEIGHT="100.00000000000001" Z="3.317355827215027">
<NAME>Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="8.828823222113082" CI_START="0.6524085775750086" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9459028211086132" LOG_CI_START="-0.18548033768540123" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2012-03-06 16:38:21 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1108" O_E="0.0" SE="0.6645800679125629" STUDY_ID="STD-de-Clarke-1976b-ZWE" TOTAL_1="10" TOTAL_2="8" VAR="0.44166666666666665" WEIGHT="12.647487177322331">
<FOOTNOTE>Oxamniquine 20 mg/kg in a divided dose of 5 mg/kg twice daily for 2 days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.8075071648848104" CI_START="0.41599772977768285" EFFECT_SIZE="1.2585365853658537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5806407292548323" LOG_CI_START="-0.38090903943988064" LOG_EFFECT_SIZE="0.09986584490747587" MODIFIED="2012-03-06 16:41:40 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1106" O_E="0.0" SE="0.5648190938793937" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="41" TOTAL_2="43" VAR="0.3190206088107393" WEIGHT="27.779302193047265">
<FOOTNOTE>Oxamniquine 20 mg/kg given as a divided dose of 10 mg/kg in one day versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.012537711817748" CI_START="1.489186719580763" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="10" LOG_CI_END="0.7000576530542219" LOG_CI_START="0.17294915456857507" LOG_EFFECT_SIZE="0.4365034038113984" MODIFIED="2012-03-06 16:42:43 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1107" O_E="0.0" SE="0.3096261412396175" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="56" TOTAL_2="51" VAR="0.09586834733893558" WEIGHT="59.57321062963041">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2258240644740366" CI_END="2.434410012123145" CI_START="1.1012244251516532" DF="6" EFFECT_SIZE="1.6373245756977264" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="28" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="0.3863937254990149" LOG_CI_START="0.04187583547732453" LOG_EFFECT_SIZE="0.21413478048816975" MODIFIED="2012-03-16 10:41:30 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.9755899926055113" P_Z="0.014833136199956031" STUDIES="7" TAU2="0.0" TOTAL_1="201" TOTAL_2="172" WEIGHT="99.99999999999999" Z="2.436427655862977">
<NAME>Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="3.110668694288899" CI_START="0.7640595462559971" EFFECT_SIZE="1.5416666666666667" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.49285375848762686" LOG_CI_START="-0.11687279377684893" LOG_EFFECT_SIZE="0.18799048235538898" MODIFIED="2012-03-06 16:47:07 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="82" O_E="0.0" SE="0.35815639499526364" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="66" TOTAL_2="37" VAR="0.1282760032760033" WEIGHT="33.35114926679915">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus 40 mg/kg in a divided dose of 20 mg/kg daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.344133602427874" CI_START="0.6042071999662748" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.014694121155254" LOG_CI_START="-0.21881410381117886" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2012-03-06 16:55:46 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="86" O_E="0.0" SE="0.724568837309472" STUDY_ID="STD-de-Clarke-1976b-ZWE" TOTAL_1="8" TOTAL_2="10" VAR="0.525" WEIGHT="5.783111741549347">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-03-06 17:05:58 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="81" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="3.253000354621508">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.534157207866272" CI_START="0.5922037035936922" EFFECT_SIZE="1.8103448275862069" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7430514919099374" LOG_CI_START="-0.22752888089593581" LOG_EFFECT_SIZE="0.25776130550700077" MODIFIED="2012-03-06 17:09:45 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="85" O_E="0.0" SE="0.5701237154365005" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="29" TOTAL_2="30" VAR="0.32504105090311985" WEIGHT="12.79145902156254">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.585229108779892" CI_START="0.536634489050427" EFFECT_SIZE="1.5686274509803921" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.661361040811484" LOG_CI_START="-0.27032141902346957" LOG_EFFECT_SIZE="0.19551981089400722" MODIFIED="2012-03-06 16:57:51 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="83" O_E="0.0" SE="0.5472748888096077" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="17" TOTAL_2="10" VAR="0.29950980392156856" WEIGHT="12.289112450792363">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="89.87545400217135" CI_START="0.24447894582506524" EFFECT_SIZE="4.6875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.953641097217251" LOG_CI_START="-0.6117585357457006" LOG_EFFECT_SIZE="0.6709412807357753" MODIFIED="2012-03-06 16:48:51 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="80" O_E="0.0" SE="1.5069284433354269" STUDY_ID="STD-Ayele-1984-ETH" TOTAL_1="15" TOTAL_2="14" VAR="2.270833333333333" WEIGHT="1.6789679249659395">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.7844248639026987" CI_START="0.6356992187945432" EFFECT_SIZE="1.3304347826086957" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4447355031980484" LOG_CI_START="-0.19674832227007405" LOG_EFFECT_SIZE="0.12399359046398716" MODIFIED="2012-03-06 17:07:03 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="84" O_E="0.0" SE="0.3768107744761233" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="46" TOTAL_2="51" VAR="0.14198635976129587" WEIGHT="30.853199239709145">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.64178224817651" CI_END="1.3945053342659244" CI_START="0.703003388243634" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9901222020098157" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="68" I2="13.826203252611197" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.1444201798697812" LOG_CI_START="-0.15304258181948258" LOG_EFFECT_SIZE="-0.004311200974850657" METHOD="MH" MODIFIED="2012-12-06 23:29:26 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.32606535908414747" P_Q="0.45144887321208504" P_Z="0.954694572171358" Q="0.5670118982179659" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013327886598078015" TOTALS="SUB" TOTAL_1="209" TOTAL_2="168" WEIGHT="200.0" Z="0.05681248027709869">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2986337958274277" CI_END="1.462716724876486" CI_START="0.4764235927809942" DF="1" EFFECT_SIZE="0.8347890495727076" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" I2="56.49589761469443" ID="CMP-008.03.01" LOG_CI_END="0.16516022719506174" LOG_CI_START="-0.32200674013448466" LOG_EFFECT_SIZE="-0.07842325646971149" MODIFIED="2012-03-16 10:41:51 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.12948797703047266" P_Z="0.5280255496520876" STUDIES="2" TAU2="0.09883025678378825" TOTAL_1="90" TOTAL_2="73" WEIGHT="100.00000000000001" Z="0.6310229081152238">
<NAME>Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="1.1477220818500204" CI_START="0.2947353532292848" EFFECT_SIZE="0.5816135084427767" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.05983673742503682" LOG_CI_START="-0.530567767809636" LOG_EFFECT_SIZE="-0.23536551519229962" MODIFIED="2012-03-06 16:59:51 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1110" O_E="0.0" SE="0.34680652892428204" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="41" TOTAL_2="31" VAR="0.12027476850450888" WEIGHT="37.37477024554691">
<FOOTNOTE>Oxamniquine 20 mg/kg in a divided dose of 10 mg/kg in one day versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4700937586903706" CI_START="0.729684127486038" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.16734503378447513" LOG_CI_START="-0.13686510067100136" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2012-03-06 17:00:56 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1109" O_E="0.0" SE="0.17869453884359868" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="49" TOTAL_2="42" VAR="0.0319317382125264" WEIGHT="62.6252297544531">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3341247232697233" CI_END="1.6886964510536016" CI_START="0.7111144211336256" DF="2" EFFECT_SIZE="1.095835936288544" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="31" I2="14.314775896022805" ID="CMP-008.03.02" LOG_CI_END="0.22755159067218597" LOG_CI_START="-0.1480605139412961" LOG_EFFECT_SIZE="0.039745538365444935" MODIFIED="2012-03-16 10:42:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.3112800748175478" P_Z="0.6782966112750857" STUDIES="3" TAU2="0.029687673650181698" TOTAL_1="119" TOTAL_2="95" WEIGHT="100.0" Z="0.41478867579408124">
<NAME>Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="3.1324354782610797" CI_START="0.6833429034741583" EFFECT_SIZE="1.4630541871921183" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.4958821341837404" LOG_CI_START="-0.1653613113757415" LOG_EFFECT_SIZE="0.16526041140399947" MODIFIED="2012-03-06 17:03:31 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="88" O_E="0.0" SE="0.3884176731294848" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="58" TOTAL_2="33" VAR="0.15086828879932326" WEIGHT="26.96140551829304">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus 40 mg/kg in a divided dose of 20 mg/kg daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-03-06 17:14:15 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="87" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="2.0853063468854525">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.382312792308821" CI_START="0.6378923861365366" EFFECT_SIZE="0.9390243902439024" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.14060632712141394" LOG_CI_START="-0.19525258154388364" LOG_EFFECT_SIZE="-0.027323127211234845" MODIFIED="2012-03-06 17:16:16 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="89" O_E="0.0" SE="0.19728518547840662" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="41" TOTAL_2="42" VAR="0.0389214444092493" WEIGHT="70.95328813482152">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.379782583654162" CI_END="1.2787645384851154" CI_START="0.6742925061916231" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9285802848887665" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" I2="88.49237618265134" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.10679058431393572" LOG_CI_START="-0.1711516668660133" LOG_EFFECT_SIZE="-0.032180541276038754" METHOD="MH" MODIFIED="2012-08-24 10:42:13 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="1.682792855874915E-4" P_Q="0.8949036590036195" P_Z="0.6499333939711079" Q="0.017450925143503156" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.21371430540015213" TOTALS="SUB" TOTAL_1="121" TOTAL_2="100" WEIGHT="200.0" Z="0.4538547243988844">
<NAME>Parasitological failure at 12 months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.01278852025696" CI_END="2.363551522675816" CI_START="0.321169320387042" DF="1" EFFECT_SIZE="0.8712635859701414" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" I2="94.1220688259934" ID="CMP-008.04.01" LOG_CI_END="0.37356507385700444" LOG_CI_START="-0.493265947275609" LOG_EFFECT_SIZE="-0.059850436709302325" MODIFIED="2012-03-16 10:42:32 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="3.7129194891294404E-5" P_Z="0.7866588299401855" STUDIES="2" TAU2="0.48845373182777074" TOTAL_1="82" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.2706518284404601">
<NAME>Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="0.7952193983894348" CI_START="0.34495182363171806" EFFECT_SIZE="0.5237483953786907" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="-0.09951303440710313" LOG_CI_START="-0.4622415547582659" LOG_EFFECT_SIZE="-0.28087729458268446" MODIFIED="2012-03-06 17:17:35 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1112" O_E="0.0" SE="0.21306852838940674" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="41" TOTAL_2="24" VAR="0.04539819779002743" WEIGHT="48.56498703126603">
<FOOTNOTE>Oxamniquine 20 mg/kg in a divided dose of 10 mg/kg in one day versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.799664730618098" CI_START="1.1027956646892303" EFFECT_SIZE="1.408780487804878" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" LOG_CI_END="0.25519160554524795" LOG_CI_START="0.04249505013844642" LOG_EFFECT_SIZE="0.14884332784184717" MODIFIED="2012-03-06 17:18:06 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1111" O_E="0.0" SE="0.12493900951088488" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="41" TOTAL_2="38" VAR="0.015609756097560983" WEIGHT="51.43501296873396">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3113178336490567" CI_START="0.6672252571014626" DF="0" EFFECT_SIZE="0.9353846153846154" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.11770796756385764" LOG_CI_START="-0.17572752230409888" LOG_EFFECT_SIZE="-0.029009777370120643" MODIFIED="2012-08-24 10:42:13 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="1.0" P_Z="0.6983608984567283" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0" Z="0.3875340291697315">
<NAME>Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</NAME>
<DICH_DATA CI_END="1.3113178336490567" CI_START="0.6672252571014626" EFFECT_SIZE="0.9353846153846154" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.11770796756385764" LOG_CI_START="-0.17572752230409888" LOG_EFFECT_SIZE="-0.029009777370120643" MODIFIED="2012-03-06 17:18:38 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="90" O_E="0.0" SE="0.1723654592775386" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="39" TOTAL_2="38" VAR="0.029709851551956816" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-008.05" MODIFIED="2012-12-10 11:47:51 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Dose (mg/kg)</P>
</TH>
<TH>
<P>Oxamniquine (lower dose) </P>
</TH>
<TH>
<P>Oxamniquine (40 mg/kg) </P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-008.05.01" MODIFIED="2012-12-06 23:55:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="3">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:34:11 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="202" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>81.7%</P>
</TD>
<TD>
<P>80%</P>
</TD>
<TD>
<P>No significant difference with H- and Wilcoxon-tests </P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:00:12 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="203" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>93.6%</P>
</TD>
<TD>
<P>78.8%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:00:56 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="204" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>119</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>99.4%</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-008.05.02" MODIFIED="2012-12-07 11:05:27 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="5">
<NAME>Three to four months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:34:22 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="205" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>78.1%</P>
</TD>
<TD>
<P>67.5%</P>
</TD>
<TD>
<P>Not statistically significant with H- and Wilcoxon- tests</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:34:32 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="206" STUDY_ID="STD-Ayele-1984-ETH">
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>73.7%</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:34:40 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="207" STUDY_ID="STD-Ayele-1986-ETH">
<TR>
<TD>
<P>162</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>68.1</P>
</TD>
<TD>
<P>42.7%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:57:50 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="208" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>93.6%</P>
</TD>
<TD>
<P>99.4%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:58:18 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="209" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>119</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>97.6%</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-008.05.03" MODIFIED="2012-12-06 23:55:34 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="3">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:34:52 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="210" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>57.1%</P>
</TD>
<TD>
<P>56.8%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:01:25 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="211" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>95.2%</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:34:59 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="212" STUDY_ID="STD-Omer-1978-SDN">
<TR>
<TD>
<P>176</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>84%</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2012-12-06 23:37:51 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="91" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:31:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="260" TOTAL_2="215" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:30:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.2288471649355885" CI_START="0.5564579507198287" EFFECT_SIZE="0.8269230769230769" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.08949787185912277" LOG_CI_START="-0.25456764796954806" LOG_EFFECT_SIZE="-0.08253488805521265" MODIFIED="2012-09-02 15:28:26 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.20210578949915245" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.040846750149075725" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:30:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.546361907164191" CI_START="0.5523679100931661" EFFECT_SIZE="0.9242081447963801" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.18931114281035993" LOG_CI_START="-0.2577715597716751" LOG_EFFECT_SIZE="-0.03423020848065758" MODIFIED="2012-09-02 15:28:12 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.2626185925917575" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.06896852517487552" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:05 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.6241471664837155" CI_START="0.48331613279402685" EFFECT_SIZE="0.885989010989011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.21062537878203866" LOG_CI_START="-0.31576870813757746" LOG_EFFECT_SIZE="-0.052571664677769435" MODIFIED="2012-09-02 15:28:38 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.30920649234933684" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.0956086549109805" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-009.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:28:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.6241471664837155" CI_START="0.48331613279402685" EFFECT_SIZE="0.885989010989011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.21062537878203866" LOG_CI_START="-0.31576870813757746" LOG_EFFECT_SIZE="-0.052571664677769435" MODIFIED="2012-09-02 15:28:45 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.30920649234933684" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.0956086549109805" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-009.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:29:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.5944515688015912" CI_START="0.5427801249065659" EFFECT_SIZE="0.9302884615384616" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2026113321574285" LOG_CI_START="-0.26537606337309116" LOG_EFFECT_SIZE="-0.03138236560783133" MODIFIED="2012-09-02 15:29:50 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.27489811270959635" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.07556897237129795" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="88" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:31:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="260" TOTAL_2="215" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.2288471649355885" CI_START="0.5564579507198287" EFFECT_SIZE="0.8269230769230769" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.08949787185912277" LOG_CI_START="-0.25456764796954806" LOG_EFFECT_SIZE="-0.08253488805521265" MODIFIED="2012-08-31 21:14:54 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.20210578949915245" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.040846750149075725" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3493848875884706" CI_START="0.44888645868396226" EFFECT_SIZE="0.7782805429864253" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.13013584197335337" LOG_CI_START="-0.3478634955284769" LOG_EFFECT_SIZE="-0.10886382677756178" MODIFIED="2012-09-02 15:46:52 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.28077917698345634" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.0788369462275071" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.6241471664837155" CI_START="0.48331613279402685" EFFECT_SIZE="0.885989010989011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.21062537878203866" LOG_CI_START="-0.31576870813757746" LOG_EFFECT_SIZE="-0.052571664677769435" MODIFIED="2012-09-02 15:46:59 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.30920649234933684" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.0956086549109805" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-009.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:47:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.6241471664837155" CI_START="0.48331613279402685" EFFECT_SIZE="0.885989010989011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.21062537878203866" LOG_CI_START="-0.31576870813757746" LOG_EFFECT_SIZE="-0.052571664677769435" MODIFIED="2012-09-02 15:47:05 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.30920649234933684" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.0956086549109805" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-009.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:47:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.5944515688015912" CI_START="0.5427801249065659" EFFECT_SIZE="0.9302884615384616" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2026113321574285" LOG_CI_START="-0.26537606337309116" LOG_EFFECT_SIZE="-0.03138236560783133" MODIFIED="2012-09-02 15:47:11 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.27489811270959635" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="52" TOTAL_2="43" VAR="0.07556897237129795" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:32:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="50" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.2706405569238604" CI_START="0.6807826730436397" EFFECT_SIZE="0.9300699300699301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.10402271324316875" LOG_CI_START="-0.16699150623912073" LOG_EFFECT_SIZE="-0.031484396497976" MODIFIED="2012-09-02 15:47:56 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.15919509406591942" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="10" TOTAL_2="6" VAR="0.02534307797465693" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-009.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:31:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.5411891297370481" CI_START="0.5979798210471676" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.18785593720064056" LOG_CI_START="-0.2233134711215037" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2012-09-02 15:47:42 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.241522945769824" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="10" TOTAL_2="6" VAR="0.05833333333333335" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-009.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:32:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.2706405569238604" CI_START="0.6807826730436397" EFFECT_SIZE="0.9300699300699301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.10402271324316875" LOG_CI_START="-0.16699150623912073" LOG_EFFECT_SIZE="-0.031484396497976" MODIFIED="2012-09-02 15:48:01 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.15919509406591942" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="10" TOTAL_2="6" VAR="0.02534307797465693" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-009.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:48:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.5411891297370481" CI_START="0.5979798210471676" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.18785593720064056" LOG_CI_START="-0.2233134711215037" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2012-09-02 15:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.241522945769824" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="10" TOTAL_2="6" VAR="0.05833333333333335" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-009.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:48:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.2706405569238604" CI_START="0.6807826730436397" EFFECT_SIZE="0.9300699300699301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.10402271324316875" LOG_CI_START="-0.16699150623912073" LOG_EFFECT_SIZE="-0.031484396497976" MODIFIED="2012-09-02 15:48:10 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.15919509406591942" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="10" TOTAL_2="6" VAR="0.02534307797465693" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:33:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:32:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.2838508499640278" CI_START="0.7789066775381417" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.10851457295398789" LOG_CI_START="-0.10851457295398785" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-02 15:48:52 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.12748399461794346" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="9" TOTAL_2="6" VAR="0.016252168883747836" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:32:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.6330540606304904" CI_START="0.6967177665499352" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.21300056186152677" LOG_CI_START="-0.1569431146610397" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2012-09-02 15:49:08 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.21730674684008836" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="9" TOTAL_2="6" VAR="0.04722222222222225" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-009.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:33:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.275397606780371" CI_START="0.6569943283789893" EFFECT_SIZE="0.9153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.10564559772019187" LOG_CI_START="-0.18243837954880396" LOG_EFFECT_SIZE="-0.03839639091430602" MODIFIED="2012-09-02 15:49:18 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.1692219542864945" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="9" TOTAL_2="6" VAR="0.028636069812540438" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-009.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:49:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.6330540606304904" CI_START="0.6967177665499352" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.21300056186152677" LOG_CI_START="-0.1569431146610397" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2012-09-02 15:49:23 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.21730674684008836" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="9" TOTAL_2="6" VAR="0.04722222222222225" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-009.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:49:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.2838508499640278" CI_START="0.7789066775381417" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.10851457295398789" LOG_CI_START="-0.10851457295398785" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-02 15:49:27 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.12748399461794346" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="9" TOTAL_2="6" VAR="0.016252168883747836" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="261" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:33:51 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="305" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of blood in stool: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="21" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:33:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.206583361348292" CI_START="0.8483096579247871" EFFECT_SIZE="1.0117096018735363" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="21" LOG_CI_END="0.08155733214858855" LOG_CI_START="-0.07144558856881211" LOG_EFFECT_SIZE="0.005055871789888234" MODIFIED="2012-09-02 15:49:53 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.08987467300607355" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="61" TOTAL_2="24" VAR="0.008077456847948646" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="22" I2="0.0" ID="CMP-009.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:33:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.1228099626148658" CI_START="0.8306129807773068" EFFECT_SIZE="0.9657228017883756" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="22" LOG_CI_END="0.050306257444291604" LOG_CI_START="-0.08060128604108908" LOG_EFFECT_SIZE="-0.015147514298398744" MODIFIED="2012-09-02 15:49:43 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.07689573904610375" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="61" TOTAL_2="24" VAR="0.005912954683446485" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="22" I2="0.0" ID="CMP-009.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:33:51 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.1068645966773878" CI_START="0.8116610289981228" EFFECT_SIZE="0.9478390461997019" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="22" LOG_CI_END="0.04409449665784369" LOG_CI_START="-0.0906253056990001" LOG_EFFECT_SIZE="-0.0232654045205782" MODIFIED="2012-09-02 15:49:58 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.07913507877818692" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="61" TOTAL_2="24" VAR="0.00626236069322985" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="22" I2="0.0" ID="CMP-009.05.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:50:02 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.1228099626148658" CI_START="0.8306129807773068" EFFECT_SIZE="0.9657228017883756" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="22" LOG_CI_END="0.050306257444291604" LOG_CI_START="-0.08060128604108908" LOG_EFFECT_SIZE="-0.015147514298398744" MODIFIED="2012-09-02 15:50:02 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.07689573904610375" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="61" TOTAL_2="24" VAR="0.005912954683446485" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="19" I2="0.0" ID="CMP-009.05.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:50:06 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.2234750177305316" CI_START="0.7416110104128356" EFFECT_SIZE="0.9525452976704055" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="19" LOG_CI_END="0.08759510587207851" LOG_CI_START="-0.1298238310129103" LOG_EFFECT_SIZE="-0.0211143625704159" MODIFIED="2012-09-02 15:50:06 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.12771295976733738" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="61" TOTAL_2="24" VAR="0.016310600092533538" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="79" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:34:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="85" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of blood in stool: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="21" I2="0.0" ID="CMP-009.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:34:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.3037328743710006" CI_START="0.88743673031388" EFFECT_SIZE="1.0756302521008403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.11518861664837621" LOG_CI_START="-0.051862600137701" LOG_EFFECT_SIZE="0.03166300825533759" MODIFIED="2012-09-02 15:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.09812671165700115" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="17" TOTAL_2="24" VAR="0.009628851540616247" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="22" I2="0.0" ID="CMP-009.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:34:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.189133438728929" CI_START="0.7791681747081384" EFFECT_SIZE="0.9625668449197861" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.07523059175241426" LOG_CI_START="-0.10836879461880009" LOG_EFFECT_SIZE="-0.01656910143319292" MODIFIED="2012-09-02 15:50:22 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.1078471883860713" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="17" TOTAL_2="24" VAR="0.011631016042780752" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-009.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:34:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.2161871979341885" CI_START="0.8667998286347001" EFFECT_SIZE="1.0267379679144386" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.0850004275458174" LOG_CI_START="-0.06208118321171607" LOG_EFFECT_SIZE="0.011459622167050685" MODIFIED="2012-09-02 15:50:43 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.0863964662246905" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="17" TOTAL_2="24" VAR="0.007464349376114086" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-009.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:50:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.2161871979341885" CI_START="0.8667998286347001" EFFECT_SIZE="1.0267379679144386" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.0850004275458174" LOG_CI_START="-0.06208118321171607" LOG_EFFECT_SIZE="0.011459622167050685" MODIFIED="2012-09-02 15:50:47 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.0863964662246905" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="17" TOTAL_2="24" VAR="0.007464349376114086" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-009.06.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:50:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.507042276004002" CI_START="0.9378469462404437" EFFECT_SIZE="1.1888544891640866" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.1781254354451754" LOG_CI_START="-0.027868031372319635" LOG_EFFECT_SIZE="0.0751287020364279" MODIFIED="2012-09-02 15:50:51 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.1210015820927026" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="17" TOTAL_2="24" VAR="0.014641382868937049" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="73" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:35:38 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="160" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-009.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:35:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="2.1159053420770095" CI_START="0.6432759935163361" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3254962350393521" LOG_CI_START="-0.19160265577812563" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2012-09-02 15:51:31 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.30374644814697793" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="32" TOTAL_2="32" VAR="0.09226190476190477" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-009.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:35:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.8824528914955307" CI_START="0.5312217928627906" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2747241167614325" LOG_CI_START="-0.27472411676143244" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-02 15:51:20 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.3227486121839514" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="32" TOTAL_2="32" VAR="0.10416666666666666" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-009.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:35:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.6847804340765011" CI_START="0.5935491532154111" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22654331026238106" LOG_CI_START="-0.22654331026238106" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-02 15:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.26614532371118854" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="32" TOTAL_2="32" VAR="0.07083333333333333" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-009.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:51:39 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.757147814579718" CI_START="0.8662683006823819" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4404600498691005" LOG_CI_START="-0.062347577429002765" LOG_EFFECT_SIZE="0.18905623622004888" MODIFIED="2012-09-02 15:51:39 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.295351689212802" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="32" TOTAL_2="32" VAR="0.0872326203208556" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-009.07.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:51:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="2.0162216745666357" CI_START="0.6603246872800943" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.30453827913684767" LOG_CI_START="-0.18024246563915886" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2012-09-02 15:51:43 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.28476260918481483" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="32" TOTAL_2="32" VAR="0.08108974358974358" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:36:39 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="12" I2="0.0" ID="CMP-009.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:35:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="2.4237656238423395" CI_START="0.658301219944936" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.38449062160265435" LOG_CI_START="-0.1815753400851003" LOG_EFFECT_SIZE="0.10145764075877704" MODIFIED="2012-09-02 15:52:47 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.33250994796708866" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="19" TOTAL_2="32" VAR="0.110562865497076" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-009.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:36:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="2.60405296636548" CI_START="0.7564503865039651" EFFECT_SIZE="1.4035087719298245" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.41564981352377056" LOG_CI_START="-0.1212195508848662" LOG_EFFECT_SIZE="0.14721513131945216" MODIFIED="2012-09-02 15:52:38 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.3153597221998474" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="19" TOTAL_2="32" VAR="0.09945175438596493" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-009.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:36:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.9734049476056024" CI_START="0.6388428285716932" EFFECT_SIZE="1.1228070175438596" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.2952162127054177" LOG_CI_START="-0.19460597608262623" LOG_EFFECT_SIZE="0.050305118311395745" MODIFIED="2012-09-02 15:52:54 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.28772397835303587" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="19" TOTAL_2="32" VAR="0.08278508771929827" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-009.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:52:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.907199155016511" CI_START="0.8063667296829476" EFFECT_SIZE="1.5311004784688995" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.4634747837353818" LOG_CI_START="-0.0934673993176779" LOG_EFFECT_SIZE="0.18500369220885196" MODIFIED="2012-09-02 15:52:58 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.32715059523363627" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="19" TOTAL_2="32" VAR="0.1070275119617225" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-009.08.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:53:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="2.1948311397986604" CI_START="0.6194267489749512" EFFECT_SIZE="1.165991902834008" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.34140111324574235" LOG_CI_START="-0.20801004424661218" LOG_EFFECT_SIZE="0.06669553449956508" MODIFIED="2012-09-02 15:53:01 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.3227268335401003" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="19" TOTAL_2="32" VAR="0.10415260908681961" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="93" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:37:13 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="190" TOTAL_2="155" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>20 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-009.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:36:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.8282206475783351" CI_START="0.6704690201076661" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.26202860947378187" LOG_CI_START="-0.17362128448967495" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2012-09-02 15:53:37 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.2559029042158893" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="38" TOTAL_2="31" VAR="0.0654862963861266" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="14" I2="0.0" ID="CMP-009.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:37:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.9049494719750446" CI_START="0.7129788610280849" EFFECT_SIZE="1.1654135338345866" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.2798834606764961" LOG_CI_START="-0.14692334627008463" LOG_EFFECT_SIZE="0.06648005720320573" MODIFIED="2012-09-02 15:53:20 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.2507084311281896" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="38" TOTAL_2="31" VAR="0.06285471743875819" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="16" I2="0.0" ID="CMP-009.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:37:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.7339350131402251" CI_START="0.7256526313341655" EFFECT_SIZE="1.1217105263157894" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.23903281634463863" LOG_CI_START="-0.13927122557715077" LOG_EFFECT_SIZE="0.049880795383743945" MODIFIED="2012-09-02 15:53:43 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.2222176668600681" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="38" TOTAL_2="31" VAR="0.049380691464732215" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-009.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:53:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.612605778339567" CI_START="0.5731454241990853" EFFECT_SIZE="1.2236842105263157" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.4170738830498991" LOG_CI_START="-0.24173517050361168" LOG_EFFECT_SIZE="0.08766935627314373" MODIFIED="2012-09-02 15:53:46 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.3869876992147426" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="38" TOTAL_2="31" VAR="0.14975947934352007" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-009.09.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:53:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.744525273568893" CI_START="0.6781978396652951" EFFECT_SIZE="1.087719298245614" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.24167726561101413" LOG_CI_START="-0.16864359795948913" LOG_EFFECT_SIZE="0.0365168338257625" MODIFIED="2012-09-02 15:53:50 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.24102450638234577" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="38" TOTAL_2="31" VAR="0.05809281267685343" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 20 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="61" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-009.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:37:51 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="115" TOTAL_2="155" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg</NAME>
<GROUP_LABEL_1>30 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 40 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-009.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:37:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.8853456880007964" CI_START="0.5948480230738502" EFFECT_SIZE="1.0590062111801242" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2753909920095932" LOG_CI_START="-0.22559397741625964" LOG_EFFECT_SIZE="0.024898507296666792" MODIFIED="2012-09-02 15:54:56 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.29428105095634016" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="23" TOTAL_2="31" VAR="0.08660133695196809" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-009.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:37:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.8853456880007964" CI_START="0.5948480230738502" EFFECT_SIZE="1.0590062111801242" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2753909920095932" LOG_CI_START="-0.22559397741625964" LOG_EFFECT_SIZE="0.024898507296666792" MODIFIED="2012-09-02 15:54:37 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.29428105095634016" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="23" TOTAL_2="31" VAR="0.08660133695196809" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-009.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-06 23:37:51 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="1.7958433144502561" CI_START="0.6677993818520432" EFFECT_SIZE="1.0951086956521738" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.25426844222098083" LOG_CI_START="-0.17535398728579732" LOG_EFFECT_SIZE="0.03945722746759176" MODIFIED="2012-09-02 15:55:03 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.2523623417576059" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="23" TOTAL_2="31" VAR="0.06368675153738268" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-009.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:55:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="3.5925487501915105" CI_START="0.7901054755101135" EFFECT_SIZE="1.684782608695652" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.555402670138348" LOG_CI_START="-0.10231492848887558" LOG_EFFECT_SIZE="0.2265438708247362" MODIFIED="2012-09-02 15:55:08 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.3863465731882525" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="23" TOTAL_2="31" VAR="0.14926367461430576" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-009.10.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-02 15:55:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>24 months</NAME>
<DICH_DATA CI_END="2.2616107131034324" CI_START="0.9139181664539365" EFFECT_SIZE="1.4376811594202898" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.3544178527111612" LOG_CI_START="-0.03909268987731455" LOG_EFFECT_SIZE="0.15766258141692333" MODIFIED="2012-09-02 15:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.23115004062507194" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="23" TOTAL_2="31" VAR="0.053430341280972404" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 30 mg/kg in a single dose versus oxamniquine 40 mg/kg in a single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2012-12-10 11:48:28 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="10">
<NAME>Oxamniquine (higher dose) versus oxamniquine 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="8.502491733370238" CI_END="1.8536767165188204" CI_START="0.22398469473917673" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6443564335789529" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" I2="52.95496749145946" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.26803399492485314" LOG_CI_START="-0.649781656743581" LOG_EFFECT_SIZE="-0.1908738309093639" METHOD="MH" MODIFIED="2012-12-06 23:38:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.07481186547314989" P_Q="0.5299830258919821" P_Z="0.41495263932854665" Q="0.39442484690713026" RANDOM="YES" SCALE="1000.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7688987647059817" TOTALS="SUB" TOTAL_1="190" TOTAL_2="159" WEIGHT="200.0" Z="0.8152090967145312">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.731007974995178" CI_START="0.20866927061547602" DF="0" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.5718261773422757" LOG_CI_START="-0.6805415019874612" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2012-03-06 19:09:19 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.0" P_Z="0.864899858423822" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.1701402266993842">
<NAME>Oxamniquine (50 mg/kg) versus oxamniquine (40 mg/kg)</NAME>
<DICH_DATA CI_END="3.731007974995178" CI_START="0.20866927061547602" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5718261773422757" LOG_CI_START="-0.6805415019874612" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2012-03-06 19:09:19 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1188" O_E="0.0" SE="0.7356469741582815" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="17" TOTAL_2="15" VAR="0.5411764705882353" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.39352232984239" CI_END="2.1145905277471524" CI_START="0.09467620296168287" DF="3" EFFECT_SIZE="0.4474387131058749" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" I2="64.25815191634413" ID="CMP-010.01.02" LOG_CI_END="0.3252262824644576" LOG_CI_START="-1.0237591679995657" LOG_EFFECT_SIZE="-0.34926644276755414" MODIFIED="2012-03-06 19:48:08 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.038541841593321746" P_Z="0.31014857731383005" STUDIES="4" TAU2="1.4917608065817827" TOTAL_1="173" TOTAL_2="144" WEIGHT="100.0" Z="1.014910351475407">
<NAME>Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</NAME>
<DICH_DATA CI_END="0.4775485626913296" CI_START="0.001709410506884698" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.3209824577211346" LOG_CI_START="-2.7671536309794167" LOG_EFFECT_SIZE="-1.5440680443502757" MODIFIED="2012-03-06 19:48:08 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="162" O_E="0.0" SE="1.4368930559145097" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="69" TOTAL_2="37" VAR="2.0646616541353384" WEIGHT="17.655352414489315">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7476410919749956" CI_START="0.30771637279942826" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2424522476467002" LOG_CI_START="-0.5118493954416127" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2012-03-06 19:10:39 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1250" O_E="0.0" SE="0.4430805190034271" STUDY_ID="STD-Ibrahim-1980-SDN" TOTAL_1="42" TOTAL_2="44" VAR="0.1963203463203463" WEIGHT="37.19601499656484">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-03-06 19:13:08 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1252" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="16.53879000674885">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.590262844543053" CI_START="0.39590554320686855" EFFECT_SIZE="2.0476190476190474" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.02490673919323" LOG_CI_START="-0.4024084175018957" LOG_EFFECT_SIZE="0.3112491608456672" MODIFIED="2012-03-06 19:14:17 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1253" O_E="0.0" SE="0.8384119883666906" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="42" TOTAL_2="43" VAR="0.7029346622369878" WEIGHT="28.60984258219699">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.641343231984076" CI_END="1.568929408080886" CI_START="0.23739165613345045" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6102874327239548" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" I2="65.85012781424672" I2_Q="6.8081705188311785" ID="CMP-010.02" LOG_CI_END="0.19560340351642752" LOG_CI_START="-0.6245345497406629" LOG_EFFECT_SIZE="-0.2144655731121177" METHOD="MH" MODIFIED="2012-12-07 00:30:58 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.012009988675978911" P_Q="0.30025672850705487" P_Z="0.30533547428843344" Q="1.0730554444175484" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.0334292410615833" TOTALS="SUB" TOTAL_1="213" TOTAL_2="184" WEIGHT="200.0" Z="1.0250587661603465">
<NAME>Parasitological failure at three to four months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.858684894789618" CI_START="0.2540950746895524" DF="0" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.6865187342365856" LOG_CI_START="-0.5950037531152353" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-03-06 19:52:55 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.0" P_Z="0.8886890176965234" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="10" WEIGHT="100.0" Z="0.13996326152212696">
<NAME>Oxamniquine (50 mg/kg) versus oxamniquine (40 mg/kg)</NAME>
<DICH_DATA CI_END="4.858684894789618" CI_START="0.2540950746895524" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6865187342365856" LOG_CI_START="-0.5950037531152353" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-03-06 19:52:55 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1189" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="6" TOTAL_2="10" VAR="0.5666666666666667" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus Oxamniquine 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.62019548666992" CI_END="1.3762408506061825" CI_START="0.1178583697876009" DF="4" EFFECT_SIZE="0.4027424773816959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" I2="70.63184589446753" ID="CMP-010.02.02" LOG_CI_END="0.1386944447540455" LOG_CI_START="-0.9286395703437518" LOG_EFFECT_SIZE="-0.3949725627948532" MODIFIED="2012-03-06 20:00:25 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.008611314315307594" P_Z="0.1468940753627394" STUDIES="5" TAU2="1.2956002400318052" TOTAL_1="207" TOTAL_2="174" WEIGHT="100.0" Z="1.4505899503042923">
<NAME>Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</NAME>
<DICH_DATA CI_END="0.7886827727314847" CI_START="0.06285899398101995" EFFECT_SIZE="0.22265625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="-0.10309764540367647" LOG_CI_START="-1.2016325738750397" LOG_EFFECT_SIZE="-0.6523651096393581" MODIFIED="2012-03-06 19:54:12 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1257" O_E="0.0" SE="0.645284854819675" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="64" TOTAL_2="38" VAR="0.4163925438596491" WEIGHT="22.96011054952595">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4996625212523392" CI_START="0.029865845159515597" EFFECT_SIZE="0.12215909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.3013232249495066" LOG_CI_START="-1.5248251908475825" LOG_EFFECT_SIZE="-0.9130742078985444" MODIFIED="2012-03-06 19:55:40 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1254" O_E="0.0" SE="0.7186911112009379" STUDY_ID="STD-Ibrahim-1980-SDN" TOTAL_1="44" TOTAL_2="43" VAR="0.5165169133192389" WEIGHT="21.691502398423467">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-03-06 19:57:51 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1258" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="10.164792013353026">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.0642675264647536" CI_START="0.07961833465131896" EFFECT_SIZE="0.40540540540540543" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3147659806191022" LOG_CI_START="-1.0989869106417296" LOG_EFFECT_SIZE="-0.39211046501131375" MODIFIED="2012-03-06 19:56:39 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1256" O_E="0.0" SE="0.8304454465162897" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="37" TOTAL_2="30" VAR="0.6896396396396397" WEIGHT="19.7998962143778">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.48707167781312" CI_START="0.7641131755441838" EFFECT_SIZE="2.0476190476190474" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.739340633437448" LOG_CI_START="-0.11684231174611358" LOG_EFFECT_SIZE="0.3112491608456672" MODIFIED="2012-03-06 20:00:25 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1255" O_E="0.0" SE="0.5029261001747551" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="42" TOTAL_2="43" VAR="0.25293466223698785" WEIGHT="25.38369882431976">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.445341618404293" CI_END="3.124442613784286" CI_START="0.11769661247986736" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6064126577918314" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="81.6356792635346" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.494772552448556" LOG_CI_START="-0.9292360367527621" LOG_EFFECT_SIZE="-0.21723174215210314" METHOD="MH" MODIFIED="2012-12-06 23:38:21 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.01962066113585037" P_Q="1.0" P_Z="0.5498513480716414" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.1586694744020631" TOTALS="SUB" TOTAL_1="101" TOTAL_2="76" WEIGHT="100.0" Z="0.5979828972180747">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>40 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 40 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.445341618404293" CI_END="3.124442613784286" CI_START="0.11769661247986736" DF="1" EFFECT_SIZE="0.6064126577918314" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="81.6356792635346" ID="CMP-010.03.01" LOG_CI_END="0.494772552448556" LOG_CI_START="-0.9292360367527621" LOG_EFFECT_SIZE="-0.21723174215210314" MODIFIED="2012-03-06 20:03:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.01962066113585037" P_Z="0.5498513480716414" STUDIES="2" TAU2="1.1586694744020631" TOTAL_1="101" TOTAL_2="76" WEIGHT="100.0" Z="0.5979828972180747">
<NAME>Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</NAME>
<DICH_DATA CI_END="0.8652982219872147" CI_START="0.06640556475315734" EFFECT_SIZE="0.2397094430992736" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.06283418867134746" LOG_CI_START="-1.1777955254463546" LOG_EFFECT_SIZE="-0.6203148570588511" MODIFIED="2012-03-06 20:02:09 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1260" O_E="0.0" SE="0.654933808369268" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="59" TOTAL_2="33" VAR="0.42893829334507294" WEIGHT="44.07143651083721">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 20 mg/kg daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.2860171619992626" CI_START="0.6945637360670723" EFFECT_SIZE="1.26007326007326" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3590794864851599" LOG_CI_START="-0.1582878954236118" LOG_EFFECT_SIZE="0.10039579553077406" MODIFIED="2012-03-06 20:03:07 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1259" O_E="0.0" SE="0.30390416114305635" STUDY_ID="STD-Abdel-Rahim-1988-SDN" TOTAL_1="42" TOTAL_2="43" VAR="0.09235773916006475" WEIGHT="55.92856348916279">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for two days versus Oxamniquine 40 mg/kg in a divided dose of 10 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-010.04" MODIFIED="2012-12-10 11:48:28 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Dose (mg/kg)</P>
</TH>
<TH>
<P>Oxamniquine (higher dose)</P>
</TH>
<TH>
<P>Oxamniquine (40 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-010.04.01" MODIFIED="2012-12-06 23:56:37 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="4">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:32:19 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="276" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>95.7%</P>
</TD>
<TD>
<P>80%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:02:05 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="277" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>78.8%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:32:31 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="278" STUDY_ID="STD-Ibrahim-1980-SDN">
<TR>
<TD>
<P>89</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>86%</P>
</TD>
<TD>
<P>56%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Arithmetic Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:02:10 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="279" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>119</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>99.9%</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-010.04.02" MODIFIED="2012-12-07 00:32:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="6">
<NAME>Three to four months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:32:44 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="280" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>89.7%</P>
</TD>
<TD>
<P>67.5%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:32:53 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="281" STUDY_ID="STD-Ayele-1984-ETH">
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD/>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:33:01 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="282" STUDY_ID="STD-Ayele-1986-ETH">
<TR>
<TD>
<P>162</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>82%</P>
</TD>
<TD>
<P>42.7%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:01:55 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="283" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>99.4%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:33:12 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="284" STUDY_ID="STD-Ibrahim-1980-SDN">
<TR>
<TD>
<P>89</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>92%</P>
</TD>
<TD>
<P>65%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Arithmetic Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:01:46 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="285" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>119</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>99.5%</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-010.04.03" MODIFIED="2012-12-06 23:56:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="4">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:33:23 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="286" STUDY_ID="STD-Abdel-Rahim-1988-SDN">
<TR>
<TD>
<P>296</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>62.1%</P>
</TD>
<TD>
<P>56.8%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:02:27 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="287" STUDY_ID="STD-Gupta-1984-ZMB">
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported how EPG was calculated</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:33:32 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="288" STUDY_ID="STD-Ibrahim-1980-SDN">
<TR>
<TD>
<P>89</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>97%</P>
</TD>
<TD>
<P>75%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Arithmetic Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:33:40 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="289" STUDY_ID="STD-Omer-1978-SDN">
<TR>
<TD>
<P>176</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>93%</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2012-12-07 00:33:09 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="11">
<NAME>Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg</NAME>
<DICH_OUTCOME CHI2="11.624493053872563" CI_END="2.0717315538505776" CI_START="1.3521913465625464" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.673731603190108" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="78" I2="22.577268890003282" I2_Q="30.572142560730917" ID="CMP-011.01" LOG_CI_END="0.31633348068983186" LOG_CI_START="0.13103815231289243" LOG_EFFECT_SIZE="0.22368581650136213" METHOD="MH" MODIFIED="2012-12-07 00:33:09 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.2353157498555115" P_Q="0.22882038151949347" P_Z="2.2223096090358535E-6" Q="4.3210320909358355" RANDOM="NO" SCALE="68.72" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="391" TOTAL_2="362" WEIGHT="400.0" Z="4.732079842868474">
<NAME>Parasitological failure</NAME>
<GROUP_LABEL_1>Lower dose (15-20 mg/kg)</GROUP_LABEL_1>
<GROUP_LABEL_2>30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3307606405178536" CI_END="2.742878390451608" CI_START="1.1405456214533098" DF="2" EFFECT_SIZE="1.768722120178431" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="18" I2="39.953655760473744" ID="CMP-011.01.01" LOG_CI_END="0.4382065529466377" LOG_CI_START="0.057112661597905345" LOG_EFFECT_SIZE="0.24765960727227151" MODIFIED="2012-12-06 23:40:25 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.18911892442606626" P_Z="0.010852140993028137" STUDIES="3" TAU2="0.0" TOTAL_1="118" TOTAL_2="112" WEIGHT="100.0" Z="2.5474242526485513">
<NAME>One month</NAME>
<DICH_DATA CI_END="18.464793725803222" CI_START="0.08462049580421353" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2663444604166862" LOG_CI_START="-1.0725244344005735" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2012-03-06 20:04:41 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1323" O_E="0.0" SE="1.3738631664034087" STUDY_ID="STD-Shafei-1979-NGA" TOTAL_1="16" TOTAL_2="20" VAR="1.8875" WEIGHT="4.387299921280503">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="68.32488905069779" CI_START="1.156421134037763" EFFECT_SIZE="8.88888888888889" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8345789351366142" LOG_CI_START="0.0631160199686228" LOG_EFFECT_SIZE="0.9488474775526188" MODIFIED="2012-03-06 20:07:04 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1322" O_E="0.0" SE="1.0405660852525311" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="45" TOTAL_2="50" VAR="1.0827777777777778" WEIGHT="4.675938073996326">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.2455574223038517" CI_START="0.9076285046038657" EFFECT_SIZE="1.4276315789473684" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.3513241651083059" LOG_CI_START="-0.04209187330079198" LOG_EFFECT_SIZE="0.15461614590375694" MODIFIED="2012-03-06 20:06:49 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1324" O_E="0.0" SE="0.2310945284023021" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="57" TOTAL_2="42" VAR="0.05340468105748242" WEIGHT="90.93676200472318">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus oxamniquine 30 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3270158303890267" CI_END="3.3200841957341067" CI_START="1.4032078595463318" DF="3" EFFECT_SIZE="2.158417994228565" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="20" I2="9.829103528815757" ID="CMP-011.01.02" LOG_CI_END="0.5211490973423115" LOG_CI_START="0.14712200856760585" LOG_EFFECT_SIZE="0.33413555295495867" MODIFIED="2012-12-07 00:33:09 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.34390028251879234" P_Z="4.6203716766395335E-4" STUDIES="4" TAU2="0.0" TOTAL_1="127" TOTAL_2="122" WEIGHT="100.00000000000001" Z="3.5018514401804124">
<NAME>Three to four months</NAME>
<DICH_DATA CI_END="2.8303175798023066" CI_START="0.5087768278288339" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.451835168887359" LOG_CI_START="-0.29347267679210925" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2012-03-06 20:09:45 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1326" O_E="0.0" SE="0.43779751788545657" STUDY_ID="STD-de-Clarke-1976b-ZWE" TOTAL_1="10" TOTAL_2="8" VAR="0.19166666666666665" WEIGHT="20.83250978376883">
<FOOTNOTE>Oxamniquine 20 mg/kg in a divided dose of 5 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 7.5 mg/kg twice daily for 2 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="9.90119447133375" CI_START="0.35507079576899003" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9956875906598601" LOG_CI_START="-0.44968504653238495" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2012-03-06 20:10:29 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1325" O_E="0.0" SE="0.8490190417966685" STUDY_ID="STD-Shafei-1979-NGA" TOTAL_1="16" TOTAL_2="20" VAR="0.7208333333333332" WEIGHT="8.33300391350753">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="23.027111515480307" CI_START="1.2352589001587218" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3622394641664468" LOG_CI_START="0.09175799170607775" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2012-03-06 20:11:06 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1328" O_E="0.0" SE="0.746287105907937" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="45" TOTAL_2="48" VAR="0.5569444444444444" WEIGHT="9.072222002609006">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.5384787968094407" CI_START="1.1917990341068039" EFFECT_SIZE="2.0535714285714284" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" LOG_CI_END="0.5488165975797541" LOG_CI_START="0.07620302911506838" LOG_EFFECT_SIZE="0.31250981334741124" MODIFIED="2012-03-06 20:11:35 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1327" O_E="0.0" SE="0.27761554959105084" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="56" TOTAL_2="46" VAR="0.07707039337474121" WEIGHT="61.762264300114644">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus oxamniquine 30 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.87214320428941" CI_END="1.7456794670963478" CI_START="0.8602232184126194" DF="1" EFFECT_SIZE="1.2254280923426093" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="0.2419645037162486" LOG_CI_START="-0.0653888395168798" LOG_EFFECT_SIZE="0.0882878320996844" MODIFIED="2012-12-06 23:40:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3503627578039685" P_Z="0.2601626761751804" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.00000000000001" Z="1.1260067606113442">
<NAME>Six months</NAME>
<DICH_DATA CI_END="4.518881967722833" CI_START="0.682442839997107" EFFECT_SIZE="1.7560975609756098" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6550309977958809" LOG_CI_START="-0.16593371837281506" LOG_EFFECT_SIZE="0.24454863971153296" MODIFIED="2011-07-28 10:39:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1330" O_E="0.0" SE="0.48223873811837786" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="41" TOTAL_2="48" VAR="0.2325542005420054" WEIGHT="18.749682424078184"/>
<DICH_DATA CI_END="1.5926633598628785" CI_START="0.763839650398606" EFFECT_SIZE="1.1029684601113172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.2021239889812652" LOG_CI_START="-0.11699780144532185" LOG_EFFECT_SIZE="0.04256309376797167" MODIFIED="2011-07-28 10:39:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1329" O_E="0.0" SE="0.18745371937491656" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="49" TOTAL_2="41" VAR="0.03513889690748997" WEIGHT="81.25031757592183"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9584473843869796" CI_START="1.0246353325008948" DF="0" EFFECT_SIZE="1.7410714285714286" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="0.47106384980921334" LOG_CI_START="0.010569327575459498" LOG_EFFECT_SIZE="0.2408165886923364" MODIFIED="2012-11-19 00:20:46 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="1.0" P_Z="0.04037080747266078" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="39" WEIGHT="100.0" Z="2.049934659058485">
<NAME>6 to 12 months</NAME>
<DICH_DATA CI_END="2.9584473843869796" CI_START="1.0246353325008948" EFFECT_SIZE="1.7410714285714286" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" LOG_CI_END="0.47106384980921334" LOG_CI_START="0.010569327575459498" LOG_EFFECT_SIZE="0.2408165886923364" MODIFIED="2012-03-06 20:11:47 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1331" O_E="0.0" SE="0.27049676184475513" STUDY_ID="STD-Gryseels-1989a-BDI" TOTAL_1="56" TOTAL_2="39" VAR="0.07316849816849819" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus oxamniquine 30 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2012-12-07 00:33:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="12">
<NAME>Oxamniquine (higher dose) versus oxamniquine 30 mg/kg</NAME>
<DICH_OUTCOME CHI2="6.653246803725937" CI_END="0.32310226666458264" CI_START="0.04595642500456536" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12185493460166466" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="33" I2="69.93948880898324" I2_Q="79.49778596494453" ID="CMP-012.01" LOG_CI_END="-0.4906599952585317" LOG_CI_START="-1.337653762864033" LOG_EFFECT_SIZE="-0.9141568790612824" METHOD="MH" MODIFIED="2012-12-06 23:41:02 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.03591426072030468" P_Q="0.027208780434323065" P_Z="2.3290090658297325E-5" Q="4.877521999771155" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="105" WEIGHT="200.0" Z="4.230762085168415">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5645765143758603" CI_START="0.14664220480260345" DF="0" EFFECT_SIZE="0.4789915966386555" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="0.19439680682939736" LOG_CI_START="-0.8337410182694762" LOG_EFFECT_SIZE="-0.31967210572003935" MODIFIED="2012-03-16 10:43:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.0" P_Z="0.22292115082910802" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0" Z="1.218797322261934">
<NAME>Oxamniquine 50 mg/kg versus oxamniquine 30 mg/kg</NAME>
<DICH_DATA CI_END="1.5645765143758603" CI_START="0.14664220480260345" EFFECT_SIZE="0.4789915966386555" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19439680682939736" LOG_CI_START="-0.8337410182694762" LOG_EFFECT_SIZE="-0.31967210572003935" MODIFIED="2012-03-07 01:56:07 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1392" O_E="0.0" SE="0.6039332478273928" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="17" TOTAL_2="19" VAR="0.364735367831343" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus Oxamniquine 30 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7349476037718049" CI_END="0.25773743242990477" CI_START="0.005021403825495159" DF="1" EFFECT_SIZE="0.035975043143501924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="26" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="-0.5888225022206278" LOG_CI_START="-2.2991748508957306" LOG_EFFECT_SIZE="-1.4439986765581792" MODIFIED="2012-03-16 10:43:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.3912841916148134" P_Z="9.347063272471364E-4" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0" Z="3.3094764385477555">
<NAME>Oxamniquine 60 mg/kg versus oxamniquine 30 mg/kg</NAME>
<DICH_DATA CI_END="0.34365346310454253" CI_START="0.0013164603189423315" EFFECT_SIZE="0.02126984126984127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="22" LOG_CI_END="-0.46387927521013766" LOG_CI_START="-2.8805922269674107" LOG_EFFECT_SIZE="-1.6722357510887742" MODIFIED="2012-03-07 01:58:46 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1418" O_E="0.0" SE="1.4195891507842688" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="69" TOTAL_2="66" VAR="2.015233357024402" WEIGHT="83.63201911589009">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 day versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9371598241474748" CI_START="0.006373082312802401" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2012-03-07 02:01:10 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1417" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="16.367980884109915">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.793448052500711" CI_END="0.5619525434198639" CI_START="0.20393037588865076" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3385250262701358" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="49" I2="53.67560045984044" I2_Q="88.49443484438136" ID="CMP-012.02" LOG_CI_END="-0.2503003588101483" LOG_CI_START="-0.6905180802626639" LOG_EFFECT_SIZE="-0.4704092195364062" METHOD="MH" MODIFIED="2012-12-07 00:33:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.055632670230655545" P_Q="0.00319708619710779" P_Z="2.804719617721547E-5" Q="8.691446152140195" RANDOM="NO" SCALE="260.07" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="162" WEIGHT="200.0" Z="4.1887687994241825">
<NAME>Parasitological failure at three to four months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08564582816704694" CI_END="1.5332977319387706" CI_START="0.4362429371604652" DF="1" EFFECT_SIZE="0.8178571428571428" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="0.18562649326493064" LOG_CI_START="-0.3602715912695931" LOG_EFFECT_SIZE="-0.08732254900233123" MODIFIED="2012-03-16 10:43:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.7697873460859216" P_Z="0.5306352197316198" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="32" WEIGHT="100.0" Z="0.6270366426683419">
<NAME>Oxamniquine 50 mg/kg versus oxamniquine 30 mg/kg</NAME>
<DICH_DATA CI_END="1.7955908899876678" CI_START="0.42639167099208125" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.2542073933223294" LOG_CI_START="-0.3701912872777029" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-03-07 02:02:45 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1393" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-de-Clarke-1976d-ZWE" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="65.71428571428571">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 12.5 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.444864721418406" CI_START="0.20522039796951436" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.38825483386173887" LOG_CI_START="-0.687779474528403" LOG_EFFECT_SIZE="-0.14976232033333206" MODIFIED="2012-03-07 01:56:46 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1394" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="6" TOTAL_2="17" VAR="0.39950980392156865" WEIGHT="34.285714285714285">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus Oxamniquine 30 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26950226667952865" CI_END="0.3910810544331849" CI_START="0.07306337619665701" DF="3" EFFECT_SIZE="0.16903757630608965" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="33" I2="0.0" ID="CMP-012.02.02" LOG_CI_END="-0.4077332225403751" LOG_CI_START="-1.1363002632806853" LOG_EFFECT_SIZE="-0.7720167429105302" MODIFIED="2012-03-16 10:44:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.9656583745190773" P_Z="3.2713984743246686E-5" STUDIES="4" TAU2="0.0" TOTAL_1="135" TOTAL_2="130" WEIGHT="99.99999999999999" Z="4.1537015180622054">
<NAME>Oxamniquine 60 mg/kg versus oxamniquine 30 mg/kg</NAME>
<DICH_DATA CI_END="4.090331773254378" CI_START="0.01112650846777186" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6117585357457006" LOG_CI_START="-1.953641097217251" LOG_EFFECT_SIZE="-0.6709412807357752" MODIFIED="2012-03-07 02:01:33 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1422" O_E="0.0" SE="1.5069284433354269" STUDY_ID="STD-Ayele-1984-ETH" TOTAL_1="14" TOTAL_2="15" VAR="2.270833333333333" WEIGHT="7.027007075928585">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9980137699856667" CI_START="0.050248132489520994" EFFECT_SIZE="0.22393822393822393" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-8.634665407501597E-4" LOG_CI_START="-1.298880074495879" LOG_EFFECT_SIZE="-0.6498717705183146" MODIFIED="2012-03-07 02:04:56 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1419" O_E="0.0" SE="0.7624613807986778" STUDY_ID="STD-Ayele-1986-ETH" TOTAL_1="37" TOTAL_2="29" VAR="0.5813473572094262" WEIGHT="22.795894873790147">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-03-07 02:06:17 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1421" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="7.261240645126205">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4468970659895141" CI_START="0.04425043736014146" EFFECT_SIZE="0.140625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" LOG_CI_END="-0.34979249660110134" LOG_CI_START="-1.3540824324880232" LOG_EFFECT_SIZE="-0.8519374645445623" MODIFIED="2012-03-07 02:07:17 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1420" O_E="0.0" SE="0.5899248796553368" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="64" TOTAL_2="66" VAR="0.34801136363636365" WEIGHT="62.91585740515506">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 day versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.014953113745703722" CI_END="0.4983553719623744" CI_START="0.056781695559721325" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16821849782743636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-0.3024608559521678" LOG_CI_START="-1.2457916431374567" LOG_EFFECT_SIZE="-0.7741262495448124" METHOD="MH" MODIFIED="2012-12-06 23:41:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.9026749574756252" P_Q="1.0" P_Z="0.0012962286539971515" Q="0.0" RANDOM="NO" SCALE="382.29" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="79" TOTAL_2="78" WEIGHT="100.0" Z="3.2168134215614836">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014953113745703722" CI_END="0.4983553719623744" CI_START="0.056781695559721325" DF="1" EFFECT_SIZE="0.16821849782743636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" I2="0.0" ID="CMP-012.03.01" LOG_CI_END="-0.3024608559521678" LOG_CI_START="-1.2457916431374567" LOG_EFFECT_SIZE="-0.7741262495448124" MODIFIED="2012-09-02 11:50:27 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.9026749574756252" P_Z="0.0012962286539971515" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="78" WEIGHT="100.0" Z="3.2168134215614836">
<NAME>Oxamniquine (60 mg/kg) versus oxamniquine (30 mg/kg)</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-03-07 02:08:23 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1423" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gupta-1984-ZMB" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="12.104283054003723">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 days versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5264668984286084" CI_START="0.05098922287272339" EFFECT_SIZE="0.1638418079096045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.27862892985689525" LOG_CI_START="-1.292521607068806" LOG_EFFECT_SIZE="-0.7855752684628505" MODIFIED="2012-03-07 02:07:35 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="1424" O_E="0.0" SE="0.5955655774439714" STUDY_ID="STD-Omer-1978-SDN" TOTAL_1="59" TOTAL_2="58" VAR="0.35469835703617114" WEIGHT="87.89571694599627">
<FOOTNOTE>Oxamniquine 60 mg/kg in a divided dose of 15 mg/kg twice daily for 2 day versus Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="13">
<NAME>Oxamniquine versus praziquantel</NAME>
<DICH_OUTCOME CHI2="27.069932334045976" CI_END="1.1189407282627168" CI_START="0.37022591723166687" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6436309947857807" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="82" I2="77.83518656064842" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.04880708199734006" LOG_CI_START="-0.431533182242438" LOG_EFFECT_SIZE="-0.19136305012254898" METHOD="MH" MODIFIED="2012-12-06 23:41:29 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="1.4050415719557563E-4" P_Q="0.7835839198105954" P_Z="0.11836752006616523" Q="1.07304869296316" RANDOM="YES" SCALE="23.13" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6936395990903207" TOTALS="SUB" TOTAL_1="265" TOTAL_2="258" WEIGHT="400.0" Z="1.5616624885924741">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Oxamniquine</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxamniquine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.915010896658197" CI_END="14.47096015828848" CI_START="0.08133479064240547" DF="1" EFFECT_SIZE="1.0848928587049433" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="44" I2="90.8383050693411" ID="CMP-013.01.01" LOG_CI_END="1.160497347816501" LOG_CI_START="-1.0897236468774276" LOG_EFFECT_SIZE="0.03538685046953675" MODIFIED="2012-11-19 00:24:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="9.538906070872821E-4" P_Z="0.9508458829416317" STUDIES="2" TAU2="3.19166878286469" TOTAL_1="117" TOTAL_2="115" WEIGHT="100.0" Z="0.061644569675726624">
<NAME>Oxamniquine 10 to 20 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="19.436686417938212" CI_START="0.9760338665556985" EFFECT_SIZE="4.355555555555555" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2886222280251969" LOG_CI_START="-0.010535112862932308" LOG_EFFECT_SIZE="0.6390435575811323" MODIFIED="2012-03-07 02:18:46 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="19" O_E="0.0" SE="0.7631314529702413" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="45" TOTAL_2="49" VAR="0.5823696145124716" WEIGHT="46.29341660937505">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5321502794122502" CI_START="0.20140605413236984" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="42" LOG_CI_END="-0.27396570548105265" LOG_CI_START="-0.6959274789821853" LOG_EFFECT_SIZE="-0.484946592231619" MODIFIED="2012-03-07 02:19:00 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="18" O_E="0.0" SE="0.247862434499031" STUDY_ID="STD-Stelma-1997-SEN" TOTAL_1="72" TOTAL_2="66" VAR="0.06143578643578644" WEIGHT="53.70658339062494">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10836070128174047" CI_END="1.4493640220362876" CI_START="0.34785069701668914" DF="1" EFFECT_SIZE="0.7100438615298598" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="0.16117747650410225" LOG_CI_START="-0.4586071220743389" LOG_EFFECT_SIZE="-0.1487148227851183" MODIFIED="2012-07-09 09:46:21 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.742018264890074" P_Z="0.3469247822453695" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.9405709573765693">
<NAME>Oxamniquine 30 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="5.230738882847126" CI_START="0.04590173690132892" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7185630406986137" LOG_CI_START="-1.3381708806415866" LOG_EFFECT_SIZE="-0.3098039199714863" MODIFIED="2012-03-07 02:21:19 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="22" O_E="0.0" SE="1.2081356863923414" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="50" TOTAL_2="49" VAR="1.4595918367346938" WEIGHT="9.080825667475999">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5573068596620732" CI_START="0.3486379609259903" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.19237419659332633" LOG_CI_START="-0.4576253271425083" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2012-03-07 02:20:12 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="21" O_E="0.0" SE="0.38181293779196374" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="19" TOTAL_2="18" VAR="0.14578111946532998" WEIGHT="90.91917433252401">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2168619829743532" CI_START="0.13148574138943434" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-013.01.03" LOG_CI_END="0.08524132315058172" LOG_CI_START="-0.8811213404946568" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-07-09 09:47:06 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="1.0" P_Z="0.10648549741492405" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="99.99999999999999" Z="1.614193334131289">
<NAME>Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.2168619829743532" CI_START="0.13148574138943434" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.08524132315058172" LOG_CI_START="-0.8811213404946568" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-03-07 02:21:42 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="29" O_E="0.0" SE="0.5676462121975466" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="15" TOTAL_2="18" VAR="0.3222222222222222" WEIGHT="99.99999999999999">
<FOOTNOTE>Oxamniquine 40 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.778610060643411" CI_END="4.844090902572455" CI_START="0.1640042807465093" DF="1" EFFECT_SIZE="0.8913201693819705" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="85.2477131586902" ID="CMP-013.01.04" LOG_CI_END="0.6852122843709291" LOG_CI_START="-0.7851448160966645" LOG_EFFECT_SIZE="-0.04996626586286773" MODIFIED="2012-11-19 00:24:31 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.009225722368829348" P_Z="0.8940284353777518" STUDIES="2" TAU2="1.2785721486837365" TOTAL_1="64" TOTAL_2="58" WEIGHT="100.0" Z="0.1332085674997321">
<NAME>Oxamniquine 50 to 60 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.0882503333180824" CI_START="0.11446582668955946" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.03672880884867023" LOG_CI_START="-0.9413241508379308" LOG_EFFECT_SIZE="-0.45229767099463025" MODIFIED="2012-03-07 02:22:43 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="31" O_E="0.0" SE="0.5745131499601416" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="17" TOTAL_2="18" VAR="0.3300653594771241" WEIGHT="46.37272952755054">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.8316132448164515" CI_START="1.029191454488592" EFFECT_SIZE="1.9858156028368794" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.5833816658243484" LOG_CI_START="0.012496171549330116" LOG_EFFECT_SIZE="0.2979389186868393" MODIFIED="2012-03-07 02:23:47 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="32" O_E="0.0" SE="0.3353409652659184" STUDY_ID="STD-de-Jonge-1990-SDN" TOTAL_1="47" TOTAL_2="40" VAR="0.11245356298547787" WEIGHT="53.62727047244946">
<FOOTNOTE>Oxamniquine 60 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.94943779888096" CI_END="1.428460789081543" CI_START="0.5161785196633101" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8586854927767178" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="56.98751385893611" I2_Q="66.83256692269075" ID="CMP-013.02" LOG_CI_END="0.1548683235992404" LOG_CI_START="-0.2872000722171714" LOG_EFFECT_SIZE="-0.0661658743089655" METHOD="MH" MODIFIED="2012-12-06 23:41:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.03020612626073782" P_Q="0.028698342137774113" P_Z="0.557399233784996" Q="9.045017119676897" RANDOM="YES" SCALE="82.23" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.42866023736921977" TOTALS="SUB" TOTAL_1="252" TOTAL_2="234" WEIGHT="400.0" Z="0.5867088978920484">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Oxamniquine</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxamniquine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.830541373365554E-4" CI_END="10.611756474847027" CI_START="1.104283801233265" DF="1" EFFECT_SIZE="3.4232135162454864" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="1.0257872749661836" LOG_CI_START="0.04308070153642333" LOG_EFFECT_SIZE="0.5344339882513035" MODIFIED="2012-11-19 00:25:51 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.9843849848365334" P_Z="0.03302254975098882" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="64" WEIGHT="99.99999999999999" Z="2.1318090209386926">
<NAME>Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="11.57633496530664" CI_START="1.0029448244932784" EFFECT_SIZE="3.4074074074074074" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0635710847557303" LOG_CI_START="0.001277041617405562" LOG_EFFECT_SIZE="0.532424063186568" MODIFIED="2012-03-07 02:26:49 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="20" O_E="0.0" SE="0.6239967793797726" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="45" TOTAL_2="46" VAR="0.38937198067632856" WEIGHT="85.57723097401251">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Praziquantel 40 mg/kg single</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="69.20970118471652" CI_START="0.17887626088886513" EFFECT_SIZE="3.5185185185185186" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8401669741633266" LOG_CI_START="-0.7474472919036058" LOG_EFFECT_SIZE="0.5463598411298605" MODIFIED="2012-03-07 02:26:00 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="529" O_E="0.0" SE="1.5199774287849126" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="26" TOTAL_2="18" VAR="2.310331384015594" WEIGHT="14.422769025987483">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Praziquantel 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.075306118299954" CI_END="2.1188498992244367" CI_START="0.39985850186529603" DF="2" EFFECT_SIZE="0.920456488043469" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="50.923932044783044" ID="CMP-013.02.02" LOG_CI_END="0.32610019208244106" LOG_CI_START="-0.3980936654990871" LOG_EFFECT_SIZE="-0.03599673670832298" MODIFIED="2012-11-19 00:26:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.13033449421779097" P_Z="0.84551530567232" STUDIES="3" TAU2="0.2728565266063502" TOTAL_1="165" TOTAL_2="154" WEIGHT="100.0" Z="0.19484370592398007">
<NAME>Oxamniquine (25 to 30 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="3.650514362698227" CI_START="0.11181410940785319" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5623540614820015" LOG_CI_START="-0.9515033909813903" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2012-03-07 02:28:00 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="25" O_E="0.0" SE="0.8892473612922432" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="48" TOTAL_2="46" VAR="0.7907608695652173" WEIGHT="17.013726455385477">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1942904324704473" CI_START="0.3296473973928622" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.07710995315954737" LOG_CI_START="-0.48195034871560816" LOG_EFFECT_SIZE="-0.2024201977780304" MODIFIED="2012-03-07 02:27:33 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="23" O_E="0.0" SE="0.3283947887145926" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="17" TOTAL_2="8" VAR="0.10784313725490191" WEIGHT="47.53378358182009">
<FOOTNOTE>Oxamniquine 30 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.765757160449767" CI_START="0.7052627731443006" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6781319090629827" LOG_CI_START="-0.15164903951381997" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2012-03-07 02:28:47 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="24" O_E="0.0" SE="0.48741743667595394" STUDY_ID="STD-Al-Aska-1990-SAU" TOTAL_1="100" TOTAL_2="100" VAR="0.23757575757575755" WEIGHT="35.45248996279444">
<FOOTNOTE>Oxamniquine 25 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1179795161169215" CI_START="0.14311532339673635" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-013.02.03" LOG_CI_END="0.04843384637787668" LOG_CI_START="-0.8443138637219518" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-08-06 23:39:05 +0100" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="1.0" P_Z="0.08058568282700539" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="1.747297867428941">
<NAME>Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.1179795161169215" CI_START="0.14311532339673635" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.04843384637787668" LOG_CI_START="-0.8443138637219518" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-03-07 02:29:23 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="30" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="10" TOTAL_2="8" VAR="0.275" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 40 mg/kg single dose versus Praziquantel 40 mg/kg single</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.314768175368353E-31" CI_END="1.475943878667632" CI_START="0.13383358747749036" DF="0" EFFECT_SIZE="0.4444444444444445" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="99.99999999999999" ID="CMP-013.02.04" LOG_CI_END="0.16906984417513796" LOG_CI_START="-0.8734348803978628" LOG_EFFECT_SIZE="-0.3521825181113625" MODIFIED="2012-11-19 00:26:42 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.0" P_Z="0.18542218890889978" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="100.0" Z="1.324243497823228">
<NAME>Oxamniquine (50 to 60 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.4759438786676315" CI_START="0.1338335874774903" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16906984417513785" LOG_CI_START="-0.873434880397863" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2012-03-07 02:29:58 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="33" O_E="0.0" SE="0.6123724356957945" STUDY_ID="STD-Teesdale-1984-MWI" TOTAL_1="6" TOTAL_2="8" VAR="0.375" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 50 mg/kg in a divided dose of 25 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.295510193766889" CI_END="1.5180082921349343" CI_START="0.9544533649318379" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2036893795421726" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="111" I2="12.583253956187786" I2_Q="12.165157359507207" ID="CMP-013.03" LOG_CI_END="0.18127414390373642" LOG_CI_START="-0.020245286597242028" LOG_EFFECT_SIZE="0.0805144286532472" METHOD="MH" MODIFIED="2012-12-06 23:41:55 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="0.32709607211863945" P_Q="0.3318879342940242" P_Z="0.11731222189762228" Q="3.4155010811358455" RANDOM="YES" SCALE="341.739973638709" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02174747315352043" TOTALS="SUB" TOTAL_1="593" TOTAL_2="574" WEIGHT="400.0" Z="1.5661554819193286">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Oxamniquine</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxamniquine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6614962548989127" CI_END="1.7420327450897903" CI_START="0.696553702795432" DF="2" EFFECT_SIZE="1.1015531575839563" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="25" I2="0.0" ID="CMP-013.03.01" LOG_CI_END="0.24105631420674656" LOG_CI_START="-0.15704539477680762" LOG_EFFECT_SIZE="0.04200545971496948" MODIFIED="2012-11-19 00:27:41 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.7183861523578198" P_Z="0.6791606170159632" STUDIES="3" TAU2="0.0" TOTAL_1="101" TOTAL_2="96" WEIGHT="100.0" Z="0.4136088157249754">
<NAME>Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="2.4009517163608796" CI_START="0.6577438023221557" EFFECT_SIZE="1.2566666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.38038342639235284" LOG_CI_START="-0.18194323542009208" LOG_EFFECT_SIZE="0.0992200954861304" MODIFIED="2012-03-07 02:32:28 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="16" O_E="0.0" SE="0.3303134647104988" STUDY_ID="STD-Branchini-1982-BRA" TOTAL_1="30" TOTAL_2="29" VAR="0.10910698496905395" WEIGHT="50.1199620107032">
<FOOTNOTE>Oxamniquine 13.8 mg/kg single dose versus Praziquantel 45.4 mg/kg single</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8310414302970852" CI_START="0.40369405905433076" EFFECT_SIZE="0.8597560975609756" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.26269817103345305" LOG_CI_START="-0.39394764181808906" LOG_EFFECT_SIZE="-0.06562473539231799" MODIFIED="2012-03-07 02:33:07 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="21" O_E="0.0" SE="0.385717000918192" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="41" TOTAL_2="47" VAR="0.14877760479732455" WEIGHT="36.75578692909357">
<FOOTNOTE>Oxamniquine 20 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.7248385182665125" CI_START="0.3762621242831433" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6743869701311649" LOG_CI_START="-0.4245094969145651" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-03-07 02:47:04 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="530" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="30" TOTAL_2="20" VAR="0.4166666666666667" WEIGHT="13.124251060203239">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Praziquantel 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.264753413289308" CI_END="4.490949887353678" CI_START="0.2248968957326074" DF="1" EFFECT_SIZE="1.0049879046817156" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="76.55198547039271" ID="CMP-013.03.02" LOG_CI_END="0.6523382089778347" LOG_CI_START="-0.6480165391197406" LOG_EFFECT_SIZE="0.0021608349290470736" MODIFIED="2012-11-19 00:28:04 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" P_CHI2="0.03891106166228131" P_Z="0.9948027354868385" STUDIES="2" TAU2="0.896176741471209" TOTAL_1="148" TOTAL_2="147" WEIGHT="100.0" Z="0.006513851152794131">
<NAME>Oxamniquine (25 to 30 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.1965522259236259" CI_START="0.200318745044963" EFFECT_SIZE="0.4895833333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.07793165901752765" LOG_CI_START="-0.6982784092252295" LOG_EFFECT_SIZE="-0.31017337510385096" MODIFIED="2012-03-07 02:34:45 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="28" O_E="0.0" SE="0.4559496363876013" STUDY_ID="STD-Taddese-1988-ETH" TOTAL_1="48" TOTAL_2="47" VAR="0.2078900709219858" WEIGHT="52.84495643018096">
<FOOTNOTE>Oxamniquine 30 mg/kg in a divided dose of 15 mg/kg in one day versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.068453103499001" CI_START="0.7162104531038027" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8493243809651997" LOG_CI_START="-0.14495934474247466" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-03-07 02:35:04 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="27" O_E="0.0" SE="0.5840471822645077" STUDY_ID="STD-Al-Aska-1990-SAU" TOTAL_1="100" TOTAL_2="100" VAR="0.3411111111111111" WEIGHT="47.15504356981905">
<FOOTNOTE>Oxamniquine 25 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.303025923058753" CI_START="1.112044485801873" DF="0" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="0.0" ID="CMP-013.03.03" LOG_CI_END="0.6337739624449674" LOG_CI_START="0.046122160943734364" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2012-11-19 00:28:38 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" P_CHI2="1.0" P_Z="0.023352280352579722" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="35" WEIGHT="100.0" Z="2.2676215943965934">
<NAME>Oxamniquine (50 to 60 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="4.303025923058753" CI_START="1.112044485801873" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.6337739624449674" LOG_CI_START="0.046122160943734364" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2012-03-07 02:35:36 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="34" O_E="0.0" SE="0.3451895771251562" STUDY_ID="STD-de-Jonge-1990-SDN" TOTAL_1="44" TOTAL_2="35" VAR="0.11915584415584417" WEIGHT="100.0">
<FOOTNOTE>Oxamniquine 60 mg/kg single dose versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2981644390655163" CI_END="1.5108061254969256" CI_START="0.8308309712913885" DF="3" EFFECT_SIZE="1.1203680291223908" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="62" I2="0.0" ID="CMP-013.03.04" LOG_CI_END="0.17920873698691497" LOG_CI_START="-0.08048732242793404" LOG_EFFECT_SIZE="0.04936070727949048" MODIFIED="2012-11-19 00:28:50 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.7295691138021737" P_Z="0.4562324962172586" STUDIES="4" TAU2="0.0" TOTAL_1="300" TOTAL_2="296" WEIGHT="100.00000000000001" Z="0.7450648942245265">
<NAME>Oxamniquine (15 to 20 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="1.615734364385656" CI_START="0.8185132588319048" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="45" LOG_CI_END="0.20836996190624585" LOG_CI_START="-0.08697428119902254" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2012-03-07 02:36:50 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="38" O_E="0.0" SE="0.1734866703776165" STUDY_ID="STD-Rezende-1985-BRA" TOTAL_1="192" TOTAL_2="184" VAR="0.030097624798711756" WEIGHT="77.31676948032825">
<FOOTNOTE>Oxamniquine 16 mg/kg single dose versus Praziquantel 55 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7559865018768297" CI_START="0.3038377408222448" EFFECT_SIZE="0.7304347826086957" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2445211731971112" LOG_CI_START="-0.5173582817805713" LOG_EFFECT_SIZE="-0.13641855429173003" MODIFIED="2012-03-07 02:41:38 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="36" O_E="0.0" SE="0.44753176321801663" STUDY_ID="STD-da-Silva-1986-BRA" TOTAL_1="46" TOTAL_2="48" VAR="0.2002846790890269" WEIGHT="11.618717562680018">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Praziquantel 55 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.895658519253885" CI_START="0.301010424873842" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9491781031442141" LOG_CI_START="-0.521418463254052" LOG_EFFECT_SIZE="0.21387981994508107" MODIFIED="2012-03-07 02:40:38 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="35" O_E="0.0" SE="0.8638357026727486" STUDY_ID="STD-da-Cunha-1986-BRA" TOTAL_1="22" TOTAL_2="24" VAR="0.7462121212121212" WEIGHT="3.118484747590841">
<FOOTNOTE>Oxamniquine 18 mg/kg single dose versus Praziquantel 65 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.0435854021873805" CI_START="0.4847183390611057" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6067666200216428" LOG_CI_START="-0.31451054866516676" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2012-03-07 02:38:10 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="37" O_E="0.0" SE="0.541162769282166" STUDY_ID="STD-Fernandes-1986-BRA" TOTAL_1="40" TOTAL_2="40" VAR="0.2928571428571428" WEIGHT="7.946028209400906">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Praziquantel 70 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:15:27 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.33" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at 12 months</NAME>
<GROUP_LABEL_1>Oxamniquine</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxamniquine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-11-19 00:29:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</NAME>
<DICH_DATA CI_END="7.306339954137879" CI_START="0.29441705759842846" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8636998754821636" LOG_CI_START="-0.5310370319491137" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2012-03-07 02:47:31 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="531" O_E="0.0" SE="0.8192753634841714" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="30" TOTAL_2="22" VAR="0.6712121212121213" WEIGHT="0.0">
<FOOTNOTE>Oxamniquine 15 mg/kg single dose versus Praziquantel 40 mg/kg in a divided dose of 20 mg/kg in one day</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-013.05" MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Dose (mg/kg)</P>
</TH>
<TH>
<P>Oxamniquine</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-013.05.01" MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="2">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2013-01-29 15:21:06 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="336" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>82.9%</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:30:08 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="337" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:06:49 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="338" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>42</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>91.7%</P>
</TD>
<TD>
<P>92.8%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:06:55 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="339" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>49</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>92.8%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:07:07 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="340" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>99.4%</P>
</TD>
<TD>
<P>92.8%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:07:01 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="341" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>99.9%</P>
</TD>
<TD>
<P>92.8%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-013.05.02" MODIFIED="2012-12-06 23:57:37 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="3">
<NAME>Three months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:30:30 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="343" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>83.6%</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:30:37 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="342" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>70.2%</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 14:45:11 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="345" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>49</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>99.1%</P>
</TD>
<TD>
<P>92.7%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported who were involved in EPG calculation</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:11:48 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="344" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>97.6%</P>
</TD>
<TD>
<P>92.7%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported who were involved in EPG calculation</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 13:12:11 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="346" STUDY_ID="STD-Teesdale-1984-MWI">
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>99.5%</P>
</TD>
<TD>
<P>92.7%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>Not reported who were involved in EPG calculation</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:30:52 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="347" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD>
<P>91</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>46.1-67.6%</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>EPG (Range) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-013.05.03" MODIFIED="2012-12-06 23:57:46 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="2">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:31:07 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="348" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>33.6%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants still excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:31:00 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="349" STUDY_ID="STD-Taddese-1988-ETH">
<TR>
<TD>
<P>100</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>73.3%</P>
</TD>
<TD>
<P>33.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants still excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:31:22 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="350" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD>
<P>91</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>32.5-97%</P>
</TD>
<TD>
<P>93.8-96.8%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>EPG (Range) of participants still excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-013.05.04" MODIFIED="2012-12-06 23:57:56 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" STUDIES="1">
<NAME>12 months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:31:31 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="351" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD>
<P>91</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>94%</P>
</TD>
<TD>
<P>96.9%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>EPG (Range) of participants still excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2012-12-07 00:34:48 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="14">
<NAME>Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="113" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-07 00:34:14 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.69" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="112" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at three to six weeks</NAME>
<GROUP_LABEL_1>Myrrh (Mirazid)</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mirazid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.542981741505084" CI_START="1.8576586359886935" EFFECT_SIZE="3.2088888888888887" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.7437434480356058" LOG_CI_START="0.26896591088094746" LOG_EFFECT_SIZE="0.5063546794582766" MODIFIED="2012-08-09 15:49:58 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Barakat-2005-EGY" TOTAL_1="45" TOTAL_2="38" VAR="0.07777777777777778" WEIGHT="0.0">
<FOOTNOTE>Myrrh (Mirazid capsules) 300 mg daily for 3 days versus Praziquantel 40 mg/kg single dose twice 3 weeks apart</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.380082267988133" CI_START="2.972268661662701" EFFECT_SIZE="4.6835443037974684" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="15" LOG_CI_END="0.8680612030607305" LOG_CI_START="0.4730880624923768" LOG_EFFECT_SIZE="0.6705746327765536" MODIFIED="2012-08-09 15:49:58 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.23200917791842895" STUDY_ID="STD-Botros-2005-EGY" TOTAL_1="79" TOTAL_2="74" VAR="0.053828258638385224" WEIGHT="0.0">
<FOOTNOTE>Myrrh (Mirazid capsules) 300 mg daily for 3 days versus Praziquantel 40 mg/kg single dose</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-014.02" MODIFIED="2012-12-07 00:34:48 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Percent egg reduction three to six weeks</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Myrrh (Mirazid: 300 mg) daily for 3 days</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-05-09 15:27:53 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="354" STUDY_ID="STD-Barakat-2005-EGY">
<TR>
<TD>
<P>104</P>
</TD>
<TD>
<P>17.2%</P>
</TD>
<TD>
<P>84%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-09 15:27:46 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="355" STUDY_ID="STD-Botros-2005-EGY">
<TR>
<TD>
<P>271</P>
</TD>
<TD>
<P>8.8%</P>
</TD>
<TD>
<P>63.7%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2012-12-10 11:50:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="15">
<NAME>Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:42:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.969594794322581" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Artesunate plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Artesunate plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0914345089905475" CI_START="0.34697292575284594" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.03799768119280957" LOG_CI_START="-0.4597044118225958" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2012-08-09 15:57:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1102" O_E="0.0" SE="0.2923526731023431" STUDY_ID="STD-De-Clercq-2000-SEN" TOTAL_1="39" TOTAL_2="36" VAR="0.08547008547008549" WEIGHT="0.0">
<FOOTNOTE>Artesunate (12 mg/kg) in a divided dose of 2.4 mg/kg daily for 5 days</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:43:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.969594794322581" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Artesunate plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Artesunate plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6406901578264204" CI_START="0.8060632250954942" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.21502657285599058" LOG_CI_START="-0.09363089214876728" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2012-08-09 15:58:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1103" O_E="0.0" SE="0.18130692282288785" STUDY_ID="STD-De-Clercq-2000-SEN" TOTAL_1="33" TOTAL_2="33" VAR="0.03287220026350461" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:43:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.969594794322581" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Artesunate plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Artesunate plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6825907749953517" CI_START="0.6360159545546235" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.22597850351481294" LOG_CI_START="-0.19653198987340015" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2012-08-09 15:57:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1105" O_E="0.0" SE="0.2481847552769093" STUDY_ID="STD-De-Clercq-2000-SEN" TOTAL_1="29" TOTAL_2="34" VAR="0.061595672751859364" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-015.04" MODIFIED="2012-12-10 11:50:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Artesunate (12 mg/kg) plus Praziquantel (40 mg/kg)</P>
</TH>
<TH>
<P>Praziquantel (40 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-015.04.01" MODIFIED="2012-12-10 11:49:41 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="1">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2012-12-10 11:49:41 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="359" STUDY_ID="STD-De-Clercq-2000-SEN">
<TR>
<TD>
<P>75</P>
</TD>
<TD>
<P>83%</P>
</TD>
<TD>
<P>62%</P>
</TD>
<TD>
<P>P &gt; 0.2380</P>
</TD>
<TD>
<P>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-015.04.02" MODIFIED="2012-12-10 11:49:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="1">
<NAME>Three months</NAME>
<OTHER_DATA MODIFIED="2012-12-10 11:49:54 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="360" STUDY_ID="STD-De-Clercq-2000-SEN">
<TR>
<TD>
<P>66</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>79%</P>
</TD>
<TD>
<P>P &gt; 0.5552</P>
</TD>
<TD>
<P>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-015.04.03" MODIFIED="2012-12-10 11:50:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="1">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-12-10 11:50:07 +0000" MODIFIED_BY="Tony Danso-Appiah" ORDER="361" STUDY_ID="STD-De-Clercq-2000-SEN">
<TR>
<TD>
<P>63</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>82%</P>
</TD>
<TD>
<P>P &gt; 0.5892</P>
</TD>
<TD>
<P>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2012-12-10 11:11:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="16">
<NAME>Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:44:07 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="895.3208206701797" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Oxamniquine plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Oxamniquine plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="59.93150212827431" CI_START="0.11200803715861513" EFFECT_SIZE="2.590909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7776551630267885" LOG_CI_START="-0.9507508133262184" LOG_EFFECT_SIZE="0.4134521748502851" MODIFIED="2012-08-09 15:58:46 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="1.6026791763371584" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="21" TOTAL_2="18" VAR="2.5685805422647525" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:44:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="895.3208206701797" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Oxamniquine plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Oxamniquine plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.553247499095681" CI_START="0.5002078114166757" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.7445470296937488" LOG_CI_START="-0.3008495304610359" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-08-09 15:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.6140711142313513" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="32" TOTAL_2="20" VAR="0.3770833333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-24 10:46:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="895.3208206701797" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at 12 months</NAME>
<GROUP_LABEL_1>Oxamniquine plus praziquantel</GROUP_LABEL_1>
<GROUP_LABEL_2>Praziquantel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Oxamniquine plus praziquantel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Praziquantel</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.80593862764522" CI_START="0.3163473187396772" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8924251324205308" LOG_CI_START="-0.49983584213259435" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2012-08-09 15:59:06 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.8178209882554793" STUDY_ID="STD-Zwingenberger-1987-BRA" TOTAL_1="28" TOTAL_2="22" VAR="0.6688311688311689" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-016.04" MODIFIED="2012-12-10 11:11:16 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Oxamniquine (7.5 mg/kg) plus Praziquantel (20 mg/kg)</P>
</TH>
<TH>
<P>Praziquantel (20 mg/kg x 2) in one day</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-016.04.01" MODIFIED="2012-12-06 23:58:55 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="1">
<NAME>Three months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:29:32 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="365" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD/>
<TD>
<P>76.9% to 99.5%</P>
</TD>
<TD>
<P/>
<P>100%</P>
<P>
<BR/>
</P>
</TD>
<TD>
<P>Not statistically significant </P>
</TD>
<TD>
<P>EPG (Range) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-016.04.02" MODIFIED="2012-12-06 23:59:04 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="1">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:29:39 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="366" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD/>
<TD>
<P>87.7%</P>
</TD>
<TD>
<P>93.8%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>EPG (Range) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-016.04.03" MODIFIED="2012-12-06 23:59:11 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="1">
<NAME>12 months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:29:49 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="367" STUDY_ID="STD-Zwingenberger-1987-BRA">
<TR>
<TD/>
<TD>
<P>93.7%</P>
</TD>
<TD>
<P>96.9%</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>EPG (Range) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2012-12-10 11:50:45 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="17">
<NAME>Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:45:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.983196903876113" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.747921332414588" CI_START="1.6037710588652314" EFFECT_SIZE="6.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.3935387268342834" LOG_CI_START="0.20514237207287997" LOG_EFFECT_SIZE="0.7993405494535817" MODIFIED="2012-08-09 16:00:02 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.6980699014436786" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="10" TOTAL_2="18" VAR="0.48730158730158724" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:45:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.983196903876113" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1864044212838425" CI_START="1.132938422971898" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.5033008960054153" LOG_CI_START="0.054206305900242564" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2012-08-09 16:00:05 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.26380038528185246" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="10" TOTAL_2="19" VAR="0.06959064327485379" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:45:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.983196903876113" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.641868310181877" CI_START="0.8178628244185551" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8831995493620579" LOG_CI_START="-0.08731953201798269" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2012-08-09 16:00:07 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="8" TOTAL_2="12" VAR="0.325" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-017.04" MODIFIED="2012-12-10 11:50:45 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Oxamniquine (4 mg/kg) plus Praziquantel (8 mg/kg)</P>
</TH>
<TH>
<P>Oxamniquine (10 mg/kg) plus Praziquantel (20 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-017.04.01" MODIFIED="2012-12-06 23:59:27 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="1">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:28:53 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="371" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>93.7%</P>
</TD>
<TD>
<P>88%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-017.04.02" MODIFIED="2012-12-06 23:59:34 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="1">
<NAME>Three months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:29:02 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="372" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>82.4%</P>
</TD>
<TD>
<P>66.3%</P>
</TD>
<TD>
<P>Not reported </P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-017.04.03" MODIFIED="2012-12-06 23:59:44 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="1">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:29:11 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="373" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>98.5%</P>
</TD>
<TD>
<P>96.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2012-12-10 11:50:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="18">
<NAME>Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:46:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.214370934536007" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at one month</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.031511992503072" CI_START="0.48829033318681064" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9557604629416147" LOG_CI_START="-0.311321873473776" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2012-08-09 16:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.7442904365691217" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="30" TOTAL_2="18" VAR="0.5539682539682539" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:46:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.214370934536007" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at three months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.281252808315129" CI_START="0.7398472024404328" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.3581734164350763" LOG_CI_START="-0.1308579640378544" LOG_EFFECT_SIZE="0.11365772619861092" MODIFIED="2012-08-09 16:01:04 +0100" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.2872594536341741" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="26" TOTAL_2="19" VAR="0.08251799370220422" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-06 23:47:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.214370934536007" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Parasitological failure at six months</NAME>
<GROUP_LABEL_1>Lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Higher dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.55985476630564" CI_START="0.4370927774942851" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6589510103844988" LOG_CI_START="-0.35942636971783465" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2012-08-09 16:01:15 +0100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.5981999141214431" STUDY_ID="STD-Creasey-1986-ZWE" TOTAL_1="17" TOTAL_2="12" VAR="0.35784313725490197" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.04" MODIFIED="2012-12-10 11:50:54 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Percent egg reduction</NAME>
<TR>
<TH>
<P>Number of participants</P>
</TH>
<TH>
<P>Oxamniquine (7.5 mg/kg) plus Praziquantel (15 mg/kg)</P>
</TH>
<TH>
<P>Oxamniquine (10 mg/kg) plus Praziquantel (20 mg/kg)</P>
</TH>
<TH>
<P>P-value</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-018.04.01" MODIFIED="2012-12-07 00:00:01 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" STUDIES="1">
<NAME>One month</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:28:12 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="377" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>96.1%</P>
</TD>
<TD>
<P>88%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-018.04.02" MODIFIED="2012-12-07 00:00:10 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" STUDIES="1">
<NAME>Three months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:28:24 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="378" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>82%</P>
</TD>
<TD>
<P>66.3%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-018.04.03" MODIFIED="2012-12-07 00:00:21 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="3" STUDIES="1">
<NAME>Six months</NAME>
<OTHER_DATA MODIFIED="2012-05-09 15:28:31 +0100" MODIFIED_BY="Tony Danso-Appiah" ORDER="379" STUDY_ID="STD-Creasey-1986-ZWE">
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>95%</P>
</TD>
<TD>
<P>96.6%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>EPG (Geometric Mean) of participants excreting eggs at follow-up</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-11-19 00:58:18 +0000" MODIFIED_BY="Tony Danso-Appiah">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-11-19 00:58:18 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-11-19 00:58:18 +0000" MODIFIED_BY="Tony Danso-Appiah" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVoAAAcyCAIAAABXRLosAABjS0lEQVR42u3dvY4cx9nF8QUMGA42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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-08-11 20:45:43 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2012-08-24 11:38:13 +0100" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2010-08-11 20:45:43 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_F8CECA1E82E26AA200FFCE219EEE489B_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="F8CECA1E82E26AA200FFCE219EEE489B">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Basel</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>